NanoCarrier  
NC-6004 -004A  NC-6004  
[STUDY_ID_REMOVED]   
CLINICAL  STUDY PROTOCOL 
IND: 118108  
A Phase 1b/2 Dose Escalation and Expansion Trial of NC -6004 
(Nanoparticle  Cisplatin) plus Gemcitabine  in Patients with  Advanced Solid 
Tumors or Squamous Non- Small Cell Lung, Biliary Tract, and Bladder 
Cancer 
NC-6004 -004A  
 
Sponsor:  NanoCarrier  Co, Ltd 
144-15 Chuo Gaiku, 226-39 Wakashiba  Kashiwa 
Chiba, 277-0871, Japan  
Sponsor  Contact:  
Director of International  Clinical Development 
NanoCarrier Co, Ltd 
Telephone:  +81-3-3241- 0551  
Medical  Monitor:  
Medical  Director,  Pharmacovigilance 
PPD, Inc.  
929 North  Front  Street  
Wilmington,  North  Carolina, 28401- 3331, USA 
Telephone: 800 -201-8725  
Current  Version 
and Date of Protocol:  Amendment  4, Version  5.0: 13 March  2017  
Previous  Dates 
and Versions:  Original,  Version  1.2: 17 October  2013  (US only)  
Amendment  1, Version  2.0: 31 December  2014  (US only)  
Amendment  2, Version  3.0: 07 July 2015 (US only)  
Amendment  3, Version  4.0: 31 July 2016 (US only)  
Amendment  3, Version  4.1: 31 August  2016 (EU only)  
Amendment  3, Version  4.2: 12 December  2016  (US and EU; 
harmonizes  versions  4.0 and 4.1) 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol   
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by NanoCarrier Co, 
Ltd. The concepts and information  contained  in this document  or generated  during the study 
are considered proprietary and may not be disclosed in whole or in part without the 
expressed, written consent of NanoCarrier Co, Ltd. 
The study will be conducted according  to the International  Council  for Harmonisation 
harmonised tripartite guideline E6(R1): Good Clinical Practice.  
NanoCarr ier 
NC-6004 -004A 
Protocol Approval  - Sponsor Signatory  NC-6004 
Protocol 
Study Title  A Phase lb/2 Dose Escalation and Expansion Trial of NC-6 004 
(Nanoparticle Cisplatin) plus Gemcitabine in Patients with A dvanced 
Solid Tumors or Squamous Non-S mall Cell Lung, Biliary  Tract, and 
Bladder Cancer  
P
rotocol Number  NC-6004- 004A  
Protocol Date Protocol Version Final 5.0 incorporating  
Amendment 4 -13  March 2017  
Protoco l accepted and ap proved by: 
    azuhiro Takahashi 
144-15 Chuo Gaiku, 226-39 Wak ashiba Kashiwa  
Chiba, 277-0871, Japan
Sign Date 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  4 Declaration of Investigator  
I have read and understood all sections of the protocol entitled “A Phase 1b/2 Dose 
Escalation and Expansion Trial of NC- 6004 (Nanoparticle Cisplatin) plus Gemcitabine in 
Patients  with Advanced Solid  Tumors  or Squamous Non-Small Cell Lung, Biliary  Tract,  and 
Bladder Cancer” and the accompanying investigator’s brochure.  
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol Version 5.0, dated 13 March 2017, the International 
Council for Harmonisation harmonised tripartite guideline E6(R1): Good Clinical Practice 
and all applicable government regulations. I will not make changes to the protocol before 
consulting with NanoCarrier Co, Ltd. or implement protocol changes without independent 
ethics committee approval except to eliminate an immediate risk to patients. I agree to 
administer study treatment only to patients  under my personal supervision or the supervision 
of a subinvestigator. 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality  will be protected. Patient  identity  will not be disclosed  to third  parties or 
appear in any study reports or publications. 
I will not disclose information  regarding this clinical  investigation  or publish results of the 
investigation without authorization from NanoCarrier Co, Ltd. 
Signature  of Principal Investigator  Date 
Printed  Name  of Principal  Investigator  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  5  
 Table  of Contents  
Table  of Contents  ...................................................................................................................... 5 
List of Tables ........................................................................................................................... 10 
Protocol  Synopsis  .................................................................................................................... 11 
List of Abbreviations  ............................................................................................................... 26 
1 Introduction  ......................................................................................................................29 
2 Study Objectives  ..............................................................................................................32 
2.1 Primary  Objectives  ................................................................................................. 32 
2.2 Secondary Objectives  ............................................................................................. 32 
2.3 Exploratory  Objectives  ........................................................................................... 32 
3 Investigational  Plan ..........................................................................................................33 
3.1 Study Design  .......................................................................................................... 33 
3.1.1 Rationale  of Study Design  ........................................................................ 42 
4 Patient  Selection  and Withdrawal  Criteria  .......................................................................44 
4.1 Selection  of Study Population  ................................................................................ 44 
4.1.1 Inclusion Criteria  ....................................................................................... 44 
4.1.2 Exclusion Criteria  ..................................................................................... 47 
4.2 Withdrawal  of Patients From  the Study  ................................................................. 49 
4.2.1 Reasons for Withdrawal/Discontinuation  .................................................. 49 
4.2.2 Handling of Withdrawals  .......................................................................... 50 
4.2.3 Replacements ............................................................................................ 50 
5 Study Treatments  .............................................................................................................51 
5.1 Method of Assigning Patients  to Treatment  Groups  .............................................. 51 
5.2 Prophylactic  Treatments  ......................................................................................... 51 
5.3 Treatments  Administered  ........................................................................................ 52 
5.4 Dose  Delays  and Modifications  .............................................................................. 54 
5.4.1 NC-6004 Dose  Delay  and Modification  ................................................... 54 
5.4.2 Gemcitabine  Dose  Delay  and Modification  .............................................. 55 
5.5 Identity  of Investigational  Product  ......................................................................... 56 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  6  
 5.5.1 NC-6004 Drug  Product  ............................................................................ 56 
5.5.2 Gemcitabine  Drug  Product  ....................................................................... 57 
5.6 Management  of Clinical Supplies  ......................................................................... 57 
5.6.1 Study Drug  Packaging and Storage  .......................................................... 57 
5.6.2 Test Article  Accountability  ....................................................................... 57 
5.7 Overdose  Management  .......................................................................................... 57 
5.7.1 Treatment  of Overdose  ............................................................................. 58 
5.8 Prophylaxis  and Management  of Hypersensitivity  Reactions  ............................... 58 
5.9 Treatment  Compliance  .......................................................................................... 59 
5.10 Prior,  Concomitant, and Subsequent  Therapy  ....................................................... 59 
5.11 Prohibited Medications  .......................................................................................... 60 
6 Study Assessments and Procedures  ................................................................................. 61 
6.1 Efficacy  Assessments  ............................................................................................ 61 
6.1.1 Disease Response  Definitions  .................................................................. 61 
6.1.2 European Organisation for Research and Treatment of Cancer Quality of  
Life Questionnaire -Core  30 ..................................................................... 62 
6.1.3 MD Anderson Symptom  Inventory  .......................................................... 63 
6.2 Pharmacokinetic and Pharmacodynamic  Assessments ......................................... 64 
6.3 Safety  and Tolerability  Assessments  ..................................................................... 65 
6.3.1 Dose -Limiting  Toxicities  and Dose  Escalation  Scheme  .......................... 65 
6.3.1.1 Definition  of Dose -Limiting  Toxicities  .................................. 65 
6.3.1.2 Dose  Escalation  Scheme  ........................................................ 66 
6.3.1.2.1 Safety  Monitoring in Part 2  ................................. 68 
6.3.2 Adverse  Events  ........................................................................................ 69 
6.3.2.1 Definitions  of Adverse  Events  ............................................... 69 
6.3.2.2 Eliciting  and Documenting Adverse  Events  .......................... 69 
6.3.2.3 Reporting Adverse  Events  ...................................................... 70 
6.3.2.4 Assessment  of Severity  .......................................................... 71 
6.3.2.5 Assessment  of Causality  ........................................................ 71 
6.3.2.6 Follow -up of Patients Reporting Adverse  Events  .................. 72 
6.3.2.7 Management Guidelines for NC -6004- Related Liver  
Dysfunction  ............................................................................ 72 
6.3.3 Assessment  of Nausea and Vomiting  ....................................................... 73 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  7  
 6.3.4 Pregnancy  .................................................................................................. 74 
6.3.5 Clinical Laboratory  Analyses  .................................................................... 74 
6.3.5.1 Hematology  and Coagulation  ................................................. 75 
6.3.5.2 Biochemistry  ...........................................................................75 
6.3.5.3 Urinalysis  ................................................................................75 
6.3.6 Electrocardiograms  .................................................................................... 75 
6.3.7 Physical  Examination  ................................................................................ 76 
6.3.8 Vital Sign Measurements .......................................................................... 76 
6.3.9 Eastern  Cooperative  Oncology Group  Performance Status  ...................... 77 
6.3.10 Audiometry  ............................................................................................... 77 
7 Statistical and Analytical Plan .........................................................................................78 
7.1 Safety  Endpoints  .................................................................................................... 78 
7.2 Exploratory  Endpoints  ............................................................................................ 78 
7.3 Sample  Size Calculations  ....................................................................................... 78 
7.4 Analysis  Sets .......................................................................................................... 79 
7.5 Description  of Subgroups  to be  Analyzed  .............................................................. 80 
7.6 Statistical Analysis  Methodology  ........................................................................... 80 
7.6.1 Efficacy  Analysis  ...................................................................................... 80 
7.6.1.1 Progression –Free  Survival  ......................................................80 
7.6.1.2 Overall  Survival  ......................................................................81 
7.6.1.3 Duration  of Response  ..............................................................81 
7.6.1.4 Disease Control  Rate ...............................................................81 
7.6.1.5 Overall  Response  Rate ............................................................82 
7.6.1.6 Quality  of Life  Analyses  .........................................................82 
7.6.1.7 Symptoms  Assessment  Analyses  ............................................82 
7.6.2 Safety  Analyses  ......................................................................................... 83 
7.6.2.1 Analyses of Adverse  Events  ....................................................83 
7.6.2.2 Severity  of Nausea and Incidence of Vomiting  ......................83 
7.6.2.3 Clinical Laboratory  Results ....................................................84 
7.6.2.4 Additional  Safety  Assessments ...............................................84 
7.6.3 Pharmacokinetic and Pharmacodynamic  Analyses  ................................... 84 
7.6.4 Study Drug  Exposure  ................................................................................ 85 
7.7 Data  Quality  Assurance  .......................................................................................... 85 
7.7.1 Data  Management  ..................................................................................... 86 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  8  
 8 Ethics  .............................................................................................................................. 87 
8.1 Independent  Ethics  Committee  or Institutional Review  Board  ............................. 87 
8.2 Ethical Conduct  of the Study  ................................................................................ 87 
8.3 Patient  Information  and Consent  ........................................................................... 87 
9 Investigator’s  Obligations  ............................................................................................... 89 
9.1 Confidentiality  ....................................................................................................... 89 
9.2 Financial  Disclosure and Obligations  .................................................................... 89 
9.3 Investigator  Documentation  .................................................................................. 90 
9.4 Study Conduct  ....................................................................................................... 90 
9.5 Adherence  to Protocol  ........................................................................................... 90 
9.6 Adverse  Events  and Study Report  Requirements  .................................................. 91 
9.7 Investigator’s  Final  Report  .................................................................................... 91 
9.8 Records  Retention  ................................................................................................. 91 
9.9 Publications  ........................................................................................................... 91 
10 Study Management  ......................................................................................................... 92 
10.1 Monitoring  ............................................................................................................. 92 
10.1.1 Monitoring of the Study  ........................................................................... 92 
10.1.2 Inspection of Records ............................................................................... 92 
10.2 Management  of Protocol  Amendments  and Deviations  ........................................ 92 
10.2.1 Modification  of the Protocol  .................................................................... 92 
10.2.2 Protocol  Violations  and Deviations  .......................................................... 93 
10.3 Study Termination  ................................................................................................. 93 
10.4 Final  Report  ........................................................................................................... 93 
11 Reference List ................................................................................................................. 95 
12 Appendices  ...................................................................................................................... 97 
12.1 Appendix:  Schedule  of Events  .............................................................................. 98 
12.2 Appendix: European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire  Core  30 ............................................................................. 101 
12.3 Appendix:  MD Anderson Symptom Inventory –Lung Cancer  ............................ 103 
12.4 Appendix:  Protocol  Amendment  ......................................................................... 105 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  9  
 12.4.1 Protocol  Amendment 1 –Protocol Version 2.0, Incorporating  Amendment  
1, Dated  31 December  2014  ................................................................... 105 
12.4.1.1 Overview  of Changes  ........................................................... 105 
12.4.1.2 Changes  to the Protocol  Text ............................................... 108 
12.4.2 Protocol  Amendment 2 –Protocol Version 3.0, Incorporating  Amendment  
2, Dated 07 July 2015  ............................................................................ 125 
12.4.2.1 Assessment  of Risk Associated  With  Amendment  2 ........... 125 
12.4.2.2 Overview  of Changes  ........................................................... 126 
12.4.2.3 Changes  to the Protocol  Text ............................................... 130 
12.4.3 Protocol  Amendment  3–Protocol  Version  4.0, Incorporating  
Amendment  3, Dated 31 July 2016  ........................................................ 156 
12.4.3.1 Assessment  of Risk Associated  With  Amendment  3, 
Version  4.0 ........................................................................... 156 
12.4.3.2 Overview  of Changes  ........................................................... 156 
12.4.3.3 Changes  to the Protocol  Text ............................................... 162 
12.4.4 Protocol  Amendment 3 –Protocol Version 4.1, Incorporating  Amendment  
3, Dated  31 August  2016  ........................................................................ 181 
12.4.4.1 Overview  of Changes  ........................................................... 181 
12.4.4.2 Changes  to the Protocol  Text ............................................... 182 
12.4.5 Protocol  Amendment  3-Protocol  Version  4.2, Incorporating  
Amendment  3-Version  4.0 (US only, dated  31 July 2016)  .................... 188 
12.4.5.1 Risk Assessment  for Amendment  3, Version  4.2 ................. 188 
12.4.5.2 Overview  of Changes  ........................................................... 188 
12.4.5.3 Changes  to the Protocol  Text ............................................... 192 
12.4.6 Protocol  Amendment  3-Protocol  Version  4.2, Incorporating  
Amendment  3-Version  4.1 (EU only, dated  31 August  2016)  ................ 204 
12.4.6.1 Risk Assessment  for Amendment  3, Version  4.2 ................. 204 
12.4.6.2 Overview  of Changes  ........................................................... 204 
12.4.6.3 Changes  to the Protocol  Text ............................................... 211 
12.4.7 Protocol  Amendment  4-Protocol  Version  5.0, Incorporating Amendment  
3- Version  4.2 (dated  12 December  2016)  .............................................. 236 
12.4.7.1 Risk Assessment  for Amendment  4, Version  5.0 ................. 236 
12.4.7.2 Overview  of Changes  ........................................................... 236 
12.4.7.3 Changes  to the Protocol  Text ............................................... 237 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  10  
 List of Tables  
Table  3-1 Dose  Levels  of NC-6004  ................................................................................. 34 
Table  5-1 Dose  Level  Cohorts  ......................................................................................... 53 
Table  12-1 Schedule  of Events  .......................................................................................... 98 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  11  
 Protocol  Synopsis  
 
Protocol  Number:  NC-6004 -004A  
Title:  A Phase  1b/2 Dose  Escalation  and Expansion  Trial  of NC-6004 
(Nanoparticle Cisplatin) plus Gemcitabine in Patients with 
Advanced Solid Tumors or Squamous Non- Small Cell Lung, 
Biliary Tract, and Bladder Cancer  
Sponsor:  NanoCarrier  Co, Ltd 
Study  Phase:  1b/2 
Study  Sites:  At least 20 sites in the United  States  and Europe  
Indication:  Part 1: Advanced solid  tumors  
Part 2: First- line metastatic squamous non- small cell lung cancer 
(NSCLC); first- line metastatic or locally advanced 
cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary  tract cancer);  and first-line metastatic  or locally  advanced 
transitional cell carcinoma (TCC) of the urinary tract (bladder cancer)  
Rationale:  NC-6004 is a polymeric micelle containing cisplatin as an active 
moiety. The nanoparticle provides sustained release of the cisplatin  and utilizes  the enhanced  permeability  retention -effect  to 
target the release of platinum to tumors. Synergistic effects of cisplatin and gemcitabine have been evaluated extensively in various  types  of tumor  cell lines,  including NSCLC cell lines,  and 
nonclinical studies have demonstrated that, in tumors in which the combination of cisplatin and gemcitabine exhibit synergistic effects, the combined effects of NC -6004 and gemcitabine also 
are synergistic. This study will establish a maximum- tolerated 
dose (MTD) and recommended Phase 2 (RPII) dose of NC -6004 
in combination with gemcitabine and evaluate the initial activity and tolerability profile.  
Objectives:  The primary  objectives  of this study  are: 
• In the dose -escalation phase of the study (Part 1), to  
determine  the dose-limiting  toxicities  (DLTs),  MTD,  and RPII 
dose of NC -6004 in combination with gemcitabine;  
• In the expansion phase of the study (Part 2), to evaluate the activity of NC -6004 in combination with gemcitabine in 
patients with first- line Stage IV  squamous NSCLC, first -line 
advanced or metastatic biliary tract cancer, and first- line 
metastatic  or locally  advanced  bladder  cancer  compared  with 
historical control as measured by local  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  12  
  
 investigator/radiologist -assessed  progression -free survival 
(PFS),  according to Response  Evaluation Criteria  in Solid 
Tumors (RECIST) version 1.1. 
The secondary objectives  of this study are: 
• To evaluate overall  response rate (ORR),  disease  control  rate 
(DCR = complete response + partial response + stable 
disease), duration of response (DOR), PFS, overall survival (OS)  
• To evaluate therapy -related  adverse  events  (AEs)  
• To evaluate the safety  and tolerability  of NC-6004 when 
combined with gemcitabine  
• To evaluate quality of life using the European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC QLQ- C30)  
• To evaluate acute and delayed symptoms using the MD Anderson Symptom  Inventory (MDASI) and a nausea and 
vomiting patient diary  
The exploratory objective of this study  is: 
• To assess  the pharmacokinetic  and pharmacodynamic  effects 
of NC- 6004. 
Patient  Population:   
Inclusion  Criteria  Each  patient  must  meet  all of the following criteria  to be enrolled 
in this study:  
1. Provide  signed  written  informed  consent  prior  to the initiation 
of any study -specific procedures.  
2. (Part 1 only)  Have  a histologically  or cytologically  confirmed 
diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.  
(Part 2 only) Cohort 1: Have histologically or cytologically confirmed  diagnosis  of Stage  IV squamous  NSCLC and have 
not received prior chemotherapy or immunotherapy for metastatic disease and are not known to be PD -L1 positive 
(known high PD-L1 expression  defined  as Tumor  Proportion 
Score [TPS] greater than or equal to 50%). Patients with known sensitizing mutation in the epidermal growth factor receptor  (EGFR)  gene  or anaplastic lymphoma  kinase  (ALK) 
fusion oncogene must have received at least 1 and up to  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  13  
 2 targeted  therapies prior  to enrollment.  
• A patient with stable, treated brain metastases is eligible, 
provided that there is no evidence of progression after 
treatment and the patient  does not require  corticosteroids, 
or, if the patient requires corticosteroids, has been receiving a stable dose of corticosteroids for at least  
14 days prior to assignment  to treatment.  
• Patients whose tumors are known to harbor an exon 19 deletion or exon 21 L858R  EGFR  mutation  must  have  had 
intolerance or have progressed on at least 1 and up to 
2 EGFR tyrosine  kinase  inhibitors.  
• Patients  whose  tumors  are known to harbor  an ALK 
translocation must have had intolerance or have 
progressed on at  least 1 and up to 2 ALK  inhibitors. 
(Part 2 only) Cohort 2: Have histologically or cytologically 
confirmed  diagnosis  of nonresectable,  recurrent,  or metastatic 
biliary tract carcinoma (intrahepatic or extrahepatic 
cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not received prior systemic anticancer therapy for advanced or metastatic disease.  
(Part 2 only) Cohort 3: Have histologically or cytologically confirmed  diagnosis  of metastatic or locally  advanced  TCC of 
the urinary tract (bladder, urethra, ureter, renal pelvis)  
(T3b -T4 N0 M0, Tany  N1-N3 M0, or Tany  Nany  M1) and are 
not candidates for surgery. 
• Patients  must  not have  received  prior  treatment with 
systemic anticancer  therapy for metastatic  or locally 
advanced urinary tract cancer.  
• Certain  mixed  histologies  that are predominantly  (>50%) 
TCC are eligible: squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated histology requires immunohistochemistry consistent with a TCC origin. Predominantly squamous or neuroendocrine tumors are excluded.  
3. Have  measurable disease per  RECIST  version 1.1. 
4. Are males  or females  aged  
≥18 years.  
5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1, with the exception of patients  in Part 2 (Cohort  3, unfit  bladder  cancer  patients)  who 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  14  
 may have  an ECOG  PS of 2.  
6. Have  adequate bone  marrow  reserve  defined as: 
• Absolute  neutrophil  count of  at least 1.5  × 109/L, 
• Platelet count  of at least 100 × 109/L, and 
•  Hemoglobin level of at least 10 g/dL (transfusion is 
allowed  to achieve  hemoglobin level  of at least 10 g/dL). 
7. Have  adequate  liver function  defined  as: 
•  Total  serum  bilirubin  <1.5 × upper  limit of normal  (ULN) 
and 
• Baseline alanine  transaminase  and aspartate transaminase  
<2.0 × ULN or, in patients  with documented hepatic 
metastasis <5.0 × ULN and  
• Serum  albumin  ≥3.5 g/dL 
8. Prothrombin  time within  normal  limits  
9. In Part 1 and in Part 2 in Cohorts  1 and 2: have  adequate  renal 
function defined as a creatinine clearance (CrCl)  
≥50 mL/minute (calculated according to the formula of 
Cockcroft  and Gault  1976)  or serum  creatinine  <1.5 mg/dL. In 
Part 2, patients in Cohort 3 (bladder cancer) must have a CrCl of ≥30 mL/min.  
•  Bladder cancer patients in Cohort 3 of Part 2 will be 
stratified  by ≥30 to <60 mL/min  and/or  ECOG PS 2 and 
≥60 mL/min  and ECOG PS 0  to 1. If 2 of 6 patients (or  
≥33%  at any  point during the  study)  in the  ≥30 to 
<60 mL/min group have a worsening of CrCl (ie, 50% reduction from  baseline for 2 consecutive  assessments,  at 
least 1 week apart),  then enrollment of patients  with CrCl  
<60 mL/min  will stop in the bladder  cancer  cohort. 
10. Have a negative pregnancy test result at screening (for  
females of childbearing potential; not applicable to patients who are unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy or postmenopausal  [no menses for the previous  12 months]). The 
test must be performed within 1 week before Day 1 of treatment.  
11. Male patients must agree to use a condom during treatment and for 90 days after dosing. Male  patients  must  agree  not to 
donate sperm for 90 days after dosing. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  15  
  
 12. For women of childbearing potential*: are willing to follow  
1 of the following  effective methods  of birth  control  from  the 
time of study  entry  to 6 months  after the last day  of treatment: 
•  Combined (estrogen - and progestogen- containing) 
hormonal  contraception associated  with inhibition  of 
ovulation (oral, intravaginal, or transdermal)  
•  Progestogen -only hormonal  contraception associated  with 
inhibition of ovulation (oral, injectable, or implantable)  
• Intrauterine  devices  
• Intrauterine  hormone -releasing  system  
•  Vasectomized  partner  who has received  medical 
assessment of surgical success  
• Bilateral tubal  occlusion  
• True  sexual  abstinence**  
*Patients  not of childbearing  potential include  those  who are 
surgically sterile or postmenopausal (no menses for the 
previous 12 months). For women not currently taking contraceptive methods at screening, low user -dependency 
contraceptive methods (eg, implantable progestogen- only 
hormonal contraception, intrauterine device, intrauterine hormone -releasing system, bilateral tubal occlusion, 
vasectomized partner) are recommended.  
**The  reliability  of sexual  abstinence  needs  to be evaluated 
in relation to the duration of the clinical trial and the 
preferred and usual lifestyle of the patient.  
13. Have  reasonably  recovered  from preceding major surgery as 
judged by the investigator or have had no major surgery within 4 weeks prior to Day 1 treatment.  
Exclusion  Criteria  Patients  meeting  any of the following  criteria  will be excluded 
from the study: 
1. Have  received  prior  platinum  therapy  in the past 3 months 
(Part  1) or 6 months  in the adjuvant  or neoadjuvant  setting 
(Part 2).  
2. Have  received  prior  cisplatin  and gemcitabine  concomitantly 
within the last 6 months or are refractory to cisplatin and gemcitabine.  
3. Are unable  to receive  platinum -based therapy  due to previous  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  16  
 toxicity.  
4. Have  unresolved toxicity  from prior radiation, chemotherapy, 
or other targeted treatment, including investigational 
treatment, with the exception of alopecia and ≤Grade 1 peripheral neuropathy according to the National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE version 4.03. Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient’s general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline toxicity.  
5. Have  evidence suggesting pulmonary  fibrosis  or interstitial 
pneumonia.  
6. Have a history of thrombocytopenia with complications including hemorrhage or bleeding of ≥Grade 2 per NCI CTCAE  version 4.03 that required  medical  intervention  or 
have any hemolytic condition or coagulation disorder that 
would make participation unsafe in the opinion of the investigator.  
7. Have  known hypersensitivity to platinum compounds  or 
gemcitabine.  
8. Have  uncontrolled diabetes  or have  hypertension requiring 
more than 3 medications for control of hypertension. 
9. Have  known active  hepatitis B  (defined as a known positive 
hepatitis B surface antigen [HBsAg] result) or hepatitis C (defined  by a known positive  hepatitis  C antibody result  and 
known quantitative  HCV  RNA results greater  than the lower 
limits of detection of the assay).  
10. Are pregnant  or breast -feeding.  
11. Have signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social condition that, in the  opinion of  the investigator, make 
it undesirable  for the patient  to participate in the study or that 
could jeopardize compliance with the protocol.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  17  
  
 12. Have  pre-existing  alcoholic  liver injury  or significant  liver 
disease.  
13. Are regularly consuming alcohol within 6 months of 
Screening defined as an average weekly intake of >21 units (or an average  daily  intake  of >3 units)  for males  or >14 units 
(or an average daily intake >2 units) for females. One unit is equivalent to 8 g of alcohol: a half -pint (approximately  
240 mL) of beer,  1 glass (125 mL) of wine,  or 1 measure 
(25 mL) of spirits.  
14. Have experienced any of the following within the 6- month 
period prior to screening: angina pectoris, coronary artery disease, cerebrovascular accident, transient ischemic attack, cardiac failure  with known ejection  fraction  less than 40%, or 
cardiac arrhythmia requiring medical therapy.  
15. Are unwilling or unable to comply with study procedures or are planning  to take a vacation for 7 or more  consecutive days 
during the treatment phase of the study without prior consent from the Medical Monitor.  
Study  Design:  This study will consist of 2 parts; Part 1 is a Phase 1b, continual 
reassessment  method dose-escalation  trial, and Part 2 is a Phase  2, 
adaptive, open- label, expansion trial evaluating activity, safety, 
and tolerability at the RPII dose identified in Part 1.  
In Part 1, patients  will receive intravenous  infusion  of NC-6004 at 
escalating  doses on Day  1 in combination with gemcitabine at the 
fixed  dose of 1250 mg/m
2 on Days  1 and 8 of a 21-day cycle.  The 
dose-escalation part of the trial will begin with a single -patient 
run-in phase. In the run -in phase, 1 patient will be enrolled 
sequentially at the following dose levels: 60, 75, 90, 105, 120, 
135, 150, 165, and 180 mg/m2 until a DLT is observed or until a 
patient  is treated  at 180 mg/m2 for 1 cycle without  a DLT.  During 
the single -subject run -in phase, after enrollment of the initial 
patient at 60 mg/m2, the first patient in each cohort will not be 
enrolled until the patient at the immediately lower c ohort has 
completed at least 1 full cycle. A Bayesian  
continual -reassessment  method per Neuenschwander  et al 2008 
(N-CRM) model will be used for dose escalation.  The N -CRM 
will model the starting dose for the remainder of the escalation using the run- in data. For the remainder of Part 1 of the study,  
4 patients  will be enrolled  as a cohort  at each dose level predicted  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  18  
 by the N-CRM  model.  If no DLT  is observed in the single -subject 
run-in phase at 180 mg/m2, the single -subject run -in phase will 
end and the next cohort will enroll 4 patients at 180 mg/m2. 
On Day 1 of each cycle,  patients  will receive NC-6004 over 
1 hour (+10- minute window) followed by an infusion of 
gemcitabine 1250 mg/m2 over 30 minutes. All patients will  
receive gemcitabine 1250 mg/m2 alone  on Day 8 of each cycle. In 
Part 1, patients will continue to receive treatment until they 
experience disease progression, experience unacceptable toxicity 
(UT), or withdraw voluntarily. If the investigator and the patient request continuation of NC -6004 administration until progressive 
disease or until the drug is no longer tolerated (whichever occurs first),  the sponsor  may agree  to supply the drug after discussion of 
the request with the investigator.  
In subsequent  cohorts, the NC-6004 dose will be increased in  
15 mg/m
2 increments based  on the toxicity  profile  of the previous 
cohort. The dose -toxicity relationship will be re -evaluated at the 
completion of the first treatment cycle in each cohort until the MTD is identified. At any time, in the absence of an MTD from the N-CRM  model, NanoCarrier can recommend  a RPII  dose less 
than or equal to the maximum administered dose based on efficacy, full safety, and/or pharmacokinetic (PK) data.  
Part 2 of the study (Phase  2 portion)  will begin after the RPII  dose 
of NC-6004 is identified  for use in combination  with gemcitabine. 
All patients will receive NC -6004 at the RPII dose (135 mg/m
2, 
established in Part 1) in combination with gemcitabine  
1250 mg/m2 by the same regimen  as in Part 1. 
Three cohorts of patients are eligible (Cohort 1: first- line 
metastatic squamous NSCLC; Cohort 2: first -line metastatic or 
locally advanced cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract cancer); and Cohort 3: first -line 
metastatic  or locally  advanced TCC of the urinary tract (bladder 
cancer). Bladder cancer patients in Cohort 3 of Part 2 will be stratified by  ≥30 to <60 mL/min and/or ECOG PS 2 (unfit) and 
≥60 mL/min  and ECOG 0 to 1 (fit).  If 2 of 6 patients  (or ≥33%  at 
any point  during the study)  in the ≥30 to <60 mL/min  group have 
a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least 1 week  apart),  then enrollment 
of patients with CrCl <60 mL/min will stop in the bladder cancer cohort.  
Part 2 will enroll up to 50 patients  each in Cohorts 1 and 2, and  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  19  
 up to 60 patients  (ie, 30 unfit  and 30 fit patients)  in Cohort  3, for a 
total of up to 160 patients in Part 2.The primary endpoint (PFS) 
will be continuously updated and compared with the historical PFS from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard model will be updated as PFS data accrue. A  hazard ratio (HR) for PFS for each cohort versus 
historical control will be obtained.  
 
 
Cohort  Biliary  Bladder 
(CrCl:  
≥60 
mL/min and ECOG  PS
 
0-1; fit) Bladder 
(CrCl:  
≥30 to  
<60 
mL/min and/or ECOG PS 2;  
unfit)  Squamous 
NSCLC 
Historical Median Duration  of 
PFS 8.8 months  7.6 
months  5.8 
months  5 months  
Historical 
PFS 
Weekly 
Hazard  0.01795  0.020755  0.02711  0.031377  
Abbreviations: CrCl, creatinine clearance; ECOG, Eastern Cooperative 
Oncology  Group;  NSCLC,  non-small  cell lung cancer;  PS, performance  status.  
 
Once  10 PFS events  have  been  observed, interim  analyses will be 
performed every 6 weeks. At each interim and at the final 
analysis, there are 3 possible outcomes for each cohort.  
• Futility – 10 PFS events have been observed in each 
cohort  and at least 1 of the following  conditions  is true: 
• Probability  (Promising  HR*)  <0.4 
• Probability  (Phase 3 Success*)  <0.4 
• Success – 25 PFS events have been observed in each 50-patient  cohort  and 15 PFS events  in each 30-patient 
bladder cancer cohort and:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  20  
  
 • Probability  (Phase  3 Success*)  >0.8 
• Inconclusive  – neither  futility  nor success.  
*Phase 3 success is defined as success in a Phase 3 clinical trial 
with 381 events - enough to provide  80% power  to detect  an HR 
of 0.75. A promising HR is defined as one less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in that cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been observed in that 50-patient cohort (Cohort 1 and 2) or 30- patient bladder cancer 
cohort  (Cohort  3, fit and unfit),  respectively.  Accrual  will stop for 
any cohort identified as futile or successful at interim. The conclusion of this Phase 2 trial will be that a Phase 3 trial with 381 events should be conducted for each cohort that is a success.  
If any indication is declared a success, the combination of NC-6004 and gemcitabine  advances  to a Phase 3 randomized,  
controlled  trial with sample  size sufficient  to observe  381 events.  
After completion  of 6 cycles of treatment  (Cohorts  1 and 3) or 
8 cycles of treatment (Cohort 2), patients will have an  
End-of-Treatment visit, will be followed with scans every  
9 weeks until disease progression,  and will be contacted  for 
survival every 12 weeks by telephone. 
Patients who discontinue treatment and have not progressed will have  an End-of-Treatment  visit,  will be followed with scans  every 
9 weeks until disease progression, and will be contacted for survival every 12 weeks by telephone. Patients who discontinue treatment due to disease progression will have an  
End-of-Treatment  visit and be contacted  for survival  every 
12 weeks by phone. 
Estimated  Study 
Duration:  Part 1 of the study  will include  a screening  period  (up to 28 days); 
as many cycles until progressive disease or until the drug is no longer tolerated (whichever occurs first); tumor assessments for response and disease progression with scans every 6 weeks; and telephone calls for survival every 12 weeks. The cycles are  
21 days in duration.  
Part 2 of the study will include  a screening  period  (up to 28 days); 
6 treatment cycles (Cohorts 1 and 3) or 8 treatment cycles  
(Cohort 2) that are 21 days in duration; tumor assessments for response and disease progression with scans every 6 weeks; and telephone calls for survival every 12 weeks.  
Patients  will receive  study  treatment  until any  of the following  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  21  
  
 occur:  
• Progressive  disease is observed  (Part 1) or completion of 
6 cycles of treatment  (Part 2; Cohorts  1 and 3) or 8 cycles of 
treatment (Part 2; Cohort 2)  
• Unacceptable toxicity  experienced  
• Grade  4 liver enzyme  elevation  
• Withdrawal  of consent  
• Major  protocol  violation  
• Required treatment delay  >14 days (except  in case of potential 
patient benefit, then the duration of the delay is to be  
approved by the sponsor)  
• Symptoms  or an intercurrent illness not consistent  with the 
protocol requirements or that justifies withdrawal 
• For Cohort  3 only, unfit bladder  cancer  patient  (≥30 to 
<60 mL/min CrCl at screening) has a worsening of CrCl (ie, 
50% reduction from  baseline  for 2 consecutive  assessments,  at 
least 1 week apart)  
• Lost to follow -up 
• Other  (eg, pregnancy, development  of contraindications  of use 
of the study drug)  
• The investigator or sponsor  determines it is in the best interest 
of the patient to discontinue the patient’s participation in the 
study.  
Efficacy  Assessments:  Disease response assessment will occur every 6 weeks until 
disease progression and will include radiological assessments per 
RECIST  version 1.1 for ORR,  DCR,  PFS,  DOR,  and OS. Patients 
who have obtained a response (partial response or complete response)  will have  a confirmatory  scan at a minimum of 4 weeks 
following the initial scan. Data will be collected continuously  for 
OS while patients are receiving study drug. After the discontinuation or completion of treatment, patients without disease progression will be followed for progression with scans every 9 weeks and for survival (by telephone contact) every  
12 weeks.  
Quality of life will be assessed before treatment on Day 1 and Day 8 of each cycle  and at the End-of-Treatment  visit using the 
EORTC QLQ- C30. 
Symptoms  will be assessed  before  treatment on  Day 1 and Day 8 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  22  
  
 of each cycle  and at the End-of-Treatment  visit using  the core MD 
Anderson Symptom Inventory or the MDASI -lung cancer (Part 1 
only).  
Pharmacokinetic  or 
Pharmacodynamic 
Assessments:  The concentration- versus -time profile of micellar platinum in 
plasma and of total platinum  in plasma  and plasma  ultrafiltrate 
(ie, free platinum) will be determined in Part 1 and in Part 2.  
Part  1 Pharmacokinetic  Time  Points  
Pharmacokinetic plasma  and plasma  ultrafiltrate  samples  will be 
collected at the following times in Part 1:  
• Before  the start of the NC-6004 infusion on Day 1 of Cycles 1 
through 6  
• At the end of  NC-6004 infusion in Cycles  1, 3, and 5  
• After the start of NC-6004 infusion at Hours  3, 6, 12, 24 (Day 
2), 48 (Day 3), 96 (Day 5), 168 (Day 8, prior to gemcitabine  
infusion),  and 336 (Day  15) in Cycles 1, 3, and 5  
• At End-of-Treatment  visit 
Part  2 Pharmacokinetic  Time  Points  
Pharmacokinetic plasma  and plasma  ultrafiltrate  will be collected 
at the following times in Part 2 for up to 6 cycles:  
• Before  the start of the NC-6004 infusion on Day 1 
• At the end of NC-6004 infusion  
• Before  gemcitabine infusion  on Day 8 
• At End-of-Treatment  visit 
Safety  Assessments:  Adverse  events  will be evaluated  at each visit during  every  cycle 
and graded according to the NCI CTCAE version 4.03 dated June 14, 2010 (only abnormal laboratory results deemed to be clinically significant will be recorded as  AEs or SAEs).  
Hematology and coagulation and biochemistry tests will be performed at screening  and on Days 1, 8, and 15 of  each cycle 
(before  any study drug infusions), and at the End-of-Treatment 
visit. Urinalyses will be performed at screening and at the  
End-of-Treatment visit. A 12 -lead electrocardiogram will be 
performed  at screening,  before  and at various  time points  after 
NC-6004 infusions in selected cycles, before and after 
gemcitabine infusions in selected cycles, and at the 
End-of-Treatment  visit.  Physical  examinations  will be performed 
and vital signs will be measured at screening, before the start of 
treatment on Day 1 of each cycle (or can be completed on  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  23  
  
 Day -1), and at the End-of-Treatment  visit.  Additionally,  on Day 1 
of Cycle 1, vital signs will be measured before the start of the  
NC-6004 infusion, every 20 minutes during the infusion, at the 
completion  of the infusion, and 1 hour after the completion  of the 
infusion. Starting in Cycle 2, vital signs will be measured before 
the NC- 6004 infusion and at the completion of the NC -6004 
infusion on Day 1 of each cycle. Vital signs will be measured before and after gemcitabine infusion on Day 8 of each cycle. Audiometry will be performed  at screening  and only as clinically 
indicated before treatment on Day 1 of each cycle and as clinically indicated at the End -of-Treatment visit.  
Nausea severity  and vomiting  incidence  will be assessed  and 
recorded using a patient diary.  
Definition  of DLT A DLT (monitored  in Part 1 only)  is defined  as the following 
treatment- related AEs or laboratory abnormalities, graded 
according to NCI CTCAE version 4.03:  
• Grade  3 or 4 febrile  neutropenia  or neutropenic  infection  
• Grade  4 neutropenia  of duration longer  than 7 days and 
unresponsive to growth factor support per institutional guidelines or American Society of Clinical Oncology guidelines  
• Grade  4 thrombocytopenia  
• Grade  3 thrombocytopenia  with clinically  significant  bleeding 
or Grade 3 thrombocytopenia requiring a platelet transfusion  
• Grade  4 life-threatening  anemia 
• Grade 3 or Grade 4 nonhematological toxicity (excluding 
alopecia and Grade 3 nausea, vomiting, diarrhea, and 
electrolyte imbalances lasting less than 48 hours or with suboptimal  prophylactic  and suboptimal  curative  treatment)  
• Grade  3 nausea,  vomiting, diarrhea,  or electrolyte imbalances 
lasting  greater  than  48 hours  despite  optimal  prophylactic  and 
curative treatment  
• Grade 4 vomiting, diarrhea, or electrolyte imbalances (life-threatening  consequences)  of any duration despite 
optimal prophylactic and curative treatment  
• ≥Grade 3 hypersensitivity reaction  
• Dosing delay  >14 days  due to toxicity  
Study  Drug,  Dosage,  NC-6004  is provided in  vials of  5 mL  containing  the equivalent of 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  24  
  
and Route of 
Administration:  50 mg cisplatin.  After  the administration  of premedications,  
NC-6004 should be mixed with 500 mL  of 5% dextrose solution. 
Saline must not be used for any dilution of NC -6004 before 
infusion  because  cisplatin  is released  easily  from  the micelle  in 
the chloride -rich environment. Saline must not be used for 
flushing infusion lines immediately before or immediately 
after NC -6004 administration.  
In each part of the study, NC -6004 will be administered  as a 
1-hour (+10 -minute window) intravenous infusion on Day 1 of 
each cycle.  The potential  dosage  levels of NC-6004 in this study 
include 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, and 240 mg/m
2. A full safety review of all AEs for all cycles as 
well as an optional PK analysis will be conducted by the investigators, the Medical Monitor, and NanoCarrier before increasing the NC -6004 dose beyond 240 mg/m
2. Gemcitabine 
1250 mg/m2 will be administered as a 30 -minute intravenous 
infusion  on Day 1 after the completion  of the NC-6004 infusion. 
Gemcitabine 1250 mg/m2 will also be administered as a  
30-minute  intravenous  infusion  on Day 8. The duration of each 
cycle will be 21 days. 
Dose  Escalation 
Design:  A Bayesian continual reassessment method per Neuenschwander  
et al 2008 (N-CRM) model is used for dose escalation and 
determination of MTD. The initial NC -6004 dose for evaluation 
will be 60 mg/m2. Sequential  doses  selected  for evaluation are 75, 
90, 105, 120, 135, 150, 165, 180, 195, 210, 225, and 240 mg/m2. 
The dose -escalation part of the trial will begin with a 
single -patient  run-in phase.  In the run-in, 1 patient  will be 
enrolled sequentially at each dose level until a DLT is observed. Dose escalation in the run -in phase will only  occur after a patient 
at a given dose level  has experienced a DLT  or has completed  the 
first cycle. The N -CRM will model the starting dose for the 
remainder of the escalation using the run- in data. For the 
remainder  of the escalation,  4 patients  will be enrolled  as a cohort 
at each dose level predicted by the N -CRM model. For the 
remainder of Part 1 of the study, dose escalation will only occur after all patients in a cohort have either experienced a DLT or completed the first cycle. If no DLT is observed in the  
single -subject  run-in phase  at 180 mg/m
2, the single -subject  
run-in phase  will end and the next cohort  will enroll  4 patients  at 
180 mg/m2. 
Sample  Size:  Up to 49 patients  with solid  tumors  will be enrolled  in Part 1 of 
the study.  Simulations  were  performed  assuming  scenarios  with 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  25  
  
 different  dose-toxicity  relationships.  The associated  mean  sample 
size in these scenarios ranged from 17.22 patients to 
25.79 patients.  
Part 2 is a 3 -cohort study with an overall sample size of up to 
160 patients with no more  than 50 patients each in Cohorts 1 and 
2 and no more than 60 patients in Cohort 3 (30 unfit and 30 fit 
bladder  cancer  patients).  The total sample  size will depend on the 
results of interim futility and superiority analyses. In order to evaluate the overall sample size, simulations were performed assuming scenarios with different HRs for PFS for each cohort compared with historical control and different sample sizes for a subsequent Phase 3 clinical trial. The associated mean sample size for this trial in these scenarios ranged from 92.7 to  
116.8 patients.  
Patients  who receive study  drug will not  be replaced.  
Statistical  Methods:  Ninety -five percent confidence intervals may be calculated for 
selected safety  and exploratory variables. Dose escalation will be 
based on the N -CRM model and the incidence of DLTs.  Adverse 
events and serious  AEs will be tabulated by system organ class 
and preferred  term. Laboratory  test results after the first dose will 
be summarized with regard to shifts from baseline values and the grade per NCI CTCAE version 4.03. Overall survival, PFS, and DOR will be summarized using Kaplan -Meier methods. The 
ORR and DCR will be summarized  and 95% confidence  intervals 
for both wi ll be created.  
In Part 2, the following posterior probabilities will be derived using a Bayesian  model  updated every  6 weeks after 10 PFS have 
occurred within a cohort:  
• Probability  (Promising  HR) 
• Probability  (Phase 3 Success)  
If any cohort at interim or final analyses has a probability 
(success in a Phase 3 trial with 381 PFS events) >0.8, that 
indication will be declared a success, and the combination of NC-6004 and gemcitabine advances to a Phase 3 randomized, 
controlled  trial with a sample  size sufficient to observe  381 PFS 
events.  
Date  of Protocol:  13 March  2017  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  26  
 List of Abbreviations 
 
Abbreviation  Definition  
ADL  activities  of daily  living  
AE adverse  event  
AI accumulation  index 
ALK  anaplastic  lymphoma  kinase  
ASCO  American  Society  of Clinical Oncology  
AUC 0-τ area under  the concentration -time curve  from  time zero to the end of the 
dosing interval  
AUC last area under  the concentration- time curve  from  time zero to the last 
quantifiable concentration  
AUC 0-∞ area under  the concentration -time curve  from  time zero to infinity  
BSA  body  surface  area 
CFR Code  of Federal Regulations  
CL clearance  
Cmax maximum  concentration  
CR complete  response  
CRA  clinical  research  associate 
CrCl  creatinine  clearance  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
DCR  disease  control  rate 
DLT  dose-limiting  toxicity  
DOR  duration of response  
ECG electrocardiogram  
ECOG  Eastern  Cooperative  Oncology  Group  
eCRF  electronic  case report  form 
EDC electronic  data capture  
EGFR  epidermal  growth factor  receptor  
EMA  European  Medicines  Agency  
EORTC  QLQ -C30 European  Organisation  for Research  and Treatment  of Cancer  Quality 
of Life Questionnaire -Core 30  
FAS Full Analysis  Set 
FDA  Food  and Drug  Administration  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  27  
  
Abbreviation  Definition  
GCP  Good  Clinical  Practice  
HR hazard  ratio 
ICF informed  consent  form 
ICH International  Council  for Harmonisation  
IEC independent  ethics  committee  
IRB institutional  review  board  
λz terminal elimination  phase rate constant  
MDSAI  MD Anderson  Symptom  Inventory  
MDSAI -LC MD Anderson  Symptom Inventory  module  specific  for lung cancer  
MRT  mean  residence  time 
MTD  maximum -tolerated  dose 
NCI National  Cancer  Institute  
N-CRM  Bayesian  continual  reassessment  method  design  per Neuenschwander  et 
al 2008  
NSCLC  non-small cell lung cancer  
ORR  overall  response rate 
OS overall  survival  
PEG-pGlu  polyethylene glycol -polyglutamate copolymer, also written as α - 
(methoxy- ω-aminopropyl, polyethylene  glycol) -block- poly(sodium 
L-glutamate) copolymer  
PFS progression- free survival  
PK pharmacokinetic  
PR partial  response  
PS performance  status  
QoL quality of life 
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
RPII recommended  Phase  2 
SAE serious  adverse  event  
SAP statistical  analysis  plan 
SD stable disease 
T½ terminal  half-life 
TCC  transitional  cell carcinoma  
TEAE  treatment -emergent  adverse  event  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  28  
  
Abbreviation  Definition  
Tmax time to maximum concentration  
ULN  upper  limit of  normal  
UT unacceptable  toxicity  
VHP  Voluntary  Harmonisation  Procedure  
Vss volume  of distribution  at steady -state 
Vz volume  of distribution  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  29  
 1 Introduction 
Platinum compounds are well established agents in the treatment of cancer ( Kelland  and 
Sharp 1999). The leading platinum compounds in cancer chemotherapy are cisplatin, 
carboplatin, and oxaliplatin. They share a number of common structural chemical 
characteristics;  however,  they exhibit  marked  interanalogue  differences in pharmacokinetics, 
adverse effect profiles, and optimal therapeutic indication.  
Cisplatin has been widely used for the treatment of cancer including lung cancer (both small 
cell and non -small cell lung cancer [NSCLC]), head and neck cancer, germ -cell tumors 
(testicular, ovarian, and extragonadal germ cell tumor), ovarian cancer, testicular tumor, bladder  cancer,  renal  pelvis/ureter  tumor,  prostate  cancer,  esophageal cancer,  cervical  cancer, 
neuroblastoma, stomach cancer, osteosarcoma, and pleura malignant mesothelioma in monotherapy and including malignant bone tumor, endometrial cancer (adjuvant 
chemotherapy and chemotherapy for metastasis/recurrence), recurrent/refractory malignant 
lymphoma, and pediatric malignant solid tumor (rhabdomyosarcoma, neuroblastoma, 
hepatoblastoma and other primary malignant liver tumor, and medulloblastoma) in combination  therapy. The mechanism  of action  of cisplatin  is the inhibition of DNA synthesis 
induced by the platinum -DNA adduct formed by cross -linking between cisplatin and specific 
base sequences. This cross- linking inhibits DNA  replication and transcription and activates 
signal transduction pathways leading to apoptosis and cell death ( Pinto  and Lippard 1985).  
As described above, cisplatin- based regimens represent the mainstay of treatment in a 
number of indications; however, its use is associated with irreversible ototoxicity and renal toxicity, which necessitates the use of pre -hydration regimens using mannitol and excludes  
its use in patients  with less than normal  renal  function. Continuous  administration  of cisplatin 
is associated  with neurotoxicity, myelotoxicity, and gastrointestinal  toxicity, including  nausea 
and vomiting. Decreased appetite, alopecia, and general disorder such as fatigue, which are common toxicological features of platinum compounds affecting patient’s quality of life 
(QoL), are also associated with cisplatin therapy ( Hartmann  and Lipp 2003).  
Nonclinical  studies  have indicated that NC-6004 (1) is preferentially  distributed  to tumors,  
(2) demonstrates  significantly  lower  toxicity  compared  to cisplatin  at an equivalent  dose, and 
(3) has increased  antitumor activity  (Uchino et al 2005).  Preferential tumor accumulation  of 
polymer  micelles  with an average diameter  of 30 nm can be explained by the mechanism  of 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  30  
 the enhanced permeability and retention effect, characterized by marked vascular 
hyperpermeability to the circulating macromolecular carrier ( >40 kilodalton) and impaired 
lymphatic drainage in the tumor ( Matsumura  and Maeda 1986 ). Furthermore, polymer 
micelles successfully avoid glomerular filtration (threshold diameter of 8 nm), and the 
hydrophilic outer shell composed of polyethylene glycol greatly extends the circulation time 
of micelles  by preventing the micelles  from being  captured  by the reticuloendothelial system, 
enhancing the specific tumor accumulation. These micelles progressively break down in the 
presence of chloride to release cisplatin and the copolymer. The cytotoxic activity of 
NC-6004 is considered  to be exerted  by the formation  of cellular  DNA adducts with released 
cisplatin. The slow release of cisplatin from NC -6004 achieves a long-period systemic 
exposure to cisplatin,  leading to its continuous antitumor effect  with a toxicity  profile  similar 
to that of cisplatin.  
Results of in vitro  cytotoxicity  studies  of NC-6004 in combination  with gemcitabine,  showed 
a synergistic effect in MOR/CPR cisplatin -refractory lung adenocarcinoma, MDA- MB-231 
breast adenocarcinoma, LS174T colon adenocarcinoma, and BxPC -3 pancreas 
adenocarcinoma cells; and an additive effect was observed in K562 chronic myelogenous 
leukemia, HT1376 bladder carcinoma, HepG2 hepatocellular carcinoma, and NCI-N87 
gastric carcinoma cells. In in vivo studies of NC-6004 in combination with gemcitabine, 
significant antitumor effects were observed in MDA -MB-231, MOR/CPR, BxPC- 3, and 
PC-3 prostate cancer  xenograft models. 
 
The results of a Phase 1 study of NC-6004 as monotherapy in patients with solid tumors (Study NC-6004-001) suggested that NC-6004 monotherapy has potential activity for the treatment of solid  tumors.  The pharmacokinetic (PK)  analysis  indicated  prolonged circulation 
of NC-6004 in the blood and delayed and sustained release of the potentially active platinum species, cisplatin, after the administration of NC -6004 ( Plummer et al 2011).  
In the first part of the Phase 1/2 study  performed  in Asia in patients  with pancreatic cancer 
(Study NC-6004- 002), NC -6004 and gemcitabine combination therapy exhibited an 
improved efficacy profile with prolonged administration period compared to that in  
Study NC-6004-001. Although, this is partly due to the aggressive prophylactic regimen for 
hypersensitivity reactions,  NC-6004 is well tolerated  even  in combination with gemcitabine, 
and further clinical results are anticipated.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  31  
 Based  on these results,  it is concluded that further clinical study  should proceed aiming  at the 
development of a new micelle formulation of cisplatin for out- patient- based therapy without 
serious toxicity.  
This study will determine the maximum tolerated dose (MTD) and recommended Phase 2 
(RPII) dose of NC -6004 in combination with gemcitabine and evaluate the activity, safety, 
and tolerability  of NC-6004 in combination with gemcitabine  in patients  with advanced solid 
tumors and first -line metastatic squamous NSCLC; first- line metastatic or locally advanced 
cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract cancer); and  
first- line metastatic or locally  advanced transitional cell carcinoma  (TCC)  of the urinary  tract 
(bladder cancer). The study will also evaluate the overall response rate (ORR), disease 
control rate (DCR), duration of response (DOR), progression -free survival (PFS), overall 
survival (OS), QoL, and therapy -related adverse events (AEs). In addition, the study will 
assess the PK and pharmacodynamic effects of NC -6004. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  32  
 2 Study Objectives  
2.1 Primary  Objectives 
The primary  objectives  of this study are: 
 
• In the dose-escalation  phase of the study (Part  1), to determine  the dose-limiting  toxicities 
(DLTs), MTD, and RPII dose of NC -6004 in combination with gemcitabine;  
• In the expansion phase of the study (Part 2), to evaluate the activity of NC -6004 in 
combination with gemcitabine in patients with first- line Stage IV squamous NSCLC, 
first- line advanced or metastatic biliary tract cancer, and first -line metastatic or locally 
advanced bladder cancer compared with historical control as measured by local 
investigator/radiologist- assessed  progression -free survival  (PFS),  according  to Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.  
 
2.2 Secondary Objectives  
The secondary objectives  of this study are: 
 
• To evaluate  ORR,  DCR (DCR = complete  response [CR]  + partial  response [PR]  + stable 
disease [SD]), DOR, PFS, and OS  
• To evaluate therapy- related  AEs 
• To evaluate  the safety  and tolerability  of NC-6004 when combined with gemcitabine  
• To evaluate QoL using the European  Organisation  for Research  and Treatment  of Cancer 
Quality of Life Questionnaire -Core 30 (EORTC QLQ- C30)  
• To evaluate acute and delayed symptoms  using the MD Anderson Symptom  Inventory 
(MDASI) and a nausea and vomiting patient diary  
 
2.3 Exploratory Objectives  
The exploratory objectives  of this study  are: 
 
• To assess the PK and pharmacodynamic  effects of NC-6004  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  33  
 3 Investigational  Plan  
3.1 Study Design  
This study will consist of 2 parts; Part 1 is a Phase 1b, continual reassessment method 
dose-escalation trial in patients with any advanced solid tumor, and Part 2 is a Phase 2, 
adaptive,  open -label,  expansion trial in patients  with squamous  NSCLC,  biliary  tract,  and 
bladder  cancer  evaluating  activity,  safety,  and tolerability  at the RPII  dose identified  in Part 1. 
 
In Part 1, patients  will receive intravenous  infusion of NC-6004 and gemcitabine  in 3-week 
treatment cycles. NC -6004 will be administered on Day 1 of each cycle and gemcitabine 
1250 mg/m2 will be administered on Day 1 of each cycle (after the administration of  
NC-6004)  and on Day 8 of each cycle.  Patients  will be treated  until disease  progression. If 
the investigator and the patient request continuation of NC -6004 administration until 
progressive disease or until the drug is no longer tolerated (whichever occurs first), the 
sponsor may  agree to supply the drug after discussion of the request with the investigator.  
A Bayesian  continual -reassessment  method per Neuenschwander  et al 2008 (N-CRM)  model 
will be  used for  dose escalation and determination of  MTD  (as described in Section 6.3.1.2). 
The initial NC -6004 dose for evaluation will be 60 mg/m2. Sequential doses selected for 
evaluation are listed in Table 3 -1. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  34  
 Table  3-1 Dose  Levels  of NC-6004  
 
Dose  Level  Name  NC-6004 Dose  Level  (mg/m2) 
1 60 
2 75 
3 90 
4 105 
5 120 
6 135 
7 150 
8 165 
9 180a 
10 195 
11 210 
12 225 
13 240b 
a If no DLT  is observed in the single -subject  run-in phase  at 180 mg/m2, the single -subject  run-in phase  will 
end and the next cohort will enroll 4 patients at 180 mg/m2. 
b A formal  review  by the safety  committee will  take place to decide if the dose can be increased  beyond 
240 mg/m2. 
 
Part 1 will begin with a single -patient run- in phase. In the run -in phase, 1 patient will be 
enrolled sequentially  at each  dose level of  NC-6004 until a  DLT  is observed. Dose  escalation 
in the run-in phase  will only occur  after a patient  at a given dose level  has experienced  a DLT 
or has completed the first cycle. The N -CRM will model the starting dose for the remainder 
of Part 1 using the run- in data. For the remainder of Part 1, 4 patients will be enrolled as a 
cohort at each dose level as predicted by the N -CRM model. The N -CRM model may enroll 
the next cohort at the previous dose level, the current dose level, or the next dose level. The 
N-CRM model will only be updated after all patients in a cohort have either experienced a 
DLT  or completed the first cycle. If no DLT  is observed in the single -subject run- in phase at 
180 mg/m2, the single -subject run -in phase will end and the next cohort will enroll 4 patients 
at 180 mg/m2. 
Once the MTD (or RPII dose) of NC -6004 is identified, dose escalation within Part 1 will 
cease.  Patients  in Part 1 who were  not assigned  to the NC-6004 dose identified  as the RPII 
dose will continue treatment cycles at their assigned dose level.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  35  
 Part 2 of the study (Phase 2 portion) will begin after the RPII dose of NC -6004 is identified 
for use in combination with gemcitabine.  All patients will receive NC -6004 at the RPII dose 
(135 mg/m2, established  in Part 1) in combination  with gemcitabine  1250 mg/m2 by the same 
regimen as in Part 1. Cohort 3 will stratify patients by creatinine clearance (CrCl) to assess 
study drug in patients with reduced kidney function (ie, CrCl of ≥30 to <60 mL/min [unfit] 
and ≥60 mL/min [fit]) in a controlled manner and with the stipulation that enrollment will 
stop if 2 of 6 patients in the ≥30 to <60 mL/min group have a worsening of CrCl (ie, 50% 
reduction from baseline for 2 consecutive assessments, at least 1 week apart).  
Three cohorts of patients are eligible (Cohort 1: first- line metastatic squamous NSCLC; 
Cohort  2: first-line metastatic or locally  advanced  cholangiocarcinoma, gallbladder  cancer,  or 
ampullary  cancer  [biliary  tract cancer];  and Cohort  3: first-line metastatic  or locally  advanced 
TCC of the urinary tract [bladder cancer]). Part 2 will enroll up to 50 patients each in  
Cohorts 1 and 2 and up to 60 patients (ie, 30 unfit and 30 fit bladder cancer patients) in Cohort 3, for a total of up to 160 patients in Part 2. The primary endpoint (PFS) will be continuously updated and compared with the historical PFS from Phase 3 pivotal cisplatin  
and gemcitabine  trials  within  each cohort. The PFS hazard  model  will be updated as PFS data 
accrue.  A hazard  ratio (HR)  for PFS for each cohort  versus historical control  will be obtained.  
 
Cohort  Biliary  Bladder 
(CrCl: ≥60 mL/min  and 
ECOG  
PS 0-1; fit) Bladder (CrCl:  ≥30 
to 
<60 mL/min 
and/or ECOG  PS 2; 
unfit)  Squamous NSCLC 
Historical Median Duration  of 
PFS 8.8 months  7.6 months  5.8 months  5 months  
Historical 
PFS Weekly 
Hazard  0.01795  0.020755  0.02711  0.031377  
Abbreviations:  CrCl:  creatinine  clearance;  ECOG,  Eastern  Cooperative  Oncology Group; 
NSCLC, non -small cell lung cancer; PS, performance status.  
 
Once  10 PFS events  have  been  observed, interim analyses will be performed  every  6 weeks. 
At each interim and at the final analysis, there are 3 possible outcomes for each cohort.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  36  
 • Futility  – 10 PFS events  have  been  observed  in each cohort  and at least 1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
• Probability  (Phase 3 Success*)  <0.4 
 
• Success – 25 PFS events  have  been  observed in each 50-patient  cohort  and 15 PFS 
events in each 30- patient bladder cancer cohort and:  
• Probability  (Phase 3 Success*)  >0.8 
• Inconclusive  – neither  futility  nor success.  
*Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events -  enough to 
provide  80% power  to detect  an HR of 0.75. A promising  HR is defined as one  less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in that 
cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been observed in that 50 -patient cohort (Cohort 1 and 2) or 30- patient bladder cancer cohort 
(Cohort  3, fit and unfit),  respectively.  Accrual  will stop for any cohort  identified  as futile  or 
successful at interim. The conclusion of this Phase 2 trial will be that a Phase 3 trial with 
381 events should be conducted for each cohort that is a success.  
If any indication is declared a success, the combination of NC -6004 and gemcitabine 
advances to a Phase 3 randomized, controlled trial with sample size sufficient to observe 
381 events.  
In Part 1, patients  will continue  to receive treatment  until they experience  disease progression. 
The maximum number of cycles a patient undergoes is at the discretion of the investigator 
and depends on response as described in the 
American Society of Clinical Oncology (ASCO) 
guidelines ( Azzoli  et al 2011). Patients who complete 4 or more cycles will be considered as 
having completed the treatment. Subject to sponsor approval, individual patients will be 
treated until progressive disease. If the investigator and the patient request continuation of 
NC-6004 administration until progressive disease or until the drug is no longer tolerated 
(whichever occurs first), the sponsor may agree to supply the drug after discussion of the request  with the investigator.  In Part 2, patients  will continue  to receive treatment for up to 
6 cycles (Cohorts 1 and 3) or 8 cycles (Cohort 2).  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  37  
 After progressive  disease  is observed (Part 1) or the completion of 6 cycles (Part 2; Cohorts  1 
and 3) or 8 cycles (Part 2; Cohort 2), patients will have an End- of-Treatment visit, will be 
followed with scans every 9 weeks until disease progression, and will be contacted for 
survival every 12 weeks by telephone. Patients who discontinue treatment and have not 
progressed will have an End- of-Treatment visit, will be followed with scans every 9 weeks 
until disease progression, and will be contacted for survival every 12 weeks by telephone. 
Patients  who discontinue  treatment due to disease  progression will have  an End-of-Treatment 
visit and be contacted for survival every 12 weeks by phone. 
Disease assessment  will be performed  using RECIST version 1.1 (Eisenhauer  et al 2009)  and 
the same imaging method used at screening should be used for all subsequent assessments.  
Screening  Period  (Day  -28 to -1) 
 
The following procedures  will be performed  during the screening  period within  28 days prior 
to the first study treatment:  
• Signed informed  consent  can be obtained within  28 days of dosing and prior  to 
performing any study evaluations.  
• Disease assessment  will be evaluated  with a baseline scan (see Section  6.1.1 for imaging 
methods)  and should be performed  within  the 28 days before  the start of study treatment.  
Screening  Period  (Day  -14 to -1) 
The following procedures  will be performed  during the screening  period within  14 days prior 
to the first study treatment:  
• Assessment  of eligibility  criteria  
• Patient  demography  
• Medical  history  (to include  a complete  history  of all surgeries and significant  diagnoses)  
• Complete  history of all cancer  treatment  (including  surgery, radiation  therapy, 
chemotherapy, etc.)  
• Physical  examination  
• Height  and weight  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  38  
 • Vital sign measurements  
• Eastern  Cooperative  Oncology Group  (ECOG)  performance  status (PS) 
• Audiometry  
• Urinalysis  
• Cardiac risk factors (history of angina pectoris, coronary artery disease or 
cerebrovascular  accident,  transient  ischemic  attack,  cardiac failure  with known ejection 
fraction less than 40%, or cardiac arrhythmia requiring medical therapy)  
• Concomitant  medication  use (including prescription or over-the-counter  medication, 
herbal or naturopathic products) within the past 30 days  
Screening  Period  (Day  -7 to -1) 
 
The following procedures  will be performed  during the screening  period within  7 days prior 
to the first study treatment:  
• Pregnancy test (serum or urine,  only for women of childbearing potential)  
• Hematology  and coagulation 
• Biochemistry  
• 12-lead electrocardiogram (ECG)  
• Safety  assessments scheduled  for Day 1 (physical  examination, ECOG PS, and review  of 
AEs and concomitant medication use) can be completed on Day –1 (not to be conducted 
in place of screening assessments)  
Day 1 of Cycle  
 
The following procedures  will be performed  on Day 1 prior  to NC-6004 infusion in each 
treatment cycles unless otherwise specified:  
• Pregnancy test (serum or urine)  on Day 1 of each cycle (at Cycle  1, serum  or urine;  test is 
not required on Day 1 of Cycle 1 if pregnancy test at screening was performed using 
serum)  
• Physical  examination  (if not performed  on Day –1) 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  39  
 • Height, weight, and calculation  of body surface area using the Mosteller formula 
(Mosteller  1987)  
• Vital sign measurements  (For additional  vital sign assessments following  dosing, refer  to 
Section 6.3.8.)  
• ECOG  PS (if not performed on Day –1) 
• Disease assessment will be evaluated beginning in Cycle  3 and continuing through the 
remainder of  the treatment cycles every  6 (±1)  weeks (ie,  every  other  cycle),  and at  the 
End-of-Treatment visit or until disease progression  
• Audiometry (only as clinically  indicated)  
• Hematology  and coagulation 
• Biochemistry  
• EORTC QLQ- C30 
• Part 1 only:  Core  MDASI  or MDASI  module  specific for lung cancer  (MDASI -LC) 
(Section 6.1.3)  
o MDASI -LC will only be performed  by patients  with NSCLC in Part 1 and 
will not be performed in Part 2  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part 1 and only 
for 2 cycles in Part 2 of the study)  
• 12-lead ECG (For additional  ECGs  following  NC-6004 dosing, refer to Section  6.3.6.)  
• PK blood sample  collection  (For additional PK samples  following  dosing, refer  to 
Section 6.2 ) 
• Adverse events  (if not performed on Day –1) 
• Concomitant  medication  use (if not performed  on Day –1) 
• Prophylactic  administrations  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  40  
 Day 8 of Each Cycle 
 
The following procedures  will be performed  on Day 8 prior  to gemcitabine  infusion in each 
treatment cycle:  
• Vital signs  
• Hematology  and coagulation 
• Biochemistry  
• EORTC QLQ- C30 
• Part 1 only:  Core  MDASI  or MDASI -LC 
o MDASI -LC will only be performed  by patients  with NSCLC in Part 1 and 
will not be performed in Part 2  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part 1 and only 
for 2 cycles in Part 2 of the study)  
• 12-lead ECG  (at Cycle  1 only, for additional  ECGs  following  gemcitabine  dosing refer  to 
Section 6.3.6)  
• PK blood sample  collection  
• Adverse  events  
• Concomitant  medication  use 
Day 15 of Each  Cycle  (Part  1: required;  Part  2: if clinically  indicated) 
 
The following procedures  will be performed  on Day  15 in each treatment  cycle:  
 
• Hematology  and coagulation 
• Biochemistry  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part 1 and is 
not collected at Day 15 in Part 2 of the study)  
• PK blood sample collection  (Cycles 1, 3, and 5 of Part 1 only)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  41  
 • Adverse  events  
• Concomitant  medication  use 
End-of-Treatment  Visit 
 
The following procedures  will be performed  within  28 days after  treatment discontinuation:  
 
• Pregnancy test (serum or urine)  
• Physical  examination  
• Vital sign measurements  
• ECOG  PS 
• Disease assessment  if scan has not previously shown  disease progression  
• Audiometry (only as clinically  indicated)  
• Hematology  and coagulation 
• Biochemistry  
• Urinalysis  
• EORTC QLQ- C30 
• Part 1 only:  Core  MDASI  or MDASI -LC 
• 12-lead ECG  
• PK blood sample  collection  
• Adverse  events  (All AEs will be followed  until it meets criteria  outlined in 
Section 6.3.2.6.)  
• Concomitant  medication  use 
Follow -Up 
 
Patients  who complete  treatment  or discontinue  treatment  without  disease  progression  will 
continue to be followed until disease progression with scans every 9 weeks. Following 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  42  
 disease  progression, patients  will be contacted  by telephone  every  12 (±1) weeks to collect 
the following data:  
• Survival  
• Adverse  events  (All AEs will  be followed  until resolution, Section  6.3.2.6 ) 
• New treatments  (targeted  therapy or chemotherapy used after study disease  progression 
and treatment completion) 
 
3.1.1 Rationale  of Study Design  
NC-6004 is a polymeric micelle containing cisplatin as an active moiety. The nanoparticle 
provides sustained release of the cisplatin and utilizes the enhanced permeability -retention 
effect to target the release of platinum to tumors. Synergistic effects of cisplatin and 
gemcitabine have been evaluated extensively in various types of tumor cell lines, including 
NSCLC cell lines, and nonclinical studies have demonstrated that, in tumors in which the 
combination  of cisplatin  and gemcitabine  exhibit  synergistic  effects,  the combined effects of 
NC-6004 and gemcitabine are synergistic.  
This study will determine the DLTs, MTD, and RPII of NC -6004 in combination with 
gemcitabine  in patients  with advanced solid  tumors  and first- line Stage  IV squamous  NSCLC, 
first- line advanced or metastatic biliary tract cancer, and first -line metastatic or locally 
advanced bladder cancer for use in future efficacy studies. The initial dose level in this study 
was selected as 60 mg/m2 based on the dose escalation and extension trial  
(Study NC-6004- 002) where  NC-6004 and gemcitabine  were  administered  to Asian  patients 
with pancreatic cancer. In Study NC -6004- 002, the MTD and recommended dose of  
NC-6004 were  determined  to be 120 mg/m2 and 90 mg/m2, respectively,  and the gemcitabine 
dose was 1000 mg/m2 × 2, one week apart, every 3 weeks for pancreatic cancer, whereas in 
the current study in the United States the gemcitabine dose is 1250 mg/m2 × 2, one week 
apart, every 3 weeks. Based upon these differences, as well as consideration of the 
differences in demographics between an Asian and a United States population, it is 
determined that the starting dose of NC -6004 in the current study should be one -half of the 
MTD and two -thirds the recommended dose determined in Study NC -6004- 002. 
Dose escalation of subsequent cohorts will be performed at 15 mg/m2 increments to more 
precisely  identify  the actual  MTD  than has been  performed  in previous  clinical  trials.  Dose  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  43  
 escalation in this study will follow an N -CRM which models the relationship between 
toxicities  and dose level.  This methodology allocates the fewest  number  of patients  to doses 
with unacceptable toxicities and, based on our modeling, is better at identifying the correct 
MTD compared to a traditional 3 + 3 trial design.  At any time, in the absence of an MTD 
from the N -CRM model, NanoCarrier can recommend a RPII  dose less than or equal to the 
maximum administered dose based on efficacy, full safety, and/or PK data. 
The study will evaluate the safety and tolerability of NC -6004 in combination with 
gemcitabine in these patients by assessment of therapy -related  AEs (particularly DLTs). 
These events are commonly  associated  with cisplatin  therapy and the intent  of this design  is 
to assess the frequency of these events using nanoparticle technology in comparison to 
historical data of cisplatin  therapy. The study will also evaluate  tolerability  by assessing  the 
severity of nausea and incidence of vomiting, commonly associated with cisplatin therapy, using a patient diary designed specifically for this purpose.  
The study will also evaluate the activity  of NC-6004 in combination with gemcitabine  in 
terms of ORR, DCR, DOR, PFS, and OS. These are standard parameters for evaluating 
cancer chemotherapies.  
The EORTC  QLQ- C30 will be used to evaluate  QoL.  The EORTC QLQ -C30 is a QoL 
questionnaire specific for cancer patients. It has been translated and validated into  
81 languages  and has been  used in more  than 3000 studies worldwide.  
 
The MDASI is a multisymptom patient- reported outcome measure for clinical and research 
use. In Part 1 only, the MDASI will be used to evaluate symptoms related to QoL  during 
treatment. The MDASI’s 13 core symptom items include those found to have the highest 
frequency  and/or severity in patients with various cancers and treatment types.  The MDASI 
has several advantages over other symptom -assessment scales in that it applies broadly 
across cancer  types  and treatments,  is easy for patients  to complete,  includes  items  related  to 
symptom interference with daily life, and it is easily translated into other languages. The MDASI -LC questionnaire is designed specifically for patients with lung cancer and will be 
used by patients with NSCLC in Part 1 of this study. 
This clinical trial will also assess the pharmacokinetics of NC -6004 in terms of micellar 
platinum  and total platinum  to determine  the pharmacodynamic  relationships  for both of 
these forms of circulating platinum.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  44  
 4 Patient Selection and Withdrawal  Criteria  
4.1 Selection  of Study Population  
Approximately 209 patients  (up to 49 patients  in Part 1 and up to 160 patients  in Part 2) will 
be enrolled  in at least 20 sites in the United  States  and Europe. Patients will be assigned  to a 
study treatment only if they meet all of the inclusion criteria and none of the exclusion 
criteria.  
 
4.1.1 Inclusion  Criteria  
Each  patient  must  meet  all of the following criteria  to be  enrolled  in this study:  
 
1. Provide  signed  written  informed  consent  prior  to the initiation  of any study -specific 
procedures.  
2. (Part 1 only) Have a histologically or cytologically confirmed diagnosis of advanced solid  tumor that has relapsed  or is refractory  to standard curative  or palliative  therapy or 
has a contraindication to standard therapy.  
 
(Part 2 only) Cohort  1: Have  histologically  or cytologically  confirmed  diagnosis of  
Stage  IV squamous  NSCLC and have  not received  prior chemotherapy or immunotherapy 
for metastatic disease and are not known to be PD -L1 positive (known high PD -L1 
expression defined as Tumor Proportion Score [TPS] greater than or equal to 50%).  
Patients  with known sensitizing  mutation  in the epidermal  growth factor  receptor  (EGFR) 
gene or anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up to 2 targeted therapies prior to enrollment. 
• A patient with stable, treated brain metastases is eligible, provided that 
there  is no evidence  of progression after treatment  and the patient  does not 
require corticosteroids, or, if the patient requires corticosteroid, has been 
receiving a stable dose of corticosteroids for at least 14 days prior to assignment to treatment.  
• Patients whose tumors are known to harbor an exon 19 deletion or 
exon 21 L858R EGFR mutation must have had intolerance or have 
progressed on at least 1 and up to 2 EGFR  tyrosine  kinase  inhibitors.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  45  
 • Patients  whose  tumors  are known to  harbor  an ALK translocation  must 
have had intolerance or have progressed on at least 1 and up to 2 ALK 
inhibitors.  
 
(Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of 
nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or 
extrahepatic cholangiocarcinoma, gallbladder  cancer,  or ampullary  carcinoma)  and have 
not received prior systemic anticancer therapy for advanced or metastatic disease.  
(Part 2 only) Cohort 3: Have histologically or cytologically confirmed diagnosis of 
metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter, renal 
pelvis)  (T3b -T4 N0 M0, Tany  N1-N3 M0, or Tany  Nany  M1) and are not candidates  for 
surgery.  
• Patients  must  not have  received  prior  treatment with systemic anticancer 
therapy for metastatic or locally advanced urinary tract cancer.  
• Certain  mixed  histologies  that are predominantly  (>50%)  TCC are eligible: 
squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated 
histology requires immunohistochemistry consistent with a TCC origin. Predominantly squamous or neuroendocrine tumors are excluded. 
 
3. Have  measurable disease per  RECIST  version 1.1. 
 
4. Are males  or females  aged  
≥18 years.  
 
5. Have  an ECOG PS of 0 to 1, with the exception of patients  in Part 2 (Cohort  3, unfit 
bladder cancer patients) who may have an ECOG PS of 2. 
6. Have  adequate bone  marrow  reserve  defined as: 
• Absolute  neutrophil  count of  at least 1.5  × 109/L, 
• Platelet count  of at least 100 × 109/L, and 
• Hemoglobin  level  of 10 g/dL  (transfusion  is allowed  to achieve  hemoglobin 
level of at least 10 g/dL).  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  46  
 7. Have  adequate  liver function  defined  as: 
• Total  serum  bilirubin  <1.5 × upper  limit  of normal  (ULN)  and 
• Baseline  alanine  transaminase,  and aspartate  transaminase <2.0 × ULN or, 
in patients with documented hepatic metastasis <5.0 × ULN and 
• Serum  albumin  ≥3.5 g/dL 
 
8. Prothrombin  time within  normal  limits  
 
9. In Part 1 and in Part 2 in Cohorts  1 and 2: have  adequate  renal function  defined  as a CrCl  
≥50 mL/min  (calculated  according  to the formula  of Cockcroft  and Gault  1976)  or serum 
creatinine <1.5 mg/dL. In Part 2, patients in Cohort 3 (bladder cancer) must have a CrCl 
of ≥30 mL/min.  
• Bladder  cancer  patients in  Cohort 3 of Part 2  will be  stratified by  ≥30 to  
<60 mL/min  and/or  ECOG PS 2 and ≥60 mL/min  and ECOG PS 0 to 1. If 
2 of 6 patients (or ≥33% at any point during the study) in the ≥30 to  
<60 mL/min  group have  a worsening of CrCl  (ie, 50% reduction from 
baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment of patients with CrCl <60 mL/min will stop in the bladder cancer cohort.  
 
10. Have  a negative  pregnancy  test result  at screening  (for females  of childbearing potential; 
not applicable to patients who are unable to become pregnant, including those with 
bilateral oophorectomy and/or hysterectomy or postmenopausal [no menses for the 
previous 12 months]). The test must be performed within 1 week before Day 1 of 
treatment.  
11. Male patients  must  agree  to use a condom  during treatment and for 90 days after dosing. 
Male patients must agree not to donate sperm for 90 days after dosing.  
12. For women  of childbearing potential*:  are willing  to follow  1 of the following  effective 
methods of birth control from the time of study entry to 6 months after the last day of 
treatment: 
• Combined (estrogen - and progestogen- containing)  hormonal  contraception  associated 
with inhibition of ovulation (oral, intravaginal, or transdermal)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  47  
 • Progestogen -only hormonal  contraception  associated  with inhibition  of ovulation 
(oral, injectable, or implantable)  
• Intrauterine  devices  
 
• Intrauterine  hormone -releasing  system  
 
• Vasectomized  partner  who has received  medical  assessment  of surgical  success  
 
• Bilateral tubal  occlusion  
 
• True  sexual  abstinence**  
 
*Patients not of childbearing potential include those who are surgically sterile or 
postmenopausal  (no menses for the previous  12 months). For women  not currently 
taking contraceptive methods at screening, low user -dependency contraceptive 
methods (eg, implantable progestogen- only hormonal contraception, intrauterine 
device, intrauterine hormone -releasing system, bilateral tubal occlusion, 
vasectomized partner) are recommended.  
**The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical  trial and the preferred  and usual  lifestyle  of the patient.  
 
13. Have  reasonably  recovered  from preceding major surgery as judged by the investigator  or 
have had no major surgery within 4 weeks prior to Day 1 treatment.  
4.1.2 Exclusion  Criteria  
Patients  meeting  any of the following  criteria will be  excluded  from the study:  
 
1. Have  received  prior  platinum  therapy  in the past 3 months  (Part 1) or 6 months  in the 
adjuvant or neoadjuvant setting (Part 2). 
2. Have  received  prior  cisplatin  and gemcitabine  concomitantly within  the last 6 months  or 
are refractory to cisplatin and gemcitabine.  
3. Are unable  to receive platinum -based  therapy due to  previous toxicity.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  48  
 4. Have  unresolved toxicity  from prior radiation, chemotherapy, or  other  targeted treatment, 
including investigational treatment, with the exception of alopecia and ≤Grade 1 
peripheral neuropathy according to the National Cancer Institute Common Terminology 
Criteria  for Adverse  Events (NCI  CTCAE)  version 4.03 ( National Cancer Institute  2010). 
Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening  is residual  toxicity  from  prior  treatment  or is a symptom  of the patient’s  general 
condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline toxicity  
5. Have  evidence suggesting pulmonary  fibrosis or interstitial pneumonia.  
 
6. Have a history of thrombocytopenia with complications including hemorrhage or 
bleeding of ≥Grade 2 according to the NCI  CTCAE version 4.03 that required medical 
intervention or have  any hemolytic  condition  or coagulation disorders  that would make 
participation unsafe in the opinion of the investigator.  
7. Have  known hypersensitivity to platinum compounds or  gemcitabine.  
 
8. Have  uncontrolled diabetes or have  hypertension requiring more  than 3 medications  for 
control of hypertension.  
9. Have known active hepatitis B (defined as a known positive hepatitis B surface antigen 
[HBsAg]  result) or hepatitis  C (defined  by a known positive  hepatitis  C antibody result or 
known quantitative HCV RNA  results greater than the lower limits of detection of the 
assay).  
10. Are pregnant  or breast -feeding.  
 
11. Have  signs  or symptoms  of organ failure,  major  chronic  illnesses other  than cancer,  or 
any concomitant medical or social conditions that, in the opinion of the investigator, 
make it undesirable for the patient to participate in the study or that could jeopardize 
compliance with the protocol.  
12. Have  pre-existing  alcoholic  liver injury or significant  liver disease.  
 
13. Are regularly consuming alcohol within 6 months of Screening defined as an average weekly  intake  of >21 units  (or an average  daily  intake  of >3 units)  for males  or >14 units 
(or an average  daily  intake  >2 units)  for females. One unit is equivalent  to 8 g of alcohol:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  49  
 a half-pint (approximately 240 mL) of beer,  1 glass (125 mL) of wine,  or 1 measure 
(25 mL) of spirits.  
14. Have experienced any of the following within the 6- month period prior to screening: 
angina pectoris, coronary artery disease or cerebrovascular accident, transient ischemic 
attack,  cardiac failure  with known ejection  fraction  less than 40%, or cardiac arrhythmia 
requiring medical therapy. 
15. Are unwilling or unable to comply with study procedures or are planning to take a 
vacation  for 7 or more  consecutive days during the treatment phase  of the study without 
prior consent from the Medical Monitor.  
4.2 Withdrawal  of Patients  From  the Study  
The duration  of the study for each patient  is defined  as the time from the date of signed 
written informed consent through the End- of-Treatment visit or until death.  
 
4.2.1 Reasons for Withdrawal/Discontinuation 
Patients may withdraw from the study at any time and for any reason without prejudice to 
their future  medical  care by the investigator  or others  at the study site. Every  effort  should be 
made to keep patients in the study. The reasons for patients not completing the study will be 
recorded.  A patient may be withdrawn from the study for any of the following reasons:  
• Disease progression  
• Unacceptable toxicity  experienced  
• Grade  4 liver enzyme  elevation  
• Withdrawal  of consent  
• Major  protocol  violation  
• Required treatment delay  >14 days (except  in case of potential  patient  benefit, which 
must be approved by the sponsor)  
• Symptoms  or an intercurrent  illness  not consistent  with the protocol  requirements  or that 
justifies withdrawal  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  50  
 • For Cohort 3 only, unfit bladder cancer patient (≥30 to <60 mL/min CrCl at screening) 
has a worsening of CrCl  (ie, 50% reduction from baseline for 2 consecutive assessments, 
at least 1 week apart)  
• Lost to follow -up 
• Other  (eg, pregnancy, development  of contraindications  of use of the study drug)  
• The investigator or sponsor  determines  it is in the best interest  of the patient  to 
discontinue the patient’s participation in the study. 
The investigator also will withdraw a patient if NanoCarrier terminates the study. Upon 
occurrence of a serious or intolerable AE, the investigator will confer with the sponsor. If a 
patient  is discontinued because of an AE, then the event  will be followed until it is resolved.  
 
4.2.2 Handling of Withdrawals  
Patients who discontinue study treatment or active participation in the study will no longer 
receive the study drug. When a patient withdraws from the study, the reason(s) for withdrawal shall be recorded by the investigator on the relevant page of the electronic case 
report form (eCRF). Whenever possible, all patients who discontinue study treatment or 
withdraw  from  the study  prematurely  will undergo all end-of-treatment assessments.  Patients 
who fail to return for final assessments will be contacted by the site. Following a minimum of 2 documented unsuccessful telephone  calls, a registered letter  will be  sent to the  patient in 
a final attempt to ensure protocol compliance.  
It is vital to obtain follow -up data on any patient withdrawn because of an  AE or serious  AE 
(SAE).  In every  case,  efforts  must  be made  to undertake  protocol -specified,  safety,  follow -up 
procedures.  
 
4.2.3 Replacements  
Patients  in Part 1 who discontinue  treatment without  DLT  before  completion  of the first cycle 
will be replaced. No other patients will be replaced.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  51  
 5 Study Treatments  
5.1 Method of Assigning  Patients  to Treatment Groups  
This is an open -label study that will be conducted in 2 parts. In both parts, NC -6004 will be 
administered as a 1 -hour (+10- minute window) intravenous infusion on Day 1 of each cycle. 
Gemcitabine  1250 mg/m2 will be  administered as a  30-minute  intravenous infusion on Day 1 
of each cycle (after  the administration  of NC-6004)  and on Day 8 of each cycle.  The duration 
of each cycle will be 21 days.  
In Part 1, patients will be assigned to receive gemcitabine 1250 mg/m2 in combination with 
NC-6004 at doses  of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 by the N-CRM  model 
(as described in Section 6.3.1.2).  
In Part 2, all patients  will receive the RPII  dose (135 mg/m2) of NC-6004 identified  in Part 1. 
Bladder cancer patients in Cohort 3 of Part 2 will be stratified by  ≥30 to <60 mL/min and/or 
ECOG  PS 2 (unfit)  and ≥60 mL/min and ECOG  PS 0 to 1 (fit). If 2 of 6 patients (or ≥33%  at 
any point during the study) in the ≥30 to <60 mL/min group have a worsening of CrCl (ie, 
50% reduction from baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment of patients with CrCl <60 mL/min will stop in the bladder cancer cohort.  
 
5.2 Prophylactic  Treatments  
All patients will receive the following  medications  before  administration  of NC-6004 on 
Day 1 of each cycle:  
• Patients  will be instructed  to take 20 mg of dexamethasone  orally  at 12 hours  and 6 hours 
before the start of NC -6004 infusion on Day 1 of each cycle. When necessary, 12 and  
6 hours  before  the first infusion may be defined as “immediately  before  sleeping”  and 
“immediately after waking up.”  
• Patients  will be given 50 mg of diphenhydramine  hydrochloride  intravenously 30 minutes 
before the start of the NC -6004 infusion on Day 1 of each cycle.  
• Patients will be given 50 mg of ranitidine intravenously or 20 mg famotidine 
intravenously 30 minutes  before  the start of NC-6004 infusion  on Day 1 of each cycle.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  52  
 • Pre-hydration will be administered over 1 to 3 hours, as outlined by institutional 
standards.  A minimum of 1 L  of 0.9% sodium chloride solution will be infused 
intravenously over 1 to 3 hours prior to NC -6004 administration, and a minimum of 
500 mL  of 0.9% sodium chloride solution will be infused over 2 hours following 
NC-6004 administration.  The 0.9%  sodium  chloride  is changeable to 0.45%  sodium  
chloride  at investigator  discretion  based  on the patient’s  condition. When  gemcitabine 
only is infused, hydration is not required.  
• At all cycles, 8 mEq (1 g) of magnesium sulfate will be added to the 1 -L 0.9% sodium 
chloride  pre-hydration regimen  for all patients.  Once  a patient’s  magnesium  level  drops 
to <1.8 mg/dL  or <lower limit of normal (Grade 1 hypomagnesemia), the investigator 
may treat as clinically warranted by supplementing with oral and/or intravenous 
magnesium.  
• For 2 days after administration  of NC-6004, dexamethasone  4 mg (twice  per day) will be 
taken orally by all patients.  
Prophylactic antiemetic medications may be administered according to standard treatment 
center  protocols  for cisplatin -based  treatments.  The use of prophylactic  growth  factor  support 
medications is also allowed according to  ASCO guidelines ( Smith  et al 2006) and is 
encouraged in patients who have experienced myelosuppression on treatment and/or in patients at high risk for experiencing febrile neutropenia.  
 
5.3 Treatments  Administered  
The duration of each treatment cycle  will be 21 days in both parts  of the study. NC-6004 will 
be administered on Day 1 of each cycle as a 1 -hour (+10- minute window) intravenous 
infusion. Note: NC- 6004 nanoparticles degrade in the presence of chloride ions.  
Therefore,  it is imperative  that saline  is never used  as either a diluent  for NC-6004 or to 
flush cannulas immediately before or immediately after the NC -6004 infusion.  
Gemcitabine  1250 mg/m2 will be administered  as a 30-minute  intravenous  infusion on Day 1 
after the completion of the NC -6004 infusion and on Day 8 of each cycle. 
In Part 1 of the study, patients  will receive treatment  until disease progression. In Part 2 of 
the study, patients  will receive treatment  for 6 cycles (Cohorts  1 and 3) or 8 cycles (Cohort  2). 
Antiemetic medications may be administered according to standard treatment center 
protocols. The use of growth factor support medications is also allowed according to ASCO 
guidelines ( Smith  et al 2006) and is encouraged in patients who have experienced  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  53  
 myelosuppression on treatment and/or  in patients  at high risk for experiencing febrile 
neutropenia.  
The dose level may escalate to 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, or 
240 mg/m2 according to observations of DLTs and the dose -level toxicity relationship 
(Section  6.3.1.2).  A full safety  review  of all AEs for all cycles as well as an optional  PK 
analysis  will be conducted by the investigators,  the Medical  Monitor,  and NanoCarrier  before 
increasing the NC -6004 dose beyond 240 mg/m2. 
In Part 1, cohorts  will receive one of the following  treatments  shown in Table  5-1 as 
identified by the N -CRM model (as described in Section 6.3.1.2).  
Table  5-1 Dose  Level  Cohorts  
 
Dose  Level  Day 1 of Each  Cycle  Day 8 of Each  Cycle  
60 mg/m2 60 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
75 mg/m2 75 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
90 mg/m2 90 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
105 mg/m2 105 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
120 mg/m2 120 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
135 mg/m2 135 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
150 mg/m2 150 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
165 mg/m2 165 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
180 mg/m2, a 180 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
195 mg/m2 195 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
210 mg/m2 210 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
225 mg/m2 225 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
240 mg/m2 240 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
a If no DLT is observed in the single -subject  run-in phase  at 180 mg/m2, the single -subject  run-in 
phase will end and the next cohort will enroll 4 patients at 180 mg/m2. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  54  
 In Part 2, on Day 1 of each  cycle,  all patients  will receive NC-6004 at the RPII  dose 
(135 mg/m2) identified  in Part 1 and 1250 mg/m2 gemcitabine.  On Day 8 of each cycle,  all 
patients in Part 2 of the study will receive 1250 mg/m2 gemcitabine.  
 
5.4 Dose  Delays  and Modifications 
The doses for NC -6004 and gemcitabine will be calculated in milligrams per square meter 
(mg/m2) at screening and will not be changed in subsequent cycles unless the patient’s body 
weight has increased or decreased by ≥10% from the patient’s weight measurement at 
screening.  Any change in a patient’s weight by ≥10% during the study will require a 
recalculation of the doses of all study drugs (Note: This threshold should not be confused 
with a change  in the patient’s  body surface area [BSA]  [m2]). Weight  will be measured  before 
treatments on Day 1 of each cycle, with calculation of BSA  before dosing on Day 1 of each 
cycle (using the Mosteller formula [ Mosteller  1987]).  
Patients  experiencing  significant toxicities  must  be immediately  and permanently withdrawn 
from treatment with NC -6004 and gemcitabine as follows:  
• Any patient  who experiences a Grade  3 or 4 hypersensitivity  reaction  during any cycle  of 
treatment 
• Any patient  who experiences 2 protocol -defined  DLTs  during treatment 
• Any patient  who experiences a recurrent  Grade  3 or 4 toxicity  (recurrence of the same 
AE) after a dose reduction  
• Any patient  who requires a  dosing delay  >14 days at  any time during treatment (except  in 
case of potential patient benefit, which must be approved by the sponsor)  
• Any patient who experiences a Grade  4 liver enzyme  elevation  
 
5.4.1 NC-6004 Dose  Delay  and Modification  
During any treatment  cycle,  investigators  should suspend further  dosing with NC-6004 for up 
to 14 days after the scheduled dose in the event of a protocol -defined DLT or any Grade 4 
hematologic toxicity or Grade 3 or 4 nonhematologic toxicity that is possibly, probably, or definitely related to NC -6004 (excluding alopecia and Grade 3 nausea, vomiting, diarrhea, 
and electrolyte imbalances lasting less than 48 hours or with suboptimal prophylactic and 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  55  
 suboptimal curative treatment).  Any patient experiencing a Grade 3 liver enzyme elevation 
should have their next dose of NC -6004 suspended until improvement to Grade 1 or lower. 
At the discretion of the investigator, the dose may also be delayed for up to 14 days for any 
toxicity  possibly or probably related to NC -6004 that does not meet DLT  criteria.  A delay  of 
more than 14 days will require the patient to be removed from the study (except in case of potential  patient  benefit, which  must  be approved  by the sponsor). The toxicity  for which  the 
dose was suspended must have improved to Grade 1 or lower prior to NC -6004 infusion.  
Following recovery to Grade 1 or lower, treatment may resume at the investigator’s 
discretion.  Patients  who resume treatment  following  a dose delay  will have  the dose of study 
drug reduced by 50% for the remainder of study treatment. If toxicities persist or recur to Grade 3 or 4 (recurrence of the same AE) after the dose reduction, study treatment will be 
terminated.  
 
5.4.2 Gemcitabine  Dose  Delay  and Modification 
For gemcitabine, investigators should withhold (for up to 14 days of the scheduled dose) or 
reduce (by 50%) the gemcitabine dose in the event of any Grade 3 or 4 nonhematologic 
toxicity that is possibly, probably, or definitely related to gemcitabine (excluding alopecia, 
nausea, and vomiting) until it is resolved to Grade 1 or lower prior to gemcitabine infusion. 
Once  resolved,  the dose can be reinstated  at the full-dose level.  Any patient  who experiences 
any unexplained dyspnea or other evidence of severe pulmonary toxicity, severe hepatic toxicity, hemolytic -uremic syndrome, or capillary leak syndrome during any cycle of 
treatment must immediately and permanently discontinue treatment with gemcitabine.  
For hematologic  toxicities,  the recommended  dose reductions  for gemcitabine  are shown  in 
the following table:  
 
Absolute  Granulocyte  Count 
(× 106/L)  Platelet  Count 
(× 106/L) % of Full Dose  
≥1000  And ≥100 000 100 
500-999 Or 50 000-99 999 75 
<500  Or <50 000 hold 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  56  
 5.5 Identity of Investigational  Product  
NanoCarrier  will provide  NC-6004 to PPD,  Inc (PPD)  and PPD will distribute  adequate 
supplies of NC -6004 to the study sites. 
The following drug supplies  will be  used in the  study:  
 
Product  Supplied As: 
NC-6004 5-mL solution of  drug product in a  vial (equivalent of 50 mg cisplatin)  
Gemcitabine  200 mg vial for injection or 1 g vial for injection  
 
5.5.1 NC-6004 Drug  Product  
NC-6004 stock  solution  defined  as the drug substance  is colorless  or pale yellow, clear 
solution with no visible  contaminants. The mean  diameter  of a micellar  nanoparticle  is 
approximately 30 nm. The number of cisplatin residues in a micellar nanoparticle is 
approximately 720. 
NC-6004 is a sterile  formulation  containing  cisplatin -incorporated  micellar  nanoparticles, 
derived from the α -(methoxy- ω-aminopropyl, polyethylene glycol) -block- poly(sodium  
L-glutamate) copolymer, also written as polyethylene glycol -polyglutamate copolymer, 
(PEG -pGlu)  and cisplatin.  It is provided preformulated  in amber  vials  containing  5 mL of 
NC-6004 formulation containing the equivalent of 50 mg cisplatin.  
Each  vial of NC-6004 drug product  contains  32.5 mg of platinum (corresponding to 50 mg of 
cisplatin), 250 mg of D -mannitol to adjust tonicity, and water for injection.  
Saline must not be used for any dilution of the NC -6004 or for flushing infusion lines 
immediately before or immediately after NC -6004 administration because cisplatin is 
released  easily  from  the micelle  in the chloride -rich environment.  After the administration 
of premedications, NC -6004 should be mixed with 500 mL  of 5% dextrose solution for 
intravenous infusion. If necessary, NC -6004 may be diluted in 5% dextrose prior to the 
preparation of final infusion 500 mL. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  57  
 5.5.2 Gemcitabine  Drug  Product  
Gemzar® (gemcitabine  for injection,  USP),  is available in sterile  single -use vials  individually 
packaged in a carton containing: 200 mg white to off -white, lyophilized powder in a  
10-mL size sterile  single -use vial or 1 g white  to off-white,  lyophilized powder  in a 
50-mL size sterile single -use vial. Vials of gemcitabine contain either 200 mg or 1 g of 
gemcitabine hydrochloride (expressed as free base) formulated with mannitol (200 mg  or 1 g, 
respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized 
powder. Hydrochloric  acid and/or  sodium  hydroxide  may have  been  added  for pH adjustment.  
 
5.6 Management of Clinical Supplies  
5.6.1 Study Drug  Packaging and Storage  
NC-6004 will be prepared  in vials  and shipped by PPD.  
 
All study drugs must be stored in a secure area (eg, a locked cabinet). NC -6004 should be 
protected  from  light and stored  refrigerated  (2° to 8°C).  Unopened vials  of gemcitabine  are 
stable until the expiration date indicated on the package when stored at controlled room 
temperature 20° to 25°C that allows for excursions between 15° and 30°C. 
 
5.6.2 Test Article Accountability 
The investigator will maintain accurate records of receipt of all test articles that are centrally provided, including dates of receipt. In addition, accurate records will be kept regarding 
when and how much test article is dispensed and used by each patient in the study. Reasons 
for departure  from the expected  dispensing regimen  must  also be recorded.  At the completion 
of the study, to satisfy regulatory  requirements regarding  drug accountability, all study  drugs 
will be reconciled and retained or destroyed according to applicable regulations.  
 
5.7 Overdose  Management  
An overdose is any dose of study treatment given to a patient or taken by a patient that exceeds the dose described  in the protocol. Any overdose, with or without  associated  AEs, 
must be promptly reported to the PPD Drug Safety Center. Overdoses without signs or  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  58  
 symptoms  do not need  to be recorded  as AEs;  in case of any AEs associated  with the 
overdose, these should be reported on relevant  AE or SAE sections in the eCRF.  
 
5.7.1 Treatment  of Overdose 
There  is no clinically  proven antidote  available for NC-6004. The expected  manifestations  of 
overdose are likely to be an exaggerated form of the adverse drug reactions anticipated with 
the administration of the drug. Therefore, patients should be carefully  monitored for signs of 
immunosuppression. Symptomatic treatment and standard supportive care measures for the management of this toxicity should be applied.  
 
5.8 Prophylaxis and Management of Hypersensitivity  Reactions  
All patients  must  receive  the following  prophylactic  treatment at each cycle to reduce  the risk 
of hypersensitivity reactions:  
• Dexamethasone  20 mg taken  orally  at 12 and 6 hours  before  the infusion  of NC-6004. 
When necessary, 12 and 6 hours before the infusion of NC -6004 may be defined as 
“immediately before sleeping” and “immediately after waking up.”  
• Diphenhydramine  hydrochloride  50 mg and either  ranitidine  50 mg or 20 mg famotidine 
will be administered intravenously 30 minutes before the infusion of NC -6004. 
• For 2 days after  administration  of NC-6004, dexamethasone  4 mg twice  per day will be 
taken orally.  
If a Grade  1 or Grade  2 hypersensitivity occurs  in a patient,  the following  medications  should 
be administered for 48 hours after NC -6004 infusion:  
• Ranitidine  150 mg orally  given 2 times  per day or 40 mg famotidine  orally  given once 
per day  
• Diphenhydramine  hydrochloride  50 mg orally  given 3 times  per day 
If a Grade 3 or higher hypersensitivity occurs, the patient should be discontinued from the 
study and must be treated immediately with hydrocortisone 20 mg administered intravenously and/or  other  appropriate  medications.  In these cases,  patients must  be carefully 
observed after the treatment.  Additional therapy per institution standard of care should also 
be followed. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  59  
 5.9 Treatment  Compliance  
Administration of the study treatments will be performed by the investigator or a qualified 
designee; therefore, compliance will be verified by  the study drug administration information.  
 
5.10 Prior,  Concomitant,  and Subsequent Therapy  
(Part 2 only) Cohort 1: For patients with Stage IV NSCLC, they may not have received prior 
chemotherapy or immunotherapy for metastatic disease. Patients with known sensitizing 
mutation in the EGFR gene or  ALK fusion oncogene must have received at least 1 and up to 
2 targeted therapies prior to enrollment. If a patient with treated, stable brain metastases is 
otherwise eligible and requires corticosteroids, the patient must have been receiving a stable 
dose of corticosteroids for at least 14 days prior to assignment to treatment. Patients whose 
tumors are known to harbor an exon 19 deletion or exon 21 L858R EGFR mutation must 
have had intolerance or have progressed on at least 1 and up to 2 EGFR tyrosine kinase 
inhibitors. Patients whose tumors are known to harbor an ALK kinase translocation must 
have had intolerance or have progressed on at least 1 and up to 2 ALK inhibitors. Patients 
with eligible  biliary  tract carcinoma  must  not have  received  prior  systemic anticancer  therapy 
for advanced or metastatic disease. Patients with eligible TCC of the urinary tract must not have received prior treatment with systemic anticancer therapy for metastatic or locally 
advanced urinary tract cancer.  
All patients  must  receive  prophylactic  treatment  at each cycle  to reduce  the risk of 
hypersensitivity reactions and nausea and/or vomiting ( Section 5.8).  
The use of antiemetic  medications  according to the site’s standard  of care is allowed.  The use 
of prophylactic growth factor support medications is also allowed according to  ASCO 
guidelines ( Smith  et al 2006) and is encouraged in patients who have experienced 
myelosuppression on treatment and/or in patients at high risk for experiencing febrile 
neutropenia.  
Use of all concomitant  medications,  including antiemetic  medications and those  required  for 
administration before the infusion on Day 1 of each cycle, will be recorded in the patient’s 
eCRF.  The minimum requirement is that drug name  and the dates of administration  are to be 
recorded. This will include all prescription drugs, herbal products, vitamins, minerals, and  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  60  
 over-the-counter  medications.  Any changes  in concomitant  medications  will also be recorded 
in the patient’s eCRF.  
Any concomitant medication deemed necessary for the welfare of the patient during the 
study may be given at the discretion  of the investigator.  However,  it is the responsibility of 
the investigator to ensure that details regarding the medication are recorded in full in the 
eCRF.  
 
5.11 Prohibited Medications 
The following products  should be avoided during  study treatment with NC-6004 and for 
1 month following treatment due to known interactions with the released cisplatin.  
• Bacillus  Calmette -Guerin  
• Clozapine  
• Natalizumab  
• Tacrolimus  (Topical)  
• Tofacitinib  
• Live vaccines 
This list is not comprehensive  and a physician or a pharmacist should evaluate other 
concomitant medications used during the trial.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  61  
 6 Study Assessments and Procedures  
Before performing any  study procedures, all potential patients will sign an informed consent 
form (ICF).  Patients  will have  the opportunity to have  any questions  answered  before  signing 
the ICF. The investigator must address all questions raised by the patient. The investigator 
will also sign the ICF.  
The Schedule  of Events  is presented  in Appendix 12.1. 
 
Disease assessment  is to be performed  within  the 28 days prior to the start of  study treatment. 
For patients with advanced solid tumors, disease assessment will be performed according to RECIST version 1.1. Patients who have obtained a response (PR or CR) will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
 
6.1 Efficacy  Assessments 
Efficacy  assessments include disease response assessments, QoL  assessments, and symptom 
changes  assessments.  Disease response assessments (Section  6.1.1)  will occur  every  6 weeks 
(±1 week), at the End- of-Treatment visit, and every 9 weeks after discontinuation or 
completion of treatment until disease progression. Quality of life will be assessed using the EORTC QLQ- C30 version 3 ( Section 6.1.2) on Days 1 and 8 of each cycle and at the  
End-of-Treatment visit. Symptom changes will be assessed using the core MDASI (Part 1 
only)  or MDASI -LC (only in patients  with NSCLC in Part 1) (Section  6.1.3)  on Days  1 and 8 
of each cycle and at the End -of-Treatment visit.  A schedule of the efficacy assessments is 
provided in Appendix 12.1. 
 
6.1.1 Disease  Response  Definitions  
• ORR:  Defined  as percentage  of patients  with CR or PR assessed  using RECIST 
version 1.1  
• DCR:  Defined  as the percentage of patients  with CR, PR, or SD assessed  using RECIST 
version 1.1  
• PFS:  Defined  as the time from the beginning of NC-6004 treatment  until objective 
tumor progression or death assessed using RECIST version 1.1 
• OS: Defined  as the time from the beginning of NC-6004 treatment  until death  or last 
contact  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  62  
 The rate of confirmed  response and tumor growth control will be determined  according  to 
RECIST version 1.1 in solid tumor patients for patients evaluable for response using the 
following imaging methods:  
Timing  
 
Disease assessment will occur at Screening and every 6 weeks (±1 week) until disease 
progression. Patients  who have obtained a response (PR or CR) will have a confirmatory 
scan at a minimum of 4 weeks following the initial scan.  
Anatomic  Coverage  
 
Imaging should include a computed tomography scan of the chest, abdomen, and pelvis. In addition, areas of known predisposition for metastases (eg, the brain for NSCLC) and any 
areas identified by the clinician as probable sites of metastasis based on clinical evaluation 
should be included in imaging  if clinically  indicated. Other  imaging may be performed  at the 
investigator’s discretion as standard of care.  
Imaging  Method  
 
The preferred  method for imaging  is computed tomography with IV contrast.  If the patient is 
allergic to contrast media or has another medical contraindication, magnetic resonance 
imaging with contrast can be used at the clinician’s discretion. It is critical that the same 
method of imaging is used throughout the study for a given patient . 
Slice  Thickness 
 
The preferred  slice thickness is 5 mm. If a larger slice thickness is used (eg, 7 mm),  the 
smallest tumor measurement that can be reported is twice the thickness of the slice.  
 
6.1.2 European Organisation for Research  and Treatment  of Cancer 
Quality of Life Questionnaire -Core 30  
The EORTC  QLQ- C30 (version 3) is a questionnaire developed to assess the QoL of cancer 
patients ( Appendix 12.2). It is a copyrighted instrument which has been translated and 
validated into 81 languages and is used in more than 3000 studies worldwide. The questionnaire for this study  is supplemented by a disease -specific  validated  module for lung 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  63  
 cancer.  The questionnaire  will be  administered  by the site before  study treatments  on Days  1 
and 8 of each cycle and at the End -of-Treatment visit.  
 
6.1.3 MD Anderson Symptom  Inventory  
The MDASI  (Cleeland  et al 2000)  is a multisymptom patient -reported outcome  measure for 
clinical  and research  use. The MDASI’s  13 core  symptom  items  include  those  found  to have 
the highest frequency and/or severity in patients with various cancers and treatment types.  
The MDASI has several advantages over other symptom -assessment scales in that it applies 
broadly across cancer types and treatments, is easy for patients to complete, includes items 
related to symptom interference  with daily  life, and it is easily  translated into other languages. 
This study will use the core MDASI ( Appendix 12.3) for all patients in Part 1 of the study 
except those patients with NSCLC.  
For patients  with NSCLC in Part 1 only, a specific MDASI  module  designed for patients with 
lung cancer will be used, MDASI -LC (Appendix 12.3). The MDASI -LC is a site -specific 
module. Along with the core MDASI’s 13 symptom items and 6 interference items, the 
MDASI -LC also assesses 3 lung  cancer -specific symptom items: coughing, constipation, and 
sore throat.  
The MDASI -LC module includes  the following:  
 
• Purpose:  To assess the severity  of multiple  lung cancer -related  symptoms  and the impact 
of these symptoms on daily functioning 
• Population:  Patients with  symptoms caused  by lung cancer  and its treatment 
• Assessment  areas:  Severity  of multiple  symptoms  and the impact  of symptoms  on daily 
functioning during the last 24 hours  
• Time  required:  5 minutes  
The core  MDASI  and the  MDASI -LC will  be administered  as a self-report paper -and-pencil 
form given  to the patient at  the site before  study treatments  on Days  1 and 8 of  each cycle in 
Part 1 only.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  64  
 6.2 Pharmacokinetic  and Pharmacodynamic  Assessments  
Pharmacokinetic samples will be collected and processed according to the instructions 
provided by the bioanalytical laboratory to the clinical  sites.  Pharmacokinetic  samples  will be 
analyzed according to the bioanalytical laboratory protocol. The concentration profiles of 
micellar platinum in plasma and total platinum in plasma and plasma ultrafiltrate (ie, free 
platinum) will be characterized. The concentration -versus -time profile will be determined in 
Part 1 and in Part 2.  
Pharmacokinetic  plasma  and plasma ultrafiltrate  samples  will be collected  at the following 
times in Part 1: 
• Before  the start of the NC-6004 infusion on Day 1 of Cycles 1  through 6  
• At the end of  NC-6004 infusion in Cycles  1, 3, and 5  
• After the start of NC-6004 infusion at  Hours 3, 6, 12, 24 (Day 2), 48 (Day  3), 96 (Day 5), 
168 (Day  8, prior  to gemcitabine infusion), and 336 (Day  15) in Cycles  1, 3, and 5 
• At End-of-Treatment  visit 
Pharmacokinetic  plasma  and plasma ultrafiltrate  samples  will be collected  at the following 
times in Part 2 for up to 6 cycles:  
• Before  the start of the NC-6004 infusion on Day 1 
• At the end of NC-6004 infusion  
• Before  gemcitabine infusion  on Day 8 
• At End-of-Treatment  visit 
Additional  PK blood sample collections  may be performed,  at the discretion  of the 
investigator, during any visit where toxicity is observed.  
Pharmacokinetics blood sampling should occur within 10% of  nominal  time for Days  1 and 2, 
±4 hours of nominal time for all other time points, and should occur within 10 minutes after 
the 12-lead ECGs  performance  at time-matched  visits  (Section  6.3.6).  All PK samples will be 
evaluable as long as the actual collection times are recorded.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  65  
 Pharmacodynamics  will be assessed  based  on Cmax (maximum concentration)  values and 
nephrotoxicity as assessed by reports of  AEs and from clinical laboratory data.  
 
6.3 Safety and Tolerability  Assessments  
Safety  will be assessed  using frequent  collection  of AE reports  (Section  6.3.2)  and clinical 
hematology and coagulation, biochemistry, and urinalysis test results ( Section 6.3.5 ). 
Adverse events will be graded according to the NCI CTCAE version 4.03 ( National Cancer  
Institute  2010). Additional safety assessments include, periodic 12 -lead ECG recordings 
(Section 6.3.6), physical examination findings ( Section 6.3.7 ), vital sign measurements 
(Section  6.3.8),  ECOG PS (Section  6.3.9),  and audiometry  (Section  6.3.10).  A schedule  of the 
safety assessments is provided in Appendix 12.1.  
 
6.3.1 Dose -Limiting  Toxicities  and Dose  Escalation  Scheme  
6.3.1.1  Definition  of Dose -Limiting  Toxicities  
A DLT (monitored  in Part 1 only)  is defined as the following  treatment -related  AEs or 
laboratory abnormalities, graded according to the NCI CTCAE version 4.03:  
• Grade  3 or 4 febrile  neutropenia  or neutropenic  infection  
• Grade  4 neutropenia  of duration longer  than 7 days and unresponsive  to growth factor 
support per institutional guidelines or ASCO guidelines  
• Grade  4 thrombocytopenia  
• Grade  3 thrombocytopenia  with clinically  significant  bleeding  or Grade  3 
thrombocytopenia requiring a platelet transfusion  
• Grade  4 life-threatening  anemia 
• Grade  3 or Grade  4 nonhematological  toxicity  (excluding alopecia and Grade  3 nausea, 
vomiting, diarrhea, and electrolyte imbalances lasting less than 48 hours or with 
suboptimal prophylactic and suboptimal curative treatment)  
• Grade  3 nausea,  vomiting, diarrhea  or electrolyte imbalances lasting  greater  than 48 hours 
despite optimal prophylactic and curative treatment  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  66  
 • Grade  4 vomiting, diarrhea,  or electrolyte  imbalances (life-threatening consequences)  of 
any duration despite optimal prophylactic and curative treatment  
• ≥Grade 3 hypersensitivity reaction  
• Dosing delay  >14 days  due to toxicity  
 
6.3.1.2  Dose  Escalation  Scheme  
To determine the MTD of NC -6004, an adaptive approach using an N -CRM model based on 
the paper by Neuenschwander  et al 2008 will be used. The standard dose selection in a 
Bayesian  N-CRM  model  is based  on point  estimates  for the probability of a DLT  at each dose. 
The uncertainty of the probability estimate is ignored. When this uncertainty is high, the risk 
of overdosing can be unacceptably high. The N -CRM classifies the probability  of a DLT into 
4 categories:  
• Under -dosing:  p∈ (0, 0.20]  
• Targeted  toxicity: p∈ (0.20, 0.33]  
• Excessive toxicity: p∈ (0.33, 0.60]  
• Unacceptable toxicity: p∈ (0.60, 1.00]  
The N -CRM is updated with the dose level and DLT status of each patient. Updates occur 
after each patient experiences a DLT or completes the first cycle in the single -patient run -in 
phase.  In the remainder  of Part 1, updates  occur  after all 4 patients  enrolled in the most  recent 
cohort  either experience a DLT  or complete  the first cycle.  Each  time the N-CRM  is updated, 
the posterior distribution of the probability of a DLT will be summarized for each dose for the 4 toxicity categories and the estimated dose- toxicity relationship curve is updated. The 
dose selection relies on maximizing the probability of targeted toxicity while controlling the 
probability of excessive or unacceptable toxicity to be no more than 25%. The interval 
between dose levels is prespecified ( Table 3 -1) and is not determined by the N -CRM 
algorithm.  
In the  run-in phase, 1 patient will be  enrolled sequentially  at the following dose  levels: 60, 75, 
90, 105, 120, 135, 150, 165, and 180 mg/m
2 until a DLT is observed or until a patient is 
treated at 180 mg/m2 for 1 cycle without a DLT. During the run- in phase of Part 1, if no DLT  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  67  
 is observed at a dose level, the next patient will be enrolled at the next higher dose level. If a 
DLT is observed at the current dose level or if the current dose level of the run -in phase is 
180 mg/m2, the first cohort of 4 patients will be enrolled at the dose level with the greatest 
posterior  probability of targeted  toxicity  that controls  the posterior  probability of excessive or 
unacceptable toxicity  to be no more  than 25%, given the run-in data.  If no DLT  is observed in 
the single -subject run -in phase  at 180 mg/m2, the single -subject run- in phase  will end and the 
next cohort will enroll 4 patients at 180 mg/m2. 
After each patient in each cohort of  4 patients either  completes the first cycle  or experiences 
a DLT, the next cohort of 4 patients will be enrolled at one of the following 3 dose levels, 
unless Part 1 of the trial is stopped: the next lower dose level, the current dose level, or the 
next higher dose level. When the current dose level is the lowest dose level, the next dose 
level  is restricted  to 2 levels:  the current  dose level  and the next higher  dose level.  Similarly, 
when the current dose level is the highest dose level, the next dose level is restricted to the next lower dose level and the current dose level. Of the 2 or 3 possible next dose levels, the dose level with the greatest posterior probability of targeted toxicity that controls the 
posterior  probability of excessive or unacceptable toxicity  to be no more  than 25%, given all 
of the data from Part 1 collected through the current cohort is selected for the next cohort.  
 
Part 1 of the trial will be stopped when:  
1. 10 cohorts  are completed,  or 
2. 2 cohorts  are treated at the MTD, or  
3. No dose level  controls  the posterior probability of excessive or unacceptable  toxicity  to 
be no more than 25%  
The dose  level  with  the greatest  posterior  probability  of targeted  toxicity  that controls  the 
posterior probability of excessive or unacceptable toxicity  to be no more than 25% when 
Part 1 is stopped is identified as the MTD.  
It is important  to note that Part 1 of the study will not  be stopped during the single -patient 
run-in phase, even if the first patient enrolled experiences a DLT.  At least 2 cohorts of  
4 patients  each must  be enrolled in order  to stop Part 1. Finally,  Part 1 will not be stopped for 
any reason other than 10 cohorts completing unless at least 2 DLTs are observed. It is 
therefore possible that more than 2 cohorts are dosed at a single dose level.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  68  
 More conservative dose escalation, evaluation of intermediate doses, and expansion of an 
existing dose level are all permissible following discussions between the sponsor and the 
investigators,  if such measures are needed  for patient  safety  or for a better  understanding of 
the dose –related toxicity, exposure, or pharmacodynamics of NC -6004. 
After determination  of the MTD,  patients  who are in cohorts  receiving  a lower  dose of 
NC-6004 will continue at the previously assigned dose. 
 
6.3.1.2.1  Safety Monitoring in Part  2 
During Part 2 of the study, patients  treated  with NC-6004 at the RPII  dose from Part 1 will be 
monitored for safety. Dose delay and modification rules for both NC -6004 and gemcitabine 
apply in Part 2 as in Part 1. 
In Part 2 (Cohort  3), if  2 of 6 patients (or  ≥33%  at any point  during the study) in the  ≥30 to  
<60 mL/min  group have a  worsening of CrCl  (ie, 50%  reduction from baseline  for 
2 consecutive assessments,  at least 1 week apart),  then enrollment  of patients  with CrCl 
<60 mL/min will stop in the bladder cancer cohort. In addition, in Part 2 (Cohort 3), if an 
unfit  bladder  cancer  patient  (≥30 to <60 mL/min  CrCl  at screening)  has a worsening of CrCl 
(ie, 50% reduction from baseline for 2 consecutive assessments, at least 1 week apart) he or 
she may be withdrawn from the study ( Section 4.2.1).  
NC-6004- related  Grade  3 or higher  related  AEs (excluding  toxicities  related  to the underlying 
disease,  alopecia and Grade  3 peripheral  neuropathy)  resulting  in study drug withdrawal prior 
to cycle 4 will be considered UTs.  
The cumulative  UT incidence  rate is defined as the number  of patients  experiencing  at least 
one UT divided by the number of patients treated in Part 2 through the current date. The cumulative UT incidence rate will be updated monthly. If at any time in Part 2 after a 
minimum of 10 patients have been treated the cumulative UT  incidence rate exceeds 30%, 
enrollment will be stopped pending a formal safety review by the sponsor, PPD Medical 
Monitor, and the investigators, who will ultimately decide whether to stop the trial.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  69  
 6.3.2 Adverse  Events  
6.3.2.1  Definitions  of Adverse  Events  
The investigator is responsible  for reporting  all AEs that are observed  or reported during the 
study, regardless of their relationship to study drug or their clinical significance.  
An AE is defined as any  untoward medical occurrence  in a patient enrolled into this study 
regardless of  its causal  relationship to study drug. Patients will be  instructed  to contact  the 
investigator at any time after randomization if any symptoms develop.  
A treatment -emergent  AE (TEAE) is defined as any  event not present before exposure to 
study drug or any event  already  present  that worsens  in either  intensity  or frequency  after 
exposure to study drug.  
An SAE is defined  as any event  that results in death, is immediately  life threatening, requires 
inpatient hospitalization or prolongation of existing hospitalization, results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect. Hospitalization for 
elective procedures or for protocol compliance is not considered an SAE. Important medical events that may not result in death, be life threatening, or require hospitalization may be 
considered SAEs when, based upon appropriate medical judgment, they may jeopardize the 
patient or may  require medical or surgical intervention to prevent one of the outcomes listed 
in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that 
do not result in inpatient hospitalization, or the development of drug dependency or drug 
abuse.  
 
6.3.2.2  Eliciting  and Documenting Adverse  Events  
Adverse  events  will be assessed  from the time the patient  signs  the ICF until 30 days after the 
last dose of study drug.  
Serious  AEs that occur  more  than 30 days after  the last dose of study drug need  not be 
reported unless the investigator considers them related to study drug. 
At every study visit, patients will be asked a standard nonleading question to elicit any 
medically  related  changes  in their well-being. They  also will be asked  if they have  been  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  70  
 hospitalized,  had any accidents,  used any new medications, or changed concomitant 
medication regimens (both prescription and over -the-counter medications).  
In addition to patient observations, AEs will be documented from any data collected on the 
AE page  of the eCRF  (eg, laboratory  values,  physical  examination  findings, ECG  changes)  or 
identified from review of other documents (eg, patient diaries) that are relevant to patient 
safety.  
 
6.3.2.3  Reporting Adverse Events  
All AEs reported  or observed during  the study will be recorded on the AE page  of the eCRF. 
Information to be collected includes drug treatment, dose, event terminology, date of onset, NCI CTCAE version 4.03 assessment of severity and relationship to study drug, date of 
resolution of the event, seriousness, any required treatment or evaluations, and outcome. 
With  the exception of disease progression, adverse  events  resulting  from concurrent  illnesses, 
reactions to concurrent illnesses, and reactions to concurrent medications also must be reported. All AEs will be followed to adequate  resolution (Section  6.3.2.6).  The NCI CTCAE 
version 4.03 will be used to grade  all AEs.  The CTCAE  includes  5 grades  (1-5), with Grade  5 
being death.  
Any AE that meets SAE criteria ( Section 6.3.2.1) must be reported to PPD immediately (ie, 
within  24 hours  after the time site personnel  first learn  about  the event). The event  is reported 
via the electronic data capture (EDC) system where site personnel complete as much of the respective AE page (eCRF) as they are able.  
If the EDC system is unavailable, the  AE information must be recorded on the manual SAE 
report form and immediately (ie, within 24 hours of awareness) sent to PPD by one of the 
following  methods  (refer to the “SAE  Guidelines”  document  for WorldReach  toll-free access 
numbers if necessary):  
 
Pharmacovigilance  Department  
United  States  SAE  Hotline:  +1 800-201 -8725 
United  States  SAE  Fax line: +1 888-488 -9697 
Europe  SAE  Hotline:  +44 1223 374 240 (to be used for questions  concerning SAEs)  
Europe  SAE  Fax line:  +44 1223 374 102 (to be used for reporting  SAEs)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  71  
 Once  the EDC  system  becomes available again,  the site needs  to transfer all data to the 
respective eCRF page of the patient.  
 
6.3.2.4  Assessment  of Severity  
The severity,  or intensity,  of an AE refers  to the extent  to which  an AE affects  the patient’s 
daily activities. The intensity of the  AE graded on a scale of 1 to 5 as follows:  
 
1: Mild;  asymptomatic  or mild symptoms;  clinical  or diagnostic  observations  only; 
intervention not indicated 
2: Moderate;  minimal,  local  or noninvasive  intervention  indicated;  limiting 
age-appropriate instrumental ADLa 
3: Severe or medically  significant  but not immediately  life-threatening;  hospitalization  or 
prolongation of hospitalization indicated; disabling; limiting self -care ADLb 
4: Life-threatening  consequences;  urgent  intervention  indicated  
5: Death  related  to AE 
a Instrumental  activities  of daily  living  (ADL)  refer to preparing  meals,  shopping for groceries  or clothes, 
using the telephone, managing money, etc.  
b Self-care ADL  refer to bathing,  dressing  and undressing,  feeding  self, using the toilet,  taking 
medications, and not bedridden.  
 
Changes in the severity of an  AE should be documented to allow an assessment of the 
duration of the event  at each level  of intensity  to be performed. Adverse  events  characterized 
as intermittent do not require documentation of onset and duration of each episode.  
 
6.3.2.5  Assessment  of Causality 
The investigator’s assessment of an  AE’s relationship to study drug (combination of 
NC-6004 and gemcitabine)  is part of the documentation process,  but it is not a factor  in 
determining  what is or  is not reported in the  study. If there  is any  doubt as to whether  a 
clinical observation is an AE, the event should be reported.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  72  
 The relationship  or association  of the test article  in causing  or contributing  to the AE will be 
characterized using the following classification and criteria:  
 
Unrelated:  This relationship  suggests  that there  is no association  between  the study  drug 
and the reported event. 
Possible:  This relationship suggests that treatment with the study drug caused or 
contributed to the  AE, ie, the event follows a reasonable temporal sequence 
from the time of drug administration  or follows  a known response pattern  to the 
study drug, but could also have been produced by other factors. 
Probable:  This relationship suggests that a reasonable temporal sequence of the event 
with drug administration exists and, based upon the known pharmacological action  of the drug, known or previously reported adverse reactions to the drug 
or class of drugs, or judgment based on the investigator’s clinical experience, the association of the event with the study drug seems likely. The event disappears or decreases on cessation or reduction of the dose of study drug. 
Definite:  This relationship  suggests that a definite  causal  relationship  exists  between  drug 
administration and the AE, and other conditions (concurrent illness, progression/expression of disease state, or concurrent medication reaction) do not appear to explain the event. The event reappears or worsens if the study 
drug is re -administered.  
 
6.3.2.6  Follow -up of Patients Reporting Adverse Events  
All AEs must be reported in detail on the appropriate page of the eCRF and followed to 
satisfactory  resolution,  until the investigator deems  the event to be chronic or not clinically 
significant, or until the patient is considered to be stable.  
 
6.3.2.7  Management Guidelines for NC-6004- Related  Liver Dysfunction  
At the onset of Grade 4 liver enzyme elevation, NC-6004 must be immediately and 
permanently discontinued. Patients should be referred promptly to a 
hepatologist/gastroenterologist/specialist to be further evaluated. Patients with Grade 4 liver enzyme elevation should have a physical examination performed and should be assessed for 
signs of fever,  rash and jaundice. Liver  function tests including  serum  transaminases,  alkaline 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  73  
 phosphatase, γ -glutamyl transpeptidase, and total bilirubin (including direct and indirect), 
albumin choline esterase, total cholesterol, as well as hematological tests including 
prothrombin time (PT), PT/international normalized ratio (INR) and eosinophil count should 
be performed. Other testing including a serological test may be performed at the 
hepatologist/gastroenterologist/specialist’s  discretion.  Patients  should then be monitored on a 
bi-weekly basis (or more frequent if indicated by the 
hepatologist/gastroenterologist/specialist) until improvement to Grade  2 or below and clinical 
stability. Section 5.4.1 provides details for management of Grade 3 liver enzyme elevation.  
 
6.3.3 Assessment  of Nausea and Vomiting  
Before  dosing on Day 1 of Cycle  1, the patient  will rate the worst  severity  of their nausea and 
the number of emetic episodes (vomiting or retching) occurring over the last 24 hours.  
For Parts 1 and 2, each patient will be given a nausea and vomiting patient diary to take 
home. This diary will be used to record the severity of nausea and incidence of emetic 
episodes over the previous 24 hours daily  on Days  2 through 21. The first 7  days of the diary 
will be recorded verbatim in the eCRF.  The patient will be given the diary and instructed on 
how and when to complete the diary before discharge from the site on Day 1 of each cycle. 
Part 1: The investigator will collect the nausea and vomiting patient diary from each patient 
on Day 8 and Day 15 for Cycle 1. For all subsequent cycles, the investigator will collect 
diaries on Day 1 (prior to dosing to capture the last 7 days of the previous cycle), Day 8, and 
Day 15. The investigator will record the worst severity of the patient’s nausea and the total 
number of emetic  episodes occurring over the previous 7 days in the eCRF  for Day 8, Day 15, 
and Day 21. 
Part 2 : T he investigator will collect the nausea and vomiting  patient diary  from each patient 
at the site on Day 8 for Cycle 1. For Cycle 2, the investigator will collect diaries on Day 1 
(prior to dosing to capture the last 7 days of the previous cycle)  and Day 8. Note that nausea 
and vomiting patient diaries will not be collected past Cycle 2. The investigator will record the worst severity  of the patient’s nausea and the total number of emetic episodes occurring 
over the previous 7 days in the eCRF for Day 8 and Day 21. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  74  
 Nausea will be rated  on the following  scale of 0 to 3: 
 
0 None  (no nausea)  
 
1 Loss  of appetite  with change  in eating  habits  
 
2 Less eating  and drinking  than normal  but without  much weight  loss 
 
3 Not able to eat food or drink, or tube feedings  are given, or hospitalization  is required 
for treatment of nausea  
 
6.3.4 Pregnancy  
Pregnancy is not regarded as an adverse event unless there is a suspicion that an 
investigational product may have interfered with the effectiveness of a contraceptive 
medication.  Any pregnancy that occurs during study participation must be reported using a 
clinical study  pregnancy  form.  To ensure patient safety, each pregnancy  must be reported to 
PPD as described for reported SAEs in Section 6.3.2.3 within 2 weeks of learning of its 
occurrence. The pregnancy must be followed- up to determine outcome (including 
spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) and status of mother and child, even if the patient was discontinued from the study. Pregnancy 
complications  and elective  terminations  for medical  reasons  should not be reported as an AE 
or SAE. Spontaneous miscarriages must be reported as an SAE.  
Any SAE occurring in association  with a pregnancy brought  to the investigator’s  attention 
after the patient has completed the study and considered by the investigator as possibly related to the study treatment must be promptly reported to PPD (Section 6.3.2.3).  
 
6.3.5 Clinical Laboratory  Analyses  
Samples for hematology and coagulation, biochemistry,  and urinalysis  will be collected  at the 
time points specified in  Appendix 12.1, Schedule of Events . All samples for clinical 
laboratory analyses will be collected according to standard procedures.  
Only abnormal laboratory test results (hematology and coagulation, biochemistry, or 
urinalysis) that are  deemed  clinically  significant  by the PI will be recorded as  AEs or SAEs 
per the NCI CTCAE version 4.03.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  75  
 6.3.5.1  Hematology and Coagulation  
Hematology will include hemoglobin, reticulocytes, red blood cell count, differential white 
blood cell count, and platelets. Coagulation will include prothrombin time and international 
normalized ratio. Hematology and coagulation tests will be performed during the screening 
period on Day -7 to -1, prior to dosing on Day 1 of Cycle  1 (if they were  last performed  more 
than 24 hours before the start of the study drug administration), weekly at each study visit prior to any treatments, and at the End -of-Treatment visit.  
 
6.3.5.2  Biochemistry  
Biochemistry will include alanine aminotransferase, aspartate aminotransferase, gamma -glutamyl  transferase,  alkaline  phosphatase, total bilirubin,  sodium,  potassium,  
calcium,  magnesium,  urea,  creatinine,  CrCl  (calculated  using the Cockcroft  and Gault  1976 
formula), total protein, albumin, and lactate dehydrogenase. Biochemistry tests will be 
performed during the screening  period on Day -7 to - 1, prior  to dosing on Day 1 of Cycle  1 
(if they were last performed more than 24 hours before the start of the study drug 
administration), weekly at each study visit prior to any treatments, and at the  
End-of-Treatment  visit.  
 
6.3.5.3  Urinalysis  
Urinalysis will be performed and will include: leukocyte esterase, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketones, bilirubin, and glucose. Urinalysis will be performed  during the screening  period  on Day -14 to -1 and at the End-of-Treatment  visit.  
 
6.3.6 Electrocardiograms  
All 12-lead ECGs  will be performed  after the patient  has adequately  rested  in the supine 
position.  
A 12-lead ECG will be performed during the screening period at Day - 7 to - 1. On Day 1 of 
Cycle 1, 12- lead ECGs will be performed before the start of the NC -6004 infusion, at 
completion  of infusion (~1 hour after start of infusion), and at Hours  3 and 24 hours  (Day  2) 
after start of infusion. On Day  8 of Cycle  1, 12-lead ECGs  will be performed  before  the start 
of gemcitabine infusion, at the completion of gemcitabine infusion, and at 1 hour after  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  76  
 completion of gemcitabine infusion. Twelve -lead ECGs will also be performed on Day 1 of 
Cycles 2 through 6 before  the start of the NC-6004 infusion and at the End-of-Treatment  visit. 
All 12 -lead ECGs should be performed within a ±30- minute window. 
Any assessments, including those that worsen from baseline, believed to be clinically 
significant  in the medical  and scientific  judgment of  the investigator  are to be recorded  as 
AEs or SAEs per the NCI CTCAE version 4.03.  
 
6.3.7 Physical  Examination 
A complete physical examination will be performed during the screening period at Day - 14 
to -1, before  study treatments  on Day –1 or Day 1 of each cycle,  and at the End-of-Treatment 
visit. Height and weight will also be assessed at the time of the screening period physical examination and before treatments on Day  1 of each cycle. Calculation of BSA  will be done 
before each dosing on Day 1 of each cycle (using the Mosteller formula [ Mosteller  1987]. 
(Note : Dose will only  be recalculated if there is a ≥10% increase or decrease in the patient’s 
weight  from the patient’s  weight  measurement  at screening. Any change  in a patient’s  weight 
by ≥10% during the study will require a recalculation of the doses of all study drugs. This threshold should not be confused with a change in the patient’s BSA  [m
2]). 
Any abnormal  assessments,  including  those  that worsen  from  baseline,  are to be recorded  as 
AEs or SAEs as per the NCI CTCAE version 4.03. 
 
6.3.8 Vital  Sign  Measurements  
Vital sign measurements will include arterial blood pressure, heart rate, respiratory  rate, and 
temperature.  Vital signs  will be measured  after the patient  has adequately  rested  in the supine 
position.  
Vital signs  will be measured  during the screening  period on Day -14 to -1. On Day 1 of 
Cycle 1, vital signs will be measured before the start of the NC -6004 infusion, every 
20 minutes during the infusion, at the completion of the infusion, and 1 hour after the  
completion of  the NC-6004 infusion. Starting in Cycle  2, vital signs will be measured before 
the start of the NC-6004 infusion and at the completion of the NC-6004 infusion on Day 1 of 
each cycle. Vital signs will be measured before and after gemcitabine infusion on Day 8 of 
each cycle. Vital signs will also be measured at the End -of-Treatment visit.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  77  
 Any abnormal  assessments,  including  those  that worsen  from  baseline,  are to be recorded  as 
AEs or SAEs as per the NCI CTCAE version 4.03. 
 
6.3.9 Eastern  Cooperative  Oncology Group Performance  Status  
The patient’s  PS will be assessed  during the screening  period on Day -14 to -1 and before 
dosing on Day –1 or Day 1 of each cycle using the ECOG PS grades ( Oken  et al 1982 ) 
below:  
0 Fully  active,  able to carry  on all predisease performance without restriction  
 
1 Restricted  in physically strenuous  activity  but ambulatory  and able to carry  out work 
of a light or sedentary nature, eg, light house work, office work 
2 Ambulatory  and capable of all self-care but unable  to carry  out any work  activities. 
Up and about more than 50% of waking hours  
3 Capable  of only limited  self-care,  confined to bed or chair  more  than 50% of waking 
hours  
4 Completely  disabled. Cannot  carry  on any self-care.  Totally  confined to bed or chair  
 
5 Dead  
 
6.3.10  Audiometry  
Audiometry will be  performed to  assess for  ototoxicity  during the screening period at  
Day -14 to -1. On Day 1 of each cycle prior  to study  treatments  and at the End-of-Treatment 
visit, audiometry will be performed only as clinically indicated.  
Any abnormal  assessments,  including  those  that worsen  from  baseline,  are to be recorded  as 
AEs or SAEs per the NCI CTCAE version 4.03.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  78  
 7 Statistical  and Analytical  Plan  
7.1 Safety Endpoints  
The safety endpoints for this study are the incidence and severity of  AEs and laboratory 
abnormalities, according to the NCI CTCAE version 4.03, the occurrence of SAEs and 
treatment discontinuations  due to AEs,  and nausea  severity  and vomiting incidence  obtained 
from the patient diary.  
 
7.2 Exploratory Endpoints 
The exploratory endpoints of this study include exploratory safety endpoints of the 
occurrence of AEs and SAEs  after 6 cycles of treatment and the following  PK endpoints  for 
micellar platinum  in plasma  and total platinum  in plasma and plasma ultrafiltrate  calculated 
for all patients using noncompartmental analysis:  
 
• Cmax (maximum concentration)  
• Tmax (time  to maximum concentration)  
• AUC last (area under  the concentration -time curve  from time zero to the last quantifiable 
concentration)  
• AUC 0-τ (area under  the concentration -time curve  from time zero to the end of the dosing 
interval) 
• AUC 0-∞ (area  under  the concentration -time curve  from time  zero to infinity) 
• AI (accumulation  index)  
• Vss (volume  of distribution at  steady -state)  
• MRT  (mean  residence time)  
• λz (terminal  elimination  phase  rate constant)  
• T½ (terminal  half-life) 
• CL (clearance)  
• Vz (volume  of distribution) 
7.3 Sample  Size Calculations 
This is a Phase 1b/2 study with an overall sample size of up to 209 patients (up to 49 patients 
in Part 1 and up to 160 patients  in Part 2). The total sample size will depend on the number  of 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  79  
 cohorts  required  to establish  an RPII  dose and the number  of patients  with NSCLC enrolled 
at the RPII dose in Part 1.  
Simulations  were  performed  assuming scenarios  with different  dose-toxicity  relationships  to 
evaluate the sample size for Part 1 (Phase 1b). The associated mean sample size in these 
scenarios ranged from 17.22 to 25.79 patients.  
Part 2 is a 3-cohort  study  with an overall  sample size of up to 160 patients  with no more  than 
50 patients each in Cohorts 1 and 2 and no more than 60 patients in Cohort 3 (30 unfit and 
30 fit bladder cancer patients). The total sample size will depend on the results of interim 
futility and superiority analyses. In order to evaluate the overall sample size, simulations 
were performed assuming scenarios with different HRs for PFS for each cohort compared 
with historical control and different sample sizes for a subsequent Phase 3 clinical trial. The 
associated mean sample size for this trial in these scenarios ranged from 92.7 to 116.8 
patients.  
No formal efficacy  analysis  will be performed  and no inference  regarding  efficacy  will be 
drawn based on the response rate of the overall study. 
Patients  who receive study  drug will not  be replaced.  
 
7.4 Analysis  Sets 
Four  analysis sets will be used  in this study:  
 
• The DLT -evaluable  analysis set consists  of all patients  in Part 1 who either  experience a 
DLT  in the first cycle or complete the first cycle without a DLT.  
• The safety  analysis  set consists  of all patients  in Part 1 or Part 2 who receive study 
product.  
• The Full Analysis  Set (FAS)  consists  of all patients  treated  at RPII  dose in Part 1 or Part 2 
who receive study product.  
• The PK analysis set consists  of all patients  in the safety  analysis  set who have  sufficient 
concentration data for PK analysis.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  80  
 7.5 Description  of Subgroups  to be Analyzed  
No subgroup analyses are planned.  
 
7.6 Statistical  Analysis  Methodology  
Ninety -five percent confidence intervals may be calculated for selected safety and 
exploratory variables.  Dose  escalation  will be based  on N-CRM  model  and DLT  incidence. 
Adverse events and SAEs will be tabulated by system organ class and preferred term.  
Laboratory test results after the first dose will be summarized with regard to shifts from 
baseline values and grade per NCI CTCAE version 4.03. Overall survival, PFS, and DOR 
will be summarized using Kaplan -Meier methods. Ninety -five percent confidence intervals 
for ORR and DCR will be constructed.  All safety analyses will be performed on the safety 
analysis  set. All efficacy  analyses  will be performed  on the FAS.  All summaries will present 
data by dose level, for patients with NSCLC dosed at the MTD, and overall.  
In Part 2, the following posterior  probabilities  will be derived  using a Bayesian  model 
updated every 6 weeks after 10 PFS have occurred within a cohort:  
• Probability  (Promising  HR) 
 
• Probability  (Phase 3 Success)  
 
If any cohort at interim or final analyses has a probability (success in a Phase 3 trial with 
381 PFS events) >0.8, that indication will be declared a success, and the combination of 
NC-6004 and gemcitabine  advances  to a Phase 3 randomized,  controlled trial with a sample 
size sufficient to observe 381 PFS events.  
 
7.6.1 Efficacy  Analysis  
7.6.1.1  Progression –Free  Survival  
Progression- free survival will be defined as the time from first dose of study  product  until the 
first date of either disease progression or death due to any cause and will be evaluated for each dose level and for all patients in the FAS. The date of disease progression will be 
defined as the earliest date of radiological disease progression as assessed by  the investigator 
using RECIST version 1.1 or clinical disease progression. For patients who have not  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  81  
 progressed or died at the time of the analysis, censoring will be performed using the date of 
the last adequate disease assessment. In addition, patients with disease progression or death 
after an extended loss to follow -up will be censored at the date of the last adequate disease 
assessment  prior  to the extended loss to follow -up. Further  details  on censoring rules  will be 
outlined in the statistical analysis plan (SAP).  
 
7.6.1.2  Overall  Survival  
Overall  survival  will be defined as the time from first dose of study product until  the date of 
death due to any cause and will be evaluated for each dose level and for all patients in the 
FAS.  For patients  who have  not died at the time of the analysis,  censoring  will be performed 
using the date the patient was last known to be alive. Further details on censoring rules will be outlined in the SAP. 
 
7.6.1.3  Duration of Response  
Duration of response will be defined as the time from the earliest date of confirmed response until the first date of either disease progression or death due to any cause and will be 
evaluated for each dose level and for all patients in the FAS.  The date of disease progression 
will be defined as the earliest date of radiological disease progression as assessed by the investigator  using RECIST  version 1.1, or clinical disease  progression. For patients  who have 
not progressed or died at the time of the analysis, censoring will be performed using the date of the last adequate disease assessment. In addition, patients with disease progression or 
death after an extended loss to follow -up will be censored at the date of the last adequate 
disease assessment prior to the extended loss to follow -up. Further details on censoring rules 
will be outlined in the SAP.  
 
7.6.1.4  Disease  Control  Rate 
Disease control  rate is defined as the proportion of patients with best overall  response  of SD 
longer than 7 weeks, confirmed PR, or confirmed CR at the time each patient discontinues study treatment.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  82  
 7.6.1.5  Overall  Response  Rate  
Overall  response  rate is defined as the proportion  of patients  with best overall  response  of 
confirmed PR or confirmed CR at the time each patient discontinues NC -6004 and 
gemcitabine.  
 
7.6.1.6  Quality of Life Analyses  
Quality  of life will be assessed  using  the EORTC  QLQ- C30. Analyses will be based  on the 
FAS.  
Each of the 30 scores of the EORTC QLQ -C30, as well as the 5 functional scales (physical, 
role, emotional,  cognitive,  social),  and 9 symptom  scales  (fatigue,  nausea  and vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) will be 
summarized by visit. Changes from baseline will be summarized by dose level, for all 
patients dosed at MTD (or RPII dose), and overall. 
The calculation of scores and methods to deal with missing  data will be handled according to 
the respective questionnaires’  standard scoring guidelines. Full details of all the QoL analyses 
will be provided in the SAP.  
 
7.6.1.7  Symptoms Assessment  Analyses  
The MDASI  core 13 symptom  items  and 6 interference  items  plus the 3 lung cancer -specific 
symptom items (MDASI -LC) will be summarized by visit.  Analyses will be based on the 
FAS.  Changes  from baseline  will be summarized  by dose level,  for all patients  with NSCLC 
dosed at MTD (or RPII dose), and overall.  
The calculation of scores and methods to deal with missing  data will be handled according to 
the respective questionnaires’  standard scoring guidelines. Full details of all the QoL analyses 
will be provided in the SAP.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  83  
 7.6.2 Safety Analyses  
7.6.2.1  Analyses of Adverse Events  
An AE will be considered to be a TEAE  if it begins  or worsens  on or after first dose date and 
before last dose date + 28 days. The following summaries of TEAEs by system organ class 
and preferred term will be provided:  
• All TEAEs  
• All serious TEAEs  
• All treatment -related  TEAEs  
• All treatment- related  serious  TEAEs  
• All TEAEs resulting  in study drug discontinuation  
• All TEAEs  by NCI CTCAE  grade  
• All TEAEs by  relationship  to study  drug 
 
 
The following summaries of TEAEs by  preferred  term will be provided:  
 
• TEAEs  with at least 5% incidence in all patients  
• Treatment -related  TEAEs  with at least 5% incidence  in all patients  
• TEAEs  with at least 5% incidence  in all patients  with NSCLC dosed at the MTD  or RPII 
dose 
• Treatment -related  TEAEs  with at least 5% incidence  in all patients  with NSCLC dosed at 
the MTD or RPII dose  
The incidence of deaths and the  primary  cause of death will be  summarized.  
 
7.6.2.2  Severity  of Nausea and Incidence  of Vomiting  
The severity  of nausea and incidence  of vomiting  as captured  in the diary  data will be 
summarized.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  84  
 7.6.2.3  Clinical Laboratory  Results  
Clinical hematology and coagulation, biochemistry, and urinalysis data will be summarized 
at each scheduled  assessment.  Numeric  hematology and coagulation and biochemistry  results 
will be summarized using change from baseline.  All results will be summarized using shift 
from baseline. Shifts for laboratory results that are can be graded with NCI CTCAE version  
4.03 will be summarized  by NCI CTCAE grade.  Shifts  for other  numeric  laboratory  results 
will be by high/normal/low flag. Shifts for all other laboratory results will be by 
normal/abnormal flag.  
Summaries by  visit will include data from scheduled assessments only, and all data will be 
reported according to the nominal visit date  for which it was recorded (ie, no visit windows 
will be applied). Unscheduled data will be included in “worst  case postbaseline”  summaries 
which will capture a worst case across all scheduled and unscheduled visits after the first dose of study treatment. Further details will be provided in the SAP.  
Numeric  clinical  hematology  and coagulation, biochemistry,  and urinalysis  results  will be 
summarized using change from baseline.  All results will be summarized using shift from 
baseline.  
 
7.6.2.4  Additional  Safety Assessments 
The results of scheduled assessments of vital signs, ECOG PS, and 12 -lead ECG will be 
summarized.  Summaries  by visit will include  data from scheduled  assessments only. All data 
will be reported according to the nominal visit date for which it was recorded (ie, no visit 
windows will be applied). Unscheduled data will be included in “worst case” summaries 
which will capture a worst case across all scheduled and unscheduled visits after the first 
dose of study treatment.  All data will be listed. Further details will be provided in the SAP.  
7.6.3 Pharmacokinetic  and Pharmacodynamic  Analyses  
Noncompartmental  analysis will be used to calculate  the following  PK parameters for total 
platinum in plasma and plasma ultrafiltrate:  
• Cmax 
• Tmax 
• AUC last 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  85  
 • AUC 0-τ 
• AUC 0-∞ 
• AI 
• Vss 
• MRT  
• λz 
• T½ 
• CL 
• Vz 
 
Data  for PK parameters will be summarized  in tables and individual  data will  be listed.  
 
7.6.4 Study Drug  Exposure 
Study drug exposure  will be summarized by  dose level and overall for  the safety  analysis set.  
Duration of treatment and total number of cycles dosed will be summarized for 
combination therapy. Total dose received (mg) will be summarized for NC -6004 and 
gemcitabine separately.  The number  of patients  dosed  by cycle will also be summarized 
using frequency counts and percentages. 
Duration  of treatment,  in days, will  be calculated  as (date  of last dose of study product  – date 
of first dose of study product + 1).  
 
7.7 Data Quality Assurance  
Steps to be taken to ensure the accuracy and reliability of data include the selection of a 
qualified investigator and appropriate study center, review of protocol procedures with the 
investigator  and associated  personnel  before  the study, and periodic  monitoring  visits  by the 
clinical research associate (CRA). Written instructions will be provided for collection, preparation, and shipment of blood and plasma samples.  
The eCRFs  will be provided to the clinical  contact  and the CRA will review  them  with site 
personnel.  
The CRA  will review  eCRFs  for accuracy  and completeness by remote  monitoring, during 
on-site monitoring visits, and after transmission to the sponsor; any discrepancies will be 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  86  
 resolved  with the investigator  or designee, as appropriate. After  entry  of the data into the 
clinical study database they will be verified for accuracy.  
 
7.7.1 Data Management  
As part of the responsibilities assumed by  participating in the study, the investigator agrees to 
maintain adequate case histories for the patients treated as part of the research under this 
protocol. The investigator agrees to maintain accurate eCRFs and source documentation as 
part of the case histories.  These source  documents  may include  laboratory  reports, ECG strips, 
and patient diaries.  
Investigative  site personnel  will enter  patient  data into Medidata Rave.  The analysis data sets 
will be a combination of these data and data from other sources (eg, laboratory data).  
Clinical data management  will be performed  in accordance  with applicable  PPD standards 
and data cleaning procedures to ensure the integrity of the data (eg, removing errors and 
inconsistencies in the data). Adverse events will be coded using MedDRA  version 16.0. 
Concomitant  medications  will be coded  using WHO Drug  Dictionary,  version 01-Jun-2013.  
 
After database lock, each study site will receive a CDROM containing all of their site 
specific eCRF data as entered into Oracle Clinical Remote Data Capture for the study, 
including full discrepancy  and audit  history. Additionally,  a CDROM  copy of all of the study 
site’s data from the study will be created and sent to the sponsor for storage. PPD will maintain a duplicate CDROM copy for its records. In all cases, patient initials will not be 
collected or transmitted to the sponsor.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  87  
 8 Ethics  
8.1 Independent Ethics  Committee  or Institutional  Review  Board  
Federal  regulations  and the International  Council  for Harmonisation  (ICH) guidelines  require 
that approval be obtained from an institutional review board (IRB)/independent ethics 
committee (IEC) before participation of human patients in research studies. Before study 
onset, the protocol, informed consent, advertisements to be used for the recruitment of study 
patients, and any other written information regarding this study to be provided to the patient 
or the patient’s legal guardian must be approved by the IRB/IEC. Documentation of all 
IRB/IEC approvals and of the IRB/IEC compliance with ICH harmonised tripartite guideline 
E6(R1):  Good Clinical Practice (GCP)  will be maintained  by the site and will be available for 
review by the sponsor or its designee. 
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must 
identify  the IRB/IEC  name  and address,  the clinical  protocol  by title or protocol  number  or 
both, and the date approval or a favorable opinion was granted. 
The investigator is responsible for obtaining continued review of the clinical research at 
intervals  not exceeding  1 year  or otherwise  specified  by the IRB/IEC.  The investigator  must 
supply the sponsor or its designee with written documentation of continued review of the 
clinical research.  
 
8.2 Ethical  Conduct of the Study 
The study will be performed  in accordance with the ethical  principles  that have  their origin  in 
the Declaration of Helsinki, ICH GCP, and all applicable regulations.  
 
8.3 Patient Information  and Consent  
A written informed consent in compliance with US Title 21 Code of Federal Regulations 
(CFR) Part 50 shall be obtained from each patient before entering the study or performing 
any unusual or nonroutine procedure that involves risk to the patient. An informed consent 
template may be provided by the sponsor to investigative sites. If any institution -specific 
modifications to study -related procedures are proposed or made by the site, the consent 
should be reviewed  by the sponsor  or its designee  or both before IRB/IEC  submission.  Once  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  88  
 reviewed, the consent will be submitted by the investigator to his or her IRB/IEC for review 
and approval  before  the start of the study. If the ICF is revised  during the course  of the study, 
all active participating patients must sign the revised form.  
Before  recruitment and enrollment,  each prospective  patient or his or her legal  guardian will 
be given a full explanation of the study and be allowed to read the approved ICF. Once the 
investigator is assured that the patient/legal guardian understands the implications of 
participating in the study, the patient/legal guardian will be asked to give consent to 
participate in the study by signing the ICF. 
The investigator shall  retain  the signed  original ICF(s) and give a copy of the signed original 
form to the patient or legal guardian.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  89  
 9 Investigator’s Obligations 
The following administrative  items  are meant  to guide  the investigator  in the conduct  of the 
study but may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the 
IRB/IEC but will not result in protocol amendments.  
 
9.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain patient confidentiality.  All records will be kept in a secure 
storage  area with limited  access.  Clinical  information  will not be released  without  the written 
permission  of the patient (or the patient’s  legal guardian),  except  as necessary  for monitoring 
and auditing by the sponsor, its designee, the Food and Drug Administration (FDA), or the 
IRB/IEC.  
The investigator and all employees  and coworkers  involved with this study  may not disclose 
or use for any purpose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties.  
 
9.2 Financial  Disclosure  and Obligations 
Investigators  are required  to provide  financial disclosure  information  to allow  the sponsor  to 
submit the complete and accurate certification or disclosure statements required under  
21 CFR 54. In addition, the investigator must provide to the sponsor a commitment to 
promptly update  this information  if any relevant  changes  occur  during the course  of the 
investigation and for 1 year following the completion of the study.  
Neither  the sponsor  nor PPD is financially  responsible  for further testing  or treatment of any 
medical condition that may be detected during the screening process. In addition, in the absence of specific arrangements, neither the sponsor nor PPD is financially responsible for 
further treatment of the patient’s disease.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  90  
 9.3 Investigator  Documentation  
Prior to beginning the study, the investigator will be asked  to comply with ICH E6(R1)  8.2 
and Title 21 of the CFR by providing the following  essential documents, including  but not 
limited to:  
• IRB/IEC  approval.  
• Original investigator -signed  investigator agreement  page  of the protocol.  
• Form  FDA 1572, fully  executed,  and all updates on a new fully  executed  Form FDA  1572.  
• Curriculum vitae  for the investigator and each subinvestigator  listed  on Form  FDA 1572  
• Financial disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements required under 21 CFR 54. In addition, the investigators must provide to the sponsor a commitment to promptly update this information  if any relevant  changes  occur  during the course  of the investigation and for 
1 year after the completion of the study. 
• IRB/IEC -approved informed consent, samples of site advertisements for recruitment for 
this study, and any other  written  information  regarding this study that is to be provided to 
the patient or legal guardian,  
 
9.4 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R1). The investigator will conduct all  aspects of  this study  in accordance with all national, 
state, and local laws or regulations. Study information from this protocol will be posted on 
publicly available clinical trial registers before enrollment of patients begins.  
 
9.5 Adherence  to Protocol  
The investigator agrees to conduct  the study as outlined  in this protocol  in accordance with 
ICH E6(R1) and all applicable guidelines and regulations.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  91  
 9.6 Adverse  Events and Study Report  Requirements  
By participating  in this study the investigator agrees to submit  reports  of SAEs  according to 
the time line and method outlined in the protocol. In addition, the investigator agrees to 
submit annual reports to the study site IRB/IEC as appropriate.  
 
9.7 Investigator’s Final  Report  
Upon completion of the study, the investigator, where applicable, should inform the 
institution;  the investigator/institution  should provide  the IRB/IEC  with a summary  of the 
study’s outcome and the sponsor and regulatory authority(ies) with any reports required. 
 
9.8 Records  Retention  
Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by the applicable regulatory 
requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to 
inform  the investigator/institution  as to when  these documents  no longer  need  to be retained.  
 
9.9 Publications 
After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript  is written  and edited, the number  and order  of authors, the publication  to which  it 
will be submitted, and other related issues.  The sponsor has final approval authority over all 
such issues.  
Data  are the property of the sponsor  and cannot  be published without  prior  authorization 
from the sponsor, but data and publication thereof will not be unduly withheld.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  92  
 10 Study Management  
10.1 Monitoring  
10.1.1  Monitoring of the Study 
The clinical  monitor,  as a representative  of the sponsor, has the obligation to follow  the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic  intervals, 
in addition to maintaining necessary telephone and letter contact. The monitor will maintain 
current personal knowledge of the study through observation, review of study records and 
source documentation, and discussion of the conduct of the study with the investigator and 
personnel.  
All aspects of the study will be carefully monitored by the sponsor or its designee for compliance  with applicable  government  regulation  with respect  to current  GCP  and current 
standard operating procedures.  
 
10.1.2  Inspection  of Records  
Investigators and institutions involved in the study will permit study- related monitoring, 
audits, IRB/IEC review, and regulatory inspections by providing direct access to all study 
records. In the event  of an audit,  the investigator  agrees  to allow  the sponsor, representatives 
of the sponsor, or a regulatory agency access to all study records.  
The investigator should promptly notify  the sponsor  and PPD of any audits scheduled  by any 
regulatory authorities and promptly forward copies of any audit reports received to the sponsor.  
 
10.2 Management of Protocol  Amendments  and Deviations 
10.2.1  Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, 
immediate hazard to the patient, must be reviewed and approved by the sponsor or its 
designee.  Amendments  to the protocol  must  be submitted  in writing  to the investigator’s 
IRB/IEC for approval before patients can be enrolled into an amended protocol.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  93  
 10.2.2  Protocol  Violations  and Deviations 
The investigator or designee must document and explain in the patient’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
patients without prior IRB/IEC approval.  As soon as possible after such an occurrence, the 
implemented  deviation or change, the reasons  for it, and any proposed protocol  amendments 
should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, 
and to the regulatory authorities, if required.  
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the investigator.  A significant deviation  occurs when  there  is nonadherence  to the protocol  by the 
patient or investigator that results in a significant, additional risk to the patient. Significant deviations can include nonadherence to inclusion or exclusion criteria or nonadherence to 
FDA regulations or ICH GCP  guidelines, and will lead to the patient being withdrawn from 
the study ( Section 4.2 ). 
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring visits. Principal investigators will be notified in writing by the monitor of deviations. The IRB/IEC  should be notified  of all protocol  deviations  in a timely  manner.  
 
10.3 Study Termination  
Although NanoCarrier  has every  intention  of completing the study, NanoCarrier  reserves the 
right to discontinue the study at any time for clinical or administrative reasons.  
The end of the study is defined as the date on which  the last patient  completes the last visit to 
the study site (includes any End- of Treatment visit to the site and any visit to the site to 
obtain confirmatory scan of response).  
 
10.4 Final  Report  
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical  study  reports  are prepared  and provided to the regulatory agency(ies)  as required  by 
the applicable  regulatory  requirement(s).  The sponsor  will also ensure  that the clinical study  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  94  
 reports  in marketing  applications  meet  the standards  of the ICH harmonised tripartite 
guideline E3: Structure and content of clinical study reports.  
Where required  by applicable  regulatory  requirements,  an investigator  signatory will be 
identified  for the approval  of the clinical study report.  The investigator  will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results.  
Upon completion  of the clinical  study  report,  the sponsor  will provide  the investigator  with 
the full summary  of the study results.  The investigator is encouraged to share the summary 
results with the study patients, as appropriate. The study results will be posted on publicly available clinical trial registers.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  95  
 11 Reference  List 
Azzoli  CG, Baker  S, Temin  S, et al. 2011 Focused  Update  of 2009 American  Society  Clinical 
Oncology clinical practice guideline update on chemotherapy for Stage IV non- small cell 
lung cancer. J Clin Oncol. 2011;29(28):3825- 31. Full guideline published (2009) in J Clin 
Oncol. 2009;27(36):6251- 66. 
Cleeland  CS, Mendoza  TR, Wang  XS, et al. Assessing  symptom  distress  in cancer:  the M. D. 
Anderson Symptom Inventory. Cancer. 2000;89(7):1634- 46. 
Cockcroft  DW,  Gault  MH. Prediction  of creatinine  clearance  from serum  creatinine.  Nephron. 
1976;16(1):31– 41. 
Eisenhauer  EA, Therasse P, Bogaerts  J, et al. New  response  evaluation criteria  in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228- 47. 
Hartmann  JT, Lipp  HP. Toxicity  of platinum  compounds. Expert  Opin  Pharmacother. 
2003;4(6):889- 901. 
Kelland  LR, Sharp  SY. Platinum  compounds  in cancer  therapy. Curr Opin  Oncol, Endocrine, 
Metabolic Invest Drugs. 1999;1:380 -5. 
Matsumura Y, Maeda H.  A new concept for macromolecular therapeutics in cancer 
chemotherapy:  mechanism  of tumoritropic  accumulation  of proteins  and the antitumor  agent 
smancs. Cancer Res. 1986;46:6387- 92. 
Mosteller  RD. Simplified  calculation  of body- surface area.  N Engl  J Med. 
1987;317(17):1098.  
National  Cancer  Institute.  Common terminology  criteria  for adverse  events  (CTCAE)  Version  
4.0 (v4.03) 14 June 2010. Available from: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010- 06-14_QuickReference_8.5x11.pdf  
Neuenschwander  B, Branson M, Gsponer  T. Critical aspects of the Bayesian  approach to 
phase I cancer trials. Stat Med. 2008;27(13):2420 -39. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  96  
 Oken  MM,  Creech  RH, Tormey, DC, et al. Toxicity  and response criteria  of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649- 55 
Pinto  AL, Lippard SJ. Binding of the antitumor  drug cis-diamminedichloroplatinum(II) 
(Cisplatin) to DNA. Biochim Biophys Acta. 1985;780(3):167- 80. 
Plummer R, Wilson RH, Calvert H, et al.) A phase I clinical study of cisplatin -incorporated 
polymeric  micelles (NC- 6004)  in patients  with solid  tumours.  Br J Cancer.  2011;104(4):593-  
8. 
Smith  TJ, Khatcheressian  J, Lyman  GH, et al. 2006 update  of recommendations  for the use of 
white blood cell growth factors: An evidence -based clinical practice guideline. J Clin Oncol. 
2006;24(19):3187- 205. 
Uchino H, Matsumura  Y, Negishi T, et al. Cisplatin -incorporating polymeric micelles 
(NC- 6004)  can reduce  nephrotoxicity  and neurotoxicity of cisplatin  in rats. Br J Cancer. 
2005;93(6):678- 87. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  97  
 12 Appendices  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  98  
 12.1 Appendix: Schedule  of Events  
Table  12-1 Schedule  of Events  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                  
Eligibility  criteria   X                 
Demography   X                 
Medical  history   X                 
Pregnancy  test 
(serum  or urine)    X Xe    X   X   X   X  
Physical 
examination   Xf  Xf    X   X   X   X  
Height,  weight,  and 
BSA  calculationg  Xg  X    X   X   X     
Vital  signsh  X  Xh  X  X X  X X  X X  X  
Performance  status 
(ECOG)   Xf  Xf    X   X   X   X  
Disease  assessmenti X          Xi   Xi   X X 
Audiometry   X  Xj    Xj   Xj   Xj   Xj  
Hematology  and 
coagulation    X Xk  X X X X X X X X X X X X  
Biochemistry    X Xk  X X X X X X X X X X X X  
Urinalysis   X               X  
EORTC  QLQ -C30    X  X  X X  X X  X X  X  
MDASI or 
MDASI -LC l    X  X  X X  X X  X X  X  
Continued  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  99  
 Table  12-1 Schedule  of Events  (Continued)  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Part 1: Nausea  and 
vomiting patient 
diarym     
X   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X   
Part 2 Nausea  and 
vomiting patient 
diarym     
X   
X   
X  
X          
Cardiac  risk factors   X                 
12-lead ECGn   X X X X  X   X      X  
Pharmacokinetic 
assessments 
(Part 1)o     
X  
Xo  
X  
X  
X    
X  
Xo  
Xo     
X  
Pharmacokinetic 
assessments 
(Part 2)p     
X   
X   
X  
X   
X  
X      
X  
Adverse  events     Xf X X X X X X X X X X X X X X 
Concomitant 
medication   Xf  Xf X X X X X X X X X X X X X Xc 
Prophylactic 
administrations     X    X   X   X     
NC-6004  
administrationa    X    X   X   X     
Gemcitabine 
administration     X  X  X X  X X  X X    
Abbreviations: BSA, body surface area; ECG, electrocardiogram; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ -C30, European Organisation for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI,  MD Anderson Symptom  Inventory;  RECIST,  Response  Evaluation  Criteria  in 
Solid Tumors; MDASI -LC, MDASI -lung cancer.  
a. In Part 1 of the study,  patients  will receive treatment  until progressive  disease.  In Part 2 of the study,  patients  will receive treatment  for 6 cycles  (Cohorts  1 and 3) 
or 8 cycles (Cohort 2).  
b. End-of-treatment  assessments will be performed within  28 days after treatment  discontinuation.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  100  
 c. After  patient discontinuation or completion of treatment  without disease  progression, patients  will be followed with scans  every 9 weeks  until disease  progression. 
Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse events.  
d. Day 15 visit is required in Part 1. In Part 2, Day  15 visit is  only necessary  if it is clinically  indicated.  
e. Not required if screening  pregnancy test was performed using serum.  
f. Safety  assessments of physical examination,  ECOG, review  of adverse events, and concomitant  medication  use can be  completed on Day -1 to allow  for early 
morning dosing. These should not be conducted in place of screening assessments. 
g. From Day -14 to -1 at screening,  only height and weight will be measured. On Day  1 of each cycle, weight will be measured before treatments and BSA  will be 
calculated before each dose using  the Mosteller formula ( Mosteller 1987). ( Note: Dose will only  be recalculated if there is a ≥10% increase or decrease in the 
patient’s weight  from the patient’s  screening weight  measurement. Any change in a patient’s weight  by ≥10% during the study will require a recalculation of the 
doses of all study drugs. This threshold should not be confused with a change in the patient’s BSA [m2]). 
h. Vital signs will be performed after the patient  has adequately  rested in the  supine position. On Day  1 of Cycle 1, vital  signs will be measured before  the start of the 
NC-6004 infusion, every 20 minutes during the infusion, at the completion of the infusion, and 1 hour after the completion of th e NC -6004 infusion. Starting in 
Cycle 2, vital signs will be measured before the start of the NC-6004 infusion and at the completion of the NC-6004 infusion on Day 1 of each cycle. Vital signs 
will be measured before and after gemcitabine infusion on Day 8 of each cycle. Vital signs will also be measured at the End-of- Treatment visit.  
i. Disease  assessment  will be  performed using RECIST  version 1.1 and the  same  imaging method used at screening should be used for all subsequent assessments. 
Beginning in Cycle  3 and continuing through the remainder of the treatment cycles,  disease will  be assessed  every 6 (±1)  weeks  (ie, every other  cycle)  and at the 
End-of-Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a confirmatory scan at a minimum of 4 weeks following the initial scan.  
j. To be performed only  as clinically  indicated.  
k. Hematology  and coagulation and biochemistry tests will be repeated prior to dosing on Day 1 of Cycle 1 if they were  last performed more  than 24 hours  before 
the start of the study drug administration. 
l. Symptom changes  will be assessed using  the core MDASI  (Part 1 only) or MDASI -LC (only in patients  with NSCLC  in Part 1). 
m. Part 1: The investigator will collect the nausea and vomiting patient diary from each patient on Day 8 and Day 15 for Cycle 1 . For all subsequent cycles, the 
investigator will collect diaries on Day 1 (prior to dosing to capture  the last 7 days of the previous cycle), Day  8, and Day 15. Part 2: The investigator will collect 
the nausea and vomiting  patient  diary  from each patient  at the site on Day 8 for Cycle  1. For  Cycle  2, the  investigator will collect  diaries on Day  1 (prior to dosing 
to capture  the last  7 days of the previous cycle) and Day 8. Note that nausea and vomiting patient diaries will not be collected past Cycle 2. For additional  details, 
see Section 6.3.3 . 
n. Twelve- lead ECGs will be performed after the patient has adequately rested in the supine position. A  12-lead ECG  will be performed during the screening period 
at Day  -7 to -1. On Day  1 of Cycle 1, 12-lead ECGs will be performed before the start of the NC -6004 infusion, at completion of infusion (~1 hour after start of 
infusion), and at Hours 3 and 24 (Day  2) after the start of infusion. On Day  8 of Cycle 1, 12-lead ECGs will  be performed before  the start of gemcitabine  infusion, 
at the end of gemcitabine infusion, and at 1 hour after completion of gemcitabine infusion. Twelve -lead ECGs will be performed on Day 1 of Cycles 2 through 6 
before the start of the NC-6004 infusion, and at the End-of- Treatment visit. All 12 -lead ECGs should be performed within a ±30-minute window. 
o. F
or Part 1, blood samples will be collected at the following times: before the start of the NC-6004 infusion on Day 1 of Cycles 1 through 6, at end of NC-6004 
infusion in Cycles 1, 3, and 5, after the start of NC -6004 infusion at Hours  3, 6, 12, 24 (Day 2), 48 (Day 3), 96 (Day  5), 168 (Day 8, prior to gemcitabine infusion), 
and 336 (Day 15) in Cycles 1, 3, and 5, and at the End-of-Treatment visit. Additional pharmacokinetic blood sample collections may be performed, at the  
discretion of the investigator, during any  visit where toxicity  is observed. Blood samples will be collected within 10 minutes after the 12 -lead ECGs performance.  
p. For Part 2 (up to 6 cycles), on the  day of NC-6004 infusion for each cycle, blood samples  will be collected before the start of the NC-6004 infusion, at  the end of 
the NC -6004 infusion, before gemcitabine infusion on Day 8, and at the End-of -Treatment visit. Additional pharmacokinetic blood sample collections may be 
performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within 10 minutes after the 12-lead 
ECGs performance.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  101  
 
12.2 Appendix: European Organisation for Research  and Treatment  of 
Cancer Quality of Life Questionnaire Core 30 
 
 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  102  
 
 f
 
に Ithe followillg questiollS please c 
Veiy poor  t  
   
 
 
 
Duringthe past week:  Not at  A Quite  VeI'}' 
All Little  a Bit Mufh 
17. Have you had di.arrhea? 2 3 4 
18_ Were  you ti1-ed? 2 3 4 
19. Didpa11i1ntetfere with your血ly activities? 2 3 4 
20. Have 111 concentratmg011things, 
like r or watchmgtelevts1011?  2 3 4 
21 t臼1se，? 2 3 4 
22. 2 3 4 
23. Did 2 3 4 
：こyo二ご二： s：ty?fつlgs? : : : : 
26. Has your physical co11d!fio11QI" medical treatme11L ) 
27. Has your physical co11ditio11or mediqlf tteatme11t mterferedwIfuyoursocialactivities?  1 3 4 
28 ::1：ご。 誓ae1la:1ca：掌盆三乞／ ） l 2 
29. 
4 5 6 ／ノ，，，，  
くク 
Veiypoor Excellent 
© Cop;nght 1993EO RTC畑1i1yof LtfeGroup . All ti芦resetved V西ot13.0 behveeul   aud37that4 
3Ho0wwo ltldy:rateyour3overal-nngtilepa6stweek?7 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  103  
 
12.3 Appendix: MD Anderson Symptom  Inventory– Lung Cancer 
Note:  The core MDASI  is the same as the MDASI -LC (shown below)  with the  exception that 
the core MDASI does not include questions 14, 15, and 16 of the MDASI -LC. 
 
 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  104  
  
 
 

NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  105  
 12.4 Appendix: Protocol  Amendments 
 
12.4.1  Protocol  Amendment 1–Protocol  Version  2.0, Incorporating 
Amendment 1, Dated 31 December 2014  
The following sections detail the changes made to the  original protocol (Version 1.2)  dated 
17 October  2013. The integrated  protocol, Version  2.0, including Amendment  1, was issued  
on 31 December  2014.  
 
12.4.1.1  Overview  of Changes 
The overview  of significant changes  includes  the following:  
 
Title  Page  – Sponsor;  Protocol  Approval  – Sponsor  Signatory  
 
The sponsor  address was updated to the following: 
144-15 Chuo Gaiku, 226-39 Wakashiba  Kashiwa 
Chiba, 277-0871, Japan  
Title  Page  – Sponsor  Contact  
The sponsor  contact  telephone  was updated to the following:  
+81-4-7197- 7623  
Synopsis  – Exclusion  Criteria; Section  4.1.2 – Exclusion  Criteria  
• Exclusion criterion #4 was updated to allow clinical judgment by the investigator to 
determine  if Grade  1 fatigue  at screening  was residual  toxicity  from prior  treatment or 
was a symptom of the patient’s general condition or disease. The investigator and Medical Monitor were to discuss the eligibility of patients with baseline toxicity.  
• Exclusion criterion  #8 was updated to exclude  patients  who had hypertension requiring 
more than 3 medications for control of hypertension. 
• Exclusion criterion  #11 was updated  to exclude  patients  who experienced any  of the of 
the listed  cardiac conditions  within  the 6-month period prior  to screening  (angina  pectoris, 
coronary artery disease, cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than 40%, or cardiac arrhythmia requiring medical therapy). Previously, any history was exclusionary regardless of how long ago it had occurred. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  106  
 Synopsis  - Study  Design;  Section  6.3.1.2 – Dose  Escalation  Scheme  
It was also added that in the run-in phase,  1 patient  will be enrolled  at the sequentially  listed 
dose levels until either a DLT is observed or a patient is treated at 180 mg/m2 for 1 cycle 
without a DLT. 
Synopsis – Study Design; Synopsis – Study Drug, Dosage, and Route of  Administration; 
Synopsis  – Dose  Escalation  Design;  Section  3.1 – Study  Design;  Table  3-1 - Dose  Levels of 
NC-6004; Table 5- 1 - Dose Level Cohorts; Section 6.2 -  Pharmacokinetic and 
Pharmacodynamics Assessments; Section 6.3.1.2 – Dose Escalation Scheme  
The study design was updated to include  that if no DLT  was observed in the single -subject 
run-in phase at 180 mg/m2, the single -subject run -in phase would end and the next cohort 
would enroll 4 subjects at 180 mg/m2. 
Synopsis  – Study  Design;  Synopsis  – Estimated  Study  Duration;  Section  3.1 - Study  
Design;  Section  5.3 - Treatments Administered; Appendix 12.1 - Schedule  of Events  
It was added that after completion of 4 to 6 cycles of treatment, individual patients could 
continue study drug, subject to sponsor approval, for an additional 4 to 6 cycles of treatment (up to a maximum of 10 total cycles)  if they had clinical  benefit, with monitoring  the same as 
that in the treatment phase.  
Synopsis  – Study  Design;  Section  3.1.1 – Rationale  of Study  Design  
It was added that at any time, in the absence of an MTD from the N -CRM model, 
NanoCarrier  can recommend  a recommended  Phase 2 dose less than or equal  to the 
maximum administered dose based on efficacy, safety, and/or PK data. 
Synopsis – Pharmacokinetic or Pharmacodynamic Assessments;  
Section  6.2 - Pharmacokinetic  and Pharmacodynamic  Assessments;  
Section  7.2 - Exploratory  Endpoints;  Section  7.6.3 – Pharmacokinetic  and 
Pharmacodynamic Analyses; Appendix 12.1 -  Schedule of Events 
Whole  blood  was removed from the PK assessments.  Note:  for the schedule of events  table 
(footnotes “k” and “l”), “whole” was removed from “whole blood samples” to increase 
clarity.  
Synopsis  – Safety  Assessments;  Section  6.3.8 – Vital Sign Measurements;  
Appendix 12.1 -  Schedule of Events 
It was added that vital signs  will be measured  before  NC-6004 infusion and at the completion 
of NC- 6004 infusion in Cycles 2 through 6 (or up to 10). Previously, vital signs were only 
measured from Cycles 2 through 6.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  107  
 Synopsis  – Definition  of a DLT;  Section  6.3.1.1  - Definition  of Dose -Limiting  Toxicities  
The definition  of 1 of the listed  DLT  criteria  was expanded to include  Grade  4 neutropenia  of 
duration longer than 7 days and unresponsive to growth factor support per institutional 
guidelines or American Society of Clinical Oncology guidelines. 
Synopsis  – Study  Drug,  Dosage, and Route  of Administration; Synopsis  – Dose  Escalation  
Design; Table 3- 1 - Dose Levels of NC -6004; Section 5.3 - Treatments Administered; 
Table 5- 1 - Dose Level Cohorts 
The following potential  dosage  levels  were  added to the  study:  195, 210, 225, and 240 mg/m2. 
Synopsis  – Study  Drug,  Dosage, and Route  of Administration; Table  3.1 – Dose  Levels of 
NC-6004; Section 5.3 – Treatments Administered  
It was added that a full safety review of all  AEs for all cycles as well as an optional PK 
analysis  will be conducted by the investigators,  the Medical  Monitor,  and NanoCarrier  before 
increasing the NC -6004 dose beyond 240 mg/m2. 
Synopsis  – Sample  Size;  Section  7.3 - Sample  Size Calculation  
The description for sample  size calculation was updated to provide  further  clarification . 
 
Section  3.1 - Study  Design;  Appendix 12.1 - Schedule  of Events  
It was clarified  in the study  design that the patient’s  signed  informed  consent  can be obtained 
within 28 days of dosing and prior to performing any study evaluations.  
Synopsis – Safety  Assessments; Section 3.1 -  Study Design; Section 6.3.7 -  Physical  
Examination; Section  6.3.9 – Eastern  Cooperative  Oncology  Group  Performance Status; 
Appendix 12.1 -  Schedule of Events 
It was confirmed that safety assessments scheduled for Day 1 (physical examination, ECOG 
performance  status,  and review  of AEs and concomitant  medication  use) can be completed  on 
Day –1 to allow for early morning dosing. These should not be conducted in place of 
screening assessments.  
Section  5.2 – Prophylactic  Treatment  
• Pre-hydration will be administered over 1 to 3 hours, as outlined by institutional 
standards.  This change  would increase the allowable window  for the pre-hydration 
infusion time. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  108  
 • The text for pre -hydration was updated to indicate that the 0.9% sodium chloride is 
changeable to 0.45% sodium chloride at investigator discretion  based  on the patient’s 
condition.  
• It was added that 8 mEq  (1 g) of magnesium  sulfate  was to  be added to the  
1-L 0.9% sodium chloride pre- hydration regimen for all patients at all cycles. Once a 
patient’s magnesium level dropped to <1.8 mg/dL  or <lower limit of normal (Grade 1 
hypomagnesemia), the investigator could treat as clinically  warranted  by supplementing 
with oral and/or intravenous magnesium.  
Section  7.4 – Analysis Sets  
The definition  of the Full Analysis Set was updated to include all patients treated  at MTD  in 
Part 1 or Part 2 who received study product. 
 
12.4.1.2  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol. Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Title  Page – Sponsor  
 
Yaesu  Yamagata Bldg, 3-2-2 Nihonbashi Chuo-ku, 
Tokyo 103-0027, Japan 
144-15 Chuo  Gaiku,  226-39 Wakashiba  Kashiwa  
Chiba,  277-0871, Japan  
 
Title  Page – Sponsor Contact  
 
Telephone:  +81-3- 3548- 0213 4-7197- 7623  
 
Protocol Approval – Sponsor Signatory  
Yaesu  Yamagata Bldg, 3-2-2 Nihonbashi Chuo-ku, 
Tokyo 103-0027, Japan  
144-15 Chuo  Gaiku,  226-39 Wakashiba  Kashiwa  
Chiba,  277-0871, Japan  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  109  
 Synopsis  – Exclusion Criteria  
… 
 
4. Have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, 
including investigational treatment, with the exception of alopecia and ≤Grade 1 
peripheral neuropathy according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events NCI CTCAE version 4.03. Clinical judgment by the 
investigator  is allowed to determine  if Grade  1 fatigue at screening  is residual  toxicity 
from prior treatment or is a symptom of the patient’s general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with 
baseline toxicity.  
… 
 
8. Have  uncontrolled diabetes or have  hypertension requiring more  than 23 medications  for 
control of hypertension. 
… 
 
11. Have  a history  of experienced  any of the following  within  the 6-month  period  prior to 
screening: angina pectoris, coronary artery disease or cerebrovascular accident, transient 
ischemic attack, cardiac failure with known ejection fraction less than 40%, or cardiac arrhythmia requiring medical therapy.  
 
Synopsis  – Study  Design  
 
… 
The dose- escalation  part of the trial will begin with a single  patient  run- in phase.  In the 
run-in phase, 1 patient will be enrolled sequentially at the following dose levels: 60, 75, 90, 
105, 120, 135, 150, 165, and 180 mg/m2 until a DLT  is observed or until  a patient  is treated 
at 180 mg/m2 for 1 cycle without a DLT. During the single -subject run -in phase, after 
enrollment of the initial patient at 60 mg/m2, the first patient in each cohort will not be 
enrolled until the patient at the immediately lower cohort has completed at least 1 full cycle. 
A Bayesian continual- reassessment method per Neuenschwander et al 2008 (N -CRM) design 
will be used for dose escalation. The N- CRM will model the starting dose for the remainder 
of the escalation  using the run- in data.  For the remainder of Part 1 of the study, 4 patients will 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  110  
 be enrolled  as a cohort at each dose level  predicted  by the N- CRM  model. If no DLT is 
observed  in the single -subject  run- in phase  at 180 mg/m2, the single -subject  run- in 
phase will end and the next cohort will enroll 4 patients at 180 mg/m2. 
… 
 
Patients will continue to receive treatment until they experience disease progression, 
experience unacceptable toxicity  (UT), withdraw voluntarily,  or complete a  maximum of 4 to 
6 10 total cycles of treatment  (4 to 6 cycles followed  by an additional  4 to 6 cycles,  if they 
have clinical benefit) , whichever occurs first. 
… 
 
At any time,  in the absence of an MTD from the N-CRM  model,  NanoCarrier can 
recommend a recommended Phase 2 dose less than or equal to the maximum 
administered dose on efficacy, full safety, and/or pharmacokinetic (PK) data.  
… 
 
After completion of 4 to 6 cycles of treatment (or up to 10 cycles) , patients will have an 
End-of-Treatment  visit,  will be followed  with scans every  9 weeks until disease  progression, 
and will be contacted for survival every 12 weeks by telephone. 
 
Synopsis  – Estimated  Study  Duration  
 
The study will include a screening  period (up to 28 days),; 4 to 6 treatment cycles, followed 
by an additional  4 to 6 cycles (up to a maximum  of 10 total cycles)  of treatment,  that are 
21 days in duration,; tumor assessments for response and disease progression with scans every 6 weeks,; and telephone calls for survival every 12 weeks. 
Patients  will receive study  treatment until any of the following  occur:  
 
• Disease progression or completion of 4 to 6 cycles of treatment (followed by an 
additional  4 to 6 cycles,  up to a maximum of 10 total cycles if they have clinical 
benefit). 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  111  
 Synopsis  – Pharmacokinetic or Pharmacodynamic Assessments  
 
The concentration -versus -time profile  of micellar  platinum in whole blood and plasma and of 
total platinum in plasma , whole blood, and plasma ultrafiltrate (ie, free platinum) will be 
determined in Part 1 and in Part 2. 
Part  1 Pharmacokinetic  Time  Points  
 
Pharmacokinetic  plasma , whole blood, and plasma  ultrafiltrate  samples will be collected  at 
the following times in Part 1:  
… 
 
Part  2 Pharmacokinetic  Time  Points  
 
Pharmacokinetic  plasma , whole blood, and plasma  ultrafiltrate  will be collected  at the 
following times in Part 2 for each cycle:  
 
Synopsis  – Safety  Assessments  
 
… 
 
Physical examinations will be performed and vital signs will be measured at Screening, 
before the start of treatment  on Day 1 of each cycle (or can be completed on  Day –1), and at 
the End- of Treatment visit.  
 
… 
 
In Cycles 2 through 6 (or up to 10), vital signs will be measured  before before NC-6004 
infusion and at the completion of the NC-6004 infusion. 
 
Synopsis  – Definition  of DLT  
 
• Grade  4 neutropenia lasting  > of duration longer than 7 days and unresponsive  to 
growth factor support per institutional guidelines or  American Society of 
Oncology guidelines . 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  112  
 Synopsis  – Study  Drug,  Dosage, and Route  of Administration  
 
The potential dosage levels of NC-6004 in this study include 60, 75, 90, 105, 120, 135, 150, 
165, and 180, 195, 210, 225, and 240 mg/m2. A full safety review of all AEs for  all cycles 
as well as an optional PK analysis will be conducted by the investigators, the Medical 
Monitor, and NanoCarrier before increasing the NC -6004 dose beyond 240 mg/m2. 
Synopsis  – Dose  Escalation Design  
 
Sequential doses selected  for evaluation are: 75, 90, 105, 120, 135, 150, 165, or 180, 195,  
210, 225, and 240 mg/m2. 
 
… 
 
If no DLT is observed  in the single -subject  run- in phase  at 180 mg/m2, the single -subject 
run- in phase will end and the next cohort will enroll 4 patients at 180 mg/m2. 
Synopsis  – Sample Size 
 
The design for Part 2 assumes p0 (the response rate for a poor drug) = 0.05, p1 (the response 
rate for a good drug) = 0.20, alpha = 0.05, and power = 80%. In the first stage of Part 2, 
testing will be performed on 10 patients, and if no patients respond at the second disease 
assessment  the trial will be terminated.  Any evidence of response,  regardless of duration, will 
be counted as a response. If the trial continues into the second stage, a total of 36 patients 
will receive study drug. The 36 patients with NSCLC dosed at MTD will provide a 95% 
chance to detect at least 1  AE of interest with underlying 8% incidence rate.  
In order to provide a 95% chance to detect at least 1  AE of interest with underlying 
8% incidence rate among patients treated at MTD, additional patients with NSCLC 
will be enrolled  at the MTD in Part  2 of the study.  Patients  will be enrolled  in 2 stages 
until  a total  of 36 patients  with  NSCLC  have been  dosed  at the MTD,  including  patients 
with NSCLC receiving the MTD level in Part 1. In the first stage of Part 2, ten patients 
treated at the MTD will be evaluated for response. If no patients respond, then the 
patients  with  NSCLC treated  at a lower  dose  level  than the MTD will be considered  and 
a discussion of terminating the trial early will be triggered.  Any evidence of response, 
regardless of duration, will be counted as a response. If at least 1 response is observed, 
the remaining 26 patients will be treated at the MTD. No formal efficacy analysis will  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  113  
 be performed  and no inference regarding  efficacy  will be drawn  based on the response 
rate of the overall study. 
Section  3.1 – Study  Design  
 
Patients  will be treated  until disease progression or up to 610 cycles  of therapy, whichever 
occurs first. After completion of 4 to 6 cycles of treatment, individual patients can 
continue study drug, subject to sponsor approval, for an additional 4 to 6 cycles of 
treatment (up to a maximum of 10 total cycles) if they have clinical benefit, with 
monitoring the same as that in the treatment phase.  
In both Part 1 and Part 2, patients will continue to receive treatment until they experience 
d
isease  progression or for up to 610 treatment  cycles,  whichever occurs first. The maximum 
number of cycles a patient undergoes (4 to 6 cyclesup to 10 total cycles) is at the discretion 
of the investigator and depends on response as described in the ASCO guideline 
(Appendix 12.4) (Azzoli et al 2011 ). Patients who complete 4 or more cycles will be 
considered as having completed the treatment. Subject to sponsor approval, individual 
patients  could  continue  study  drug  for an additional 4 to 6 cycles of treatment  (up to a 
maximum of 10 total cycles) if they have clinical benefit, with monitoring the same as that in the treatment phase . 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  114  
 Section  3.1 – Study  Design,  Table 3-1 Dose  Levels of NC-6004  
 
Table  3-1 Dose  Levels  of NC-6004  
 
Dose  Level  Name  NC-6004 Dose Level  (mg/m2) 
1 60 
2 75 
3 90 
4 105 
5 120 
6 135 
7 150 
8 165 
9 180a 
10 195 
11 210 
12 225 
13 240b 
a If no DLT is observed  in the single -subject  run-in phase  at 180 mg/m2, the single -subject  run-in phase 
will end and the next cohort will enroll 4 patients at 180 mg/m2. 
b A formal  review  by the safety  committee will take place  to decide if the dose can be increased  beyond 
240 mg/m2. 
 
Section  3.1 – Study  Design  
 
The N-CRM  model will only be updated after all patients  in a cohort have either  experienced 
a DLT  or completed the first cycle. If no DLT is observed in the single -subject run- in 
phase at 180 mg/m2, the single -subject run -in phase will end and the next cohort will 
enroll 4 patients at 180 mg/m2. 
… 
 
In both Part 1 and Part 2, patients will continue to receive treatment until they experience 
disease  progression or for up to 610 treatment  cycles,  whichever occurs first. The maximum 
number of cycles a patient undergoes (4 to 6up to 10 total cycles) is at the discretion of the 
investigator and depends on response as described in the ASCO guideline ( Appendix 12.4) 
(Azzoli et al 2011). Patients who complete 4 or more cycles will be considered as having  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  115  
 completed  the treatment.  Subject  to sponsor  approval, individual  patients  can continue 
study drug for an additional 4 to 6 cycles of treatment (up to a maximum of 10 total 
cycles)  if they have clinical benefit,  with  monitoring  the same as that in the treatment 
phase.  
After the completion of 4 to 6 cycles of  treatment (or up to 10 cycles) , patients will have  an 
End-of-Treatment  visit,  will be followed  with  scans every  9 weeks until disease progression, 
and will be contaced for survival every 12 weeks by phone. 
… 
Screening  Period  (Day  -28 to -1) 
The following procedure s will be performed  during the screening  period within  28 days prior 
to the first study treatment :  
• Signed informed  consent  can be obtained within  28 days of dosing  and prior  to 
performing any study evaluations.  
Screening  Period  (Day  -14 to -1) 
The following procedures will be performed  during the screening  period within  14 days prior 
to the first study treatment:  
• Signed informed  consent obtained from the patient prior to performing any study 
evaluations  
… Screening  Period  (Day  -7 to -1) 
… 
• Safety  assessments scheduled for Day 1 (physical  examination, ECOG  performance 
status, and review of AEs and concomitant medication use) can be completed on 
Day-1 (not to be conducted in place of screening assessments).  
Day 1 of Cycle  
 
… 
 
• Physical  examination  (if not performed  on Day –1) 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  116  
 • ECOG  performance  status (if not performed  on Day –1) 
… 
• Adverse events (if not performed  on Day –1) 
• Concomitant medication  use (if not performed  on Day –1) 
 
Section  3.1.1 – Rationale of Study  Design  
… 
 
At any time,  in the absence of an MTD from the N-CRM  model,  NanoCarrier can 
recommend a recommended Phase 2 dose less than or equal to the maximum 
administered dose based on efficacy, full safety, and/or PK data. 
 
Section  4.1.2 – Exclusion Criteria  
 
4. Have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, 
including investigational treatment, with the exception of alopecia and ≤Grade 1 
peripheral neuropathy according to the National Cancer Institute Common Terminology 
Criteria  for Adverse Events  (NCI  CTCAE)  version 4.03 ( National Cancer  Institute  2010). 
Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient’s 
general condition or disease. The investigator and Medical Monitor will discuss the 
eligibility of patients with baseline toxicity.  
… 
 
8. Have  uncontrolled diabetes or have hypertension requiring more  than 2 3 medications  for 
control of hypertension. 
… 
 
11.  Have  a history  of experienced  any of the following  within  the 6-month  period  prior  to 
screening: angina pectoris, coronary artery disease or cerebrovascular accident, transient 
ischemic attack, cardiac failure with known ejection fraction less than 40%, or cardiac arrhythmia requiring medical therapy.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  117  
 Section  5.2 – Prophylactic Treatment  
… 
• Pre-hydration will be administered  over 1 to 3 hours,  as outlined  by institutional 
standards . A minimum of 1 L  of 0.9% sodium chloride solution will be infused 
intravenously over 21 to 3 hours prior to NC-6004 administration, and a minimum of 
500 mL of 0.9% sodium chloride solution will be infused over 2 hours following 
NC-6004 administration.  The 0.9% sodium  chloride  is changeable to 0.45% sodium 
chloride at investigator discretion based on the patient’s condition. When 
gemcitabine only is infused, hydration is not required. 
• At all cycles,  8 mEq  (1 g) of magnesium  sulfate  will be added to the  
1-L 0.9% sodium  chloride  pre-hydration regimen  for all patients.  Once  a patient’s 
magnesium level drops to <1.8 mg/dL or <lower limit of normal (Grade 1 
hypomagnesemia), the investigator may treat as clinically warranted by supplementing with oral and/or intravenous magnesium.  
 
Section  5.3 - Treatments Administered  
 
… 
In each part of the study, patients will receive treatment for 4 to 6 cycles as directed in the 
ASCO guidelines ( Appendix 12.4) or until disease progression, whichever occurs first. After 
the initial 4 to 6 cycles of treatment, individual patients can continue study drug, 
subject to sponsor approval, for an additional 4 to 6 cycles of treatment (up to a 
maximum of 10 total cycles) if they have clinical benefit, with monitoring the same as 
that in the treatment phase. Prophylactic antiemetic medications may be administered 
according to standard treatment center protocols.  
The dose level may escalate to 75, 90, 105, 120, 135, 150, 165, or 180, 195, 210, 225, or 
240 mg/m2 according to observations of DLTs and the dose- level toxicity relationship 
(Section 6.3.1.2). A full safety review of all AEs for  all cycles as well as an optional PK 
analysis will be conducted by the investigators,  the Medical  Monitor, and NanoCarrier 
before increasing the NC -6004 dose beyond 240 mg/m2. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  118  
  
Section  5.3 - Treatments Administered,  Table  5-1 Dose  Level  Cohorts  
 
… 
 
Dose  Level  Day 1 of Each  Cycle  Day 8 of Each  Cycle  
60 mg/m2 60 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
 
75 mg/m2 75 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
 
90 mg/m2 90 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
 
105 mg/m2 105 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
 
120 mg/m2 120 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
135 mg/m2 135 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
 
150 mg/m2 150 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
165 mg/m2 165 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
 
180 mg/m2, a 180 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
 
195 mg/m2 195 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
 
210 mg/m2 210 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
225 mg/m2 225 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine  1250  mg/m2 gemcitabine  
 
240 mg/m2 240 mg/m2 NC-6004;  
1250  mg/m2 gemcitabine   
1250  mg/m2 gemcitabine  
a If no DLT is observed in the single -subject run -in phase at 180 mg/m2, the 
single -subject  run-in phase  will end and the next cohort  will enroll  4 patients  at 
180 mg/m2. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  119  
 Section  6.2 – Pharmacokinetic and Pharmacodynamic Assessments  
 
… 
Pharmacokinetic samples will be analyzed for concentrations of micellar platinum in whole 
blood and plasma and total platinum in plasma, whole blood, and plasma  ultrafiltrate  (ie, free 
platinum). The concentration versus time profile will be determined in Part 1 and in Part 2.  
Pharmacokinetic  p lasma , whole blood, and plasma  ultrafiltrate  samples will be collected  at 
the following times in Part 1:  
… 
 
Pharmacokinetic  plasma , whole blood, and plasma  ultrafiltrate  samples will be collected  at 
the following times in Part 2 for each cycle:  
 
Section  6.3.1.1 – Definition  of Dose -Limiting  Toxicities  
 
… 
• Grade  4 neutropenia lasting  > of duration longer than 7 days and unresponsive  to 
growth factor support per institutional guidelines or  ASCO guidelines  
Section  6.3.1.2 – Dose  Escalation Scheme  
… 
In the run- in phase,  1 patient  will be enrolled  sequentially  at the following  dose  levels: 
60, 75, 90, 105, 120, 135, 150, 165, and 180 mg/m2 until a DLT is observed or until a 
patient is treated at 180 mg/m2 for 1 cycle without a DLT. 
… 
 
If no DLT  is observed  in the single  subject  run-in phase  at 180 mg/m2, the single -subject 
run- in phase will end and the next cohort will enroll 4 patients at 180 mg/m2. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  120  
 Section  6.3.7 – Physical  Examination  
A complete physical examination will be performed during the screening period at Day -14 
to -1, before study treatments on Day –1 or Day 1 of each cycle,  and at the End-of-Treatment 
visit.  
Section  6.3.8 – Vital Sign  Measurements  
… 
 
In Cycles 2 through 6 (or up to Cycle  10, if there is  clinical  benefit) , vital signs will be 
measured  before the start  of the NC-6004 infusion and at  the completion  of the NC-6004 
infusion.  
Section  6.3.9 - Eastern  Cooperative Oncology Group  Performance Status  
The patient’s  performance status  will be assessed  during the screening  period on Day -14 
to -1 and before dosing on Day –1 or Day 1 of each cycle using the ECOG performance 
status grades ( Oken et al 1982) below.  
Section  7.2 – Exploratory Endpoints  
The exploratory endpoints of this study include exploratory safety endpoints of the occurrence of AEs and SAEs  after 4 to 6 cycles of treatment and the following  PK endpoints 
for micellar  platinum in whole blood and plasma and total platinum in plasma , whole blood, 
and plasma ultrafiltrate calculated for all patients using noncompartmental analysis:  
Section  7.3 – Sample Size Calculations  
… 
In Part 2 of the study, additional patients with NSCLC will be enrolled at the MTD until a 
total of 36 patients with NSCLC have been dosed at the MTD, including patients with NSCLC receiving the MTD dose level in Part 1. In order to provide a 95% chance to 
detect at least 1  AE of interest with an underlying 8% incidence rate among patients 
treated at MTD, additional patients with NSCLC will be enrolled at the MTD in Part 2 
of the study.  Patients  will be enrolled  in 2 stages until  a total of 36 patients  with  NSCLC 
have been dosed at the MTD, including patients with NSCLC receiving the MTD level in Part 1. In the first stage of Part 2, ten patients treated at the MTD will be evaluated 
for response. If no patients respond, then the patients with NSCLC treated at a lower 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  121  
 dose level than the MTD will be considered and a discussion of terminating the trial 
early  will be triggered.  Any evidence of response,  regardless of duration,  will be counted 
as a response.  If at least  1 response  if observed,  the remaining  26 patients  will be treated 
at the MTD. No formal efficacy analysis will be performed and no inference regarding 
efficacy will be drawn based on the response rate of the overall study.  
The design for Part 2 assumes p0 (the response rate for a poor drug) = 0.05, p1 (the response 
rate for a good drug) = 0.20, alpha = 0.05, and power = 80%. In the first stage of Part 2, 
testing will be performed on 10 patients. If no patients respond at the second disease 
assessment  the trial will be terminated.  Any evidence of response,  regardless of duration, will 
be counted as a response. If the trial continues into the second stage, a total of 36 patients 
will receive study drug. 
Section  7.4 – Analysis Sets  
… 
• The Full Analysis Set (FAS)  consists  of all patients  treated  at MTD in Part 1 or Part 2 
who receive study product. 
Section  7.6.3 – Pharmacokinetic  and Pharmacodynamic Analyses  
Noncompartmental analysis will be used to calculate  the following  PK parameters for total 
platinum in plasma , whole blood, and plasma ultrafiltrate:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  122  
 12.1 Appendix: Schedule  of Events  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycles  7-10a End-of- 
Treatmentab Follow - 
upbc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15   
Informed  consent  X X                
Eligibility  criteria   X                
Demography   X                
Medical  history   X                
Pregnancy  test (serum  or urine)    X  
 
Xcd              
Physical  examination   Xe  Xe   X   X   X   X  
Height,  weight,  and BSA  calculation    
 
Xdf  X   X   X   X     
Vital  signs   X   
 
Xeg X  X X  X X  X X  X  
Performance  status  (ECOG)   Xe  Xe   X   X   X   X  
Disease  assessmentfh X          
 
Xfh   Xh   X X 
Audiometry   X   
 
Xgi   Xg    
 
Xgi   Xi    
 
Xgi  
Hematology    X  
 
Xhj X X X X X X X X X X X X  
Biochemistry    X  
 
Xhj X X X X X X X X X X X X  
Urinalysis  (dipstick)   X              X  
EORTC  QLQ -C30    X X  X X  X X  X X  X  
MDASI  or MDASI -LC    X X  X X  X X  X X  X  
Nausea  and vomiting  patient  diaryik    X X X X X X X X X X X X   
Cardiac  risk factors   X                
12-lead ECGjl   X X X  X   X   X   X  
Pharmacokinetic  assessments  (Part  1)k    X X X X   X  
 
Xkm  
 
Xkm    X  
Pharmacokinetic  assessments  (Part  2)ln    X X  X X  X X     X  
Adverse  events     Xe X X X X X X X X X X X X X 
Concomitant  medication   Xe  Xe X X X X X X X X X X X X X 
Prophylactic  administrations     X   X   X   X     
NC-6004  administrationa    X   X   X   X     
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  123  
  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycles  7-10a End-of- 
Treatmentab Follow - 
upbc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15 Day 
1 Day 
8 Day 
15   
Gemcitabine  administration     X X  X X  X X  X X    
Abbreviations:  BSA,  body surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group;  EORTC QLQ -C30,  European  Organisation  for 
Research and Treatment of Cancer Quality of Life Questionnaire- Core 30; MDASI, MD Anderson Symptom Inventory; RECIST, Response Evaluation 
Criteria in Solid Tumors; MDASI -LC, MDASI -lung cancer.  
a An optional  extension  of an additional  4 to 6 cycles  of treatment  (up to 10 cycles  of treatment  [including  gemcitabine if the patient  is tolerating 
NC-6004]) is allowed, with monitoring the same as that in the treatment phase of the protocol.  
ab End-of-treatment  assessments  will be performed  within  28 days after treatment  discontinuation.  
bc After  patient discontinuation or completion  of treatment without disease progression,  patients will  be followed with  scans every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
cd  N ot  required  if screening  pregnancy test was performed  using  serum.  
e Safety  assessments  of physical  examination,  ECOG,  review  of AEs,  and concomitant  medication  use can be completed  on Day -1 to allow  for early 
morning dosing. These should not be conducted in place of screening assessments.  
df  H eight and weight  only.  
eg On Day 1 of Cycle  1, vital signs will  be measured  before  the start of the NC-6004 infusion, every 20 minutes  during the infusion,  at the completion  of the 
infusion, and 1 hour after the completion of  the NC -6004 infusion. In Cycles 2 through 610, vital signs will be measured before the start of  the NC -6004 
infusion and at the completion of the NC -6004 infusion. Vital signs will be measured before and after gemcitabine infusion on Day 8 of each cycle.  
fh Disease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used for all subsequent 
assessments. Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will be assessed every  6 (±1) weeks  (ie, every  other 
cycle) and at the End -of-Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
gi  To be performed  only as clinically  indicated.  
hj Hematology  or biochemistry  tests will  be repeated  prior  to dosing  on Day 1 of Cycle  1 if they were  last performed more than 24 hours  before  the start of  the 
study drug administration.  
ik Diary  issued on Day 1 of each cycle. Assessment  is performed at  the site before  dosing on Days  1 and Day  8 as well  as Day 15 (no dosing on Day 15) of 
each cycle. Patient completes diary at home on Days 2 through 8 and returns diary on Day 8.  
jl Twelve -lead ECGs will be performed after the patient has rested in the supine position for at least 5 minutes. On Day  1 of Cycle 1, 12- lead ECGs will be 
performed before the start of the NC -6004 infusion, at completion of infusion (~1 hour after start of infusion), and at Hours 3 and 24 (Day 2) after the start 
of infusion. On  Day 8 of Cycle 1, 12 -lead ECGs will be performed before the start of  gemcitabine infusion, at the end of gemcitabine infusion, and at 1 hour 
after completion  of gemcitabine  infusion.  Twelve -lead ECGs will be performed  on Day 1 of Cycles  2 through  6 before  the start of the NC-6004  infusion,  and 
at the End -of-Treatment visit.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  124  
 km For Part 1, whole  blood samples will  be collected  at the following  times:  before  the start of the NC-6004  infusion on Day 1 of Cycles  1 through  6, at end of 
NC-6004 infusion in Cycles 1, 3, and 5, after the start of NC -6004 infusion at Hours 3, 6, 12, 24 (Day  2), 48 (Day  3), 96 (Day  5), 168 and prior to 
gemcitabine infusion (Day 8), and 336 (Day 15) n in Cycles 1, 3, and 5, and at the End -of-Treatment visit. Additional pharmacokinetic blood sample 
collections may be performed, at the discretion of the investigator, during any visit where toxicity is observed.  
ln For Part 2, on the day of NC-6004  infusion  for each cycle, whole  blood  samples will  be collected  before  the start of the NC-6004  infusion,  at the end of the 
NC-6004 infusion, before gemcitabine infusion on Day 8, and at the End -of-Treatment visit. Additional pharmacokinetic blood sample collections may be 
performed, at the discretion of the investigator, during any visit where toxicity is observed.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  125  
 12.4.2  Protocol  Amendment 2–Protocol  Version  3.0, Incorporating 
Amendment 2, Dated 07 July 2015  
The following sections detail the changes made to  Amendment 1 of the protocol 
(Version  2.0) dated  31 December  2014. The integrated  protocol,  Version  3.0, including  
Amendment 2, was issued on 07 July  2015.  
 
12.4.2.1  Assessment  of Risk  Associated  With  Amendment  2 
The combination of gemcitabine and cisplatin has been used in chemo -naïve patients with 
bladder, biliary  tract cancer,  as well as NSCLC,  and the toxicity  profile was similar overall  in 
the 3 diseases. Nonclinical data suggested that NC -6004 has the potential to be at least as 
active as cisplatin with less renal toxicity and neurotoxicity compared with cisplatin, and 
clinical data of the combination of gemcitabine and NC -6004 in recurrent NSCLC showed 
good activity with a manageable toxicity  profile.  Thus, the overall risk of this combination in 
chemo -naïve  patients  with bladder  and biliary  tract cancer  would be similar  to the known risk 
to NSCLC patients.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  126  
 12.4.2.2  Overview  of Changes 
The overview  of significant changes  includes  the following:  
 
Title  Page  – Title; Protocol  Approval  – Sponsor  Signature  – Study  Title; Protocol  
Synopsis – Title  
The title was amended to capture the added indications.  The previous title was “... in Patients 
with Advanced Solid  Tumors  or Non-Small  Cell Lung Cancer” and the amended title is …“in 
Patients with  Advanced Solid Tumors or Squamous Non- Small Cell Lung, Biliary  Tract, and 
Bladder Cancer.”  
Title  Page  – Sponsor  Contact;  Protocol  Approval  – Sponsor  Signatory  – Protocol  accepted  
and approved by  
Sponsor  contact  name  was changed to Kazuhiro Takahashi,  and his role and contact 
information were added as applicable.  
Title  Page  – Project  Manager  
Project manager  name and contact  information  were  removed  from the protocol.  
Protocol  Synopsis  – Indication;  Section  1 – Introduction;  Section  3.1.1  – Rationale  of 
Study Design  
The indication for Part 2 was updated to first -line metastatic squamous NSCLC; first -line 
metastatic  or locally  advanced cholangiocarcinoma, gallbladder  cancer,  or ampullary  cancer 
(biliary tract cancer); and first- line metastatic or locally advanced TCC of the urinary tract 
(bladder cancer).  
Protocol  Synopsis  – Rationale;  Protocol  Synopsis  – Objectives;  Protocol  Synopsis  – Study 
Design; Section 1 – Introduction; Section 2.1 – Primary Objectives; Section 3.1 – Study 
Design; Section 3.1.1 – Rationale of Study Design; Section 5.1 – Method of  Assigning 
Patients to Treatment Groups; Section 5.3 – Treatments Administered;  
Section  6.3.1.2.1 - Safety  Monitoring  in Part 2; Section  7.3 – Sample  Size Calculation; 
Section 7.4 – Analysis Sets; Section 7.6.1.6 – Quality of Life  Analyses;  
Section  7.6.1.7 - Symptoms  Assessment  Analyses;  Section  7.6.2.1 – Analyses of Adverse 
Events  
It was added  that a recommended  Phase 2 (RPII) dose would be established  in the study in 
addition to the maximum -tolerated dose, which was previously stated.  As applicable, the 
NC-6004 dose used in Phase 2 of the study was changed from the MTD to the RPII dose. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  127  
 Protocol  Synopsis  – Objectives;  Section  2.1 – Primary Objectives 
The second primary objective was amended to reflect the updated indications in Part 2 of 
first- line Stage IV squamous NSCLC, first- line advanced or metastatic biliary tract cancer, 
and first-line metastatic or locally  advanced  bladder  cancer  compared  with historical  control  
as measured  by local  investigator/radiologist- assessed  PFS,  according to RECIST  version 1.1. 
Protocol  Synopsis  – Objectives;  Section  2.2 – Secondary  Objectives 
The DCR  in the first secondary  objective  was defined  as CR+PR+SD.  A third  secondary 
objective of “To evaluate the safety and tolerability of NC -6004 when combined with 
gemcitabine” was added.  
Protocol  Synopsis  – Patient  Population,  Inclusion Criteria; Section  4.1.1 – Inclusion  
Criteria  
Inclusion criterion  2 was updated to include  new definitions  for Part 2 cohorts. Cohort  1 will 
include Stage IV squamous NSCLC patients who did not receive prior chemotherapy for metastatic disease. It was added that patients with known sensitizing mutation in the EGFR gene or  ALK fusion oncogene must have received at least 1 and up to 2 targeted therapies 
prior to enrollment.  
It was  also clarified  that for patients  whose  tumors  are known to  harbor  an exon 19 deletion 
or an exon 21 L858R  EGFR  mutation  that they must  have  had tolerance  or have  progressed 
on at least 1 and up to 2 EGFR tyrosine kinase inhibitors.  
It was also clarified  that for patients  whose  tumors  are known to harbor  an ALK translocation 
that they must have had intolerance or have progressed on at least 1 and up to 2 ALK 
inhibitors.  
For Part 2, Cohort 2, patients had to have a histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder  cancer,  or ampullary  carcinoma)  and have  not 
received prior systemic anticancer therapy for advanced or metastatic disease.  
For Part 2, Cohort 3, patients had to have a histologically or cytologically confirmed diagnosis of metastatic or locally  advanced  TCC of the urinary tract (bladder, urethra, ureter, 
renal  pelvis)  (T3b -T4 N0 M0, Tany  N1-N3 M0, or Tany  Nany  M1) and are not candidates for 
surgery. Patients must not have received prior treatment with systemic anticancer therapy  for 
metastatic  or locally  advanced  urinary tract cancer. In  addition, certain  mixed  histologies  that 
are predominantly (>50%) TCC are eligible: squamous, adenocarcinoma, and undifferentiated.  Mixed  undifferentiated  histology  requires  immunohistochemistry  consistent 
with a TCC origin. Predominantly squamous or neuroendocrine tumors are excluded.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  128  
 Protocol  Synopsis  – Patient  Population,  Exclusion  Criteria; Section  4.1.2 – Exclusion  
Criteria  
Exclusion criterion  1 was amended  to exclude  prior  platinum  therapy in the past 3 months  for 
Part 1 of the study and in the past 6 months in the adjuvant or neoadjuvant setting for Part 2 
of the study.  
Protocol  Synopsis  – Study  Design;  Section  3.1 – Study  Design  
Text was added to specify that the study design is adaptive. Dosing in Part 1 was amended such that patients  will receive intravenous  infusion of NC-6004 at escalating  doses  on Day 1 
in combination with gemcitabine at the fixed dose of 1250 mg/m
2 on Days 1 and 8 of a  
21-day cycle.  The duration  of treatment for Part 1 was changed to until progressive  disease or 
until the drug is no longer tolerated (whichever occurs first). The sponsor may agree to supply the drug after discussion of the request with the investigator.  
All patients  in Part 2 will receive  the RPII  dose of NC-6004 in combination with gemcitabine 
1250 mg/m
2 by the same regimen in Part 1. It was added that stage 2 will continue in each 
cohort after achieving the minimum threshold of clinical responses required and enroll up to 50 patients in each cohort for a total of up to 150 patients in Part 2. The primary endpoint (PFS) will be continuously updated and compared with the historical PFS from Phase 3 
pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard model will be 
updated as PFS data accrue.  A HR for PFS for each cohort versus historical control will be 
obtained. The historical median durations of PFS and PFS weekly hazard for each cohort were added.  
In addition, once 10 PFS events have been observed, interim analyses will be performed 
every 6 weeks. At each interim and at the final analysis, there are 3 possible outcomes for 
each cohort, which include futility, success, or inconclusive. Each out is defined. Phase 3 
success is defined as success in a Phase 3 clinical trail with 381 events – enough to provide 
80% power  to detect  an HR of 0.75.  A promising  HR is defined as one less than  0.85. Futility 
can only be declared for a cohort after 10 PFS events have been observed in that cohort. Success can only be declared  for a cohort  after 25 PFS events  have  been  observed in that 
cohort. Accrual will stop for any cohort identified as futile or successful at interim. The 
conclusion of this Phase 2 trial will be that a Phase 3 trial with 381 events should be conducted for each cohort that is a success.  
Protocol  Synopsis  – Study  Design;  Protocol  Synopsis  – Sample  Size;  Section  3.1 – Study  
Design; Section 7.3 – Sample Size Calculations  
The Part 2 sample size was added to include  up to 150 patients  with no more  than 50 patients 
per cohort. The method to determine the sample size was also added. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  129  
 Protocol  Synopsis  – Study  Design;  Protocol  Synopsis  – Estimated  Study  Duration;  
Section 3.1 – Study Design; Table 12 -1 Schedule of Events, footnote “a” 
The number  of cycles of treatment in Part 2 was changed to 6 cycles (Cohorts  1 and 3) or 
8 cycles of treatment (Cohort 2).  
Protocol Synopsis – Efficacy Assessments; Section 3.1 – Study Design;  
Section  3.1.1 - Rationale  of Study  Design;  Section  6.1 – Efficacy Assessments;  
Section  6.1.3 – MD Anderson  Symptom  Inventory;  Table  12-1 Schedule  of Events, 
footnote “l”  
It was clarified  that MD Anderson Symptom  Inventory- lung cancer  (MDASI -LC) was to be 
conducted in Part 1 only. 
Protocol  Synopsis  – Pharmacokinetic  or Pharmacodynamic  Assessments;  Section  6.2 – 
Pharmacokinetic and Pharmacodynamic  Assessments;  Table 12- 1 Schedule of Events, 
footnote “p” 
For the Part 2 pharmacokinetic  time points, it was added that plasma and ultrafiltrate  will be 
collected for up to 6 cycles. 
Protocol  Synopsis  – Safety  Assessments;  Section  6.38 – Vital  Sign Measurments;  
Table 12- 1 Schedule of Events, footnote “h” 
It was clarified  that vital signs  will be measured  before  the NC-6004 infusion and at the 
completion of the NC -6004 infusion on Day 1 of each cycle starting in Cycle 2.  
Protocol  Synopsis  – Statistical Methods;  Section  7.6 – Statistical Analysis Methodology  
Text was removed that stated  that no statistical  testing  is planned  for this study. The statistical 
methods for Part 2 were added and will include a Bayesian model updated every 6 weeks 
after 10 PFS have occurred within a cohort.  
Section  6.2 – Pharmacokinetic  and Pharmacodynamic  Assessments  
It was clarified  that the concentration  profiles  of micellar platinum  in plasma  and total 
platinum in plasma and plasma ultrafiltrate will be characterized.  
Section  12.4 – Appendix:  American  Society of Clinical Oncology  Guideline  
 
This appendix was  removed.  
Section  12.4.2.1 – Assessment  of Risk Associated  With  Amendment  2 
A assessment  of the risk associated  with Amendment  2 was added.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  130  
 12.4.2.3  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol. Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Title  Page – Title  
 
A Phase 1/b2 Dose  Escalation  and Expansion Trial  of NC-6004 (Nanoparticle  Cisplatin)  plus 
Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non -Small Cell Lung , 
Biliary Tract, and Bladder Cancer  
Title  Page – Sponsor Contact  
 
Atsuhiro  MasadaKazuhiro  Takahashi  
Director of International  Clinical Development 
NanoCarrier Co, Ltd 
Telephone: +81-4-7197-76233- 3241- 0551  
 
Title  Page – Project  Manager  
 
Project  Manager:  Cynthia Nelson  
Senior Project  Manager, PPD  Global Project  Management 
PPD, Inc.  
Telephone: 317-473- 1980  
 
Protocol Approval – Sponsor Signatory  
 
A Phase 1/b2 Dose  Escalation  and Expansion Trial  of NC-6004 (Nanoparticle  Cisplatin)  plus 
Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non -Small Cell Lung , 
Biliary Tract, and Bladder Cancer  
… 
 
Protocol accepted  and approved by: 
 
Director of International  Clinical Development 
Atsuhiro Masada Kazuhiro Takahashi  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  131  
 Protocol Synopsis  – Title 
 
A Phase 1/b2 Dose  Escalation  and Expansion Trial  of NC-6004 (Nanoparticle  Cisplatin)  plus 
Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non -Small Cell Lung , 
Biliary Tract, and Bladder Cancer  
Protocol Synopsis  – Study  Sites  
 
Approximately 6 At least  20 sites in  the United States 
 
Protocol Synopsis  – Indication  
 
… 
 
Part 2: Relapsed  non- small  cell lung cancer  (NSCLC)  First -line metastatic  squamous 
non- small cell lung cancer (NSCLC); first-line metastatic or locally advanced 
cholangiocarcinoma, gallbladder  cancer,  or ampullary  cancer (biliary  tract  cancer);  and 
first- line metastatic or locally advanced transitional cell carcinoma (TCC) of the 
urinary tract (bladder cancer)  
Protocol Synopsis  – Rationale  
 
… 
 
This study will establish a maximum- tolerated dose (MTD) and recommended Phase 2 
(RPII)  dose  of NC-6004 in combination with gemcitabine and evaluate  the initial activity 
and tolerability profile.  
Protocol Synopsis  – Objectives 
 
The primary  objectives of this study are: 
 
• In the dose- escalation  phase of the study (Part  1), to determine  the dose- limiting  toxicities 
(DLTs) , and MTD, and RPII dose of NC-6004 in combination with gemcitabine. 
• In the expansion phase of the study (Part 2), to evaluate the activity of NC -6004 in 
combination  with  gemcitabine  in patients  with  first-line Stage IV squamous  NSCLC, 
first- line advanced or metastatic biliary tract cancer, and first -line metastatic or 
locally advanced bladder cancer compared with historical control as measured by  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  132  
 local investigator/radiologist- assessed  progression -free survival (PFS),  according  to 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. , safety, and  
tolerability of NC -6004 in combination with gemcitabine in patients with relapsed  
(second - or third line) squamous and nonsquamous Stage IIIB/IV NSCLC. 
The secondary objectives  of this study are: 
 
• To evaluate overall response rate (ORR),  disease  control rate (DCR = complete  response  
+ partial response + stable  disease),  duration of response (DOR),  PFS,  overall survival 
(OS)  
… 
 
• To evaluate the safety  and tolerability  of NC-6004 when  combined with  gemcitabine  
 
Protocol Synopsis  – Patient  Population: Inclusion  Criteria  
 
… 
 
(Part 2 only) Cohort 1: Have  histologically  or cytologically confirmed  diagnosis of 
Stage IIIB or IV squamous NSCLC and have not received 1 or 2 lines of prior  
chemotherapy or targeted therapy  for Stage IIIB or IV  NSCLC (second - or third -line). for 
metastatic  disease.  Patients  with  known sensitizing  mutation  in the epidermal  growth 
factor receptor  (EGFR) gene or  anaplastic lymphoma kinase (ALK) fusion oncogene 
must have received at least 1 and up to 2 targeted therapies prior to enrollment . 
… 
 
• Patients  whose tumors  are known to harbor an exon  19 deletion or exon 21 L858R EGFR 
mutation must have had intolerance or have progressed on or had intolerance to anat 
least 1 and up to 2 EGFR tyrosine kinase inhibitor s. 
• P atients whose tumors are known to harbor an ALK translocation must have had 
intolerance  or have progressed  on or had intolerance to crizotinib at least  1 and up to 2 
ALK inhibitors . 
• (Part  2 only)  Cohort 2: Have histologically or cytologically confirmed 
diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  133  
 (intrahepatic or  extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary 
carcinoma)  and have not received  prior  systemic  anticancer therapy  for advanced or 
metastatic disease.  
• (Part 2 only) Cohort 3: Have histologically or  cytologically confirmed 
diagnosis of metastatic  or locally  advanced TCC of the urinary  tract  (bladder,  urethra, 
ureter, renal pelvis) (T3b -T4 N0 M0, Tany N1 -N3 M0, or  Tany Nany M1) and are not 
candidates for surgery.  
• Patients  must  not have received  prior  treatment  with  systemic  anticancer therapy 
for metastatic or locally advanced urinary tract cancer.  
• Certain mixed histologies that are predominantly (>50%) TCC are eligible: 
squamous,  adenocarcinoma, and undifferentiated.  Mixed  undifferentiated  histology 
requires immunohistochemistry consistent with a TCC origin. Predominantly 
squamous or neuroendocrine tumors are excluded.  
Protocol Synopsis  – Exclusion Criteria  
 
… 
 
1. Have  received  prior platinum therapy  in the past 3 months (Part  1) or 6 months  in the 
adjuvant or neoadjuvant setting (Part 2). 
Protocol Synopsis  – Study  Design  
 
This study will consist of  2 parts; Part 1  is a Phase 1b, continual reassessment method  
dose- escalation  trial, and Part 2 is a Phase 2, adaptive, two-stage,  open- label,  expansion trial 
evaluating activity, safety, and tolerability at the MTD RPII dose identified in Part 1. 
In Part 1, patients will receive intravenous infusion of NC-6004 at escalating doses on 
Day 1 in combination  with gemcitabine  at the fixed  dose  of 1250 mg/m2 on Days 1 and 8 
of a 21- day cycle. Doses of NC-6004 and gemcitabine will be administered  as intravenous  
infusions in 3-week  cycles (ie, 21 days will separate administration  of the combined doses of 
NC-6004 and gemcitabine on Day 1 of each cycle). 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  134  
 In Part 1, patients will continue to receive treatment until they experience disease 
progression, experience unacceptable toxicity  (UT),  or withdraw  voluntarily, or complete a 
maximum of 10 total cycles of treatment (4 to 6 cycles followed by an additional 4 to 
6  cycles, if they have clinical benefit), whichever occurs first . If the investigator and the 
patient request continuation of NC -6004 administration until progressive disease or 
until  the drug  is no longer tolerated  (whichever occurs first),  the sponsor may agree to 
supply the drug after discussion of the request with the investigator. 
… 
 
Part 2 of the study (Phase 2 portion) will begin after the MTD  RPII dose of NC-6004 is 
identified for use in combination with gemcitabine. All patients and will be conducted only 
in patients  with NSCLC.  Part 2 will be conducted in two stages. In  the first stage,  10 patients  
with NSCLC will receive NC -6004 at the MTD  RPII  dose  in combination with gemcitabine 
1250 mg/m2 by the same regimen as in Part 1. 
Three cohorts of patients  are eligible  (Cohort 1: first-line metastatic  squamous  NSCLC; 
Cohort 2: first-line metastatic or locally advanced cholangiocarcinoma, gallbladder 
cancer, or ampullary cancer (biliary tract cancer); and Cohort 3: first -line metastatic  
or locally advanced TCC of the urinary tract (bladder cancer). Stage 2 will continue in each cohort after achieving the minimum threshold of clinical responses required and 
enroll up to 50 patients in each cohort for a total of up to 150 patients in Part 2. The 
primary endpoint (PFS) will be continuously  updated and compared with the historical 
PFS from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard model will be updated as PFS data accrue. A hazard ratio (HR) for PFS for  
each cohort versus historical control will be obtained . 
 
Cohort  Biliary  Bladder  Squamous 
NSCLC 
Historical 
Median 
Duration of PFS 8.8 months  7.6 months  5 months  
Historical 
PFS Weekly 
Hazard  0.01795  0.020755  0.031377  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  135  
 Once  10 PFS events have been  observed,  interim analyses will be performed  every  
6 weeks.  At each  interim  and at the final analysis, there are 3 possible  outcomes for each 
cohort.  
• Futility  – 10 PFS events have been  observed  in each  cohort and at least  1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
• Probability  (Phase  3 Success*)  <0.4 
 
• Success – 25 PFS events have been  observed  in each  cohort and: 
• Probability  (Phase  3 Success*)  >0.8 
 
• Inconclusive – neither  futility  nor success.  
 
* Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events - 
enough to provide 80% power  to detect  an HR of 0.75. A promising  HR is defined as 
one less than 0.85. 
Futility  can only be declared  for a cohort after 10  PFS events have been  observed  in 
that cohort. Success can only be declared  for a cohort after  25 PFS events have been 
observed in that cohort. Accrual will stop for any cohort identified as futile or 
successful at interim. The conclusion of this Phase 2 trial will be that a  Phase 3 trial 
with 381 events should be conducted for each cohort that is a success.  
If any indication is declared a success, the combination of NC -6004 and gemcitabine 
advances to a Phase  3 randomized,  controlled  trial with  sample  size sufficient  to observe 
381 events.  
If at least one patient in the first stage is a responder (defined as CR or PR per RECIST 1.1  
by the week  12 disease assessment)  then 26 additional patients  with NSCLC  will be enrolled 
in the second stage of Part 2. 
After completion of 4 to 6 cycles of treatment  (Cohorts 1 and 3) or 8 cycles of treatment 
(Cohort 2) (or up to 10 cycles), patients will have an End-of- Treatment visit, will be 
followed with scans every 9 weeks until disease progression, and will be contacted for survival every 12 weeks by telephone. 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  136  
 Protocol Synopsis  – Estimated  Study  Duration  
 
The Part  1 of the study will include a screening  period (up to 28 days); as many  cycles until 
progressive disease or until the drug is no longer tolerated (whichever occurs first); 
tumor assessments for response and disease progression with scans every 6 weeks; and 
telephone calls for survival every 12 weeks. The cycles are 21 days in duration.  
Part  2  of the  study  will include  a screening  period  (up to 28 days) ; 4 to 6 treatment  cycles 
(Cohorts 1 and 3) or 8 treatment  cycles (Cohort  2), followed  by an additional 4 to 6 cycles 
(up to a maximum of 10 total cycles) of treatment,  that are 21 days in duration; tumor 
assessments for response and disease progression with scans every 6 weeks; and telephone 
calls for survival every 12 weeks.  
Patients  will receive study  treatment until any of the following  occur:  
 
• Disease progression or completion of 4 to 6 cycles of treatment (followed by an  
additional 4 to 6 cycles,  up to a maximum 10 total cycles,  if they have clinical  benefit)  
Progressive disease is observed (Part 1) or completion of 6 cycles of treatment 
(Part 2; Cohorts 1 and 3) or 8 cycles of treatment (Part 2; Cohort 2)  
… 
 
Protocol Synopsis  – Efficacy  Assessments  
 
… 
 
Symptoms will be assessed  before treatment  on Day  1 and Day 8 of each  cycle and at the 
End of Treatment  visit using the core MD Anderson Symptom Inventory (MDASI)  or the 
MDASI lung cancer (Part 1 only) (MDASI -LC). 
Protocol Synopsis  – Pharmacokinetic or Pharmacodynamic Assessments  
 
… 
 
Pharmacokinetic  plasma  and plasma ultrafiltrate  will be collected  at the following times  in 
Part 2 for each cycle up to 6 cycles : 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  137  
 Protocol Synopsis  – Safety  Assessments  
 
… 
 
Additionally, in  on Day 1 of Cycle 1, vital signs will be measured before the start of the 
NC-6004 infusion, every 20 minutes during the infusion, at the completion of the infusion, 
and 1 hour after the completion of the infusion. In Cycles 2 through 6 (or up to 10) Starting 
in Cycle 2 , vital signs will be measured before NC -6004 infusion and at the completion of 
the NC-6004 infusion on Day 1 of each cycle . 
… 
 
Protocol Synopsis  – Sample Size 
 
… 
 
Part 2 of the study (Phase 2 portion) will begin after the MTD of NC -6004 is identified for 
use in combination with gemcitabine and will be conducted only in patients with NSCLC. 
Part 2 will be conducted in two stages. In  the first stage,  10 patients  with NSCLC will receive 
NC-6004 at the MTD in combination with gemcitabine 1250 mg/m2 by the same regimen as 
in Part 1. If at least one patient in the first stage is a responder (defined as CR or PR per 
RECIST 1.1 by the week 12 disease assessment) then 26 additional patients with NSCLC 
will be enrolled in the second stage of Part 2.  
In order to provide a 95% chance to detect at least 1  AE of interest with an underlying 8% 
incidence rate among patients treated at MTD, additional patients with NSCLC will be  
enrolled at the MTD  in Part 2 of the study. Patients  will be enrolled in 2 stages until a total of 
36 patients with NSCLC have been dosed at the MTD, including patients with NSCLC 
receiving  the MTD level in Part 1. In the first stage of Part 2, ten patients treated at the MTD  
will be evaluated for response. If no patients respond, then the patients with NSCLC treated  
at a lower dose level than the MTD will be considered and a discussion of terminating the  
trial early  will be triggered. Any evidence of response,  regardless of duration, will be counted 
as a response. If at least 1 response is observed, the remaining 26 patients will be treated at  
the MTD. No formal efficacy  analysis will be performed and no inference regarding  efficacy  
will be drawn based on the response rate of the overall study . 
Part  2 is a 3-cohort study  with  an overall sample  size of up to 150 patients  with  no more 
than 50 patients per cohort. The total sample size will depend on the results of interim  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  138  
 futility and superiority analyses. In order to evaluate the overall sample size, 
simulations were  performed assuming scenarios with  different  HRs for  PFS for  each 
cohort compared with historical control and different sample sizes for a subsequent 
Phase  3 clinical trial.  The associated mean  sample  size for this trial in these scenarios 
ranged from 136 to 146 patients.  
Patients  who receive study  drug  will not be replaced.  
 
Protocol Synopsis  – Statistical Methods  
 
No formal statistical testing is planned for this study . Ninety-five percent confidence 
intervals  may be calculated  for selected  safety  and exploratory variables.  Dose  escalation  will 
be based on the N- CRM model and the incidence of DLTs. Adverse events and serious AEs 
will be tabulated by system organ class and preferred term. Laboratory test results after the first dose will be summarized with regard to shifts from baseline values and the grade per 
NCI CTCAE version 4.03. Overall survival, PFS, and DOR will be summarized using 
Kaplan -Meier methods. The ORR and DCR will be summarized and 95% confidence 
intervals for both will be created.  
In Part  2, the following  posterior  probabilities  will be derived  using  a Bayesian model 
updated every 6 weeks after 10 PFS have occurred within a cohort:  
• Probability  (Promising  HR) 
 
• Probability  (Phase  3 Success)  
 
If any cohort at interim or final analyses has a probability (success in a Phase 3 trial 
with 381 PFS events) >0.8, that indication will be declared a success, and the 
combination  of NC-6004 and gemcitabine  advances to a Phase  3 randomized,  controlled 
trial with a sample size sufficient to observe 381 PFS events.  
Section  1 – Introduction  
 
… 
 
This study will determine the maximum tolerated dose (MTD) and recommended Phase 2 
(RPII) dose of NC-6004 in combination with gemcitabine and evaluate the activity, safety, 
and tolerability  of NC-6004 in combination with gemcitabine  in patients with advanced solid  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  139  
 tumors and first-line metastatic squamous NSCLC; first -line metastatic or locally 
advanced cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract 
cancer);  and first- line metastatic  or locally  advanced transitional cell carcinoma  (TCC) 
of the urinary tract (bladder cancer) second- or third line squamous and nonsquamous 
Stage IIIB/IV NSCLC . 
… 
 
Section  2.1 – Primary Objectives  
 
The primary  objectives of this study are: 
 
• In the dose- escalation  phase of the study (Part  1), to determine  the dose- limiting  toxicities 
(DLTs) and, MTD , and RPII dose of NC-6004 in combination with gemcitabine; 
• In the expansion phase of the study (Part 2), to evaluate the activity, safety, and 
tolerability  of NC-6004 in combination with gemcitabine in patients with relapsed  
(second - or third -line) squamous and nonsquamous Stage IIIB/ first- line Stage IV 
squamous NSCLC, first -line advanced or metastatic biliary tract cancer, and first 
line metastatic  or locally  advanced bladder  cancer compared with  historical  control 
as measured by local investigator/radiologist- assessed progression -free survival 
(PFS), according to Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1. 
Section  2.1 – Primary Objectives  
 
The secondary objectives  of this study are: 
 
• To evaluate ORR,  DCR (DCR = complete  response [CR]  + partial response [PR]  + 
stable disease [SD]) , DOR, PFS, and OS 
• To evaluate therapy- related  AEs 
• To evaluate the safety  and tolerability  of NC-6004 when  combined with  gemcitabine  
… 
 
Section  3.1 – Study  Design  
 
This study will consist of 2 parts; Part 1 is a Phase 1b, continual reassessment method 
dose- escalation  trial in patients  with any advanced solid  tumor,  and Part 2 is a Phase 2, 
adaptive two-stage,  open- label,  expansion trial in patients with squamous  NSCLC, biliary  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  140  
 tract,  and bladder  cancer evaluating activity,  safety,  and tolerability  at the MTD  RPII  dose 
identified  in Part 1. 
 
In Part 1, patients will receive intravenous  infusion of NC-6004 and gemcitabine  in 3-week 
treatment cycles. NC -6004 will be administered on Day 1 of each cycle and gemcitabine 
1250 mg/m2 will be administered on Day 1 of each cycle (after the administration of  
NC-6004) and on Day 8 of each cycle.  Patients  will be treated  until disease  progression or up 
to 10 cycles of therapy, whichever occurs first. If the investigator and the patient request 
continuation  of NC-6004 administration  until  progressive  disease  or until  the drug  is no 
longer tolerated (whichever occurs first), the sponsor may agree to supply the drug 
after discussion of the request with the investigator. After completion of 4 to 6 cycles of 
treatment, individual patients can continue study drug, subject to sponsor approval, for an 
additional 4 to 6 cycles of treatment (up to a maximum of 10 total cycles) if they have 
clinical benefit, with monitoring the same as that in the treatment phase . 
… 
 
Once the MTD (or RPII dose) of NC- 6004 is identified, dose escalation within Part 1 will 
cease.  Patients  in Part 1 who  were  not assigned  to the NC-6004 dose identified  as the MTD  
RPII dose will continue treatment cycles at their assigned dose level.  
Part 2 of the study (Phase 2 portion) will begin after the MTD  RPII dose of NC-6004 is 
identified  for use in combination with gemcitabine and will be conducted only in patients 
with NSCLC. Part 2 will be conducted in two stages. In the first stage, 10 patients with 
NSCLC All patients will receive NC -6004 at the MTD  RPII dose in combination with 
gemcitabine 1250 mg/m2 by the same regimen as in Part 1. 
Three cohorts of patients  are eligible  (Cohort 1: first-line metastatic  squamous  NSCLC; 
Cohort 2: first-line metastatic or locally advanced cholangiocarcinoma, gallbladder 
cancer,  or ampullary  cancer (biliary  tract  cancer);  and Cohort 3: first-line metastatic  or 
locally advanced TCC of the urinary tract (bladder cancer). Stage 2 will continue in each cohort after achieving the minimum threshold of clinical responses required and 
enroll up to 50 patients in each cohort for a total of up to 150 patients in Part 2. The primary endpoint (PFS) will be continuously  updated and compared with the historical 
PFS from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard model  will be updated as PFS data  accrue.  A hazard  ratio  (HR)  for PFS for each 
cohort versus historical control will be obtained.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  141  
  
Cohort  Biliary  Bladder  Squamous 
NSCLC 
Historical 
Median Duration  of 
PFS 8.8 months  7.6 months  5 months  
Historical 
PFS Weekly 
Hazard  0.01795  0.020755  0.031377  
Once  10 PFS events have  been  observed,  interim analyses  will be performed  every  
6 weeks.  At each  interim  and at the final analysis, there are 3 possible  outcomes  for each 
cohort.  
 
• Futility  – 10 PFS events have  been  observed  in each  cohort  and at least  1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
• Probability  (Phase  3 Success*)  <0.4 
 
• Success – 25 PFS events have  been  observed  in each  cohort  and: 
• Probability  (Phase  3 Success*)  >0.8 
 
• Inconclusive – neither  futility  nor success.  
 
* Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events -  
enough to provide  80%  power  to detect  an HR of 0.75. A promising  HR is defined  as 
one less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in 
that cohort. Success can only be declared for a cohort after 25 PFS events have been 
observed  in that cohort. Accrual  will stop for any cohort  identified  as futile  or successful 
at interim. The conclusion of this Phase 2 trial will be that a Phase 3 trial with  
381 events should be conducted for each  cohort that  is a success.  
 
If any indication is declared a success, the combination of NC -6004 and gemcitabine 
advances  to a Phase  3 randomized,  controlled  trial with  sample  size sufficient  to observe 
381 events.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  142  
 If at least one patient in the first stage is a responder (defined as CR or PR per RECIST 1.1  
by the week  12 disease assessment)  then 26 additional patients  with NSCLC  will be enrolled 
in the second stage of Part 2. Approximately 36 patients with NSCLC will be treated at the  
MTD, including any patients with NSCLC receiving the MTD in Part 1 and patients 
receiving the MTD in Part 2. Evaluation will include patients with NSCLC treated at the  
MTD in either part of the study . 
In both Part 1 and Part 2, patients will continue to receive treatment until they experience 
disease progression or for up to 10 treatment cycles, whichever occurs first . The maximum 
number of cycles a patient undergoes (up to 10 total cycles) is at the discretion of the 
investigator and depends on response as described in the American Society of Clinical 
Oncology (ASCO) guideline s (Appendix 12.4) ( Azzoli et al 2011). Patients who complete 4 
or more cycles will be considered as having completed the treatment. Subject to sponsor 
approval, individual patients can continue study drug for an additional 4 to 6 cycles of 
treatment (up to a maximum of 10 total cycles)  if they have clinical  benefit, with monitoring  
the same as that in the treatment phase will be treated until progressive disease. If the 
investigator and the patient request continuation of NC -6004 administration until 
progressive  disease or until  the drug  is no longer tolerated  (whichever occurs first),  the 
sponsor may agree to supply the drug after discussion of the request with the investigator. In Part 2, patients will continue to receive treatment for up to 6 cycles 
(Cohorts 1 and 3) or 8 cycles (Cohort 2).  
After the completion of 4 to 6 cycles of treatment (or up to 10 cycles) 
 progressive disease is 
observed (Part 1) or the completion of 6 cycles (Part 2; Cohorts 1 and 3) or 8 cycles 
(Part  2; Cohort 2), patients will have  an End-of-Treatment  visit,  will be followed with scans 
every  9 weeks until disease  progression, and will be contacted  for survival every  12 weeks by 
telephone.  
… 
 
Section  3.1 – Study  Design – Day 1 of Cycle 
 
… 
 
• EORTC QLQ- C30 
• Core  MDASI  or MDASI  module specific for lung cancer  (MDASI -LC) (Section 6.1.3) 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  143  
 o MDASI -LC will only be performed  by patients  with  NSCLC  in Part  1 
and will not be performed in Part 2  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part  1 and 
only for 2 cycles in Part 2 of the study)  
… 
 
Section  3.1 – Study  Design  – Day 8 of Each  Cycle  
 
… 
 
• EORTC QLQ- C30 
• Core  MDASI  or MDASI -LC 
o MDASI -LC will only be performed  by patients  with  NSCLC  in Part  1 
and will not be performed in Part 2  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part  1 and 
only for 2 cycles in Part 2 of the study)  
… 
 
Section  3.1 – Study  Design  – Day 15 of Each  Cycle (Part  1: required;  Part 2: if clinically  
indicated)  
… 
 
• Biochemistry  
• Nausea and vomiting patient  diary  completion  (completed  in all cycles in Part  1 and is 
not collected at Day 15 in Part 2 of the study)  
… 
 
Section  3.1 – Study  Design  – End-of-Treatment  Visit 
 
… 
 
• EORTC QLQ- C30 
• Core  MDASI  or MDASI -LC (Part  1 only)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  144  
 • 12-lead ECG  
… 
 
Section  3.1.1 – Rationale of Study  Design  
 
… 
 
This study will determine the DLTs and, MTD , and RPII of NC-6004 in combination with 
gemcitabine in patients with advanced solid tumors and relapsed Stage IIIB/ first -line 
Stage IV  squamous NSCLC, first -line advanced or metastatic biliary tract cancer, and 
first- line metastatic  or locally advanced bladder  cancer for use in future  efficacy  studies.  
… 
 
The MDASI -LC questionnaire is designed specifically  for patients with lung cancer  and will 
be used by patients with NSCLC in Part 1 of this study.  
… 
 
Section  4.1 – Selection  of Study  Population  
 
Approximately 199 85 patients  (up to 49 patients  in Part 1 and up to 36 150 patients in Part 
2) will be enrolled  in at approximately 6 least  20 sites in the United  States.  Patients  will be 
assigned to a study treatment only if they meet all of the inclusion criteria and none of the 
exclusion criteria.  
Section  4.1.1 – Inclusion  Criteria  
 
2. (Part 1 only) Have a histologically or cytologically confirmed diagnosis of advanced 
solid  tumor that has relapsed  or is refractory  to standard curative or palliative  therapy or 
has a contraindication to standard therapy. 
 
(Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of Stage IIIB or IV squamous NSCLC and have not received 1 or 2 lines of prior 
chemotherapy for metastatic  disease.  Patients  with  known  sensitizing  mutation  in the 
epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase 
(ALK) fusion oncogene must have received at least 1 and up to 2 targeted therapies  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  145  
 prior  to enrollment  or targeted  therapy  for Stage  IIIB or IV NSCLC (second- or third - 
line). 
• A patient with stable, treated brain metastases is eligible, provided that 
there  is no evidence of progression after treatment  and the patient does not 
require corticosteroids, or, if the patient requires corticosteroid, has been 
receiving a stable dose of corticosteroids for at least 14 days prior to 
assignment to treatment.  
• Patients  whose tumors  are known to harbor an exon  19 deletion or exon 21 
L858R epidermal growth factor receptor (EGFR) mutation must have had 
intolerance or  have progressed on or had intolerance to an at least 1 and 
up to 2 EGFR tyrosine kinase inhibitor s. 
• P atients  whose  tumors  are known to harbor an anaplastic lymphoma kinase  
ALK translocation must have had intolerance or have progressed on or  
had intolerance to crizotinib  at least 1 and up to 2 ALK inhibitors . 
 
(Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or 
extrahepatic cholangiocarcinoma, gallbladder  cancer,  or ampullary  carcinoma)  and 
have not received prior systemic anticancer therapy for advanced or metastatic disease.  
(Part  2 only)  Cohort 3: Have histologically or cytologically confirmed  diagnosis of 
metastatic  or locally  advanced TCC of the urinary  tract  (bladder,  urethra,  ureter, 
renal pelvis) (T3b -T4 N0 M0, Tany N1- N3 M0, or  Tany Nany M1) and are not 
candidates for surgery.  
• Patients must not have received prior treatment with systemic 
anticancer  therapy  for metastatic  or locally  advanced urinary  tract 
cancer.  
• Certain mixed histologies that are predominantly (>50%) TCC are 
eligible: squamous, adenocarcinoma, and undifferentiated. Mixed 
undifferentiated histology  requires immunohistochemistry  consistent  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  146  
 with  a TCC  origin. Predominantly  squamous  or neuroendocrine 
tumors are excluded.  
Section  4.1.2 – Exclusion Criteria  
 
Patients  meeting  any of the following criteria will  be excluded from the study:  
 
1. Have  received  prior platinum therapy  in the past 3 months (Part  1) or 6 months  in the 
adjuvant or neoadjuvant setting (Part 2). 
… 
Section  5.1 – Method  of Assigning  Patients  to Treatment  Groups  
 
… 
 
In Part 2, all patients will receive the MTD  RPII  dose  of NC-6004 identified  in Part 1 
 
Section  5.2 – Prophylactic Treatments  
 
… 
 
Prophylactic antiemetic  medications  may be administered  according to standard treatment 
center protocols for cisplatin -based treatments. The use of prophylactic growth factor 
support  medications  is also allowed according  to ASCO  guidelines  (Smith  et al 2006) 
and is encouraged in patients who have experienced myelosuppression on treatment 
and/or in patients at high risk for experiencing febrile neutropenia . 
Section  5.3 – Treatments Administered  
 
… 
 
In each part Part  1 of the study, patients will receive treatment until  disease progression.  In 
Part 2 of the study, patients will receive treatment for 4 to  6 cycles (Cohorts 1 and 3) or 
8 cycles (Cohort 2) as directed in the  ASCO guidelines ( Appendix 12.4) or until disease  
progression, whichever occurs first. After the initial 4 to 6 cycles of treatment, individual 
patients can continue study  drug, subject to sponsor approval, for an additional 4 to 6 cycles 
of treatment (up to a maximum of 10 total cycles) if they have clinical benefit, with  
monitoring the same as that in the treatment phase . Prophylactic A antiemetic medications  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  147  
 may be administered according to standard  treatment center  protocols. The use of growth 
factor support  medications  is also allowed according  to ASCO  guidelines  (Smith  et al 
2006) and is encouraged in patients who have experienced myelosuppression on 
treatment and/or in patients at high risk for experiencing febrile neutropenia . 
… 
 
In Part 2, on Day 1 of each cycle, all  patients  will receive NC-6004 at the MTD  RPII  dose 
identified in Part 1 and 1250 mg/m2 gemcitabine. On Day 8 of each cycle, all patients in 
Part 2 of the study will receive 1250 mg/m2 gemcitabine.  
Section  5.10 – Prior,  Concomitant,  and Subsequent  Therapy  
 
(Part 2 only) Cohort 1: For patients with Stage IV  NSCLC, they may not have received 
prior  chemotherapy for metastatic disease. Patients with known sensitizing mutation in 
the EGFR gene or  ALK fusion oncogene must have received at least 1 and up to 2 
targeted  therapies prior  to enrollment.  If a patient  with  treated,  stable  brain metastases 
is otherwise  eligible  and requires corticosteroids,  the patient  must  have  been  receiving  a 
stable dose of corticosteroids for at least 14 days prior to assignment to treatment.  
Patients whose tumors are known to harbor an exon 19 deletion or exon 21 L858R 
EGFR mutation must  have had intolerance  or have progressed  on at least  1 and up to 2 
EGFR tyrosine kinase inhibitors. Patients whose tumors are known to harbor an ALK 
kinase  translocation must have had intolerance  or have progressed on at  least  1 and up 
to 2 ALK inhibitors. Patients with eligible biliary tract carcinoma must not have 
received  prior  systemic anticancer therapy  for advanced or metastatic disease.  Patients 
with eligible TCC of the urinary tract must not have received prior treatment with 
systemic anticancer therapy for metastatic or locally advanced urinary tract cancer. 
Prior chemotherapy  or targeted therapy for first - or second- line, Stage IIIB/IV NSCLC is  
allowed  and required for entry  in Part 2 of the trial. All patients must receive prophylactic 
treatment at each cycle to reduce the risk of hypersensitivity reactions and nausea and/or vomiting ( Section 5.8 ). 
The use of antiemetic  medications according to the site’s standard  of care is allowed. The use 
of prophylactic growth factor support medications is also allowed according to ASCO 
guidelines ( Smith et al 2006 ) and is encouraged in patients who have experienced  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  148  
 myelosuppression  on treatment  and/or  in patients  at high  risk for experiencing  febrile 
neutropenia.  
… 
 
Section  6.1 – Efficacy  Assessments  
 
… 
 
Symptom changes will be assessed  using  the core MDASI  or MDASI -LC (only  in patients 
with NSCLC in Part 1) ( Section 6.1.3) on Days 1 and 8 of each cycle and at the End-of- 
Treatment visit.  
… 
 
Section  6.1.3 – MD Anderson  Symptom Inventory 
 
… 
 
For patients with NSCLC in Part 1 and Part 2 only, a specific  MDASI  module designed for 
patients with lung cancer will be used, MDASI- LC (Appendix 12.3).  
… 
 
The core MDASI  and the MDASI -LC will  be administered  as a self-report paper -and-pencil 
form given  to the patient at  the site before study treatments  on Days  1 and 8 of each cycle in 
Part 1 only (as described in Study Manual). 
Section  6.2 – Pharmacokinetic and Pharmacodynamic Assessments  
 
… 
 
Pharmacokinetic samples will be  analyzed for according to the  bioanalytical laboratory 
protocol. The concentrations profiles  of micellar platinum in plasma  and total platinum in 
plasma and plasma ultrafiltrate (ie, free platinum) will be characterized.  
… 
 
Pharmacokinetic  plasma  and plasma  ultrafiltrate  samples will be collected  at the following 
times in Part 2 for up to 6 cycles : 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  149  
 … 
 
Section  6.3.1.2.1 – Safety  Monitoring  in Part 2 
 
During Part 2 of the study, patients  treated  with NC-6004 at the MTD  RPII  dose  from Part 1 
will be monitored for safety.  
… 
 
Section  6.3.3 – Assessment  of Nausea  and Vomiting  
 
… 
 
The investigator will collect  the diaries on  Day 8, Day 15 (Part  1 only) , and Day 22. 
 
… 
 
The patient  must return  the diary  to the site on Day 8, Day 15 (Part  1 only) , and Day 22 
(Day 1 of the next cycle) of each cycle.  
… 
 
Section  6.3.8 – Vital Sign  Measurements  
 
… 
 
In Cycles 2 through 6 (or up to Cycle  10, if there  is clinical benefit) Starting  in Cycle  2, vital 
signs will be measured before the start of the NC -6004 infusion and at the completion of the 
NC-6004 infusion on Day 1 of each cycle . 
… 
 
Section  7.2 – Exploratory Endpoints  
 
The exploratory endpoints of this study include exploratory safety endpoints of the 
occurrence of AEs and SAEs  after 4 to 6 cycles of treatment and the following  PK endpoints 
for micellar platinum in plasma and total platinum in plasma and plasma ultrafiltrate calculated for all patients using noncompartmental analysis:  
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  150  
 Section  7.3 – Sample Size Calculations  
 
This is a Phase 1b/2 study  with an overall sample size of up to 85 199 patients (up to 
49 patients in Part 1 and up to 36 150 patients in Part 2). The total sample size will depend on 
the number of cohorts required to establish an MTD  RPII dose and the number of patients 
with NSCLC enrolled at the MTD  RPII dose in Part 1.  
… 
 
Part  2 is a 3-cohort study  with  an overall sample  size of up to 150 patients  with  no more 
than 50 patients per cohort. The total sample size will depend on the results of interim 
futility and superiority analyses. In order to evaluate the overall sample size, 
simulations were performed assuming scenarios with different HRs for PFS for each 
cohort compared with historical control and different sample sizes for a subsequent 
Phase 3 clinical trial. The associated mean sample size for this trial in these scenarios 
ranged from 136 to 146 patients.  
In Part 2 of the study, additional patients with NSCLC will be enrolled at the MTD until a  
total of 36 patients with NSCLC have been dosed at the MTD, including patients with 
NSCLC receiving  the MTD  dose level  in Part 1. In order to provide a 95% chance to detect  
at least 1 AE of interest  with an underlying 8% incidence rate among patients treated  at MTD,  
additional patients with NSCLC will be enrolled at the MTD in Part 2 of the study. Patients  
will be enrolled in 2 stages until a total of 36 patients with NSCLC have been dosed at the 
MTD, including patients with NSCLC receiving the MTD level in Part 1. In the first stage of 
Part 2, ten patients treated at the MTD will be evaluated for response. If no patients respond,  
then the patients with NSCLC treated at a lower dose level than the MTD will be considered  
and a discussion of terminating the trial early will be triggered. Any evidence of response, 
regardless of duration, will be counted as a response. If at least 1 response if observed, the 
remaining 26 patients will be treated at the MTD. No formal efficacy analysis will be 
performed and no inference regarding efficacy will be drawn based on the response rate of 
the overall study.  
 
A total of 36 patients with NSCLC will be sufficient to identify toxicities of interest arising  
from  treatment  with NC-6004. Toxicities  at the MTD  with 36 patients enrolled  (ie, those  with 
an incidence of at least 8%), will be observed with a probability of at least 95.03% 
(1-[1-0.08]36), and common toxicities  (ie, those with an incidence of at least 20%) will be 
observed with a probability of at least 99.97% (1- [1-0.2]36). 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  151  
 Patients  who receive study  drug  will not be replaced.  
 
Patients  in Part 1 who discontinue treatment without DLT  prior to completing the first cycle 
will be replaced.  
Section  7.4 – Analysis Sets  
 
... 
 
• The Full Analysis Set (FAS)  consists  of all patients  treated  at MTD  RPII  dose  in Part 1 
or Part 2 who receive study product. 
… 
 
Section  7.6 – Statistical Analysis Methodology  
 
No formal statistical testing  is planned for this study . Ninety -five percent  confidence 
intervals may be calculated for selected safety and exploratory variables.  
… 
 
All summaries  will present data by dose level,  for patients  with NSCLC dosed  at the MTD, 
and overall. 
In Part  2, the following  posterior probabilities  will be derived  using  a Bayesian model 
updated every 6 weeks after 10 PFS have occurred within a cohort:  
• Probability  (Promising  HR) 
 
• Probability  (Phase  3 Success)  
 
If any cohort at interim or final analyses has a probability (success in a Phase 3 trial 
with 381 PFS events) >0.8, that indication will be declared a success, and the 
combination  of NC-6004 and gemcitabine  advances to a Phase  3 randomized,  controlled 
trial with a sample size sufficient to observe 381 PFS events.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  152  
 Section  7.6.1.6 – Quality  of Life Analyses  
 
… 
 
Changes from baseline will be summarized  by dose level,  for all patients  with NSCLC  dosed 
at MTD (or RPII dose) , and overall 
… 
 
Section  7.6.1.7 – Symptoms  Assessment  Analyses 
 
… 
 
Changes from baseline will be summarized  by dose level,  for all patients  with NSCLC  dosed 
at MTD (or RPII dose) , and overall 
… 
 
Section  7.6.2.1 – Analyses of Adverse Events  
 
… 
 
• TEAEs  with at least 5% incidence in all patients  with NSCLC dosed at the MTD  or RPII 
dose 
• Treatment -related  TEAEs  with at least 5% incidence in all patients  with NSCLC dosed at 
the MTD or RPII dose 
… 
 
Section  11 – Reference List 
 
… 
 
Smith  TJ, Khatcheressian  J, Lyman GH, et al. 2006 update  of recommendations  for the 
use of white blood cell growth factors: An evidence -based clinical practice guideline. J 
Clin Oncol. 2006;24(19):3187-205. 
Section  12.1 – Appendix: Schedule  of Events  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  153  
  
 
Table  12-1 Schedule  of Events  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onward 
Cycles 7 -10a End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                 
Eligibility  criteria   X                
Demography   X                
Medical  history   X                
Pregnancy  test (serum  or urine)    X  
 
Xde              
Physical  examination    
 
Xef   
 
Xef   X   X   X   X  
Height,  weight,  and BSA 
calculation   Xfg  X   X   X   X     
Vital  signs   X   
 
Xgh X  X X  X X  X X  X  
Performance  status  (ECOG)    
 
Xef   
 
Xef   X   X   X   X  
Disease  assessmenthi X          
 
Xhi    
 
Xhi   X X 
Audiometry   X   
 
Xij    
 
Xij    
 
Xij    
 
Xij    
 
Xij  
Hematology    X  
 
Xjk X X X X X X X X X X X X  
Biochemistry    X  
 
Xjk X X X X X X X X X X X X  
Urinalysis  (dipstick)   X              X  
EORTC  QLQ -C30    X X  X X  X X  X X  X  
MDASI  or MDASI -LCl    X X  X X  X X  X X  X  
Nausea  and vomiting  patient 
diarykm    X X X X X X X X X X X X   
Part  2 Nausea  and vomiting 
patient diarym    X X  X X          
Cardiac  risk factors   X                
12-lead ECGln   X X X  X   X      X  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  154  
  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onward 
Cycles 7 -10a End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Pharmacokinetic  assessments 
(Part 1)ko    X X X X   X Xmo Xmo    X  
Pharmacokinetic  assessments 
(Part 2) np    X X  X X  X X     X  
Adverse  events      
 
Xef X X X X X X X X X X X X X 
Concomitant  medication    
 
Xef   
 
Xef X X X X X X X X X X X X X 
Prophylactic  administrations     X   X   X   X     
NC-6004  administrationa    X   X   X   X     
Gemcitabine  administration     X X  X X  X X  X X    
Abbreviations:  BSA,  body  surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group; EORTC  QLQ -C30,  European  Organisation  for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI, MD Anderson Symptom  Inventory;  RECIST,  Response Evaluation  Criteria 
in Solid Tumors; MDASI -LC, MDASI- lung cancer.  
a. In Part  1 of the study, patients  will receive treatment  until  progressive disease.  In Part  2 of the study, patients  will receive treatment  for 6 cycles 
(Cohorts 1 and 3) or 8 cycles (Cohort 2). An optional extension of an additional 4 to 6 cycles of treatment (up to 10 cycles of treatment [including 
gemcitabine if the patient is tolerating NC- 6004]) is allowed, with monitoring the same as that in the treatment phase of the protocol.  
b. End-of-treatment  assessments will be performed  within  28 days after treatment  discontinuation.  
c. After patient discontinuation  or completion  of treatment  without disease progression,  patients  will be followed with  scans  every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
d. Day 15 visit is required  in Part  1. In Part  2, Day 15 visit is only necessary  if it is clinically  indicated.  
de.  Not required  if screening  pregnancy test was performed  using  serum.  
ef. Safety  assessments of physical examination,  ECOG,  review  of AEs,  and concomitant medication  use can be completed  on Day -1 to allow  for early  morning 
dosing. These should not be conducted in place of screening assessments.  
fg. Height  and weight  only.  
gh.  On Day  1 of Cycle 1, vital signs will be measured before the start of the NC -6004 infusion, every 20 minutes during the infusion, at the completion of the 
infusion,  and 1 hour after the completion  of the NC-6004  infusion.  Starting  in Cycle  2 In Cycles  2 through 10, vital signs  will be measured  before  the start 
of the NC-6004 infusion  and at  the completion  of the NC-6004 infusion on Day 1 of each  cycle. Vital signs will  be measured before  and after gemcitabine 
infusion on Day 8 of each cycle.  
hi. D isease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used for all subsequent 
assessments. Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will be assessed every  6 (±1) weeks  (ie, every  other  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  155  
 cycle)  and at the End- of-Treatment  visit or until disease progression.  Patients  who have  obtained  a partial response or complete  response will have  a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
ij.  To be performed  only as clinically  indicated.  
jk. Hematology  or biochemistry tests will  be repeated  prior  to dosing on Day 1 of Cycle  1 if they were  last performed more than 24 hours  before  the start of  the 
study drug administration.  
l. Symptom  changes  will be assessed using  the core MDASI  or MDASI -LC (only  in patients  with  NSCLC  in Part  1). 
km. Diary  issued on Day 1 of each cycle. Assessment  is performed  at the site before  dosing on Days  1 and Day 8 as well  as Day 15 (Day 15 diary  collected  in 
Part 1 only; note: no dosing on Day 15) of each cycle. Patient completes diary at home on Days 2 through 8 and returns diary on Day 8.  
ln. Twelve -lead ECGs will be performed after the patient has rested in the supine position for at least 5 minutes. On Day  1 of Cycle 1, 12 -lead ECGs will be 
performed  before  the start  of the NC-6004  infusion,  at completion  of infusion (~1 hour after start of infusion),  and at Hours  3 and 24 (Day  2) after the start of 
infusion. On Day 8 of Cycle 1, 12- lead ECGs will be performed before the start of gemcitabine infusion, at the end of gemcitabine infusion, and at 1 hour 
after completion  of gemcitabine  infusion.  Twelve -lead ECGs will be performed  on Day 1 of Cycles  2 through  6 before  the start of the NC-6004  infusion,  and 
at the End -of-Treatment visit.  
mo. For Part  1, blood samples will be collected at the following times: before the start of the NC- 6004 infusion on Day 1 of Cycles 1 through 6, at end of NC - 
6004 infusion  in Cycles  1, 3, and  5, after the  start of NC-6004 infusion at Hours  3, 6, 12,  24 (Day  2), 48 (Day  3), 96  (Day  5), 168  and prior  to gemcitabine 
infusion (Day 8), and 336 (Day 15) in Cycles 1, 3, and 5, and at the End -of-Treatment visit. Additional pharmacokinetic blood sample collections may be 
performed, at the discretion of the investigator, during any visit where toxicity is observed.  
np. Fo r Part  2 (up to 6 cycles) , on the day of NC -6004 infusion for each cycle, blood samples will be collected before the start of the NC -6004 infusion, at the 
end of the NC-6004  infusion, before  gemcitabine  infusion  on Day 8, and at the End-of-Treatment  visit. Additional  pharmacokinetic  blood  sample  collections 
may be performed, at the discretion of the investigator, during any visit where toxicity is observed.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  156  
 Section  12.4 – Appendix:  American  Society of Clinical Oncology  Guideline  
 
This appendix was  removed.  
 
12.4.3  Protocol  Amendment 3–Protocol  Version  4.0, Incorporating 
Amendment 3, Dated 31 July 2016  
The following sections detail the changes made to Amendment 2 of the protocol (Version  3.0) 
dated 07 July 2015. The integrated protocol, Version 4.0, including Amendment 3, was issued 
on 31 July 2016. 
 
12.4.3.1  Assessment  of Risk  Associated  With  Amendment  3, 
Version 4.0 
No patients  treated  with NC-6004 in Study NC-6004- 004A  at the MTD  and gemcitabine  with 
normal renal function (≥50 mL/min) experienced a clinically significant decrease in CrCl 
after initial study drug administration. Creatinine clearance values were stable with no 
decrease in all patients beyond the first cycle through up to 10 cycles. Therefore, patients 
with CrCl <60 mL/min are not expected to experience clinically meaningful decreases in 
renal function after treatment with NC -6004 and gemcitabine. However, increased renal 
function monitoring and protocol -mandated discontinuation will mitigate this risk.  
 
12.4.3.2  Overview  of Changes 
The overview  of significant changes  includes  the following:  
 
Protocol  Synopsis  – Study  Sites; Section  4.1 – Selection  of Study  Population  
 
The study site details were  updated to at least  20 sites in the  Unites  States  and Europe. 
 
Protocol  Synopsis  – Inclusion  Criteria; Section  4.1.1 – Inclusion  Criteria  
 
The inclusion  criterion  5 was  updated to the following:  
 
5. Have  an Eastern  Cooperative  Oncology Group (ECOG)  PS of 0 to 1, with the exception of 
patients in Part 2 (Cohort 3, unfit bladder cancer patients) who may have an ECOG PS of 2. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  157  
 Protocol  Synopsis  – Inclusion Criteria;  Protocol  Synopsis  – Study  Design;  Section  
3.1 - Study  Design;  Section  4.1.1 – Inclusion  Criteria;  Section  5.1 – Method  of Assigning  
Patients to Treatment Groups; Section 6.3.1.2.1 - Safety Monitoring in Part 2  
The inclusion  criterion  8 and study design  were  updated to reflect  the following:  
 
8. In Part 1 and in Part 2 in Cohorts  1 and 2: have adequate renal  function defined  as a CrCl  
≥50 mL/minute  (calculated  according  to the formula  of Cockcroft  and Gault  1976)  or serum 
creatinine <1.5 mg/dL. In Part 2, patients in Cohort 3 (bladder cancer) must have a CrCl of  
≥30 mL/min.  
 
• Bladder  cancer  patients in  Cohort 3 of Part 2  will be  stratified by  ≥30 to  
<60 mL/min  and/or  ECOG PS 2 and ≥60 mL/min  and ECOG PS 0 to 1. If 2 of 
6 patients (or ≥33% at any point during the study) in the ≥30 to <60 mL/min 
group have a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least 1 week  apart),  then enrollment  of patients 
with CrCl <60 mL/min will stop in the bladder cancer cohort.  
Protocol  Synopsis  – Inclusion  Criteria; Section  4.1.1 – Inclusion  Criteria  
 
The inclusion  criterion  9 was  updated to the following:  
 
9. Have a negative pregnancy  test result at screening  (for females of childbearing  potential; 
not applicable to  patients  who are unable  to become pregnant, including those  with  bilateral 
oophorectomy and/or hysterectomy or postmenopausal [no menses for the previous  
12 months]). The test must  be performed  within 1  week  before Day  1 of treatment.  
 
Protocol  Synopsis  – Inclusion  Criteria; Section  4.1.1 – Inclusion  Criteria  
 
The inclusion  criterion  10 was added as follows:  
 
10. Male  patients  must  agree to  use a condom  during treatment and for 90 days after dosing. 
Male patients must agree not to donate sperm for 90 days after dosing.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  158  
 Protocol  Synopsis  – Inclusion  Criteria; Section  4.1.1 – Inclusion  Criteria  
 
The inclusion  criterion  11 was updated to the following:  
 
11. For women  of childbearing potential*:  are willing  to abstain  from heterosexual  activity  or 
practice physical barrier contraception follow 1 of the following effective methods of birth 
control from the time of study entry to 6 months after the last day of treatment.:  
• Combined (estrogen  and progestogen  containing)  hormonal  contraception  associated 
with inhibition of ovulation (oral, intravaginal, or transdermal)  
• Progestogen -only hormonal  contraception  associated  with inhibition  of ovulation 
(oral, injectable, or implantable)  
• Intrauterine  devices  
• Intrauterine  hormone -releasing  system  
• Vasectomized  partner  who has received  medical  assessment  of surgical  success  
• Bilateral tubal  occlusion  
• True  sexual  abstinence**  
*Patients not of childbearing potential include those who are surgically sterile or 
postmenopausal (no menses for the previous 12 months). For women not currently taking contraceptive methods at screening, low user dependency contraceptive methods (eg, 
implantable progestogen -only hormonal contraception, intrauterine device, intrauterine 
hormone -releasing  system,  bilateral tubal  occlusion, vasectomized  partner) are recommended.  
**The  reliability  of sexual  abstinence needs  to be evaluated  in relation  to the duration of the 
clinical trial and the preferred and usual lifestyle of the patient.  
Protocol  Synopsis  – Study  Design;  Section  3.1 – Study  Design  
 
All references to “two -stage” and a minimum threshold  of clinical  responses in Part 2 were 
removed.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  159  
 Protocol  Synopsis  – Study  Design;  Section  3.1 - Study  Design;  Section  5.1 - Method  of 
Assigning Patients to Treatment Groups; Section 5.3 -  Treatments Administered  
The RPII  dose of 135 mg/m2 was added to  the protocol.  
 
Protocol  Synopsis  – Study  Design;  Section  3.1 - Study  Design  
 
The historical median duration of PFS and PFS weekly hazard were added for the unfit 
bladder  cancer  cohort. A successful  outcome  for unfit and fit bladder  cancer  patient  cohorts 
with 30 planned patients was updated to 15 PFS events.  
Protocol  Synopsis  – Study  Design;  Protocol  Synopsis  – Sample  Size;  Section  3.1 - Study  
Design; Section 4.1 – Selection of Study Population; Section 7.3 -  Sample Size 
Calculations  
The total sample  size in Part 2 of the study was changed to 160 patients  with no more  than 
50 patients  each in  Cohorts 1 and 2 and no more  than 60 patients  in Cohort  3 (30 unfit and 
30 fit bladder  cancer  patients).  The simulated  mean  sample sizes for  this trial were  updated to 
92.7 to 116.8 patients.  
 
Protocol  Synopsis  – Estimated  Study  Duration;  Section  4.2.1 – Reasons  for 
Withdrawal/Discontinuation  
A study treatment discontinuation rule  was added as follows:  
 
• For Cohort  3 only, unfit  bladder  cancer  patient (≥30  to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for 2 
consecutive assessments, at least 1 week apart)  
Protocol  Synopsis  – Definition  of a DLT;  Section  6.3.1.1 – Definition  of Dose -Limiting  
Toxicities  
It was clarified  that DLTs  will only be monitored in Part 1 of the study.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  160  
 Section  3.1 - Study  Design;  Section  12.1 - Appendix:  Schedule  of Events 
 
A serum  or urine  pregnancy test was added to Day 1 of each cycle and at the 
End-of-Treatment visit.  
Section  3.1 - Study  Design;  Section  12.1 - Appendix:  Schedule  of Events;  
Section 6.1.3 -  MD Anderson Symptom Inventory 
It was clarified that the MDASI  will only be performed in  Part 1.  
 
Section  5.1 - Method  of Assigning  Patients  to Treatment  Groups;  Section  5.3 - Treatments 
Administered  
A +10- minute  window  was added for the 1-hour administration of NC-6004 infusion. 
 
Section  5.4 - Dose  Delays  and Modifications;  Section  5.4.1 – NC-6004 Dose  Delays and 
Modifications  
Updated “Grade 3 or 4 toxicity”  to “Grade  3 or 4 toxicity  (recurrence  of the same AE)”  to 
more clearly define the recurrence of DLTs that could lead to study drug withdrawn.  
Section 3.1 - Study Design; Section 5.4 -  Dose Delays and Modifications; Section 6.3.7 -  
Physical  Examination;  Section  11 - Reference List;  Section  12.1 - Appendix:  Schedule  of 
Events, footnote g 
It was added that the doses of NC -6004 and gemcitabine will be calculated in milligrams per 
square meter (mg/m2) at screening and will not be changed in subsequent cycles unless the 
patient’s body weight increases or decreases by at least 10% from the patient’s screening 
weight measurement. This threshold should not be confused with a change in the patient’s 
body surface  area (mg/m2). Any change  in a patient’s  weight  by at least 10% during the study 
will require a recalculation of the doses of NC -6004 and gemcitabine. Weight will be 
measured before treatments on Day 1 of each cycle, with a calculation of body surface area 
before each dosing on Day 1 of each cycle (using the Mosteller formula [ Mosteller 1987]).  
Section  5.5.2 - Gemcitabine  Drug  Product;  Section  5.6.1 - Study  Drug  Packaging and 
Storage  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  161  
 The generic gemcitabine was added to the protocol to clarify that it is acceptable for generic 
gemcitabine to be administered in this study  (as per the original intent of the Protocol Author) 
in place of Gemzar.  
Section  5.6.2 – Test Article Accountability  
 
It was clarified  that the PI should maintain  accurate records of receipt  of all test articles  that 
are centrally provided.  
Section  6.2 - Pharmacokinetic and Pharmacodynamic Assessments Section  
12.1 - Appendix: Schedule  of Events  
 
A 10- minute  window after ECG performance was added for the pharmacokinetic blood 
sampling.  
Section  6.3.2.5 - Assessment of  Causality  
 
“Study drug” was updated to “study drug (NC-6004 and gemcitabine)”  to indicate  that the 
assessment of an  AE’s relatedness was to the combination of NC -6004 and gemcitabine. 
Section  6.3.6 – Electrocardiograms; Section  12.1 - Appendix: Schedule  of Events  
 
A ±10- minute  window for performance  of 12- lead ECGs  was added.  
 
Section  6.3.6 – Electrocardiograms; Section  6.3.8 - Vital  Sign  Measurements 
Section 12.1 - Appendix: Schedule of Events, footnote n 
The text “rest  for at least 5 minutes”  was updated to “adequately  rested”  for the patient 
before ECGs and vital sign measurements.  
Section  10.2.2 - Protocol Violations  and Deviations  
 
Text was updated to clarify  that Part 2 of this study  will not require sponsor approval prior to 
each patient being enrolled in the study. 
Section  12.1 - Appendix: Schedule  of Events  
 
A column was added to the Schedule of Events Table  (Table  12-1) to clearly  show that ECGs 
will be also performed on Day 2 of Cycle 1. For completeness, PK assessments, AE 
monitoring, and concomitant medication review were also added to Day 2 of Cycle 1. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  162  
 12.4.3.3  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol. Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Protocol Synopsis  – Study  Sites  
 
Study Sites:  At least 20 sites in the United  States  and Europe.  
 
Protocol Synopsis  –Inclusion Criteria  
 
… 
 
5. Have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1, with the exception 
of patients  in Part  2 (Cohort 3, unfit  bladder  cancer patients) who may have an ECOG 
PS of 2 . 
… 
 
8. In Part 1 and in Part 2 in Cohorts 1 and 2 : Hhave adequate renal function defined as a 
creatinine clearance (CrCl) ≥50 mL/minute (calculated according to the formula of 
Cockcroft and Gault  1976) or serum  creatinine  <1.5 mg/dL. In Part  2, patients  in Cohort 3 
(bladder cancer) must have a CrCl of ≥30 mL/min.  
• Bladder  cancer patients in  Cohort 3 of Part 2 will be stratified  by ≥30 to 
<60 mL/min  and/or  ECOG  PS 2 and ≥60 mL/min  and ECOG  PS 0 to 1. If 
2 of 6 patients (or ≥33% at any point during the study) in the ≥30 to  
<60 mL/min  group have a worsening  of CrCl  (ie, 50% reduction from 
baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment  of patients  with  CrCl  <60 mL/min  will stop in the bladder 
cancer cohort.  
9. Have a negative pregnancy  test result at screening  (for females of childbearing  potential; 
not applicable  to patients  who are unable to  become pregnant, including those with  bilateral 
oophorectomy and/or hysterectomy or postmenopausal [no menses for the previous 
12 months] ). The test must  be performed  within  1 week  before Day  1 of treatment.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  163  
 10. Male patients  must  agree to use a condom  during  treatment and for 90 days after 
dosing. Male patients must agree not to donate sperm for 90 days after dosing.  
11. For women  of childbearing  potential*: Aare willing  to abstain  from heterosexual 
activity or practice physical barrier contraception follow 1 of the following effective 
methods of birth control from the time of study entry to 6 months after the last day of 
treatment.: 
• Combined (estrogen  and progestogen containing)  hormonal contraception 
associated  with  inhibition  of ovulation (oral,  intravaginal, or transdermal)  
• Progestogen- only hormonal contraception  associated  with  inhibition  of 
ovulation (oral, injectable, or implantable)  
• Intrauterine  devices  
• Intrauterine  hormone -releasing  system  
• Vasectomized  partner  
• Bilateral tubal  occlusion  
• True  sexual abstinence**  
*Patients not of childbearing potential include those who are surgically sterile or postmenopausal (no menses for the previous 12 months). For women not currently taking  contraceptive methods  at screening,  low user dependency  contraceptive methods 
(eg, implantable progestogen-only hormonal contraception, intrauterine device, intrauterine  hormone -releasing  system,  bilateral tubal  occlusion,  vasectomized  partner) 
are recommended.  
**The reliability  of sexual  abstinence  needs  to be evaluated in relation  to the duration 
of the clinical trial and the preferred and usual lifestyle of the patient.  
Protocol Synopsis  – Study  Design  
 
This study will consist of 2 parts; Part 1  is a Phase 1b, continual reassessment method  
dose- escalation  trial, and Part 2 is a Phase 2, adaptive,  two-stage , open- label,  expansion trial 
evaluating activity, safety, and tolerability at the RPII dose identified in Part 1.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  164  
 … 
 
Part 2 of the study (Phase 2 portion) will begin after the RPII dose of NC-6004 is identified 
for use in combination  with gemcitabine.  All patients will receive  NC-6004 at the RPII  dose 
(135 mg/m2, established in Part 1) in combination with gemcitabine 1250 mg/m2 by the 
same regimen as in Part 1.  
Three cohorts of patients are eligible (Cohort 1: first- line metastatic squamous NSCLC; 
Cohort 2: first-line metastatic or locally  advanced  cholangiocarcinoma, gallbladder cancer,  or 
ampullary  cancer  (biliary  tract cancer);  and Cohort 3: first-line metastatic  or locally  advanced 
TCC of the urinary tract (bladder cancer). Bladder cancer patients in Cohort 3 of Part 2 
will be stratified by ≥30 to <60 mL/min and/or ECOG  PS 2 (unfit) and ≥60 mL/min and 
ECOG  PS 0 to 1 (fit). If 2 of 6 patients (or ≥33% at any point during the study) in the  
≥30 to  <60 mL/min  group have a worsening  of CrCl  (ie, 50% reduction  from  baseline 
for 2 consecutive assessments,  at least  1 week  apart), then enrollment  of patients  with 
CrCl <60 mL/min will stop in the bladder cancer cohort.  
Stage Part  2 will continue  in each cohort after achieving the minimum threshold  of clinical  
responses required and enroll up to 50 patients each in Cohorts 1 and 2, and up to 60 
patients in Cohort 3, for a total of up to 150 160 patients in Part 2.  
… 
 
Cohort  Biliary  Bladder  (CrCl:  
≥60 mL/min 
and ECOG  PS 
0-1; fit)  Bladder  (CrCl:  
≥30 to <60 mL/min  and/or 
ECOG PS 2;  
unfit)  Squamous 
NSCLC 
Historical 
Median Duration  of PFS 8.8 months  7.6 months  5.8 months  5 months  
Historical PFS 
Weekly  Hazard  0.01795  0.020755  0.02711  0.031377  
Abbreviations:  CrCl, creatinine clearance;  ECOG, Eastern  Cooperative  Oncology  Group;  NSCLC,  non- 
small cell lung cancer; PS, performance status.  
Once  10 PFS events have been  observed, interim analyses will be performed  every  6 weeks. 
At each interim and at the final analysis, there are 3 possible outcomes for each cohort.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  165  
 • Futility  – 10 PFS events  have  been  observed  in each cohort  and at least 1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
 
• Probability  (Phase 3 Success*)  <0.4 
 
• Success – 25 PFS events  have  been  observed in each 50-patient  cohort  and 15 PFS 
events in each 30- patient bladder cancer cohort and:  
• Probability  (Phase 3 Success*)  >0.8 
 
• Inconclusive  – neither  futility  nor success.  
 
* Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events -  enough to 
provide  80% power  to detect  an HR of 0.75. A promising  HR is defined as one  less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in that 
cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been 
observed in that 50-patient cohort (Cohort 1 and 2) or 30- patient bladder cancer cohort 
(Cohort  3, fit and unfit),  respectively . Accrual  will stop for any cohort  identified  as futile  or 
successful at interim.  The conclusion of this Phase 2 trial will be that a Phase 3 trial with 381 
events should be conducted for each cohort that is a success.  
Protocol  Synopsis  – Estimated  Study  Duration  
 
… 
 
Patients  will receive study  treatment until any of the following  occur:  
… 
 
• For Cohort  3 only, unfit  bladder  cancer patient  (≥30 to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least  1 week  apart)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  166  
 Protocol Synopsis  – Definition  of DLT  
 
A DLT (monitored  in Part  1 only)  is defined  as the following  treatment- related  AEs or 
laboratory abnormalities, graded according to NCI CTCAE version 4.03: 
Protocol Synopsis  – Sample  Size 
 
… 
 
Part 2 is a 3 -cohort study with an overall sample size of up to 150160 patients with no more 
than 50 patients per cohort in Cohorts 1 and 2 and no more than 60 patients in Cohort 3 
(30 unfit and 30 fit bladder cancer patients) . The total sample size will depend on the 
results of interim  futility  and superiority  analyses.  In order to evaluate  the overall sample size, 
simulations were performed assuming scenarios with different HRs for PFS for each cohort 
compared with historical control and different sample sizes for a subsequent Phase 3 clinical 
trial. The associated mean sample size for this trial in these scenarios ranged from 136  92.7 
to 146 116.8 patients.  
 
Protocol Synopsis  – Study  Drug,  Dosage, and Route  of Administration  
 
… 
 
In each part of the study, NC-6004 will be administered  as a 1 hour (+10- minute  window)  
intravenous infusion on Day 1 of each cycle.  
 
Section  3.1 - Study  Design  
 
This study will consist of 2 parts; Part 1 is a Phase 1b, continual reassessment method 
dose- escalation trial in patients with any advanced solid tumor, and Part 2 is a Phase 2, 
adaptive two-stage, open- label,  expansion trial in patients with squamous NSCLC,  biliary 
tract, and bladder cancer evaluating activity, safety, and tolerability at the RPII dose 
identified in Part 1.  
… 
Part 2 of the study (Phase 2 portion) will begin after the RPII dose of NC-6004 is identified 
for use in combination  with gemcitabine.  All patients will receive  NC-6004 at the RPII  dose 
(135 mg/m2, established in Part 1) in combination with gemcitabine 1250 mg/m2 by the 
same regimen as in Part 1. Cohort 3 will stratify  patients by creatinine clearance (CrCl) 
to assess study drug in patients with reduced kidney function (ie, CrCl of <60 to  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  167  
 ≥30 mL/min [unfit] and ≥60 mL/min [fit]) in a controlled manner and with the 
stipulation  that enrollment  will stop if 2 of 6 patients  in the <30 to ≥60 mL/min  group 
have a worsening of CrCl (ie, 50% reduction from baseline for 2 consecutive 
assessments, at least 1 week apart).  
Three cohorts of patients are eligible (Cohort 1: first- line metastatic squamous NSCLC; 
Cohort 2: first-line metastatic or locally  advanced  cholangiocarcinoma, gallbladder cancer,  or 
ampullary  cancer  (biliary  tract cancer);  and Cohort 3: first-line metastatic  or locally  advanced 
TCC of the urinary tract (bladder cancer). Stage 2 will continue in each cohort after 
achieving the minimum threshold of clinical responses required and Part 2 will enroll up to 
50 patients each in Cohorts 1 and 2, and up to 60 patients in Cohort 3, for a total of up  
to 160 patients in Part 2. in each cohort for a total of up to 150 patients in Part 2.  The 
primary endpoint (PFS) will be continuously updated and compared with the historical PFS 
from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard 
model will be updated as PFS data accrue.  A hazard ratio (HR) for PFS for each cohort 
versus historical control will be obtained.  
 
Cohort  Biliary  Bladder 
(CrCl: ≥60 
mL/min; fit) Bladder 
(CrCl:  ≥30 to  
<60 mL/min; 
unfit)  Squamous 
NSCLC 
Historical 
Median 
Duration  of 
PFS 8.8 months  7.6 months  5.8 months  5 months  
Historical PFS Weekly 
Hazard  0.01795  0.020755  0.02711  0.031377  
Abbreviations:  CrCl: creatinine clearance;  ECOG,  Eastern  Cooperative  Oncology  Group; 
NSCLC, non -small cell lung cancer; PS, performance status.  
 
Once  10 PFS events have been  observed, interim analyses will be performed  every  6 weeks. 
At each interim and at the final analysis, there are 3 possible outcomes for each cohort.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  168  
 • Futility  – 10 PFS events have been  observed  in each cohort and at least 1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
 
• Probability  (Phase 3 Success*)  <0.4 
 
• Success – 25 PFS events have been  observed in each 50-patient  cohort and 15 PFS 
events in each 30- patient bladder cancer cohort and: 
• Probability  (Phase 3 Success*)  >0.8 
 
• Inconclusive – neither  futility  nor success.  
 
* Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events - enough to 
provide 80% power to detect  an HR of 0.75. A promising  HR is defined as one less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in that 
cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been 
observed in that 50-patient or  30-patient bladder  cancer cohort , respectively . Accrual will 
stop for any cohort identified  as futile  or successful  at interim.  The conclusion of this Phase 2 
trial will be that a Phase 3 trial with 381 events should be conducted for each cohort that is a 
success.  
… 
Day 1 of Cycle  
The following procedures will be performed  on Day 1 prior to NC-6004 infusion in each 
treatment cycles unless otherwise specified:  
• Pregnancy test (serum or urine) on Day 1 of each cycle (at Cycle 1 only, serum or 
urine; test is not required if pregnancy test at screening  was performed  using  serum)  
• Physical  examination  (if not performed  on Day –1) 
• Height, weight, and calculation  of body surface  area using  the Mosteller  formula 
(Mosteller 1987) 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  169  
 • Part  1 only: Core  MDASI  or MDASI  module specific for lung cancer  (MDASI -LC) 
(Section 6.1.3) 
… 
Day 8 of Each Cycle 
… 
• Part  1 only: Core  MDASI  or MDASI -LC 
… End-of-Treatment  Visit 
The following procedures will be performed within  28 days after treatment discontinuation:  
 
• Pregnancy  test (serum  or urine)  
… 
• Part  1 only: Core  MDASI  or MDASI -LC (Part 1 only)  
Section  3.1.1 –Rationale of Study  Design  
… 
In Part  1 only, Tthe MDASI  will be used to evaluate symptoms  related  to QoL during 
treatment.  
Section  4.1 –Selection  of Study  Population  
Approximately 209 199 patients (up to 49 patients in Part 1 and up to 160 150 patients in 
Part 2) will be enrolled  in at least 20 sites in the United  States  and Europe . Patients  will be 
assigned to a study treatment only if they meet all of the inclusion criteria and none of the 
exclusion criteria.  
Section  4.1.1 – Inclusion  Criteria  
 
5. Have  an ECOG  PS of 0 to 1, with  the exception  of patients  in Part  2 (Cohort 3, unfit 
bladder cancer patients) who may have an ECOG PS of 2 . 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  170  
 … 
 
8. In Part  1 and in Part 2 in Cohorts 1 and 2: Hhave adequate renal function defined as a 
CrCl ≥50 mL/minute (calculated according to the formula of Cockcroft and Gault 1976) or 
serum  creatinine  <1.5 mg/dL. In Part  2, patients  in Cohort 3 (bladder  cancer)  must  have 
a CrCl of ≥30 mL/min.  
• Bladder  cancer patients in  Cohort 3 of Part 2 will be stratified  by ≥30 to 
<60 mL/min  and/or  ECOG  PS 2 and ≥60 mL/min  and ECOG  PS 0 to 1. If 
2 of 6 patients (or ≥33% at any point during the study) in the ≥30 to  
<60 mL/min  group have a worsening  of CrCl  (ie, 50% reduction from 
baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment  of patients  with  CrCl  <60 mL/min  will stop in the bladder 
cancer cohort.  
9. Have a negative pregnancy  test result at screening  (for females of childbearing  potential; 
not applicable  to patients  who are unable to  become pregnant, including those with  bilateral 
oophorectomy and/or hysterectomy or postmenopausal [no menses for the previous 
12 months] ). The test must  be performed  within  1 week  before Day  1 of treatment.  
 
10. Male patients  must  agree to use a condom  during  treatment and for 90 days after 
dosing. Male patients must agree not to donate sperm for 90 days after dosing.  
11. For women  of childbearing  potential*: Aare willing  to abstain  from heterosexual 
activity or practice physical barrier contraception follow 1 of the following effective 
methods of birth control from the time of study entry to 6 months after the last day of 
treatment.: 
• Combined (estrogen  and progestogen containing)  hormonal contraception 
associated  with  inhibition  of ovulation (oral,  intravaginal, or transdermal)  
• Progestogen- only hormonal contraception  associated  with  inhibition  of 
ovulation (oral, injectable, or implantable)  
• Intrauterine  devices  
• Intra -uterine  hormone -releasing  system  
• Vasectomized  partner  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  171  
 • Bilateral tubal  occlusion  
• True  sexual  abstinence**.  
*Patients not of childbearing potential include those who are surgically sterile or 
postmenopausal (no menses for the previous 12 months). For women not currently taking  contraceptive methods  at screening,  low user dependency  contraceptive methods 
(eg, implantable progestogen -only hormonal contraception, intrauterine device, 
intrauterine  hormone -releasing  system,  bilateral  tubal  occlusion,  vasectomized  partner) 
are recommended.  
**The  reliability  of sexual  abstinence  needs  to be evaluated  in relation  to the duration 
of the clinical trial and the preferred and usual lifestyle of the patient.  
… 
 
Section  4.2.1 – Reasons  for Withdrawal/Discontinuation  
 
… 
 
A patient  may be withdrawn from the  study for any of the following reasons:  
 
… 
 
• For Cohort  3 only, unfit  bladder  cancer patient  (≥30 to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least  1 week  apart)  
Section  5.1 - Method  of Assigning  Patients  to Treatment  Groups  
This is an open -label study that will be conducted in 2 parts. In both parts, NC -6004 will be 
administered  as a 1-hour (+10- minute  window)  intravenous  infusion  on Day 1 of each cycle. 
Gemcitabine 1250 mg/m
2 will be administered as a 30 -minute intravenous infusion on Day 1 
of each cycle (after  the administration  of NC-6004)  and on Day 8 of each cycle.  The duration 
of each cycle will be 21 days.  
… 
 
In Part 2, all patients  will receive the RPII  dose (135 mg/m2) of NC -6004 identified  in Part 1. 
Bladder  cancer patients  in Cohort  3 of Part  2 will be stratified  by ≥30 to <60 mL/min  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  172  
 and/or  ECOG  PS 2 (unfit) and ≥60 mL/min  and ECOG  PS 0 to 1 (fit) . If 2 of 6 patients 
(or ≥33% at any point during the study) in the ≥30 to <60 mL/min group have a 
worsening of CrCl (ie, 50% reduction from baseline for 2 consecutive assessments, at 
least 1 week apart), then enrollment of patients with CrCl <60 mL/min will stop in the 
bladder cancer cohort.  
Section  5.3 - Treatments Administered  
The duration of each treatment cycle  will be 21 days in both parts  of the study. NC-6004 will 
be administered on Day 1 of each cycle as a 1 -hour (+10- minute window) intravenous 
infusion.  
… 
 
In Part 2, on Day 1 of each cycle,  all patients  will receive  NC-6004 at the RPII  dose 
(135 mg/m2) identified  in Part 1 and 1250 mg/m2 gemcitabine.  On Day 8 of each cycle,  all 
patients in Part 2 of the study will receive 1250 mg/m2 gemcitabine.  
Section  5.4 - Dose  Delays and Modifications  
 
The doses for NC -6004 and gemcitabine will be calculated in milligrams per square 
meter (mg/m2) at screening, and will not be changed in subsequent cycles unless the 
patient’s body weight has increased or decreased by ≥10% from the patient’s weight measurement  at screening.  Any change  in a patient’s  weight  by ≥10%  during  the study 
will require  a recalculation  of the  doses of all  study  drugs  (Note:  This  threshold  should 
not be confused  with  a change  of a patient’s  body  surface area  [BSA]  [mg/m
2]). Weight 
will be measured before treatments on Day 1 of each cycle, with calculation of BSA before dosing on Day 1 of each cycle (using the Mosteller formula [ Mosteller 1987 ]). 
Patients  experiencing  significant toxicities  must  be immediately  and permanently withdrawn 
from treatment with NC -6004 and gemcitabine as follows:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  173  
 • Any patient who experiences a Grade  3 or 4 hypersensitivity  reaction  during any 
cycle of treatment  
• Any patient who experiences 2 protocol-defined DLTs  during treatment 
 
• Any patient who experiences a recurrent Grade  3 or 4 toxicity  (recurrence  of the 
same AE) after a dose reduction  
Section  5.4.1 – NC-6004 Dose  Delays and Modifications  
 
… 
 
Following recovery to Grade 1 or lower, treatment may resume at the investigator’s 
discretion.  Patients  who resume treatment following  a dose delay  will have the dose of study 
drug reduced by 50% for the remainder of study treatment. If toxicities persist or recur to 
Grade 3 or 4 (recurrence of the same AE) after the dose reduction, study treatment will be 
terminated.  
Section  5.5.2 - Gemcitabine  Drug  Product  
 
Gemzar® (gemcitabine  for injection,  USP),  is available in sterile  single- use vials  individually 
packaged in a carton containing: 200 mg white to off-white, lyophilized powder in a 
10-mL size sterile  single -use vial or 1 g white  to off-white,  lyophilized powder in a 
50-mL size sterile  single -use vial. Vials  of gemcitabine Gemzar  contain  either  200 mg or 1 g 
of gemcitabine hydrochloride (expressed as free base) formulated with mannitol (200 mg or 
1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile 
lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for 
pH adjustment. 
Section  5.6.1 - Study  Drug  Packaging and Storage  
 
All study drugs must be stored  in a secure area (eg, a locked cabinet).  NC-6004 should be 
protected from light and stored refrigerated (2 ° to 8 °C). Unopened vials 
of Gemzar  (gemcitabine)  are stable  until the expiration date indicated  on the package when 
stored at controlled room temperature 20° to 25°C that allows for excursions between 15° and 30°C. 
Section  5.6.2 – Test Article Accountability  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  174  
 The investigator will maintain  accurate records  of receipt  of all test articles  that are 
centrally provided , including dates of receipt.  
Section  6.1 – Efficacy  Assessments  
 
… 
 
Symptom  changes will be assessed  using the core MDASI  (Part  1 only)  or MDASI -LC (only 
in patients with NSCLC in Part 1) (Section 6.1.3 ) on Days 1 and 8 of each cycle and at the 
End-of-Treatment visit.  
… 
 
Section  6.2 - Pharmacokinetic  and Pharmacodynamic  Assessments  
 
… 
 
Pharmacokinetics blood sampling should occur  within  10% of nominal  time for Days  1 and 2 
and ±4 hours of  nominal time  for all other time points, and should occur  within 10 minutes 
after the 12 -lead ECGs performance at time -matched visits (Section 6.3.6). All PK 
samples will be evaluable as long as the actual collection times are recorded.  
Section  6.3.1.1 – Definition  of Dose -Limiting  Toxicities  
 
A DLT (monitored  in Part  1 only)  is defined  as the following  treatment -related  AEs or 
laboratory abnormalities, graded according to the NCI CTCAE version 4.03:  
Section  6.3.1.2.1 - Safety  Monitoring  in Part 2 
 
During Part 2 of the study, patients  treated  with NC-6004 at the RPII  dose from Part 1 will be 
monitored for safety. Dose delay and modification rules for both NC -6004 and gemcitabine 
apply in Part 2 as in Part 1. 
In Part  2 (Cohort  3) if 2 of 6 patients  (or ≥33% at any point  during  the study)  in the ≥30 
to <60 mL/min group have a worsening of CrCl (ie, 50% reduction from baseline for 2 
consecutive assessments, at least 1 week apart), then enrollment of patients with CrCl  
<60 mL/min will stop in the bladder  cancer cohort. In addition, in Part 2 (Cohort 3), if 
an unfit  bladder  cancer patient  (≥30  to <60 mL/min  CrCl  at screening)  has a worsening  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  175  
 of CrCl  (ie, 50% reduction  from  baseline  for 2 consecutive  assessments,  at least  1 week 
apart) he or she may be withdrawn from the study (Section 4.2.1). 
Section  6.3.2.5 - Assessment of  Causality  
 
The investigator’s assessment of an  AE’s relationship to study drug (combination of 
NC-6004 and gemcitabine)  is part of the documentation process,  but it is not a factor  in 
determining what is or is not reported in the study. If there is any doubt as to whether a 
clinical observation is an AE, the event should be reported. 
Section  6.3.6 – Electrocardiograms  
 
All 12-lead ECGs  will be performed  after the patient has adequately  rested  in the supine 
position for at least 5 minutes . 
On Day  1 of Cycle  1, 12- lead ECGs  will be performed  before  the start of the  NC-6004 
infusion, at  completion  of infusion (~1  hour after start  of infusion), and at Hours 3 and 
24 hours (Day 2) after start of infusion. On Day 8 of Cycle 1, 12- lead ECGs will be  
performed before  the start of gemcitabine infusion,  at the completion  of gemcitabine  infusion, 
and at 1 hour after completion of gemcitabine infusion. Twelve- lead ECGs will also be 
performed on Day 1 of Cycles 2 through 6 before the start of the NC-6004 infusion and at the 
End-of-Treatment visit.  All 12 -lead ECGs should be performed within a ±10 -minute 
window.  
Section  6.3.7 - Physical  Examination  
 
A complete physical examination will be performed during the screening period at Day -14 
to -1, before study treatments  on Day –1 or Day 1 of each cycle,  and at the End-of-Treatment 
visit. Height and weight will also be assessed at the time of the screening period physical examination and before treatments on Day  1 of each cycle . with  Calculation of BSA  will be 
done before each dosing on Day 1 of each cycle (using the Mosteller formula  
[Mosteller 1987]. ( Note: Dose will only be recalculated if there is a ≥10% increase or 
decrease in the patient’s weight from the patient’s weight measurement at screening. 
Any change  in a patient’s weight by ≥10% during the  study will require  a recalculation 
of the doses  of all study  drugs.  This  threshold  should not be confused  with  a change of a 
patient’s BSA [mg/m2]). 
Section  6.3.8 - Vital  Sign  Measurements  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  176  
 Vital sign measurements  will include arterial blood pressure,  heart  rate, respiratory  rate, and 
temperature. Vital signs will be measured after the patient has adequately rested in the 
supine position for at least 5 minutes . 
Section  7.3 - Sample Size Calculations  
 
This is a Phase 1b/2 study with an overall sample size of up to 199 209 patients (up to 49 
patients  in Part 1 and up to 150160 patients  in Part 2). The total sample size will depend on 
the number of cohorts required to establish an RPII dose and the number of patients with 
NSCLC enrolled at the RPII dose in Part 1.  
… 
 
Part 2 is a 3 -cohort study with an overall sample size of up to 150 160 patients with no more 
than 50 patients per cohort in Cohorts 1 and 2 and no more than 60 patients in Cohort 3. 
The total sample  size will depend on the results of interim futility  and superiority  analyses. In 
order to evaluate the overall sample size, simulations were performed assuming scenarios with different HRs for PFS for each cohort compared with historical control and different 
sample sizes for a subsequent Phase 3 clinical trial.  The associated mean sample size for this 
trial in these scenarios ranged from 92.7136 to 116.8 146 patients.  
Section  10.2.2 - Protocol Violations  and Deviations  
 
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the investigator.  A significant deviation occurs when  there  is nonadherence to the protocol by the 
patient or investigator that results in a significant, additional risk to the patient. Significant deviations can include nonadherence to inclusion or exclusion criteria, enrollment of the  
patient without prior sponsor approval, or nonadherence to FDA regulations or ICH GCP 
guidelines, and will lead to the patient being withdrawn from the study (Section 4.2). 
Section  11 - Reference List 
 
… 
 
Mosteller  RD. Simplified  calculation  of body -surface area. N Engl  J Med. 
1987;317(17):1098.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  177  
 Section  12.1 - Appendix:  Schedule  of Events  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  178  
 Table  12-1 Schedule  of Events  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                  
Eligibility  criteria   X                 
Demography   X                 
Medical  history   X                 
Pregnancy  test (serum  or urine)    X Xe    X   X   X   X  
Physical  examination   Xf  Xf    X   X   X   X  
Height,  weight,  and BSA 
calculationg  Xg  X    X   X   X     
Vital  signsh  X  Xh  X  X X  X X  X X  X  
Performance  status  (ECOG)   Xf  Xf    X   X   X   X  
Disease  assessmenti X          Xi   Xi   X X 
Audiometry   X  Xj    Xj   Xj   Xj   Xj  
Hematology    X Xk  X X X X X X X X X X X X  
Biochemistry    X Xk  X X X X X X X X X X X X  
Urinalysis  (dipstick)   X               X  
EORTC  QLQ -C30    X  X  X X  X X  X X  X  
MDASI  or MDASI -LCl    X  X  X X  X X  X X  X  
Nausea  and vomiting  patient 
diarym    X  X X X X X X X X X X X   
Part 2 Nausea  and vomiting  patient 
diarym    X  X  X X          
Cardiac  risk factors   X                 
12-lead ECGn   X X X X  X   X      X  
Pharmacokinetic  assessments 
(Part 1)o    X X X X X   X Xo Xo    X  
Pharmacokinetic  assessments 
(Part 2)p    X  X  X X  X X     X  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  179  
  
 
 
Procedure  Screening  Cycle 1 Cycle 2 Cycles 3-6 Cycle 7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Adverse  events     Xf X X X X X X X X X X X X X X 
Concomitant  medication   Xf  Xf X X X X X X X X X X X X X X 
Prophylactic  administrations     X    X   X   X     
NC-6004  administrationa    X    X   X   X     
Gemcitabine  administration     X  X  X X  X X  X X    
 
Abbreviations:  BSA,  body  surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group; EORTC  QLQ -C30,  European  Organisation  for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI, MD Anderson Symptom  Inventory;  RECIST,  Response Evaluation  Criteria 
in Solid Tumors; MDASI -LC, MDASI- lung cancer.  
 
 
a. In Part 1 of the study,  patients will  receive treatment  until progressive  disease. In  Part 2 of the study,  patients will  receive treatment  for 6 cycles  (Cohorts  1 
and 3) or 8 cycles (Cohort 2).  
b. End-of-treatment  assessments will be performed  within  28 days after treatment  discontinuation.  
c. After patient discontinuation  or completion  of treatment  without disease progression,  patients  will be followed with  scans  every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
d. Day 15 visit is required  in Part 1. In Part 2, Day 15 visit is only necessary  if it is clinically  indicated.  
e. Not required  if screening  pregnancy  test was performed  using  serum.  
f. Safety  assessments of physical  examination,  ECOG,  review  of AEs, and concomitant medication use can be completed  on Day -1 to allow  for early  morning 
dosing. These should not be conducted in place of screening assessments.  
g. Height and weight only.  From Day - 14 to -1 at screening, only height and weight will be measured, On Day 1 of Cycle 1 through 7, weight will be 
measured before treatments and BSA will be calculated before each dose using the Mosteller formula ( Mosteller 1987 ). (Note: Dose will only be 
recalculated if there is a ≥10% increase or decrease in the patient’s weight from the patient’s screening weight measurement. Any change in a 
patient’s  weight  by ≥10%  during  the study  will require a recalculation  of the doses  of all study  drugs.  This  threshold should  not be confused  with  a 
change of a patient’s BSA [mg/m2]). 
h. On Day  1 of Cycle 1, vital signs will be measured before the start of the NC- 6004 infusion, every 20 minutes during the infusion, at the completion of the 
infusion,  and 1 hour after the completion  of the NC-6004 infusion.  Starting  in Cycle 2, vital signs will  be measured  before  the start of the NC-6004  infusion 
and at  the completion  of the NC-6004 infusion on Day 1 of each cycle. Vital signs will  be measured before and after gemcitabine  infusion  on Day 8 of each 
cycle.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  180  
 i. Disease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used fo r all subsequent 
assessments. Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will be assessed every  6 (±1)  weeks  (ie, every  other 
cycle) and at the End -of-Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
j. To be performed  only as clinically  indicated.  
k. Hematology  or biochemistry  tests will be repeated  prior  to dosing  on Day 1 of Cycle 1 if they were  last performed more than  24 hours  before  the start of  the 
study drug administration.  
l. Symptom  changes  will be assessed using  the core MDASI  (Part  1 only)  or MDASI-LC (only  in patients  with NSCLC in Part 1). 
m. Diary  issued on  Day 1 of each cycle. Assessment  is performed at  the site before  dosing  on Day  1 and Day 8 as well  as Day 15 (Day  15 diary  collected in  Part 
1 only; note: no dosing on Day 15) of each cycle. Patient completes diary at home on Days 2 through 8 and returns diary on Da y 8. 
n. Twelve -lead ECGs will be performed after the patient has adequately rested in the supine position for at least 5  minutes . On Day  1 of Cycle 1, 12 -lead 
ECGs will be performed before the start of the NC- 6004 infusion, at completion of infusion (~1 hour after start of infusion), and at Hours 3 and 24 (Day 2) 
after the start of infusion. On  Day 8 of Cycle  1, 12 -lead ECGs will  be performed before  the start of gemcitabine  infusion, at the end of  gemcitabine  infusion, 
and at 1 hour after completion  of gemcitabine infusion.  Twelve -lead ECGs will  be performed  on Day 1 of Cycles  2 through  6 before  the start of the NC- 6004 
infusion, and at the End -of-Treatment visit. All 12 -lead ECGs can be performed within a ±10 -minute window. 
o. For Part  1, blood samples will be collected at the following times: before the start of the NC- 6004 infusion on Day 1 of Cycles 1 through 6, at end of NC - 
6004 infusion  in Cycles  1, 3, and  5, after the  start of NC-6004 infusion at Hours  3, 6, 12,  24 (Day  2), 48 (Day  3), 96  (Day  5), 168  and prior  to gemcitabine 
infusion (Day 8), and 336 (Day 15) in Cycles 1, 3, and 5, and at the End -of-Treatment visit. Additional pharmacokinetic blood sample collections may be 
performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within 10 minutes after the 
12-lead ECGs performance.  
p. For Part 2 (up to 6 cycles), on the day of NC -6004 infusion for each cycle, blood samples will be collected before the start of the NC -6004 infusion, at the 
end of the NC-6004  infusion, before  gemcitabine  infusion  on Day 8, and at the End-of-Treatment  visit. Additional  pharmacokinetic  blood  sample  collections 
may be performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within 10 minutes 
after the 12 -lead ECGs performance.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  181  
 12.4.4  Protocol  Amendment 3–Protocol  Version  4.1, Incorporating 
Amendment 3, Dated 31 August 2016  
The following sections detail the changes made to  Amendment 2 of the protocol 
(Version  3.0) dated  07 July 2015. The integrated  protocol,  Version  4.1, including 
Amendment  3, was issued  on 31 August 2016.  
 
12.4.4.1  Overview  of Changes 
The overview  of significant changes  includes  the following:  
 
Inclusion criteria numbers 9, 10, 11 (Synopsis and Section 4.1.1) and the Schedule of Events 
(Table 12 -1, Section 12.1) were amended per the recommendation by the Voluntary 
Harmonisation Procedure (VHP) on 25 July 2016. These changes were made to account for the toxic reproductive characteristics of cisplatin and gemcitabine, and to adequately define contraceptive  measures  that comply  with the “Recommendations  related  to contraception  and 
pregnancy testing in clinical trials” per the Clinical Trials Facilitation Group (CTFG).  
Inclusion criterion  #9 added that a negative  pregnancy test is not applicable  for female 
patients who are postmenopausal (defined as no menses for the previous 12 months).  
Inclusion criterion  #10 added the  requirement that male  patients  must  agree to  use a condom 
during treatment and for 90 days after dosing. Male  patients must agree not to donate  sperm 
for 90 days after dosing.  
Inclusion criterion #11 added that women of childbearing potential should be willing to follow  1 of the following  effective  methods  of birth  control  from  the time of study entry  to 
6 months after the last day of treatment:  
• Combined (estrogen - and progestogen- containing)  hormonal  contraception  associated 
with inhibition of ovulation (oral, intravaginal, or transdermal)  
• Progestogen -only hormonal  contraception  associated  with inhibition  of ovulation 
(oral, injectable, or implantable)  
• Intrauterine  devices  
• Intrauterine   hormone -releasing  system  
• Vasectomized  partner  who has received  medical  assessment  of surgical  success  
• Bilateral tubal  occlusion  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  182  
 • True  sexual abstinence  
 
In the Schedule of Events, pregnancy testing  was added  for Day 1 of Cycle  2, Cycles 3 
through 6, and Cycle 7 Onward, and at the End of Treatment. 
 
12.4.4.2  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol.  Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Synopsis  – Inclusion  Criteria  
 
… 
 
9. Have a negative pregnancy test result at screening (for females of childbearing 
potential; not applicable to patients who are unable to become pregnant, including 
those with bilateral oophorectomy  and/or hysterectomy ). or postmenopausal [no 
menses for the previous  12 months]).  The test must  be performed  within  1 week 
before Day 1 of treatment.  
10. Male patients must agree to  use a condom  during  treatment  and for 90 days 
after  dosing.  Male patients  must  agree not  to donate  sperm  for 90 days  after 
dosing.  
11. For women of childbearing potential*: are willing to abstain from heterosexual 
activity  or practice physical barrier contraception follow  1 of the following  effective 
methods of birth control from the  time of study entry  to 6 months after the last day 
of treatment : 
• Combined (estrogen - and progestogen-containing) hormonal  contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal) 
• Progestogen- only hormonal contraception  associated  with  inhibition  of 
ovulation (oral, injectable, or implantable)  
• Intrauterine  devices  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  183  
 • Intrauterine  hormone -releasing  system  
 
• Vasectomized  partner  who has received  medical assessment  of surgical 
success  
• Bilateral tubal  occlusion  
 
• True  sexual abstinence**  
 
*Patients  not of childbearing  potential include  those  who are surgically  sterile  or 
postmenopausal (no menses for the previous 12 months). For women not 
currently taking contraceptive methods at screening, low user- dependency 
contraceptive methods (eg, implantable progestogen- only hormonal 
contraception, intrauterine device, intrauterine hormone- releasing system, 
bilateral tubal occlusion, vasectomized partner) are recommended.  
**The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the clinical  trial and the preferred  and usual  lifestyle  of the patient.  
Section  4.1.1 – Inclusion  Criteria  
 
… 
 
9. Have a negative pregnancy test result at screening (for females of childbearing potential; not applicable to patients who are unable to become pregnant, including 
those with bilateral oophorectomy  and/or hysterectomy ). or postmenopausal [no 
menses for the previous  12 months]).  The test must  be performed  within  1 week 
before Day 1 of treatment.  
10. Male patients must agree to  use a condom  during  treatment  and for 90 days 
after  dosing.  Male patients  must  agree not  to donate  sperm  for 90 days  after 
dosing.  
11. For women of childbearing potential*: are willing to abstain from heterosexual 
activity  or practice physical barrier contraception follow  1 of the following  effective 
methods of birth control from the time of study entry to 6 months after  the last 
day of treatment:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  184  
 • Combined (estrogen - and progestogen -containing)  hormonal  contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal)  
• Progestogen -only hormonal  contraception  associated  with  inhibition  of 
ovulation (oral, injectable, or implantable)  
• Intrauterine  devices  
 
• Intrauterine  hormone -releasing  system  
 
• Vasectomized  partner  who has received  medical assessment  of surgical 
success  
• Bilateral tubal  occlusion  
 
• True  sexual  abstinence**  
 
*Patients not of childbearing potential include those who are surgically sterile or 
postmenopausal  (no menses for the previous  12 months).  For women  not currently 
taking contraceptive methods at screening, low user- dependency contraceptive 
methods (eg, implantable progestogen -only hormonal contraception, intrauterine 
device, intrauterine hormone- releasing system, bilateral tubal occlusion, 
vasectomized partner) are recommended.  
**The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the clinical  trial and the preferred  and usual  lifestyle  of the patient.  
Table  12-1, Section  12.1 – Schedule  of Events  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  185  
 Table  12-1 Schedule  of Events  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                 
Eligibility  criteria   X                
Demography   X                
Medical  history   X                
Pregnancy  test (serum  or urine)    X Xe   X   X   X   X  
Physical  examination   Xf  Xf   X   X   X   X  
Height,  weight,  and BSA 
calculation   Xg  X   X   X   X     
Vital  signs   X  Xh X  X X  X X  X X  X  
Performance  status  (ECOG)   Xf  Xf   X   X   X   X  
Disease  assessmenti X         Xi   Xi   X X 
Audiometry   X  Xj   Xj   Xj   Xj   Xj  
Hematology    X Xk X X X X X X X X X X X X  
Biochemistry    X Xk X X X X X X X X X X X X  
Urinalysis  (dipstick)   X              X  
EORTC  QLQ -C30    X X  X X  X X  X X  X  
MDASI  or MDASI -LCl    X X  X X  X X  X X  X  
Nausea  and vomiting  patient 
diarym    X X X X X X X X X X X X   
Part 2 Nausea  and vomiting  patient 
diarym    X X  X X          
Cardiac  risk factors   X                
12-lead ECGn   X X X  X   X      X  
Pharmacokinetic  assessments 
(Part 1)o    X X X X   X Xo Xo    X  
Pharmacokinetic  assessments 
(Part 2)p    X X  X X  X X     X  
Adverse  events     Xf X X X X X X X X X X X X X 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  186  
  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Concomitant  medication   Xf  Xf X X X X X X X X X X X X X 
Prophylactic  administrations     X   X   X   X     
NC-6004  administrationa    X   X   X   X     
Gemcitabine  administration     X X  X X  X X  X X    
Abbreviations:  BSA,  body  surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group; EORTC  QLQ -C30,  European  Organisation  for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI,  MD Anderson Symptom  Inventory;  RECIST,  Response  Evaluation  Criteria 
in Solid Tumors; MDASI -LC, MDASI- lung cancer.  
a. In Part 1 of the study,  patients will  receive treatment  until progressive  disease.  In Part 2 of the study,  patients will  receive treatment  for 6 cycles  (Cohorts  1 
and 3) or 8 cycles (Cohort 2).  
b. End-of-treatment  assessments will be performed  within  28 days after treatment  discontinuation.  
c. After patient  discontinuation  or completion  of treatment  without  disease progression,  patients  will be followed with  scans  every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
d. Day 15 visit is required  in Part 1. In Part 2, Day 15 visit is only necessary  if it is clinically  indicated.  
e. Not required  if screening  pregnancy  test was performed  using  serum.  
f. Safety  assessments of physical  examination,  ECOG,  review  of AEs,  and concomitant medication use can be completed  on Day -1 to allow  for early  morning 
dosing. These should not be conducted in place of screening assessments.  
g. Height and weight  only.  
h. On Day  1 of Cycle 1, vital signs will be measured before the start of the NC- 6004 infusion, every 20 minutes during the infusion, at the completion of the 
infusion,  and 1 hour after the completion  of the NC-6004 infusion.  Starting  in Cycle  2, vital signs will  be measured  before  the start of the NC-6004  infusion 
and at  the completion  of the NC-6004 infusion on Day 1 of each cycle. Vital  signs will  be measured before and after gemcitabine  infusion  on Day 8 of each 
cycle.  
i. Disease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used fo r all subsequent 
assessments.  Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will  be assessed  every  6 (±1) weeks  (ie, every  other 
cycle) and at the End -of-Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
j. To be performed  only as clinically  indicated.  
k. Hematology  or biochemistry  tests will  be repeated  prior  to dosing  on Day 1 of Cycle  1 if they were  last performed more than  24 hours  before  the start of  the 
study drug administration.  
l. Symptom  changes  will be assessed  using  the core MDASI or MDASI- LC (only in patients  with NSCLC in Part 1). 
m. Diary  issued on  Day 1 of each cycle. Assessment  is performed at  the site before  dosing  on Day  1 and Day 8 as well  as Day 15 (Day  15 diary  collected in  Part 
1 only; note: no dosing on Day 15) of each cycle. Patient completes diary at home on Days 2 through 8 and returns diary on Da y 8. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  187  
 n. Twelve -lead ECGs will be performed after the patient has rested in the supine position for at least 5 minutes. On Day  1 of Cycle 1, 12- lead ECGs will be 
performed before the start of the NC -6004 infusion, at completion of infusion (~1 hour after start of infusion), and at Hours 3 and 24 (Day 2) after the start 
of infusion. On  Day 8 of Cycle 1, 12 -lead ECGs will be performed before the start of  gemcitabine infusion, at the end of gemcitabine infusion, and at 1 hour 
after completion  of gemcitabine  infusion.  Twelve -lead ECGs will  be performed  on Day 1 of Cycles  2 through  6 before  the start of the NC-6004  infusion,  and 
at the End -of-Treatment visit.  
o. For Part  1, blood samples will be collected at the following times: before the start of the NC- 6004 infusion on Day 1 of Cycles 1 through 6, at end of NC - 
6004 infusion  in Cycles  1, 3, and 5, after the  start of NC-6004 infusion at Hours  3, 6, 12,  24 (Day  2), 48 (Day  3), 96  (Day  5), 168  and prior  to gemcitabine 
infusion (Day 8), and 336 (Day 15) in Cycles 1, 3, and 5, and at the End -of-Treatment visit. Additional pharmacokinetic blood sample collections may be 
performed, at the discretion of the investigator, during any visit where toxicity is observed.  
p. For Part 2 (up to 6 cycles), on the day of NC -6004 infusion for each cycle, blood samples will be collected before the start of the NC -6004 infusion, at the 
end of the NC-6004  infusion, before  gemcitabine  infusion  on Day 8, and at the End-of-Treatment  visit. Additional  pharmacokinetic  blood  sample  collections 
may be performed, at the discretion of the investigator, during any visit where toxicity is observed.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  188  
 12.4.5  Protocol  Amendment 3-Protocol  Version  4.2, Incorporating 
Amendment 3- Version 4.0 (US only, dated 31 July 2016) 
The following sections detail  the changes made  to Protocol  Amendment  3-Version  4.0 (US 
only, dated 31 July 2016). Version 4.0 was submitted to the FDA  and not subsequently 
modified.  
Version 4.0 included European Medicines  Agency (EMA) VHP -requested changes in 
addition to other changes not specifically requested by the VHP. Following submission of 
Version  4.0 to the VHP,  the VHP  requested  a version of the protocol  that only included the 
VHP -requested changes; therefore, Protocol  Amendment 3 -Version 4.1 (dated  
31 August  2016)  was submitted  to the VHP  (EU only)  to meet  this request.  
 
Protocol  Amendment  3-Version  4.2 (US and EU) harmonizes  Versions  4.0 and 4.1 and was 
finalized  on 12 December  2016. A separate summary  of the changes  made  to Version  4.1 is 
included in Section 12.4.6. 
 
12.4.5.1  Risk  Assessment  for Amendment  3, Version  4.2 
No anticipated  increased  patient  risk has been  introduced with the updates  made  during  this 
protocol amendment. Based on new safety information received from an ongoing non- US, 
non-IND, Japanese trial with NC -6004 (Study NC -6004- 007), additional exclusion criteria 
have been added to mitigate risk of liver toxicity in patients predisposed to liver injury. In 
addition, sites and investigators have been instructed to closely monitor ongoing NC -6004 
patients who are known to have pre -existing alcoholic liver injury and/or concurrent heavy 
alcohol consumption for newly emerging liver injury.  
 
12.4.5.2  Overview  of Changes 
The overview  of significant changes  includes  the following:  
 
Title  Page  – Current  Version  and Date  of Protocol;  Title  Page  – Previous  Dates  and 
Versions  
The current  and previous  protocol  amendment  versions  and applicable  regions  were  updated 
to provide complete transparency and increased clarity.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  189  
 Declaration  of Investigator 
 
A declaration  of investigator page,  which  includes  a principal  investigator  signature  line was 
added.  
Protocol  Synopsis  – Exclusion  Criteria;  Section  4.1.2 – Exclusion  Criteria  
 
The exclusion criteria  11 and 12 were  added to reflect  the following:  
 
11. Have  pre-existing  alcoholic  liver injury or significant liver disease.  
 
12. Are regularly consuming alcohol within 6 months of Screening defined as an average 
weekly  intake  of >21 units  (or an average  daily  intake  of >3 units)  for males or >14 units  (or 
an average daily intake >2 units) for females. One unit is equivalent to 8 g of alcohol: a  
half-pint (approximately  240 mL) of beer,  1 glass  (125 mL) of wine,  or 1 measure (25 mL) of 
spirits.  
Protocol  Synopsis  – Study  Design  
 
A +10- minute  window was added to the 1-hour infusion of NC-6004 infusion.  
 
Protocol  Synopsis  – Study  Design;  Section  3.1 – Study  Design  
 
It was clarified  that all patients  who discontinue  treatment  and have  not progressed  will have 
an End- of-Treatment visit, will be followed with scans every 9 weeks until disease 
progression, and will be contacted for survival every 12 weeks by telephone. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  190  
 Protocol  Synopsis  – Safety  Assessments;  Section  6.3.5 – Clinical Laboratory  Analyses 
 
It was specified  that only abnormal  laboratory  results  deemed  to be clinically  significant will 
be recorded as AEs or SAEs.  
Protocol  Synopsis  – Safety  Assessments  
 
For internal consistency, it  was added that audiometry  will also be performed  as clinically 
indicated at the End- of-Treatment visit.  
Section  3.1 - Study  Design  
 
A cross- reference to the amendment -specified  imaging  methods  was added.  
 
At the Follow -up visit,  text was updated to specify  that new treatments  would be collected 
(Previous text stated medication history would be collected).  
Section  3.1 - Study  Design  
 
Text was added to specify that pregnancy testing at Cycle 1, serum or urine; test is not 
required on Day 1 of Cycle  1 if pregnancy  test at  screening  was performed  using serum.  
Section  5.2 – Prophylactic  Treatments;  Section  5.8 – Prophylaxis  and Management  of 
Hypersensitivity Reactions 
It was added  that 20 mg famotidine  can be given intravenously as an option in place of 50 mg 
of ranitidine given intravenously.  
Section  5.8 – Prophylaxis  and Management  of Hypersensitivity Reactions  
 
If a Grade 1 or Grade 2 hypersensitivity occurs in a patient, it was added that 40 mg 
famotidine  can be given orally once  per day as an option in place of ranitidine  150 mg orally 
given 2 times per day.  
Section  6.1.1 – Disease Response Definitions  
 
Guidelines  for imaging, including the timing,  anatomic  coverage, imaging  method, and slice 
thickness were added.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  191  
 Section  6.1.3 – MD Anderson  Symptom  Inventory 
 
Reference to the Study Manual was removed from the protocol.  
 
Section  6.3.2.3 – Reporting Adverse Events  
 
Text was added  to clarifying  the process for capturing events  in the EDC system,  and 
European SAE hotline and fax line numbers were added.  
Section  6.3.3 – Assessment  of Nausea  and Vomiting; Section  12.1 - Appendix:  Schedule  of 
Events, footnote m  
Text was added  to specify  the process  for administering  and capturing data in the nausea and 
vomiting patient diary.  
Section  6.3.5.3 – Urinalysis;  Section  12.1 - Appendix:  Schedule  of Events  
 
Reference to a dipstick  urinalysis  was removed to allow  flexibility  in the type of urinalysis 
testing.  
Section  6.3.6 – Electrocardiograms;  Section  6.3.8 - Vital  Sign  Measurements;  
Section 12.1 -  Appendix: Schedule of Events, footnote h and n  
Text was also added to specify  that ECGs  will be performed  during the screening  period  at 
Day –7 to –1 and that vital signs will also be measured at the End- of-Treatment visit.  The 
ECG performance window was updated to a ±30- minute window. 
Section  12.1 - Appendix:  Schedule  of Events,  footnote  g 
 
Text was updated to specify  that weight  will be measured  on Day 1 of each cycle.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  192  
 12.4.5.3  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol. Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Protocol Synopsis  – Exclusion  Criteria  
 
… 
 
11. Have pre-existing  alcoholic liver  injury  or significant liver  disease.  
 
12. Are regularly consuming alcohol within 6 months of Screening defined as an 
average weekly  intake  of >21 units  (or an average daily  intake  of >3 units)  for males  or 
>14 units  (or an average daily  intake  >2 units)  for females.  One unit is equivalent  to 8 g 
of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 
1 measure (25 mL) of spirits.  
 
Protocol Synopsis  – Study  Design  
 
… 
 
On Day 1 of each  cycle,  patients  will receive NC -6004 over 1 hour (+10- minute  window)  
followed  by an infusion of gemcitabine  1250 mg/m2 over 30 minutes.  
 
Protocol Synopsis  – Study  Design  
 
… 
 
Patients  who discontinue treatment due to an AE and have not progressed will have an 
End-of-Treatment  visit,  will be followed  with scans every  9 weeks until disease  progression, 
and will be contacted for survival every 12 weeks by telephone. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  193  
 Protocol Synopsis  – Safety  Assessments  
 
Adverse events will be evaluated at each visit during every cycle and graded according to 
NCI CTCAE  version 4.03 dated  June 14, 2010 (only  abnormal laboratory results deemed 
to be clinically  significant will be recorded  as AEs or SAES)  (NCI  CTCAE  version 4.03) . 
… 
 
Audiometry will be performed  at screening  and only as clinically  indicated  before treatment 
on Day 1 of each cycle and as clinically indicated at the End-of- Treatment visit. 
Section  3.1 - Study  Design  
 
… 
 
Patients  who discontinue treatment due to an AE and have not progressed will have an 
End-of-Treatment  visit,  will be followed  with scans every  9 weeks until disease  progression, 
and will be contacted for survival every 12 weeks by telephone. 
… 
 
The following procedures will be performed  during the screening  period within  28 days prior 
to the first study treatment:  
• Signed informed  consent can be obtained within  28 days of dosing and prior to 
performing any study evaluations. 
• Disease assessment will be evaluated with a baseline computed tomography scan (see 
Section  6.1.1 for imaging methods)  and should be performed  within  the 28 days before 
the start of study treatment.  
… 
 
The following procedures will be performed  on Day 1 prior to NC-6004 infusion in each 
treatment cycles unless otherwise specified:  
• Pregnancy test (serum or urine) on Day 1 of each cycle (at Cycle  1, serum  or urine; test is 
not required on Day 1 of Cycle 1 if pregnancy test at screening was performed using 
serum)  
Follow -Up 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  194  
 Patients  who complete treatment  or discontinue  treatment  without disease progression will 
continue to be followed until disease progression with scans every 9 weeks. Following 
disease progression, patients will be contacted by telephone every 12 (±1) weeks to collect the following data:  
• Survival  
• Adverse events (All AEs will  be followed  until resolution, Section  6.3.2.6)  
• Medication  history New treatments  (targeted  therapy or chemotherapy used after study 
disease progression and treatment completion)  
Section  4.1.2 – Exclusion Criteria  
 
… 
11. Have pre-existing  alcoholic liver  injury  or significant liver  disease.  
12. Are regularly consuming alcohol within 6 months of Screening defined as an 
average weekly  intake  of >21 units  (or an average daily  intake  of >3 units)  for males  or 
>14 units  (or an average daily  intake  >2 units)  for females.  One unit is equivalent  to 8 g 
of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 
1 measure (25 mL) of spirits.  
 
Section  5.2 – Prophylactic Treatments  
 
All patients will receive the following  medications  before administration  of NC-6004 on 
Day 1 of each cycle: 
… 
 
• Patients will be given 50 mg of ranitidine intravenously or 20 mg famotidine 
intravenously  30 minutes  before the start of NC-6004 infusion  on Day 1 of each cycle.  
Section  5.8 – Prophylaxis and Management of Hypersensitivity Reactions  
 
All patients  must receive  the following  prophylactic treatment at each cycle to reduce the risk 
of hypersensitivity reactions:  
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  195  
 • Diphenhydramine  hydrochloride  50 mg and either ranitidine  50 mg or 20 
mg famotidine  will be administered  intravenously 30 minutes  before  the infusion of 
NC-6004.  
… 
 
If a Grade  1 or Grade  2 hypersensitivity occurs  in a patient,  the following  medications  should 
be administered for 48 hours after NC -6004 infusion:  
• Ranitidine  150 mg orally  given 2 times  per day or 40 mg famotidine  orally given  once 
per day  
Section  6.1.1 – Disease Response Definitions  
 
… 
The rate of confirmed  response  and tumor growth control  will be determined  according  to 
RECIST  version 1.1 in solid tumor patients for patients evaluable for response using the 
following imaging methods:  
Timing  
 
Disease assessment  will occur at Screening  and every  6 weeks (±1 week)  until  disease 
progression. Patients who have obtained a response (PR or CR) will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
Anatomic  Coverage  
 
Imaging should include  a computed tomography scan  of the chest,  abdomen,  and pelvis. 
In addition, areas of known predisposition for metastases (eg, the brain for NSCLC) 
and any areas  identified  by the clinician  as probable  sites of metastasis  based  on clinical 
evaluation should be included in imaging if clinically indicated. Other imaging may be performed at the investigator’s discretion as standard of care.  
Imaging Method  
 
The preferred method for imaging is computed tomography with IV contrast. If the 
patient  is allergic  to contrast  media  or has another  medical  contraindication,  magnetic 
resonance imaging with contrast can be used at the clinician’s discretion. It is critical that the same method of imaging is used throughout the study for a given patient.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  196  
 Slice  Thickness  
 
The preferred  slice thickness  is 5 mm.  If a larger slice thickness  is used  (eg, 7 mm),  the 
smallest tumor measurement that can be reported is twice the thickness of the slice.  
The ORR, DCR, and DOR will be determined immediately prior to the initiation of 
maintenance therapy. The OS and PFS will be determined at the end of the study for 
evaluable patients without censoring at the initiation of maintenance therapy.  Patients who  
have obtained a response (PR or CR) will have a confirmatory  scan at  a minimum  of 4 weeks 
following the initial scan.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  197  
 Section  6.1.3 – MD Anderson  Symptom Inventory 
 
… 
 
The core MDASI  and the MDASI -LC will  be administered  as a self -report paper-and-pencil 
form given  to the patient at  the site before study treatments  on Days  1 and 8 of each cycle in 
Part 1 only (as described in Study Manual). 
Section  6.3.2.3 – Reporting Adverse Events  
 
… 
 
Any AE that meets SAE criteria (Section 6.3.2.1) must be reported to PPD immediately (ie, 
within 24 hours after the time site personnel first learn about the event). The following 
contact information  is to be used for SAE  reportingThe  event  is reported  via the electronic 
data  capture  (EDC)  system  where site personnel  complete as much of the respective AE 
page (eCRF) as they are able. 
If the EDC system is unavailable, the  AE information must be recorded on the manual 
SAE  report  form and immediately  (ie, within  24 hours  of awareness)  sent to PPD  by one 
of the following  methods  (refer to the “SAE Guidelines”  document  for WorldReach  toll- 
free access numbers if necessary):  
Pharmacovigilance Department  
 
United  States  SAE  Hotline:  +1 800-201- 8725  
 
United  States  SAE  Fax line: +1 888-488- 9697  
 
Europe SAE Hotline:  +44 1223 374 240 (to be used  for questions 
concerning SAEs)  
Europe  SAE  Fax line: +44 1223 374 102 (to be used  for reporting  SAEs)  
 
 
 
Once  the EDC system  becomes available again, the site needs  to transfer all data  to the 
respective eCRF page of the patient.  
Section  6.3.3 - Assessment  of Nausea  and Vomiting  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  198  
 … 
 
For Parts  1 and 2, e Each patient will be given a nausea and vomiting patient diary  to take 
home. This diary will be used to record the severity of nausea and incidence of emetic 
episodes over the previous 24 hours daily on Days 2 through 21. The first 7 days of the 
diary will be recorded verbatim  in the eCRF.  The patient will be given the diary and 
instructed on how and when to complete the diary before discharge from the site on Day 1 of each cycle. 
Part 1: The investigator will collect the n
 ausea and vomiting patient diary from each 
patient diaries on Day 8 and Day 15 for Cycle 1. For all subsequent cycles, the 
investigator  will collect  diaries on Day 1 (prior  to dosing  to capture  the last 7 days of the 
previous cycle), Day 8, and Day 15 (Part 1 only), and Day 22. The first 7 days of the diary 
will be recorded verbatim in the eCRF.  The investigator will record the worst severity of the 
patient’s nausea and the total number of emetic episodes occurring over the previous 7 days 
in the eCRF for Day 8 , Day 15, and Day 21. The patient will be given the diary and 
instructed on how and when to complete the diary before discharge from the site on Day  1 of 
each cycle. The patient must return the diary to the site on Day 8, Day 15 (Part 1 only), and 
Day 22 (Day 1 of the next cycle) of each cycle. 
Part 2: The investigator will collect the nausea and vomiting patient diary from each patient  at the site on Day 8 for Cycle  1. For Cycle  2, the investigator  will collect  diaries 
on Day 1 (prior to dosing to capture the last 7 days of the previous cycle) and Day 8. 
Note that nausea and vomiting patient diaries will not be collected past Cycle 2. The 
investigator will record the worst severity of the patient’s nausea and the total number 
of emetic  episodes occurring  over the previous 7  days in the  eCRF  for Day 8 and Day 21. 
Section  6.3.5 – Clinical Laboratory Analyses  
 
… 
 
Any Only  abnormal laboratory  test results (hematology, biochemistry,  or urinalysis) that are 
deemed clinically significant by the PI will are to be recorded as AEs or SAEs per the NCI 
CTCAE version 4.03. 
Section  6.3.5.3 – Urinalysis 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  199  
 Urinalysis  will be performed  using a dipstick test and will include: leukocyte esterase,  nitrite, 
urobilinogen, protein, pH, blood, specific gravity, ketones, bilirubin, and glucose. 
Section  6.3.6 – Electrocardiograms  
 
… 
 
A 12- lead ECG  will be performed during the screening period at Day -7 to -1. On Day 1 
of Cycle 1, 12- lead ECGs will be performed before the start of the NC -6004 infusion, at 
completion of infusion (~1 hour after start of infusion), and at Hours 3 and 24 hours (Day 2) 
after start of infusion. On Day 8 of Cycle 1, 12- lead ECGs will be performed before the start 
of gemcitabine infusion, at the completion of gemcitabine infusion, and at 1 hour after completion of gemcitabine infusion. Twelve -lead ECGs will also be performed on Day 1 of 
Cycles 2 through 6 before the start of the NC-6004 infusion and at the End-of-Treatment  visit. 
All 12 -lead ECGs should be performed within a ± 310-minute window. 
Section  6.3.8 - Vital  Sign  Measurements  
 
… 
 
Vital signs  will also be measured  at the End-of-Treatment  visit.  
 
Section  7.3 - Sample Size Calculations  
 
… 
 
Part 2 is a 3-cohort study with an overall sample size of up to 150 160 patients  with no more 
than 50 patients in Cohorts 1 and 2 and no more than 60 patients in Cohort 3 (30 unfit and 
30 fit bladder cancer patients) . 
Section  12.1 - Appendix: Schedule  of Events  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  200  
 Table 12-1 Schedule  of Events  
 
 
Procedure  Screening  Cycle 1 Cycle 2 Cycles 3-6 Cycle 7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                  
Eligibility  criteria   X                 
Demography   X                 
Medical  history   X                 
Pregnancy  test (serum  or urine)    X Xe    X   X   X   X  
Physical  examination   Xf  Xf    X   X   X   X  
Height,  weight,  and BSA 
calculationg  Xg  X    X   X   X     
Vital  signsh  X  Xh  X  X X  X X  X X  X  
Performance  status  (ECOG)   Xf  Xf    X   X   X   X  
Disease  assessmenti X          Xi   Xi   X X 
Audiometry   X  Xj    Xj   Xj   Xj   Xj  
Hematology    X Xk  X X X X X X X X X X X X  
Biochemistry    X Xk  X X X X X X X X X X X X  
Urinalysis  (dipstick)   X               X  
EORTC  QLQ -C30    X  X  X X  X X  X X  X  
MDASI  or MDASI -LCl    X  X  X X  X X  X X  X  
Part  1: Nausea  and vomiting 
patient diarym    X  X X X X X X X X X X X   
Part 2 Nausea  and vomiting  patient 
diarym    X  X  X X          
Cardiac  risk factors   X                 
12-lead ECGn   X X X X  X   X      X  
Pharmacokinetic  assessments 
(Part 1)o    X X X X X   X Xo Xo    X  
Pharmacokinetic  assessments 
(Part 2)p    X  X  X X  X X     X  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  201  
  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Adverse  events     Xf X X X X X X X X X X X X X X 
Concomitant  medication   Xf  Xf X X X X X X X X X X X X X Xc 
Prophylactic  administrations     X    X   X   X     
NC-6004  administrationa    X    X   X   X     
Gemcitabine  administration     X  X  X X  X X  X X    
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  202  
 Abbreviations:  BSA,  body  surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group; EORTC  QLQ -C30,  European  Organisation  for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI, MD Anderson Symptom  Inventory;  RECIST,  Response Evaluation  Criteria 
in Solid Tumors; MDASI -LC, MDASI- lung cancer.  
a. In Part 1 of the study,  patients  will receive treatment  until progressive  disease.  In Part 2 of the study,  patients  will receive treatment  for 6 cycles  (Cohorts  1 
and 3) or 8 cycles (Cohort 2).  
b. End-of-treatment  assessments will be performed  within  28 days after treatment  discontinuation.  
c. After patient discontinuation  or completion  of treatment  without disease progression,  patients  will be followed with  scans  every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
d. Day 15 visit is required  in Part 1. In Part 2, Day 15 visit is only necessary  if it is clinically  indicated.  
e. Not required  if screening  pregnancy  test was performed  using  serum.  
f. Safety  assessments  of physical  examination,  ECOG,  review  of adverse events,  and concomitant medication  use can be completed  on Day -1 to allow  for 
early morning dosing. These should not be conducted in place of screening assessments.  
g. From  Day -14 to -1 at screening, only height and weight will be measured. On Day 1 of Cycle 1 through 7 each cycle, weight will be measured before 
treatments  and BSA  will be calculated  before  each dose using  the Mosteller  formula  (Mosteller  1987 ). (Note:  Dose  will only be recalculated  if there  is a 
≥10%  increase or decrease in the patient’s  weight  from  the patient’s  screening  weight measurement.  Any change in a patient’s  weight  by ≥10%  during the 
study will require a recalculation of the doses of all study  drugs. This threshold should not be confused with a change in the patient’s BSA  [m2]). 
h. On Day  1 of Cycle 1, vital signs will be measured before the start of the NC- 6004 infusion, every 20 minutes during the infusion, at the completion of the 
infusion,  and 1 hour after the completion of the NC-6004  infusion.  Starting  in Cycle 2, vital signs  will be measured  before  the start of the NC-6004  infusion 
and at  the completion  of the NC-6004 infusion on Day 1 of each cycle.  Vital  signs will  be measured before and after gemcitabine  infusion  on Day 8 of each 
cycle. Vital signs will also be measured at the End -of-Treatment visit.  
i. Disease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used fo r all subsequent 
assessments. Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will be assessed every  6 (±1) weeks  (ie, every  other 
cycle) and at the End of  Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
j. To be performed  only as clinically  indicated.  
k. Hematology  orand biochemistry  tests will  be repeated  prior  to dosing on Day 1 of Cycle  1 if they were  last performed more  than 24 hours  before  the start of 
the study drug administration.  
l. Symptom  changes  will be assessed  using  the core MDASI (Part  1 only)  or MDASI -LC (only  in patients  with NSCLC in Part 1). 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  203  
 m. Part 1:  The investigator  will collect the nausea and vomiting patient diary from each patient on Day 8 and Day 15 for Cycle 1. For  all subsequent 
cycles,  the investigator  will collect  diaries  on Day 1 (prior  to dosing  to capture the last 7 days  of the previous  cycle),  Day 8, and Day 15. Part  2: The 
investigator  will collect the nausea and vomiting patient diary from  each patient at the site on Day 8 for Cycle 1. For Cycle 2, the investigator will 
collect diaries on Day 1 (prior to dosing to capture the last 7 days of the previous cycle) and Day 8. Note that nausea and v omiting patient diaries 
will not be collected past Cycle 2. For additional details, see Section 6.3.3. Diary  issued on Day 1 of each cycle.  Assessment is performed at the site  
before dosing on Day 1 and Day  8 as well as Day 15 (Day  15 diary collected in Part 1 only; note: no dosing on Day 15) of each cycle. Patient completes  
diary at home on Days 2 through 8 and returns diary on Day 8.  
n. Twelve -lead ECGs  will be performed  after the patient has adequately  rested  in the supine  position.  A 12-lead ECG  will be performed  during  the screening 
period at Day – 7 to –1. On Day  1 of Cycle 1, 12- lead ECGs will be performed before the start of the NC- 6004 infusion, at completion of infusion (~1 hour 
after start of infusion), and at Hours 3 and 24 (Day  2) after the start of infusion. On Day  8 of Cycle 1, 12- lead ECGs will be performed before the start of 
gemcitabine infusion, at the end of gemcitabine infusion, and at 1 hour after completion of gemcitabine infusion. Twelve -lead ECGs will be performed on 
Day 1 of Cycles 2 through 6 before the start of the NC -6004 infusion, and at the End -of Treatment visit.  All 12 -lead ECGs should be performed within a  
±301-minute  window.  
o. For Part 1, blood samples  will be collected  at the following  times:  before  the start of the NC-6004  infusion  on Day 1 of Cycles  1 through 6, at end of 
NC-6004 infusion in Cycles  1, 3, and 5, after the  start of NC-6004 infusion at Hours  3, 6, 12, 24  (Day  2), 48 (Day  3), 96 (Day 5), 168  and (Day 8,  prior  to 
gemcitabine infusion (Day 8), and 336 (Day 15) in Cycles 1, 3, and 5, and at the End -of-Treatment visit.  Additional pharmacokinetic blood sample 
collections may  be performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within  
10 minutes  after the 12-lead ECGs  performance.  
p. For Part 2 (up to 6 cycles), on the day of NC -6004 infusion for each cycle, blood samples will be collected before the start of the NC -6004 infusion, at the 
end of the NC-6004  infusion, before  gemcitabine  infusion  on Day 8, and at the End-of-Treatment  visit.  Additional  pharmacokinetic  blood  sample  collections 
may be performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within 10 minutes after 
the 12- lead ECGs performance.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  204  
 12.4.6  Protocol  Amendment 3-Protocol  Version  4.2, Incorporating 
Amendment 3-Version  4.1 (EU only,  dated 31 August 2016)  
The following sections detail  the changes made  to Protocol  Amendment  3-Version  4.1 (EU 
only, dated 31 August 2016). 
Protocol  Amendment  3-Version  4.0 (US only, dated  31 July 2016)  included EMA  
VHP -requested changes in addition to other changes not specifically requested by the VHP. 
Following submission of Version  4.0 to the VHP,  the VHP  requested  a version  of the protocol 
that only included the VHP -requested changes; therefore, Version 4.1 was submitted to the 
VHP  to meet this request. Version 4.0 was submitted to the FDA  and not subsequently 
modified.  
Protocol  Amendment  3-Version  4.2 (US and EU) harmonizes  Versions  4.0 and 4.1 and was 
finalized  on 12 December  2016. A separate summary  of the changes  made  to Version  4.0 is 
included in Section 12.4.5. 
 
12.4.6.1  Risk  Assessment  for Amendment  3, Version  4.2 
Because the following  sections  detail  the changes  made  to Protocol  Amendment  
3-Version 4.1 (EU only, dated 31 August 2016), the risk associated with this amendment 
comprises both the risk described  in Section  12.4.3.1 and the risk assessed  in the following 
text and repeated in Section 12.4.5.1. 
No anticipated  increased  patient  risk has been  introduced with the updates  made  during  this 
protocol amendment. Based on new safety information received from an ongoing non- US, 
non-IND, Japanese trial with NC -6004 (Study NC -6004- 007), additional exclusion criteria 
have been added to mitigate risk of liver toxicity in patients predisposed to liver injury. In 
addition, sites and investigators have been instructed to closely monitor ongoing NC -6004 
patients who are known to have pre -existing alcoholic liver injury and/or concurrent heavy 
alcohol consumption, for newly emerging liver injury.  
 
12.4.6.2  Overview  of Changes 
The overview  of significant changes  includes  the following:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  205  
 Title  Page  – Current  Version  and Date  of Protocol;  Title  Page  – Previous  Dates  and 
Versions  
The current  and previous  protocol  amendment  versions  and applicable  regions  were  updated 
to provide complete transparency and increased clarity.  
Declaration  of Investigator 
 
A declaration  of investigator  page,  which  includes  a principal investigator  signature  line was 
added.  
Protocol  Synopsis  – Study  Sites; Section  4.1 – Selection  of Study  Population  
 
The study site details were  updated to at least  20 sites in the  Unites  States  and Europe. 
 
Protocol  Synopsis  – Inclusion  Criteria; Section  4.1.1 – Inclusion  Criteria  
 
The inclusion  criterion  5 was  updated to the following:  
 
5. Have  an Eastern  Cooperative  Oncology Group (ECOG)  PS of 0 to 1, with the exception of 
patients in Part 2 (Cohort 3, unfit bladder cancer patients) who may have an ECOG PS  
of 2. 
Protocol  Synopsis  – Inclusion Criteria;  Protocol  Synopsis  – Study  Design;  
Section 3.1 - Study Design; Section 4.1.1 – Inclusion Criteria; Section 5.1 – Method of 
Assigning  Patients  to Treatment  Groups;  Section  6.3.1.2.1 - Safety  Monitoring in Part 2 
The inclusion  criterion  8 and study design  were  updated to reflect  the following:  
 
8. In Part 1 and in Part 2 in Cohorts 1 and 2: have adequate renal function defined as a 
creatinine  clearance (CrCl)  ≥50 mL/minute  (calculated  according to the formula  of Cockcroft 
and Gault 1976) or serum creatinine <1.5 mg/dL. In Part 2, patients in Cohort 3 (bladder 
cancer) must have a CrCl of ≥30 mL/min.  
• Bladder  cancer  patients in  Cohort 3 of Part 2  will be  stratified by  ≥30 to  
<60 mL/min  and/or  ECOG PS 2 and ≥60 mL/min  and ECOG PS 0 to 1. If 2 of 
6 patients (or ≥33% at any point during the study) in the ≥30 to <60 mL/min 
group have a worsening of CrCl (ie, 50% reduction from baseline for  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  206  
 2 consecutive assessments,  at least 1 week  apart),  then enrollment  of patients 
with CrCl <60 mL/min will stop in the bladder cancer cohort.  
Protocol  Synopsis  – Exclusion  Criteria;  Section  4.1.2 – Exclusion  Criteria  
 
The exclusion criteria  11 and 12 were  added to reflect  the following:  
 
11. Have  pre-existing  alcoholic  liver injury or significant liver disease.  
 
12. Are regularly consuming alcohol within 6 months of Screening defined as an average 
weekly  intake  of >21 units  (or an average  daily  intake  of >3 units)  for males or >14 units  (or 
an average daily intake >2 units) for females. One unit is equivalent to 8 g of alcohol: a  
half-pint (approximately  240 mL) of beer,  1 glass  (125 mL) of wine,  or 1 measure (25 mL) of 
spirits.  
Protocol  Synopsis  – Study  Design;  Section  3.1 – Study  Design  
 
All references to “two -stage” and a minimum threshold  of clinical  responses in Part 2 were 
removed.  
Protocol  Synopsis  – Study  Design;  Protocol  Synopsis  – Study  Drug,  Dosage, and Route  of 
Administration; Section 5.1 -  Method of  Assigning Patients to Treatment Groups;  
Section  5.3 - Treatments Administered  
 
A +10- minute  window was  added to the 1-hour infusion of NC-6004.  
 
Protocol  Synopsis  – Study  Design;  Section  3.1 - Study  Design;  Section  5.1 - Method  of 
Assigning Patients to Treatment Groups; Section 5.3 -  Treatments Administered  
The RPII  dose of 135 mg/m2 was added to  the protocol.  
 
Protocol  Synopsis  – Study  Design;  Section  3.1 - Study  Design  
 
The historical median duration of PFS and PFS weekly hazard were added for the unfit 
bladder  cancer  cohort. A successful  outcome  for unfit and fit bladder  cancer  patient  cohorts 
with 30 planned patients was updated to 15 PFS events.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  207  
 Protocol  Synopsis  – Study  Design;  Protocol  Synopsis  – Sample  Size;  Section  3.1 - Study  
Design; Section 4.1 – Selection of Study Population; Section 7.3 -  Sample Size 
Calculations  
The total sample  size in Part 2 of the study was changed to 160 patients  with no more  than 
50 patients  each in  Cohorts 1 and 2 and no more  than 60 patients  in Cohort  3 (30 unfit and 
30 fit bladder  cancer  patients).  The simulated  mean  sample sizes for  this trial were  updated to 
92.7 to 116.8 patients.  
 
Protocol  Synopsis  – Study  Design;  Section  3.1 – Study  Design  
 
It was clarified  that all patients  who discontinue  treatment  and have  not progressed  will have 
an End- of-Treatment visit, will be followed with scans every 9 weeks until disease 
progression, and will be contacted for survival every 12 weeks by telephone. 
Protocol  Synopsis  – Estimated  Study  Duration;  Section  4.2.1 – Reasons  for 
Withdrawal/Discontinuation  
A study treatment discontinuation rule  was added as follows:  
 
• For Cohort  3 only, unfit  bladder  cancer  patient (≥30  to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least 1 week  apart)  
Protocol  Synopsis  – Safety  Assessments;  Section  6.3.5 – Clinical Laboratory  Analyses 
 
It was specified  that only abnormal  laboratory  results  deemed  to be clinically  significant will 
be recorded as AEs or SAEs.  
Protocol  Synopsis  – Safety  Assessments  
 
For internal consistency, it  was added that audiometry  will also be performed  as clinically 
indicated at the End- of-Treatment visit.  
Protocol  Synopsis  – Definition  of a DLT;  Section  6.3.1.1 – Definition  of Dose -Limiting  
Toxicities  
It was clarified  that DLTs  will only be monitored in Part 1 of the study.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  208  
 Section  3.1 - Study  Design;  Section  3.1.1 – Rationale  of Study  Design;  
Section  6.1 - Efficacy  Assessments;  Section  12.1 - Appendix:  Schedule  of Events;  
 
It was clarified that the MDASI  will only be performed in  Part 1.  
 
Section  3.1 - Study  Design  
 
A cross- reference to the amendment -specified  imaging  methods  was added.  
 
At the Follow -up visit,  text was updated to specify  that new treatments  would be collected 
(Previous text stated medication history would be collected).  
Section  3.1 - Study  Design  
 
Text was added to specify  that at Cycle  1, either  serum  or urine;  test is not required on Day 1 
of Cycle 1 if pregnancy test at screening was performed using serum.  
Section  5.2 – Prophylactic  Treatments;  Section  5.8 – Prophylaxis  and Management  of 
Hypersensitivity Reactions 
It was added  that 20 mg famotidine  can be given intravenously as an option in place of 50 mg 
of ranitidine given intravenously.  
Section  5.8 – Prophylaxis  and Management  of Hypersensitivity Reactions  
 
If a Grade 1 or Grade 2 hypersensitivity occurs in a patient, it was added that 40 mg 
famotidine  can be given orally once  per day as an option in place of ranitidine  150 mg orally 
given 2 times per day.  
Section  3.1 - Study  Design;  Section  5.4 - Dose  Delays and Modifications;  
Section  6.3.7 -  Physical Examination; Section 11 -  Reference List; Section  12.1 - Appendix: 
Schedule of Events, footnote g  
It was added that the doses  of NC-6004 and gemcitabine  will be calculated  in milligrams  per 
square meter (mg/m2) at screening and will not be changed in subsequent cycles unless the 
patient’s body weight increases or decreases by at least 10% from the patient’s screening 
weight measurement. This threshold should not be confused with a change in the patient’s 
body surface area (m2). Any change in a patient’s weight by at least 10% during the study 
will require a recalculation of the doses of NC -6004 and gemcitabine. Weight will be  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  209  
 measured  before  treatments  on Day 1 of each cycle,  with a calculation  of body surface area 
before each dosing on Day 1 of each cycle (using  the Mosteller formula [ Mosteller 1987]).  
Section  5.4 - Dose  Delays  and Modifications;  Section  5.4.1 – NC-6004 Dose  Delays and 
Modifications  
Updated “Grade 3 or 4 toxicity”  to “Grade  3 or 4 toxicity  (recurrence  of the same AE)”  to 
more clearly define the recurrence of events that could lead to study drug withdrawal.  
Section  5.5.2 - Gemcitabine  Drug  Product;  Section  5.6.1 - Study  Drug  Packaging and 
Storage  
The generic  gemcitabine  was added to the protocol  to clarify  that it is acceptable for generic 
gemcitabine to be administered in this study (as per the original intent of the protocol) in 
place of Gemzar.  
Section  5.6.2 – Test Article Accountability  
 
It was clarified  that the PI should maintain  accurate records of receipt  of all test articles  that 
are centrally provided.  
Section  6.1.1 – Disease Response Definitions  
 
Guidelines  for imaging, including the timing,  anatomic  coverage, imaging  method, and slice 
thickness were added.  
Section  6.1.3 – MD Anderson  Symptom  Inventory 
 
Reference to the Study Manual was removed from the protocol.  
 
Section  6.2 - Pharmacokinetic  and Pharmacodynamic  Assessments;  
Section 12.1 -  Appendix: Schedule of Events, footnotes o and p 
A 10-minute  window  after ECG performance  was added for  the PK blood sampling.  
 
Section  6.3.2.3 – Reporting Adverse Events  
 
Text was added  to clarifying  the process for capturing events  in the EDC system,  and 
European SAE hotline and fax line numbers were added.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  210  
 Section  6.3.2.5 - Assessment of  Causality  
 
“Study drug” was updated to “study drug (NC-6004 and gemcitabine)”  to indicate  that the 
assessment of an  AE’s relatedness was to the combination of NC -6004 and gemcitabine. 
Section  6.3.3 – Assessment  of Nausea  and Vomiting; Section  12.1 - Appendix: Schedule  of 
Events, footnote m 
Text was added  to specify  the process  for administering  and capturing data in the nausea and 
vomiting patient diary. 
Section  6.3.5.3 – Urinalysis;  Section  12.1 - Appendix: Schedule  of Events  
 
Reference to a dipstick  urinalysis  was removed to allow  flexibility  in the type of urinalysis 
testing.  
Section  6.3.6 – Electrocardiograms; Section  6.3.8 - Vital  Sign  Measurements;  
Section 12.1 - Appendix: Schedule of Events, footnotes n and h 
The text “rest for at least 5 minutes” was updated to “adequately rested” for the patient 
before ECGs  and vital sign measurements.  Text was also added  to specify  that ECGs  will be 
performed during the screening period at Day –7 to –1 and that vital signs will also be measured at the End -of-Treatment visit.  
Section  6.3.6 – Electrocardiograms; Section  12.1 - Appendix: Schedule  of Events,  
footnote n 
A ±30- minute  window for collection  of 12- lead ECGs  was added.  
 
Section  10.2.2 - Protocol Violations  and Deviations  
 
Text was updated to clarify  that Part 2 of this study  will not require sponsor approval prior to 
each patient being enrolled in the study. 
Section  12.1 - Appendix: Schedule  of Events  
 
A column was added to the Schedule of Events Table  (Table  12-1) to clearly  show that ECGs 
will be also performed on Day 2 of Cycle 1. For completeness, PK assessments, AE 
monitoring, and concomitant medication review were also added to Day 2 of Cycle 1. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  211  
 12.4.6.3  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol. Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not highlighted. 
Protocol Synopsis  – Study  Sites  
 
Study Sites:  At least 20 sites in the United  States  and Europe.  
 
Protocol Synopsis  – Inclusion  Criteria  
 
… 
 
5. Have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1, with the exception 
of patients  in Part  2 (Cohort 3, unfit  bladder  cancer patients) who may have an ECOG 
PS of 2 . 
… 
 
8. In Part 1 and in Part 2 in Cohorts 1 and 2 : Hhave adequate renal function defined as a 
creatinine clearance (CrCl) ≥50 mL/minute (calculated according to the formula of 
Cockcroft and Gault  1976) or serum  creatinine  <1.5 mg/dL. In Part  2, patients  in Cohort 3 
(bladder cancer) must have a CrCl of ≥30 mL/min.  
• Bladder  cancer patients in  Cohort 3 of Part 2 will be stratified  by ≥30 to 
<60 mL/min  and/or  ECOG  PS 2 and ≥60 mL/min  and ECOG  PS 0 to 1. If 
2 of 6 patients (or ≥33% at any point during the study) in the ≥30 to  
<60 mL/min  group have a worsening  of CrCl  (ie, 50% reduction from 
baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment  of patients  with  CrCl  <60 mL/min  will stop in the bladder 
cancer cohort.  
Protocol Synopsis  – Exclusion  Criteria  
 
… 
 
11. Have pre-existing  alcoholic liver  injury  or significant liver  disease.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  212  
 12. Are regularly consuming alcohol within 6 months of Screening defined as an 
average weekly  intake  of >21 units  (or an average daily  intake  of >3 units)  for males  or 
>14 units  (or an average daily  intake  >2 units)  for females.  One unit is equivalent  to 8 g 
of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 
1 measure (25 mL) of spirits.  
 
Protocol Synopsis  – Study  Design  
 
This study will consist of 2 parts; Part 1  is a Phase 1b, continual reassessment method  
dose- escalation  trial, and Part 2 is a Phase 2, adaptive,  two-stage,  open- label,  expansion trial 
evaluating activity, safety, and tolerability at the RPII dose identified in Part 1.  
… 
 
On Day 1 of each  cycle,  patients  will receive NC -6004 over 1 hour (+10- minute  window)  
followed  by an infusion of gemcitabine 1250 mg/m2 over 30 minutes.  
 
… 
 
Part 2 of the study (Phase 2 portion) will begin after the RPII dose of NC-6004 is identified 
for use in combination  with gemcitabine.  All patients will receive  NC-6004 at the RPII  dose 
(135 mg/m2, established in Part 1) in combination with gemcitabine 1250 mg/m2 by the 
same regimen as in Part 1.  
Three cohorts of patients are eligible (Cohort 1: first- line metastatic squamous NSCLC; 
Cohort 2: first-line metastatic or locally  advanced  cholangiocarcinoma, gallbladder cancer,  or 
ampullary  cancer  (biliary  tract cancer);  and Cohort 3: first-line metastatic  or locally  advanced 
TCC of the urinary tract (bladder cancer). Bladder cancer patients in Cohort 3 of Part 2 
will be stratified by ≥30 to <60 mL/min and/or ECOG  PS 2 (unfit) and ≥60 mL/min and 
ECOG  PS 0 to 1 (fit). If 2 of 6 patients (or ≥33% at any point during the study) in the  
≥30 to  <60 mL/min  group have a worsening  of CrCl  (ie, 50% reduction  from  baseline 
for 2 consecutive assessments,  at least  1 week  apart), then enrollment  of patients  with 
CrCl <60 mL/min will stop in the bladder cancer cohort.  
Stage Part  2 will continue  in each cohort after achieving the minimum threshold  of clinical  
responses required and enroll up to 50 patients each in Cohorts 1 and 2, and up to 60 
patients in Cohort 3, for a total of up to 150 160 patients in Part 2.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  213  
 … 
 
Cohort  Biliary  Bladder  (CrCl:  
≥60 mL/min 
and ECOG  PS 
0-1; fit)  Bladder  (CrCl:  
≥30 to  
<60 mL/min and/or  ECOG 
PS 2; unfit)  Squamous 
NSCLC 
Historical 
Median Duration  of PFS 8.8 months  7.6 months  5.8 months  5 months  
Historical PFS 
Weekly  Hazard  0.01795  0.020755  0.02711  0.031377  
Abbreviations:  CrCl,  creatinine clearance;  ECOG, Eastern  Cooperative  Oncology  Group;  NSCLC, 
non-small cell lung cancer; PS, performance status.  
Once  10 PFS events  have  been  observed, interim analyses will be performed  every  6 weeks. 
At each interim and at the final analysis, there are 3 possible outcomes for each cohort.  
• Futility  – 10 PFS events  have  been  observed  in each cohort  and at least 1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
 
• Probability  (Phase 3 Success*)  <0.4 
 
• Success – 25 PFS events  have  been  observed in each 50-patient  cohort  and 15 PFS 
events in each 30- patient bladder cancer cohort and:  
• Probability  (Phase 3 Success*)  >0.8 
 
• Inconclusive  – neither  futility  nor success.  
 
*Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events -  enough to 
provide  80% power  to detect  an HR of 0.75. A promising  HR is defined as one  less than 0.85. 
*Futility can only be declared for a cohort after 10 PFS events have been observed in that 
cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been 
observed in that 50-patient cohort (Cohort 1 and 2) or 30- patient bladder cancer cohort 
(Cohort  3, fit and unfit),  respectively . Accrual  will stop for any cohort  identified  as futile  or 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  214  
 successful  at interim.  The conclusion of this Phase 2 trial will be that a Phase 3 trial with 381 
events should be conducted for each cohort that is a success.  
… 
 
Patients  who discontinue treatment due to an AE and have not progressed will have an 
End-of-Treatment  visit,  will be followed  with scans every  9 weeks until disease  progression, 
and will be contacted for survival every 12 weeks by telephone. 
Protocol Synopsis  – Estimated  Study  Duration  
 
… 
 
Patients  will receive study  treatment until any of the following  occur:  
… 
 
• For Cohort 3 only, unfit  bladder  cancer patient  (≥30 to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least  1 week  apart)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  215  
 Protocol Synopsis  – Safety  Assessments  
 
Adverse events will be evaluated at each visit during every cycle and graded according to 
NCI CTCAE  version 4.03 dated  June 14, 2010 (only  abnormal laboratory results deemed 
to be clinically  significant will be recorded  as AEs or SAES)  (NCI  CTCAE  version 4.03) . 
… 
 
Audiometry will be performed  at screening  and only as clinically  indicated  before treatment 
on Day 1 of each cycle and as clinically indicated at the End-of- Treatment visit. 
Protocol Synopsis  – Definition  of DLT  
 
A DLT (monitored  in Part  1 only)  is defined  as the following  treatment- related  AEs or 
laboratory abnormalities, graded according to NCI CTCAE version 4.03: 
 
Protocol Synopsis  – Study  Drug,  Dosage, and Route  of Administration  
 
In each part of the study, NC-6004 will be administered  as a 1-hour (+10- minute  window)  
intravenous infusion on Day 1 of each cycle.  
 
Protocol Synopsis  – Sample  Size 
 
… 
 
Part 2 is a 3 -cohort study with an overall sample size of up to 150160 patients with no more 
than 50 patients per cohort in Cohorts 1 and 2 and no more than 60 patients in Cohort 3 
(30 unfit and 30 fit bladder cancer patients) . The total sample size will depend on the 
results of  interim futility  and superiority analyses. In order  to evaluate  the overall sample size, 
simulations were performed assuming scenarios with different HRs for PFS for each cohort compared with historical control and different sample sizes for a subsequent Phase 3 clinical trial. The associated mean sample size for this trial in these scenarios ranged from 136  92.7 
to 146 116.8 patients.  
 
Section  3.1 - Study  Design  
 
This study will consist of 2 parts; Part 1 is a Phase 1b, continual reassessment method dose- escalation trial in patients with any advanced solid tumor, and Part 2 is a Phase 2, 
adaptive two-stage, open- label,  expansion trial in patients with squamous NSCLC,  biliary  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  216  
 tract,  and bladder cancer  evaluating activity,  safety,  and tolerability  at the RPII  dose 
identified in Part 1.  
… 
Part 2 of the study (Phase 2 portion) will begin after the RPII dose of NC-6004 is identified 
for use in combination  with gemcitabine.  All patients will receive  NC-6004 at the RPII  dose 
(135 mg/m2, established in Part 1) in combination with gemcitabine 1250 mg/m2 by the 
same regimen as in Part 1. Cohort 3 will stratify  patients by creatinine clearance (CrCl) 
to assess study drug in patients with reduced kidney function (ie, CrCl of <60 to  
≥30 mL/min [unfit] and ≥60 mL/min [fit]) in a controlled manner and with the 
stipulation  that enrollment  will stop if 2 of 6 patients  in the <30 to ≥60 mL/min  group 
have a worsening of CrCl (ie, 50% reduction from baseline for 2 consecutive assessments, at least 1 week apart).  
Three cohorts of patients are eligible (Cohort 1: first- line metastatic squamous NSCLC; 
Cohort 2: first- line metastatic  or locally  advanced cholangiocarcinoma, gallbladder cancer,  or 
ampullary cancer [(biliary tract cancer)] ; and Cohort 3: first -line metastatic or locally 
advanced TCC of the urinary tract [ (bladder cancer ]). Stage 2 will continue in each cohort  
after achieving the minimum threshold of clinical responses required and Part 2 will enroll 
up to 50 patients each  in Cohorts 1 and 2, and up to 60 patients  in Cohort 3, for a total of 
up to 160 patients in Part 2. in each cohort for a total of up to 150 patients in Part 2. The 
primary endpoint (PFS) will be continuously updated and compared with the historical PFS 
from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard 
model will be updated as PFS data accrue.  A hazard ratio (HR) for PFS for each cohort 
versus historical control will be obtained.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  217  
  
Cohort  Biliary  Bladder 
(CrCl: ≥60 mL/min; fit) Bladder (CrCl:  ≥30 
to 
<60 mL/min; 
unfit)  Squamous 
NSCLC 
Historical 
Median 
Duration  of 
PFS 8.8 months  7.6 months  5.8 months  5 months  
Historical PFS Weekly 
Hazard  0.01795  0.020755  0.02711  0.031377  
 
Abbreviations:  CrCl: creatinine clearance;  ECOG,  Eastern  Cooperative  Oncology  Group; 
NSCLC, non -small cell lung cancer; PS, performance status.  
 
Once  10 PFS events  have  been  observed, interim analyses will be performed  every  6 weeks. 
At each interim and at the final analysis, there are 3 possible outcomes for each cohort.  
• Futility  – 10 PFS events  have  been  observed  in each cohort  and at least 1 of the 
following conditions is true:  
• Probability  (Promising  HR*)  <0.4 
 
• Probability  (Phase 3 Success*)  <0.4 
 
• Success – 25 PFS events  have  been  observed in each 50-patient  cohort  and 15 PFS 
events in each 30- patient bladder cancer cohort and:  
• Probability  (Phase 3 Success*)  >0.8 
 
• Inconclusive  – neither  futility  nor success.  
 
* Phase 3 success is defined as success in a Phase 3 clinical trial with 381 events -  enough to 
provide  80% power  to detect  an HR of 0.75. A promising  HR is defined as one  less than 0.85. 
*Futility  can only be declared  for a cohort  after 10 PFS events  have  been  observed in that 
cohort. Success can only be declared for a cohort after 25 or 15 PFS events have been 
observed in that 50-patient (Cohort 1 and 2) or 30- patient bladder cancer cohort  
(Cohort  3, fit and unfit),  respectively . Accrual  will stop for any cohort  identified  as futile  or 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  218  
 successful  at interim.  The conclusion of this Phase 2 trial will be that a Phase 3 trial with 381 
events should be conducted for each cohort that is a success.  
… 
 
Patients  who discontinue treatment due to an AE and have not progressed will have an 
End-of-Treatment  visit,  will be followed  with scans every  9 weeks until disease  progression, 
and will be contacted for survival every 12 weeks by telephone. 
… 
 
The following procedures will be performed  during the screening  period within  28 days prior 
to the first study treatment:  
• Signed informed  consent can be obtained within  28 days of dosing and prior to 
performing any study evaluations. 
• Disease assessment will be evaluated with a baseline computed tomography scan (see 
Section  6.1.1 for imaging methods)  and should be performed  within  the 28 days before 
the start of study treatment.  
… 
 
The following procedures will be performed  on Day 1 prior to NC-6004 infusion in each 
treatment cycles unless otherwise specified:  
• Pregnancy test (serum or urine) on Day 1 of each cycle (at Cycle  1, serum  or urine; test is 
not required on Day 1 of Cycle 1 if pregnancy test at screening was performed using 
serum)  
… 
 
• Height, weight, and calculation  of body surface  area using  the Mosteller  formula 
(Mosteller 1987) 
… 
• Part  1 only: Core  MDASI  or MDASI  module specific for lung cancer  (MDASI -LC) 
(Section 6.1.3) 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  219  
 Day 8 of Each  Cycle 
… 
• Part  1 only: Core  MDASI  or MDASI -LC 
… 
Follow -Up 
Patients  who complete treatment  or discontinue  treatment  without disease progression will 
continue to be followed until disease progression with scans every 9 weeks. Following 
disease progression, patients will be contacted by telephone every 12 (±1) weeks to collect the following data:  
• Survival  
• Adverse events (All AEs will  be followed  until resolution, Section  6.3.2.6)  
• Medication  history New treatments  (targeted  therapy or chemotherapy used after study 
disease progression and treatment completion)  
• Section  3.1.1 –Rationale of Study  Design  
• … 
• In Part  1 only, Tthe MDASI  will be used to evaluate symptoms  related  to QoL during 
treatment.  
Section  4.1 –Selection  of Study  Population  
Approximately 209 199 patients (up to 49 patients in Part 1 and up to 160 150 patients in 
Part 2) will be enrolled  in at least 20 sites in the United  States  and Europe . Patients  will be 
assigned to a study treatment only if they meet all of the inclusion criteria and none of the exclusion criteria.  
Section  4.1.1 – Inclusion  Criteria  
 
5. Have  an ECOG  PS of 0 to 1, with  the exception  of patients  in Part  2 (Cohort 3, unfit 
bladder cancer patients) who may have an ECOG PS of 2 . 
… 
 
8. In Part  1 and in Part  2 in Cohorts 1 and 2: Hhave adequate renal  function  defined as a 
CrCl ≥50 mL/minute (calculated according to the formula of Cockcroft and Gault 1976) or  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  220  
 serum  creatinine  <1.5 mg/dL. In Part  2, patients  in Cohort  3 (bladder  cancer)  must  have 
a CrCl of ≥30 mL/min.  
• Bladder  cancer patients  in Cohort  3 of Part  2 will be stratified  by ≥30 to 
<60 mL/min  and/or  ECOG  PS 2 and ≥60 mL/min  and ECOG  PS 0 to 1. If 
2 of 6 patients (or ≥33% at any point during the study) in the ≥30 to  
<60 mL/min  group  have  a worsening  of CrCl  (ie, 50% reduction from 
baseline for 2 consecutive assessments, at least 1 week apart), then 
enrollment  of patients  with  CrCl  <60 mL/min  will stop in the bladder 
cancer cohort.  
Section  4.1.2 – Exclusion  Criteria  
… 
11. Have  pre-existing  alcoholic  liver  injury  or significant liver  disease.  
12. Are regularly consuming alcohol within 6 months of Screening defined as an 
average  weekly  intake  of >21 units  (or an average  daily  intake  of >3 units)  for males  or 
>14 units  (or an average  daily  intake  >2 units)  for females.  One unit is equivalent  to 8 g 
of alcohol: a half -pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or  
1 measure (25 mL)  of spirits.  
 
Section  4.2.1 – Reasons  for Withdrawal/Discontinuation  
 
… 
 
A patient  may be withdrawn from the  study for any of the following reasons:  
 
… 
 
• For Cohort  3 only, unfit  bladder  cancer patient  (≥30 to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least  1 week  apart)  
Section  5.1 - Method  of Assigning  Patients  to Treatment  Groups  
This is an open -label study that will be conducted in 2 parts. In both parts, NC -6004 will be 
administered  as a 1-hour (+10- minute  window)  intravenous  infusion  on Day 1 of each cycle. 
Gemcitabine 1250 mg/m2 will be administered as a 30 -minute intravenous infusion on Day 1 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  221  
 of each cycle (after  the administration  of NC-6004)  and on Day 8 of each cycle.  The duration 
of each cycle will be 21 days.  
… 
 
In Part 2, all patients  will receive the RPII  dose (135 mg/m2) of NC-6004 identified  in Part 1. 
Bladder cancer patients in Cohort 3 of Part 2 will be stratified by ≥30 to <60 mL/min 
and/or  ECOG  PS 2 (unfit) and ≥60 mL/min and ECOG  PS 0 to 1 (fit). If 2 of 6 patients 
(or ≥33% at any point during the study) in the ≥30 to <60 mL/min group have a worsening of CrCl (ie, 50% reduction from baseline for 2 consecutive assessments, at 
least 1 week apart), then enrollment of patients with CrCl <60 mL/min will stop in the 
bladder cancer cohort.  
Section  5.2 – Prophylactic  Treatments  
 
All patients will receive the following  medications  before  administration  of NC-6004 on 
Day 1 of each cycle:  
… 
 
• Patients will be given 50 mg of ranitidine intravenously or 20 mg famotidine 
intravenously  30 minutes  before  the start of NC-6004 infusion  on Day 1 of each cycle.  
Section  5.3 - Treatments Administered  
The duration of each treatment cycle  will be 21 days in both parts  of the study. NC-6004 will 
be administered on Day 1 of each cycle as a 1 -hour (+10- minute window) intravenous 
infusion.  
… 
 
In Part 2, on Day 1 of each cycle,  all patients  will receive  NC-6004 at the RPII  dose 
(135 mg/m
2) identified  in Part 1 and 1250 mg/m2 gemcitabine.  On Day 8 of each cycle,  all 
patients in Part 2 of the study will receive 1250 mg/m2 gemcitabine.  
Section  5.4 - Dose  Delays and Modifications  
 
The doses for NC-6004 and gemcitabine  will be calculated  in milligrams  per square 
meter  (mg/m2) at screening,  and will not be changed  in subsequent  cycles unless  the 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  222  
 patient’s body weight has increased or decreased by ≥10% from the patient’s weight 
measurement  at screening.  Any change  in a patient’s  weight  by ≥10% during  the study 
will require a recalculation of the doses of all study drugs ( Note:  This threshold should 
not be confused  with  a change  of a patient’s  body  surface area  [BSA]  [m2]). Weight  will 
be measured before treatments on Day 1 of each cycle, with calculation of BSA  before 
dosing on Day 1 of each cycle (using the Mosteller formula [ Mosteller 1987]).  
Patients  experiencing  significant toxicities  must  be immediately  and permanently withdrawn 
from treatment with NC -6004 and gemcitabine as follows:  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  223  
 • Any patient who experiences a Grade  3 or 4 hypersensitivity  reaction  during any 
cycle of treatment  
• Any patient who experiences 2 protocol-defined DLTs  during treatment 
 
• Any patient who experiences a recurrent Grade  3 or 4 toxicity  (recurrence  of the 
same AE) after a dose reduction  
Section  5.4.1 – NC-6004 Dose  Delays and Modifications  
 
… 
 
Following recovery to Grade 1 or lower, treatment may resume at the investigator’s 
discretion.  Patients  who resume treatment following  a dose delay  will have the dose of study 
drug reduced by 50% for the remainder of study treatment. If toxicities persist or recur to 
Grade 3 or 4 (recurrence of the same AE) after the dose reduction, study treatment will be 
terminated.  
Section  5.5.2 - Gemcitabine  Drug  Product  
 
Gemzar® (gemcitabine  for injection,  USP),  is available in sterile  single- use vials  individually 
packaged in a carton containing: 200 mg white to off-white, lyophilized powder in a 
10-mL size sterile  single -use vial or 1 g white  to off-white,  lyophilized powder in a 
50-mL size sterile  single -use vial. Vials  of gemcitabine Gemzar  contain  either  200 mg or 1 g 
of gemcitabine hydrochloride (expressed as free base) formulated with mannitol (200 mg or 
1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile 
lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for 
pH adjustment. 
Section  5.6.1 - Study  Drug  Packaging and Storage  
 
All study drugs must be stored  in a secure area (eg, a locked cabinet).  NC-6004 should be 
protected from light and stored refrigerated (2 ° to 8 °C). Unopened vials 
of Gemzar  (gemcitabine)  are stable  until the expiration date indicated  on the package when 
stored at controlled room temperature 20° to 25°C that allows for excursions between 15° and 30°C. 
Section  5.6.2 – Test Article Accountability  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  224  
 The investigator will maintain  accurate records  of receipt  of all test articles  that are 
centrally provided , including dates of receipt.  
Section  5.8 – Prophylaxis  and Management  of Hypersensitivity Reactions  
 
All patients  must  receive  the following  prophylactic  treatment at each cycle to reduce  the risk 
of hypersensitivity reactions:  
… 
 
• Diphenhydramine  hydrochloride  50 mg and either ranitidine  50 mg or 
20 mg famotidine  will be administered  intravenously 30 minutes  before  the infusion  of 
NC-6004.  
… 
 
If a Grade  1 or Grade  2 hypersensitivity occurs  in a patient,  the following  medications  should 
be administered for 48 hours after NC -6004 infusion:  
• Ranitidine  150 mg orally  given 2 times  per day or 20 mg famotidine  given 
intravenously once per day  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  225  
 Section  6.1 – Efficacy  Assessments  
 
… 
 
Symptom  changes will be assessed  using the core MDASI  (Part  1 only)  or MDASI -LC (only 
in patients with NSCLC in Part 1) (Section 6.1.3 ) on Days 1 and 8 of each cycle and at the 
End-of-Treatment visit.  
Section  6.1.1 – Disease Response Definitions  
 
… 
 
The rate of confirmed  response  and tumor growth control  will be determined  according  to 
RECIST  version 1.1 in solid tumor patients for patients evaluable for response using the 
following imaging methods:  
Timing  
 
Disease assessment  will occur at Screening  and every  6 weeks (±1 week)  until  disease 
progression. Patients who have obtained a response (PR or CR) will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
Anatomic  Coverage  
 
Imaging should include  a computed tomography scan  of the chest,  abdomen,  and pelvis. 
In addition, areas of known predisposition for metastases (eg, the brain for NSCLC) and any areas  identified  by the clinician  as probable  sites of metastasis  based  on clinical 
evaluation should be included in imaging if clinically indicated. Other imaging may be performed at the investigator’s discretion as standard of care.  
Imaging Method  
 
The preferred method for imaging is computed tomography with IV contrast. If the 
patient  is allergic  to contrast  media  or has another  medical  contraindication,  magnetic 
resonance imaging with contrast can be used at the clinician’s discretion. It is critical that the same method of imaging is used throughout the study for a given patient.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  226  
 Slice  Thickness  
 
The preferred  slice thickness  is 5 mm.  If a larger slice thickness  is used  (eg, 7 mm),  the 
smallest tumor measurement that can be reported is twice the thickness of the slice.  
The ORR, DCR, and DOR will be determined immediately prior to the initiation of 
maintenance therapy. The OS and PFS will be determined at the end of the study for 
evaluable patients without censoring at the initiation of maintenance therapy.  Patients who  
have obtained a response (PR or CR) will have a confirmatory  scan at  a minimum  of 4 weeks 
following the initial scan.  
Section  6.1.3 – MD Anderson  Symptom Inventory 
 
… 
 
The core MDASI  and the MDASI -LC will  be administered  as a self -report paper-and-pencil 
form given  to the patient at  the site before study treatments  on Days  1 and 8 of each cycle in 
Part 1 only (as described in Study Manual). 
Section  6.2 - Pharmacokinetic and Pharmacodynamic Assessments  
 
… 
 
Pharmacokinetics blood sampling should occur within 10% of nominal time  for Days 1 and 
2, and ±4 hours of nominal time for all other time points, and should occur within 10 
minutes  after  the 12-lead ECGs  performance at time -matched  visits  (Section  6.3.6). All 
PK samples will be evaluable as long as the actual collection times are recorded.  
Section  6.3.1.1 – Definition  of Dose -Limiting  Toxicities  
 
A DLT (monitored  in Part  1 only) is defined  as the following  treatment -related  AEs or 
laboratory abnormalities, graded according to the NCI CTCAE version 4.03: 
Section  6.3.1.2.1 - Safety  Monitoring  in Part 2 
 
During Part 2 of the study, patients  treated  with NC-6004 at the RPII  dose from Part 1 will be 
monitored for safety. Dose delay and modification rules for both NC-6004 and gemcitabine 
apply in Part 2 as in Part 1. 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  227  
 In Part  2 (Cohort 3), if 2 of 6 patients  (or ≥33%  at any point  during  the study)  in the 
≥30 to <60 mL/min  group  have a worsening  of CrCl  (ie, 50% reduction  from  baseline 
for 2 consecutive assessments,  at least  1 week  apart),  then enrollment  of patients  with 
CrCl <60 mL/min will stop in the bladder cancer cohort. In addition, in Part 2 
(Cohort 3), if an unfit bladder  cancer patient (≥30 to <60 mL/min CrCl at screening)  
has a worsening  of CrCl  (ie, 50% reduction from  baseline  for 2 consecutive assessments, 
at least 1 week apart) he or she may be withdrawn from the study (Section 4.2.1). 
Section  6.3.2.3 – Reporting Adverse Events  
 
… 
 
Any AE that meets SAE  criteria  (Section  6.3.2.1) must be reported  to PPD immediately  (ie, 
within 24 hours after the time site personnel first learn about the event).The following 
contact information is to be used for SAE reporting; The event is reported via the 
electronic data capture (EDC) system where site personnel complete as much of the 
respective AE page (eCRF) as they are able.  
If the EDC system is unavailable, the  AE information must be recorded on the manual 
SAE  report  form and immediately  (ie, within  24 hours  of awareness)  sent to PPD  by one 
of the following  methods  (refer to the “SAE Guidelines”  document  for WorldReach  toll- 
free access numbers if necessary):  
Pharmacovigilance Department  
 
United  States  SAE  Hotline:  +1 800-201- 8725  
 
United  States  SAE  Fax line: +1 888-488- 9697  
 
Europe SAE Hotline:  +44 1223 374 240 (to be used  for questions 
concerning SAEs)  
Europe  SAE  Fax line: +44 1223 374 102 (to be used  for reporting  SAEs)  
 
 
 
Once  the EDC system  becomes available again, the site needs  to transfer all data  to the 
respective eCRF page of the patient.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  228  
 Section  6.3.2.5 - Assessment of  Causality  
 
The investigator’s assessment of an  AE’s relationship to study drug (combination of 
NC-6004 and gemcitabine)  is part of the documentation process,  but it is not a factor  in 
determining what is or is not reported in the study. If there is any doubt as to whether a 
clinical observation is an AE, the event should be reported. 
Section  6.3.3 - Assessment  of Nausea  and Vomiting  
 
… 
 
For Parts  1 and 2, e Each patient will be given a nausea and vomiting patient diary  to take 
home. This diary will be used to record the severity of nausea and incidence of emetic 
episodes over the previous 24 hours daily on Days 2 through 21. The first 7 days of the 
diary will be recorded verbatim  in the eCRF.  The patient will be given the diary and 
instructed on how and when to complete the diary before discharge from the site on 
Day 1 of each cycle. 
Part 1: The investigator will collect the n ausea and vomiting patient diary from each 
patient diaries on Day 8 and Day 15 for Cycle 1. For all subsequent cycles, the 
investigator  will collect  diaries on Day 1 (prior  to dosing  to capture  the last 7 days of the 
previous cycle), Day 8, and Day 15 (Part 1 only), and Day 22. The first 7 days of the diary 
will be recorded verbatim in the eCRF.  The investigator will record the worst severity of the 
patient’s nausea and the total number of emetic episodes occurring over the previous 7 days 
in the eCRF for Day 8 , Day 15, and Day 21. The patient will be given the diary and 
instructed on how and when to complete the diary before discharge from the site on Day  1 of 
each cycle. The patient must return the diary to the site on Day 8, Day 15 (Part 1 only), and 
Day 22 (Day 1 of the next cycle) of each cycle. 
Part 2: The investigator will collect the nausea and vomiting patient diary from each patient  at the site on Day 8 for Cycle  1. For Cycle  2, the investigator  will collect  diaries 
on Day 1 (prior to dosing to capture the last 7 days of the previous cycle) and Day 8. 
Note that nausea and vomiting patient diaries will not be collected past Cycle 2. The 
investigator will record the worst severity of the patient’s nausea and the total number of emetic  episodes occurring  over the previous 7  days in the  eCRF  for Day 8 and Day 21. 
Section  6.3.5 – Clinical Laboratory Analyses  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  229  
 … 
 
Any Only  abnormal laboratory  test results (hematology, biochemistry,  or urinalysis) that are 
deemed clinically significant by the  PI will are to be recorded as AEs or SAEs per  the NCI 
CTCAE version 4.03. 
Section  6.3.5.3 – Urinalysis 
 
Urinalysis  will be performed  using a dipstick test  and will include: leukocyte esterase,  nitrite, 
urobilinogen, protein, pH, blood, specific gravity, ketones, bilirubin, and glucose. 
Section  6.3.6 – Electrocardiograms  
 
All 12-lead ECGs  will be performed  after the patient has adequately  rested  in the supine 
position for at least 5 minutes . 
A 12- lead ECG  will be performed during the screening period at Day -7 to -1. On Day 1 
of Cycle 1, 12- lead ECGs will be performed before the start of the NC -6004 infusion, at 
completion of infusion (~1 hour after start of infusion), and at Hours 3 and 24 hours (Day 2) 
after start of infusion. On Day 8 of Cycle 1, 12- lead ECGs will be performed before the start 
of gemcitabine infusion, at the completion of gemcitabine infusion, and at 1 hour after completion of gemcitabine infusion. Twelve -lead ECGs will also be performed on Day 1 of 
Cycles 2 through 6 before the start of the NC-6004 infusion and at the End-of-Treatment  visit. 
All 12 -lead ECGs should be performed within a ±30- minute window.  
Section  6.3.7 - Physical  Examination  
 
A complete physical examination will be performed during the screening period at Day -14 
to -1, before study treatments  on Day –1 or Day 1 of each cycle,  and at the End-of-Treatment 
visit. Height and weight will also be assessed at the time of the screening period physical examination and before treatments on Day  1 of each cycle . with  Calculation of BSA  will be 
done before each dosing on Day 1 of each cycle (using the Mosteller formula  
[Mosteller 1987]. ( Note: Dose will only be recalculated if there is a ≥10% increase or 
decrease in the patient’s weight from the patient’s weight measurement at screening. Any change  in a patient’s weight by ≥10% during the  study will require  a recalculation 
of the doses  of all study  drugs.  This  threshold  should not be confused  with  a change of a 
patient’s BSA [m
2]). 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  230  
 Section  6.3.8 - Vital  Sign  Measurements  
 
Vital sign measurements  will include arterial blood pressure,  heart  rate, respiratory  rate, and 
temperature. Vital signs will be measured after the patient has adequately rested in the 
supine position for at least 5 minutes . 
… 
 
Vital signs  will also be measured  at the End-of-Treatment  visit.  
 
Section  7.3 - Sample Size Calculations  
 
This is a Phase 1b/2 study  with an overall sample size of up to 199 209 patients (up to 
49 patients in Part 1 and up to 150160 patients in Part 2).  The total sample size will depend 
on the number of cohorts required  to establish  an RPII  dose and the number of patients with 
NSCLC enrolled at the RPII dose in Part 1.  
… 
 
Part 2 is a 3-cohort study with an overall sample size of up to 150 160 patients with no more 
than 50 patients per cohort  each in Cohorts 1 and 2 and no more than 60 patients in 
Cohort 3 (30 unfit and 30 fit bladder cancer patients) . The total sample size will depend 
on the results of interim futility and superiority analyses. In order to evaluate the overall sample size, simulations were performed assuming  scenarios with different HRs for PFS for 
each cohort compared with historical control and different sample sizes for a subsequent Phase 3 clinical  trial. The associated  mean  sample size for this trial in these  scenarios ranged 
from 92.7136  to 116.8 146 patients.  
Section  10.2.2 - Protocol Violations  and Deviations  
 
… 
 
A deviation from the protocol is an unintended or unanticipated departure from the procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the 
investigator.  A significant deviation occurs when  there  is nonadherence to the protocol by the 
patient or investigator that results in a significant, additional risk to the patient. Significant 
deviations can include nonadherence to inclusion or exclusion criteria, enrollment of the  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  231  
 patient  without prior sponsor approval,  or nonadherence to FDA regulations or ICH GCP 
guidelines, and will lead to the patient being withdrawn from the study (Section 4.2). 
Section  11 - Reference List 
 
… 
 
Mosteller  RD. Simplified  calculation  of body -surface area. N Engl  J Med. 
1987;317(17):1098.  
Section  12.1 - Appendix: Schedule  of Events  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  232  
 Table 12-1 Schedule  of Events  
 
 
Procedure  Screening  Cycle 1 Cycle 2 Cycles 3-6 Cycle 7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Informed  consent  X                  
Eligibility  criteria   X                 
Demography   X                 
Medical  history   X                 
Pregnancy  test (serum  or urine)    X Xe    X   X   X   X  
Physical  examination   Xf  Xf    X   X   X   X  
Height,  weight,  and BSA 
calculationg  Xg  X    X   X   X     
Vital  signsh  X  Xh  X  X X  X X  X X  X  
Performance  status  (ECOG)   Xf  Xf    X   X   X   X  
Disease  assessmenti X          Xi   Xi   X X 
Audiometry   X  Xj    Xj   Xj   Xj   Xj  
Hematology    X Xk  X X X X X X X X X X X X  
Biochemistry    X Xk  X X X X X X X X X X X X  
Urinalysis  (dipstick)   X               X  
EORTC  QLQ -C30    X  X  X X  X X  X X  X  
MDASI  or MDASI -LCl    X  X  X X  X X  X X  X  
Part  1: Nausea  and vomiting 
patient diarym    X  X X X X X X X X X X X   
Part 2 Nausea  and vomiting  patient 
diarym    X  X  X X          
Cardiac  risk factors   X                 
12-lead ECGn   X X X X  X   X      X  
Pharmacokinetic  assessments 
(Part 1)o    X X X X X   X Xo Xo    X  
Pharmacokinetic  assessments 
(Part 2)p    X  X  X X  X X     X  
Adverse  events     Xf X X X X X X X X X X X X X X 
Concomitant  medication   Xf  Xf X X X X X X X X X X X X X Xc 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  233  
  
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow -upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
Prophylactic  administrations     X    X   X   X     
NC-6004  administrationa    X    X   X   X     
Gemcitabine  administration     X  X  X X  X X  X X    
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  234  
 Abbreviations:  BSA,  body  surface area;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative  Oncology  Group; EORTC  QLQ -C30,  European  Organisation  for 
Research  and Treatment  of Cancer  Quality  of Life Questionnaire -Core  30; MDASI, MD Anderson Symptom  Inventory;  RECIST,  Response Evaluation  Criteria 
in Solid Tumors; MDASI -LC, MDASI- lung cancer.  
a. In Part 1 of the study,  patients  will receive treatment  until progressive  disease.  In Part 2 of the study,  patients  will receive treatment  for 6 cycles  (Cohorts  1 
and 3) or 8 cycles (Cohort 2).  
b. End-of-treatment  assessments will be performed  within  28 days after treatment  discontinuation.  
c. After patient discontinuation  or completion  of treatment  without disease progression,  patients  will be followed with  scans  every  9 weeks  until disease 
progression. Patients will be called every 12 (±1) weeks to collect data on patient survival, new treatments, and adverse eve nts. 
d. Day 15 visit is required  in Part 1. In Part 2, Day 15 visit is only necessary  if it is clinically  indicated.  
e. Not required  if screening  pregnancy  test was performed  using  serum.  
f. Safety  assessments  of physical  examination,  ECOG,  review  of adverse events,  and concomitant medication  use can be completed  on Day -1 to allow  for 
early morning dosing. These should not be conducted in place of screening assessments.  
g. From Day -14 to -1 at screening, only height and weight will be measured. On Day 1 of each cycle, weight will be measured before treatments an d 
BSA  will be calculated before each dose using the Mosteller formula ( Mosteller 1987 ). (Note: Dose will only be recalculated if there is a ≥10% 
increase or decrease  in the patient’s  weight  from  the patient’s  screening  weight  measurement.  Any change  in a patient’s  weight  by ≥10%  during  the 
study will require a recalculation of the doses of all study drugs. This threshold should not be confused with a change in th e patient’s BSA  [m2]). 
g. Height and weight  only.  
h. Vital signs will be measured after the patient has adequately rested in the supine position for at least 5 minutes. On Day 1 of Cycle 1, vital signs will be 
measured  before  the start of the NC-6004 infusion,  every  20 minutes  during the infusion,  at the  completion  of the infusion,  and 1 hour after the completion 
of the NC -6004 infusion. Starting in Cycle 2, vital signs will be measured before the start of the NC -6004 infusion and at the completion of the NC -6004 
infusion on Day 1 of each cycle. Vital signs will be measured before and after gemcitabine infusion on Day 8 of each cycle. Vital signs will also be 
measured at the End -of-Treatment visit.  
i. Disease assessment will be performed using RECIST version 1.1 and the same imaging method used at screening should be used fo r all subsequent 
assessments. Beginning  in Cycle  3 and continuing through  the remainder  of the treatment cycles,  disease will be assessed every  6 (±1) weeks  (ie, every  other 
cycle) and at the End of  Treatment visit or until disease progression. Patients who have obtained a partial response or complete response will have a 
confirmatory scan at a minimum of 4 weeks following the initial scan.  
j. To be performed  only as clinically  indicated.  
k. Hematology  and biochemistry  tests will  be repeated  prior  to dosing on Day 1 of Cycle 1 if they were  last performed more than  24 hours  before  the start of 
the study drug administration.  
l. Symptom  changes  will be assessed using  the core MDASI  (Part  1 only)  or MDASI-LC (only  in patients  with NSCLC in Part 1). 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  235  
 m. Part 1:  The investigator  will collect the nausea and vomiting patient diary from each patient on Day 8 and Day 15 for Cycle 1. For  all subsequent 
cycles,  the investigator  will collect  diaries  on Day 1 (prior  to dosing  to capture the last 7 days  of the previous  cycle),  Day 8, and Day 15. Part  2: The 
investigator  will collect the nausea and vomiting patient diary from  each patient at the site on Day 8 for Cycle 1. For Cycle 2, the investigator will 
collect diaries on Day 1 (prior to dosing to capture the last 7 days of the previous cycle) and Day 8. Note that nausea and v omiting patient diaries 
will not be collected past Cycle 2. For additional details, see Section 6.3.3. Diary  issued on Day 1 of each cycle.  Assessment is performed at the site  
before dosing on Day 1 and Day  8 as well as Day 15 (Day  15 diary collected in Part 1 only; note: no dosing on Day 15) of each cycle. Patient completes  
diary at home on Days 2 through 8 and returns diary on Day 8.  
n. Twelve -lead ECGs  will be performed  after the patient has adequately  rested  in the supine position  for at least 5 minutes . A 12-lead ECG  will be performed 
during the screening period at Day – 7 to –1. On Day  1 of Cycle 1, 12 -lead ECGs will be performed before the start of the NC- 6004 infusion, at  
completion of  infusion (~1 hour after start of  infusion), and at Hours 3 and 24 (Day 2) after the start of  infusion. On Day 8 of  Cycle 1, 12 -lead ECGs will be 
performed before the start of gemcitabine infusion, at the end of gemcitabine infusion, and at 1 hour after completion of gem citabine infusion. Twelve -lead 
ECGs will be performed on Day  1 of Cycles 2 through 6 before the start of the NC -6004 infusion, and at the End -of Treatment visit. All 12 -lead ECGs 
should be performed within a ±30 -minute window.  
n.o. Fo r  Part 1, blood samples  will be collected  at the following  times:  before  the start of the NC-6004  infusion on Day 1 of Cycles  1 through  6, at end of 
NC-6004 infusion in Cycles  1, 3, and 5,  after the  start of NC-6004 infusion at Hours  3, 6, 12, 24  (Day  2), 48  (Day  3), 96  (Day  5), 168 and (Day  8, prior  to 
gemcitabine infusion (Day 8), and 336 (Day 15) in Cycles 1, 3, and 5, and at the End -of-Treatment visit.  Additional pharmacokinetic blood sample 
collections may  be performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within  
10 minutes  after  the 12-lead ECGs  performance.  
o.p. For Part  2 (up to 6 cycles), on the day of NC -6004 infusion for each cycle, blood samples will be collected before the start of the NC -6004 infusion, at the 
end of the NC-6004  infusion, before  gemcitabine  infusion  on Day 8, and at the End-of-Treatment  visit.  Additional  pharmacokinetic  blood  sample  collections 
may be performed, at the discretion of the investigator, during any visit where toxicity is observed. Blood samples will be collected within 10 minutes 
after the 12 -lead ECGs performance.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  236  
 12.4.7  Protocol  Amendment 4-Protocol  Version  5.0, Incorporating 
Amendment 3- Version 4.2 (dated 12 December 2016)  
The following sections detail  the changes made  to Protocol  Amendment  3-Version  4.2 (dated 
12 December 2016). The integrated protocol, Version 5.0, including Amendment 4, was  
issued  on 13 March  2017.  
 
12.4.7.1  Risk  Assessment  for Amendment  4, Version  5.0 
No anticipated increased patient risk has been introduced with the updates made during this 
protocol  amendment. Detailed  management  guidelines  for NC-6004- related  liver dysfunction 
have been added in Section 6.3.2.7. 
 
12.4.7.2  Overview  of Changes 
The overview  of significant changes  includes  the following. (Note  that minor  word  changes 
and copyedits are not identified). Global changes for Protocol  Amendment 4, Version 5.0 
include the following changes resulting from FDA  feedback on IND 118108:  
• Revised  the entry  criteria  to require  baseline alanine  transaminase and aspartate 
transaminase <2.0 × ULN or, in patients with documented hepatic metastasis  
<5.0 × ULN  and also serum  albumin ≥3.5 g/dL, and prothrombin time within  normal 
limits.  
• Revised  the entry  criteria  (Part 2 only)  Cohort  1 to require  that patients  histologically 
or cytologically confirmed diagnosis of Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for metastatic disease and are not 
known to be PD -L1 positive (known high PD -L1 expression defined as Tumor 
Proportion Score [TPS] greater than or equal to 50%).  
• Added a criterion to exclude patients with known active hepatitis B (defined as a 
known positive  HBsAg  result)  or hepatitis  C (defined by a known positive  hepatitis  C 
antibody result and known quantitative HCV RNA  results greater than the lower 
limits of detection of the assay).  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  237  
 • Revised  Section  5.4.1 NC-6004 Dose  Delay  and Modification  to hold NC-6004 in the 
event of a Grade 3 liver enzyme elevation until return to Grade ≤1. NC -6004 to be 
immediately and permanently discontinued for Grade 4 liver enzyme elevation.  
• Revised  the protocol to include a section  with detailed  management  guidelines for 
NC-6004-related liver dysfunction. 
 
12.4.7.3  Changes to the Protocol  Text 
In this section,  all affected  protocol sections are detailed;  the sequence of the sections follows 
the structure of the original protocol.  Additions to the protocol text are shown in bold and 
deletions are shown in strikethrough text. Minor or obvious editorial and grammatical 
corrections are not described.  
Protocol Synopsis  – Inclusion  Criteria  
 
Inclusion Criterion  2 (Cohort 1) was revised:  
 
2. (Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of 
Stage IV squamous NSCLC and have not received prior chemotherapy or 
immunotherapy for metastatic disease and are not known to be PD -L1 positive 
(known high PD-L1 expression  defined as Tumor  Proportion Score [TPS]  greater 
than or equal to 50%). Patients with known sensitizing mutation in the epidermal 
growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion 
oncogene must have received at least 1 and up to 2 targeted therapies prior to 
enrollment.  
Inclusion Criterion  7 was revised:  
 
7. Have  adequate liver function  defined  as: 
 
• Total  serum  bilirubin  <1.5 × upper limit  of normal (ULN)  and 
 
• Baseline Aalanine transaminase,  and aspartate transaminase <2.50 × ULN or, in 
patients with documented hepatic metastasis ≤ <5.0 × ULN and 
• Serum  albumin  ≥3.5 g/dL  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  238  
 Inclusion criterion  8 was added:  
 
8. Prothrombin time  within  normal  limits  
 
Protocol  Synopsis  – Exclusion  Criteria  
 
… 
 
Exclusion Criterion  9 was added:  
 
9. Have known active hepatitis B (defined as a known positive hepatitis B surface 
antigen [HBsAg] result) or hepatitis C (defined by a known positive hepatitis C 
antibody  result  and known quantitative  HCV  RNA  results greater than the lower 
limits of detection of the assay).  
 
 
Protocol  Synopsis  – Estimated  Study  Duration  
 
… 
 
Part 2 of the study will include a screening period (up to 28 days); 6 treatment cycles 
(Cohorts 1 and 3) or 8 treatment cycles (Cohort 2) that are 21 days in duration; tumor assessments for response  and disease progression with scans every  6 weeks;  and telephone 
calls for survival every 12 weeks.  
Patients  will receive study  treatment until any of the following  occur:  
… 
• Grade  4 liver  enzyme elevation  
Protocol  Synopsis  – Safety  Assessments  
 
… 
 
Hematology  and coagulation and biochemistry tests will be performed at screening and on 
Days 1, 8, and 15 of each cycle (before any study drug infusions), and at the End of 
Treatment  visit.  Urinalyses  will be performed  at screening  and at the End of Treatment  visit.  
Section  3.1 – Study  Design  
 
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  239  
 Screening  Period  (Day  -7 to -1) 
 
The following procedures  will be performed  during the screening  period within  7 days prior 
to the first study treatment:  
… 
 
• Hematology  and coagulation  
… 
 
Day 1 of Cycle  
 
The following procedures  will be performed  on Day 1 prior  to NC-6004 infusion in each 
treatment cycles unless otherwise specified:  
… 
 
• Hematology  and coagulation 
Day 8 of Each Cycle  
The following procedures  will be performed  on Day 8 prior  to gemcitabine  infusion in each 
treatment cycle:  
… 
 
• Hematology  and coagulation  
… 
 
Day 15 of Each  Cycle  (Part  1: required;  Part  2: if clinically  indicated) 
 
The following procedures  will be performed  on Day  15 in each treatment cycle:  
 
• Hematology  and coagulation  
… 
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  240  
 End-of-Treatment  Visit 
 
The following procedures will be performed  within  28 days after  treatment discontinuation:  
 
… 
 
• Hematology and coagulation  
Section  4.1.1 – Inclusion  Criteria  
 
Inclusion Criterion  2 (Cohort 1) was revised:  
 
2. (Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of 
Stage IV squamous NSCLC and have not received prior chemotherapy or 
immunotherapy for metastatic disease and are not known to be PD -L1 positive 
(known high PD-L1 expression  defined as Tumor  Proportion Score [TPS]  greater 
than or equal to 50%). Patients with known sensitizing mutation in the epidermal 
growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion 
oncogene must have received at least 1 and up to 2 targeted therapies prior to 
enrollment.  
Inclusion Criterion  7 was revised:  
 
7. Have  adequate liver function  defined  as: 
 
• Total  serum  bilirubin  <1.5 × upper limit  of normal (ULN)  and 
 
• Baseline Aalanine transaminase,  and aspartate transaminase <2.50 × ULN or, in 
patients with documented hepatic metastasis ≤ <5.0 × ULN and 
• Serum  albumin  ≥3.5 g/dL  
 
Inclusion criterion  8 was added:  
 
9. Prothrombin time  within  normal limits  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  241  
 Section  4.1.2 – Exclusion  Criteria  
 
… 
 
Exclusion Criterion  9 was added:  
 
9. Have known active hepatitis B (defined as a known positive hepatitis B surface 
antigen [HBsAg] result) or hepatitis C (defined by a known positive hepatitis C antibody  result  and known quantitative  HCV  RNA  results greater than the lower 
limits of detection of the assay).  
Section  4.2.1 – Reasons  for Withdrawal/Discontinuation  
 
… 
 
A patient  may be withdrawn from the  study for any of the following reasons:  
 
• Disease progression  
 
• Unacceptable toxicity  experienced  
 
• Grade  4 liver  enzyme elevation  
 
• Withdrawal  of consent  
 
• Major  protocol  violation  
 
• Required treatment delay  >14 days (except  in case of potential  patient  benefit, which 
must be approved by the sponsor)  
• Symptoms  or an intercurrent  illness  not consistent  with the protocol  requirements  or 
that justifies withdrawal  
• For Cohort  3 only, unfit  bladder  cancer  patient  (≥30  to <60 mL/min  CrCl  at 
screening) has a worsening of CrCl (ie, 50% reduction from baseline for  
2 consecutive assessments,  at least 1 week  apart)  
 
• Lost to follow -up 
 
• Other  (eg, pregnancy, development  of contraindications  of use of the study drug)  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  242  
 • The investigator or sponsor  determines  it is in the best interest  of the patient  to 
discontinue the patient’s participation in the study. 
Section  5.4 - Dose  Delays and Modifications  
 
… 
 
• Any patient  who experiences a Grade  3 or 4 hypersensitivity  reaction  during any 
cycle of treatment.  
• Any patient  who experiences 2 protocol -defined  DLTs  during treatment.  
 
• Any patient  who experiences a recurrent  Grade  3 or 4 toxicity  (recurrence of the same 
AE) after a dose reduction. 
• Any patient who requires a dosing delay >14 days at any time during treatment 
(except  in case of potential  patient  benefit, which  must  be approved by the sponsor).  
• Any patient  who experiences a Grade  4 liver  enzyme  elevation.  
 
Section  5.4.1 – NC-6004 Dose  Delay  and Modification  
 
During any treatment  cycle,  investigators  should suspend further  dosing with NC-6004 for up 
to 14 days after the scheduled dose in the event of a protocol -defined DLT or any Grade 4 
hematologic toxicity or Grade 3 or 4 nonhematologic toxicity that is possibly, probably, or 
definitely related to NC -6004 (excluding alopecia and Grade 3 nausea, vomiting, diarrhea, 
and electrolyte imbalances lasting less than 48 hours or with suboptimal prophylactic and suboptimal curative treatment). Any patient experiencing a Grade 3 liver enzyme 
elevation should have their next dose of NC -6004 suspended until improvement to 
Grade 1 or lower.  At the discretion of the investigator, the dose may also be delayed for up 
to 14 days for any toxicity possibly or probably related to NC -6004 that does not meet DLT 
criteria.  A delay of more than 14 days will require the patient to be removed from the study 
(except in case of potential patient benefit, which must be approved by the sponsor). The 
toxicity for which the dose was suspended must have improved to Grade 1 or lower prior to 
NC-6004 infusion.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  243  
 Section  5.10 – Prior,  Concomitant,  and Subsequent  Therapy  
 
(Part 2 only)  Cohort  1: For patients with Stage  IV NSCLC,  they may not have  received  prior 
chemotherapy or immunotherapy for metastatic disease.  
Section  6.3 – Safety  and Tolerability  Assessments 
 
Safety  will be assessed  using frequent  collection  of AE reports  (Section  6.3.2)  and clinical 
hematology and coagulation , biochemistry, and urinalysis test results (Section 6.3.5).  
Section  6.3.2.7 – Management  Guidelines  for NC 6004- Related  Liver  Dysfunction  
 
At the onset of Grade 4 liver enzyme elevation, NC -6004 must be immediately and 
permanently discontinued. Patients should be referred promptly to a 
hepatologist/gastroenterologist/specialist to be further  evaluated. Patients with Grade 4 
liver enzyme elevation should have a physical examination performed and should be assessed for signs of fever, rash and jaundice. Liver function tests including serum 
transaminases, alkaline phosphatase, γ -glutamyl transpeptidase, and total bilirubin 
(including direct and indirect), albumin choline esterase, total cholesterol, as well as hematological  tests  including  prothrombin  time  (PT),  PT/international  normalized  ratio 
(INR) and eosinophil count should be performed. Other testing including a serological test may be performed at the hepatologist/gastroenterologist/specialist’s discretion.  
Patients should then be monitored on a bi -weekly basis (or more frequent if indicated 
by the hepatologist/gastroenterologist/specialist) until  improvement  to Grade  2 or below 
and clinical stability. Section 5.4.1 provides details for management of Grade 3 liver 
enzyme elevation.  
Section  6.3.5 – Clinical Laboratory  Analyses  
 
Samples for hematology and coagulation , biochemistry,  and urinalysis  will be collected  at 
the time points specified in  Appendix 12.1, Schedule of Events.  
… 
 
Only abnormal laboratory test results (hematology and coagulation , biochemistry, or 
urinalysis) that are  deemed  clinically  significant  by the PI will be recorded as  AEs or SAEs 
per the NCI CTCAE version 4.03.  
NanoCarrier  
NC-6004 -004A  NC-6004  
Protocol  
Page  244  
 Section  6.3.5.1 – Hematology and Coagulation  
 
Hematology will include hemoglobin, reticulocytes, red blood cell count, differential white 
blood cell count, and platelets, and. Coagulation will include prothrombin time and 
international normalized  ratio.  Hematology and coagulation tests will be performed  during 
the screening period on Day -7 to -1, prior to dosing on Day 1 of Cycle 1 (if they were last 
performed more than 24 hours before the start of the study drug administration), weekly at 
each study visit prior to any treatments, and at the End -of-Treatment visit.  
Section  7.6.2.3 – Clinical Laboratory Results  
 
Clinical hematology and coagulation , biochemistry, and urinalysis data will be summarized 
at each scheduled assessment. Numeric hematology and coagulation and biochemistry 
results will be summarized using change from baseline.  
… 
 
Numeric  clinical  hematology and coagulation , biochemistry, and urinalysis  results  will be 
summarized using change from baseline.  
Page  245  
 NanoCarrier  NC-6004 
NC-6004 -004A Protocol  
Table  12-1 – Schedule  of Events  
 
 
 
Procedure  Screening  Cycle  1 Cycle  2 Cycles  3-6 Cycle  7 Onwarda End-of- 
Treatmentb Follow - 
upc 
Day 
-28 
to -1 Day 
-14 
to -1 Day 
-7 
to -1 Day 
1 Day 
2 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d Day 
1 Day 
8 Day 
15d   
…                   
Hematology  and 
coagulation    X Xk  X X X X X X X X X X X X  
…                   
… 
 
k. Hematology  and coagulation  and biochemistry  tests will  be repeated prior to dosing on Day  1 of Cycle  1 if they were  last performed more  than 24 hours  before  the start 
of the study drug administration.  